mongolmed.mnmongolmed.mn/uploads/editions/pdf/6c8c08972727529022d9d6...ÌÎÍÃÎËÛÍ...

ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍ, 2015, 1 (171)

ÃÀÐ×ÈÃ

Ðåäàêöèéí çóðâàñ 3

Ï.ÍÿìäàâààÎí÷òîé àíàãààõ óõààí 3

Ñóäàëãàà, øèíæèëãýý 4

Áèîàíàãààõ 4

1. Ñ.Áààñàíñ¿ðýí, Po-Shen Wang, Ý.ªëçèéñàéõàí, Ä.Ýíýáèø, Ñ.Àìàðñàéõàí, Yi-Jang Lee, À.ØèéðýâíÿìáàÄàâñàãíû õàâäàð áà MDM2 SNP309 õàìààðëûã ìîíãîë õ¿ì¿¿ñò ñóäàëñàí íü

4

2. Ã.Õóëàí, Á.Õóëàí, Í.Ýíõòóÿà, Ñ.ªíºðñàéõàí Ýìíýëãèéí íàíî-á¿òýýãäýõ¿¿íèé õîðóó ÷àíàðûã In-vitro îð÷èíä ñóäàëñàí ä¿í

9

Ýìíýëç¿é 13

3. Í.Áààñàíæàâ, Ä.Àëòàíãýðýë, Ì.Ãàíáààòàð, Ö.Ëî÷èí, Ä.ÝðäýíýáîëäÖºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä öºñíèé õ¿¿äèéã äóðàíãààð àâàõ àñóóäàëä 13

4. Í.Áîðõ¿¿, Ò.Öýíäñ¿ðýíÁ¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýýíèé áýëòãýëä áóðãóéäàõ áîëîí óóñìàë óóõ àðãûí õàðüöóóëñàí ñóäàëãàà

16

5. Ã.Ñàðàíöýöýã, Ñ.Ò¿âøèíãýðýëÕºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöààíû ñóäàëãàà

21

Íèéãìèéí ýð¿¿ë ìýíä 25

6. Ý.Òóÿà, Ë.Íÿìñ¿ðýí, Á.Õîíãîðçóë, Ï.Óíäàðìàà, Í.Àìàðäóëàì, Æ.Õèøèãò, Á.Áóðìààæàâ, È.Áîëîðìàà, Õàðàà, Îðõîí ãîëûí óñíû ÷àíàðûã ñóäàëñàí ä¿í

25

7. Ë.Íÿìñ¿ðýí, Î.Îþóí-Ýðäýíý, Ý.Òóÿà, Á.Äîðæõàíä, Ý.Ýðäýíý÷èìýã, Á.Áóðìààæàâ, È.Áîëîðìàà, Ñýëýíãý ìºðíèé ñàâ ãàçðûí îéðîëöîîõ ñóìäûí õ¿í àìûí äóíäàõ ãýäýñíèé õàëäâàðûí ºâ÷ëºëèéã ñóäàëñàí ä¿íãýýñ

30

8. Á.Ýíõòóíãàëàã, Á.Öîãçîëìàà, Æàêóé Âåáñòåð, Î.×èìýäñ¿ðýí, Æ.Áàòæàðãàë, Ìîíãîë÷óóäûí íèéòëýã õýðýãëýäýã õîîëíû äàâñíû àãóóëàìæèéã ñóäàëñàí ä¿í 36

9. Ð.Äàâààäîðæ, Ä.Áààòàðöîë, Ñ.Îþóíòóíãàëàã, Ä.Ñóâä, Ã.Î÷, Ã.Óÿíãà, Ã.Õóëàí, Á.Õóëàí, Á.Ãîâüãýðýë, Ñ.ªíºðñàéõàíÁè÷èë óóðõàé ýðõëýã÷äèéí ìºíãºí óñíû ýð¿¿ë ìýíäèéí íºëººëºë, àðõàã õîðäëîãîòîé çàðèì ºâ÷òºíèéã èëð¿¿ëñýí òóõàé

43

10. Ö.Ñîëîíãî, Á.Ñóâä, Ç.Ãýðýëìàà, Á.ÁóðìààæàâÏåðèíàòàëü øàëòãààíòàé ýíäýãäëèéã ýðãýìæ ñóäëàãààíû àðãààð ñóäàëñàí íü, Ìîíãîë óëñ 49

Ýìç¿é, óëàìæëàëò àíàãààõ óõààí 54

11. Æ.Áàò-Ýðäýíý, Ì.Óóãàíöýöýã, Ò.Àëèìàà, ×.×èìýäðàã÷ààÒóðøèëòûí àìüòàíä ¿¿ñãýñýí ýòèëèéí ñïèðòèéí äóðøèëä ×àííàäñýëøè æîðûí ¿ç¿¿ëýõ íºëºº 54

Ëåêö, Òîéì, Çºâëºãºº 61

12. Ä.Áàÿñãàëàí, Â.Äýëãýðìàà,À.Òîâóóäîðæ Ýïèëåïñèòýé õ¿ì¿¿ñèéí ñýòãýë ç¿é-íèéãìèéí àñóóäàë 61

13. Ç.Õèøèãñ¿ðýí, Ä.Îþóíñ¿ðýíÕ¿¿õýä ºñâºð íàñíûõíû àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîäëîãî õèéõ ¿çýãäëèéí òóõàéä 67

Ø¿¿ìæ, áîäîë, ýðãýö¿¿ëýë, 74

14. Í.Ìºíõò¿âøèíÕèïïîêðàò áóñ õàðèí Èìõîòåï-Àíàãààõ óõààíû æèíõýíý ýöýã

74

Ìýäýýëýë, ñóðòàë÷èëãàà 78

15. 2014 îíä Ìîíãîëûí àíàãààõ óõààíû ñàëáàðò ýðäìèéí çýðýã õàìãààëñàí ñóäëàà÷èä 78

16. ÌÀÓÀ-èéí ãèø¿¿äèéí 2014 îíû ¿éë àæèëëàãààíû òàéëàí 83

ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍ, 2015, 1 (171)

CONTENT

Editorial 3

Precision medicine by P.Nymadawa 3

Original articles 4

Biomedicine 4

1. Association between MDM2-SNP309 and bladder cancer in Mongolian peopleS.Baasansuren, Po-Shen Wang, E.Ulziisaikhan, D.Enebish, S.Amarsaikhan, Yi-Jang Lee, À.Shiirevnyamba

4

2. In vitro study: Toxicity of nanoproducts in medical applicationKhulan.G, Khulan.B, Enkhtuya.N, Unursaikhan.S

9

Clinical medicine 13

3. Laparoscopic cholecystectomy in surgicaltreatment of acute cholecystitisN.Baasanjav, B.Batbold, Bastuya, D.Altangerel, M.Ganbaatar, Ts.Lochin, D.Erdenebold, J.Gankhuyg

13

4. Survival of breast cancer patientsG.Sarantsetseg, S.Tuvshingerel

16

5. Prospective, randomized trial comparing a salt laxative solution with use water enema for colonoscopy preparationN.Borkhuu, T.Tsendsuren

21

Public Health 25

6. Water quality analysis of Kharaa and Orkhon riverE.Tuya, L.Nyamsuren,B.Khongorzul, P.Undarmaa,N.Amardulam,J.Khishigt, B.Burmaajav, I.Bolormaa

25

7. Some results of the study on gastrointestinal infectious diseases among people who live in soums are located in the near of the Selenge River BasinNyamsuren.L, Oyun-Erdene.O, Tuya.E,Dorjkhand.B, Erdenechimeg.E, Burmaajav.B, Bolormaa.I

30

8. Study on salt content in commonly consumed meals of MongoliansBatsaikhan Enkhtungalag, Bayandorj Tsogzolmaa, Jacqui Webster, Ochir Chimedsuren, Jamayan Batjargal

36

9. The health impact assessment of mercury on artisanal and small scale miners and revealed chronic mercury intoxicated patientsR.Davaadorj, D.Baatartsol, S.Ouyntungalag, D.Suvd, G.Och, G.Uyanga, G.Khulan, B.Khulan, B.Govigerel, S.Unursaikhan

43

10. Infant mortality rates in Ìongolia caused by “certain conditions originating in the perinatal period” (ICD code p00-p96)Ts.Solongo, B.Suvd, Z.Gerelmaa, B.Burmaajav

49

Pharmacy and Traditional medicine 54

11. Effect of Channadselshi on voluntary alcoholicwistar ratsJ.Bat-Erdene, M.Uugantsetseg, T.Alimaa, Ch.Chimedragchaa

54

Lecture, Review and Consultation 61

12. Psychosocial problem of people with epilepsyD.Bayasgalan,V.Delgermaa, A.Tovuudorj

61

13. Z. Khishigsuren, D.Oyunsuren 67

Critiques, thoughts and reflections 74

14. Not Hippocrates but Imhotep is the True Father of Medicine N.Munkhtuvshin

74

Information and Advertisement 78

15. Scientists obtained scientific degree in 2014 in Medicine, Mongolia 78

16. Annual report of members of MAM’s 83

ÑÓÄÀËÃÀÀ, ØÈÍÆÈËÃÝÝ 3

Õ¿íèé ãåíîìèêñèéí ñóäàëãàà ºðãºæèí ã¿íçãèéð÷ áóéí øóóä ¿ð äàãàâàð áîëæ, àíàãààõ óõààíä áîäüãàëæñàí àíàãààõ óõààí áóþó ýì÷èëãýý ñýðãèéëýëòèéã õóâü õ¿íèé ãåíåòèê îíöëîãò òóëãóóðëàí õèéõ ñóäàëãàà ýð÷èìæèæ áàéãàà áèëýý [1].

ÀÍÓ-ûí Åðºíõèéëºã÷ Áàðàê Îáàìà ýíý 2015 îíû íýãä¿ãýýð ñàðûí 30-íä áîäüãàëæñàí àíàãààõ óõààíû îëîëòûã ÀÍÓ-ûí ýìíýëç¿éí ïðàêòèêò íýâòð¿¿ëýõ çîðèëãîòîé “Îí÷òîé àíàãààõ óõààí” ñàíàà÷ëàãà (Presicion Medicine Initiative) ýõë¿¿ëæ áàéãààãàà ìýäýãäýæ, Åðºíõèéëºã÷èéí 2016 îíû òºñºâò ýíý ÷èãëýëèéí ñóäàëãàà, øèíæèëãýýã äýìæèõ çîðèëãîîð 215 ñàÿ äîëëàð òóñãàõ áîëñíîî çàðëàëàà [2]. Èíãýñíýýð ÀÍÓ “áîäüãàëæñàí àíàãààõ óõààí”-ûã ñóäàëãààíû ÿâöóó õ¿ðýýíýýñ óëñ îðíûõîî ýð¿¿ë ìýíäèéí ¿éë÷èëãýýíèé ò¿âøèíä õ¿ðãýõ çîðèîëò òàâüëàà.

ÀÍÓ-ûí Åðºíõèéëºã÷èéí ñàíàà÷èëñàí ýíýõ¿¿ “Îíî÷òîé àíàãààõ óõààí” ñàíàà÷ëàãûí õ¿ðýýíä:

- Õîðò õàâäðûí ýì÷èëãýýíèé ¿ð ä¿íã õàâäðûí áèîëîãèéí ñóäëàãààíû øèíýõýí îëîëòîä òóëãóóðëàí ñàéæðóóëàõ,

- Áîäüãàëæñàí àíàãààõ óõààíû ñóäàëãààã ã¿íçãèéð¿¿ëýí ïðàêòèêèéí ýð¿¿ë ìýíäèéí ¿éë÷èëãýýòýé õîëáîõ ñóäëàà÷äûí áàã á¿ðä¿¿ëýõ,

- Îí÷òîé àíàãààõ óõààíû ¿éë÷èëãýý àâ÷ áóé èðãýäèéí õóâèéí íóóöûã õàìãààëàõ,

- Áîäüãàëæñàí àíàãààõ óõààíû ýðõç¿éí áàòàëãààã ñàéæðóóëàõ,

- Íèéòèéí ¿éë÷èëãýý – õóâèéí ñàëáàðûí ò¿íøëýëèéã (public-private partnership) äýìæèõ çîðèëò òàâüæ áóé àæýý.

Òèéìýýñ 2016 îíä Åðºíõèéëºã÷èéí òºñâººñ ýíý ñàíàà÷ëàãûí õ¿ðýýíä çàðöóóëàõ 215 ñàÿ àì.äîëëàðààñ:

- 130 ñàÿ äîëëàðûã áîäüãàëæñàí àíàãààõ óõààíû îëîëòûã ýð¿¿ë ìýíäèéí ¿éë÷èëãýýíä íýâòð¿¿ëýõ ñóäëàà÷äûí áàã, ñóäàëãàà áîëîâñðóóëàëòûí ìàòåðèàëàà ñîëèëöîõ

ìýäýýëëèéí ñ¿ëæýý áàéãóóëàõàä çîðèóëàí ¯íäýñíèé ýð¿¿ë ìýíäèéí õ¿ðýýëýí(NIH)-ä,

- 70 ñàÿ äîëëàðûã õîðò õàâðûí áîäüãàëæñàí ýì÷èëãýýíèé øèíý àðãà áîëîâñðóóëàí íýâòð¿¿ëýõ ñóäàëãààã ýð÷èìæ¿¿ëýõ çîðèëãîîð Õàâäàð ñóäëàëûí ¿íäýñíèé õ¿ðýýëýí(NCI)-ä,

- 10 ñàÿ äîëëàðûã áîäüãàëæñàí àíàãààõ óõààíû îëîëòûã ýð¿¿ë ìýíäèéí ¿éë÷èëãýýíä íýâòð¿¿ëýõ ¿éë àæèëëàãààã çîõèöóóëàõ ýðõç¿éí àêòóóäûã áîëîâñðóóëàí õýðýãæ¿¿ëæ ýõëýõýä çîðèóëàí Õ¿íñ, ýìèéí õÿíàëòûí àãåíòëàã(FDA)-ò,

- 5 ñàÿ äîëëàðûã áîäüãàëæñàí àíàãààõ óõààíû îëîëòûã ýð¿¿ë ìýíäèéí ¿éë÷èëãýýíä íýâòð¿¿ëýõ ñòàíäàðò, óäèðäàìæóóäûã áîëîâñðóóëàí íèéòýä ò¿ãýýõýä çîðèóëàí Ýð¿¿ë ìýíäèéí ìýäýýëëèéí òåõíîëîãèéí ¿íäýñíèé çîõèöóóëàã÷èéí àëáà(ONC)-íä õóâààðèëàõààð òóñ òóñ òºëºâëºñºí áàéíà.

Ìºí Öàãààí îðäíû âýá-ñàéòàä “Îí÷òîé àíãààõ óõààíû ñàíàà÷ëàãà” áëîã [3] íýýæ, ýíý õºòºëáºðèéí ÿâö, òºñâººñ çàðöóóëæ áóé õºðºíãèéã õýðõýí ¿ð àøèãòàé çàðöóóëæ áàéãààä ºðãºí îëíû õÿíàëò òàâèõ, òàíèëöàõ áîëîëöîî íýýæ ºã÷ýý.

Èéíõ¿¿ 21 äãýýð çóóíû àíàãààõ óõààíû øèíý õóâüñãàëûí îëîëòóóä ýð¿¿ë ìýíäèéí ïðàêòèê ¿éë÷èëãýýíä íýâòýð÷ ýõëýõ øàí òàòàãäëàà.

Íîì ç¿é

1. Íÿìäàâàà, Ï. (2012): Áîäüãàëæñàí àíàãààõ óõààí, Ìîíãîëûí àíàãààõ óõààí, 1(156):5-6;

2. The White House – Office of the Press Secretary (2015): FACT SHEET: President Obama’s Precision Medicine Initiative, http://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative accessed on Feb.5, 2014;

3. https://www.whitehouse.gov/blog/2015/01/30/precision-medicine-initiative-data-driven-treatments-unique-your-own-body

ÐÅÄÀÊÖÈÉÍ ÇÓÐÂÀÑ

ÎÍ×ÒÎÉ ÀÍÀÃÀÀÕ ÓÕÀÀÍ

Àêàäåìè÷ Ï.ÍÿìäàâààØÓÀ, ÌÀÓÀ

ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍ, 2015, 1 (171) 4

ÑÓÄÀËÃÀÀ, ØÈÍÆÈËÃÝÝ

ÁÈÎÀÍÀÃÀÀÕ

Äàâñàãíû õàâäàð áà MDM2 SNP309 ìàðêåðûí õàìààðëûã

ìîíãîë õ¿ì¿¿ñò ñóäàëñàí íü

Ñ.Áààñàíñ¿ðýí1, Po-Shen Wang2, Ý.ªëçèéñàéõàí1, Ñ.Àìàðñàéõàí1, Yi-Jang Lee2, À. Øèéðýâíÿìáà1

1Ìýñ çàñëûí òýíõèì, ÀÓÑ, ÀØÓ¯ÈÑ2Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taiwan

Email:[email protected]

Aâstract

Association between MDM2-SNP309 polymorphism and bladder cancer in Mongolians

Baasansuren S1, Po-Shen Wang2, Ulziisaikhan E1, Amarsaikhan S1, Yi-Jang Lee2, Shiirevnyamba A*1

1Division of Urology, Department of Surgery, School of Medicine, Mongolian National University of Medical Sciences,

2Biomedical Imaging and Radiological Sciences, National Yang-Ming University, TaiwanEmail: [email protected]

*Corresponding author

BackgroundThe mouse double minute 2 (MDM2) is a negative regulator of the p53 tumor suppressor protein. Overexpression of MDM2 is associated with poor survival and is a useful predictive factor for poor prognosis in various cancers in human. Studies revealed a genetic polymorphism located in intron 1 of the MDM2 gene, MDM2-SNP309, (a change from T to G) is main functional polymorphism and important to develop tumors. However, inconsistent associations between the MDM2-SNP309 and the risk or early onset age of human different cancers have been reported worldwide. These conflicting results may have depended on different patient subgroups and ethnicities studies. We studied the association of the MDM2-SNP309 polymorphism andbladder cancer in Mongolian patients for the first time.

Objective To investigate association between MDM2-SNP309 and the risk bladder cancer or early onset age of the cancer in Mongolian patients.

Materials and Methods We genotyped MDM2-SNP309 in 44 patients with bladder cancer and 44 age and gender matched healthy controls among Mongolian people.Genomic DNA was extracted from whole blood samples by the standard method of Qiagen mini blood DNA extraction kit (Qiagen Inc., Valencia, CA) and PCR amplification was performed using 100 ng genomic DNA template according to manufacturer’s protocol (Invitrogen, Carlsbad, CA). MDM2 SNP309 genotyping was carried out by restriction fragment length polymorphism assay.

Results The allele frequencies of MDM2 SNP309 in the 44 bladder cancer patients were wild-type (T/T) 27.3%, homozygous (G/G) 34.1% and heterozygous (T/G) 38.6% whereas in the control cases were wild-type (T/T) 29.5%, homozygous (G/G) 20.5% and heterozygous (T/G) 50.0%. The proportion of homozygous (G/G) genotype was higher for bladder cancer cases than for healthy controls. Compared to the low-risk (wild type) genotype, an increased risk association with bladder cancer was shown for the GG genotype (OR=2.0, 95% CI=1.03-1.84). There is also a significant difference in median age onset of bladder cancer between GG low and high risk genotypes T/T and T/G (p=0,003)( p=0.0001), respectively (Figure2).

Conclusion: The current sample data suggests that MDM2 SNP309 GG genotype may be associated with the risk of bladder cancer as well as an earlier age onset in Mongolian patients with bladder cancer.

Key words: bladder cancer, MDM2 SNP309, polymorphism

Pp. 4-8, Tables 3, Figures 2, References 15


¯íäýñëýë

Mouse double minute 2 homolog (MDM2) áóþó Å3 ubiquitin-protein ligase Mdm 2 óóðàã íü 491 àìèí õ¿÷ëèéí äàðààëàë á¿õèé 56 kDa ìîëåêóë æèíòýé áººìèéí óóðàã áºãººä ò¿¿íèéã êîäëîã÷ MDM2 ãåí õ¿íèé 12-ð õðîìîñîìûí q 14.3-q 15-ð õýñýãò áàéðëàäàã. Ýíý óóðãèéí ¿íäñýí ¿¿ðýã íü p53 õàâäàð äàðàíãóéëàã÷ óóðãèéí trans-activation domain-èéã òàíüæ, p53 ãåíèéí òðàíñêðèïöèéí èäýâõèéã ñààòóóëàõ ¿éëäýëòýé [1]. Ñ¿¿ëèéí ¿åèéí ñóäàëãààãààð MDM2 ãåíèéí ¿éë àæèëëàãàà íü óëààí õîîëîé, á¿ä¿¿í, øóëóóí ãýäýñ, ºíäãºâ÷, äàâñàã, ýëýã çýðýã ýðõòíèé õàâäðûí ¿åä õýò èäýâõèæñýí áàéäàã íü òîäîðõîéëîãäñîí áà ýíý õýò èäýâõèæèëòèéã óã ãåíèéí ïðîìîòåð õýñãèéí 1-ð èíòðîíû 309 äýõ áàéðëàë äàõü íýã íóêëåîòèäèéí ïîëèìîðô õýëáýðøèëòýé (SNP309) õîëáîí òàéëáàðëàæ áàéíà. Ýíý ïîëèìîðôèçìûí Ò àëëåëü G àëëåëýýð ñîëèãäîõ íü MDM2ãåíèéã Sp1 òðàíñêðèïöèéí ôàêòîðò ìýäðýã áîëãîæ óëìààð MDM2-ûí ìPÍÕ áîëîí óóðãèéí òºâøèíã èõýñãýæ P53 ãåíèéí òðàíñêðèïöèéí èäýâõèéã íü ñààòóóëæ óëìààð õàâäàð ¿¿ñýõ ýðñäýëèéã áèé áîëãîäîã áàéíà [2]. Òóõàéëáàë ýëýãíèé Ñ âèðóñûí õàëäâàðûí ãàðàëòàé àðõàã ¿ðýâñýëòýé ßïîí, Ìîðîêà õ¿ì¿¿ñò ýëýãíèé õàâäàð ¿¿ñãýõ ýðñäýëò õ¿÷èí ç¿éë áîëäîã áîë ýëýãíèé Â âèð¿ñèéí ãàðàëòàé àðõàã ¿ðýâñýëòýé Ñîëîíãîñ õ¿ì¿¿ñò ìºí ýðñäýëò õ¿÷èí ç¿éë áîëæ áàéíà [3-5].

Äàâñàãíû õàâäàð íü óðîëîãèéí õîðò õàâäðóóäûí äîòîð òîõèîëäëîîðîî ÀÍÓ-ä ò¿ð¿¿ áóë÷èðõàéí õîðò õàâäðûí äàðàà 2-ðò îðæ áàéõàä ìàíàé îðîíä áººðíèé õîðò õàâäðûí äàðàà ìºí 2-ð áàéðàíä îðæ áàéíà [6-7]. Ò¿¿í÷ëýí ºíäºð õºãæèëòýé áàðóóíû îðíóóäàä ýðýãòýé÷¿¿äýä òîõèîëääîã íèéò õîðò õàâäðûí ýõíèé 4-ò, ýìýãòýé÷¿¿äýä ýõíèé 8-ä îðäîã ò¿ãýýìýë òîõèîëääîã õàâäðûí íýã þì [8]. MDM2 SNP309 ïîëèìîðôèçìûã äàâñàãíû õàâäàðòàé õîëáîí Òóðê, ßïîí, Èñïàíè çýðýã îðíû õ¿ì¿¿ñò ñóäàëæ MDM2 SNP309 T àëëåëü íü G àëëåëààðñîëèãäîõ íü äàâñàãíû õàâäàð ¿¿ñýõýä íºëººòýé áîëîõûã òîãòîîñîí ñóäàëãààíóóä õýâëýãäñýí áîëîâ÷ çàðèì ¿ð ä¿íã¿¿ä íü õàðèëöàí àäèëã¿é áàéíà [9-11]. Áèä ýíý óäàà Ìîíãîë äàâñàãíû õàâäàðòàé õ¿ì¿¿ñèéí MDM2 SNP309-èéí ïîëèìîðôèçìûã ñóäàëæ, õàâäðààð ºâäºõ ýðñäýë áîëîõ ýñýõ, õàâäðààð ºâäºæ ýõëýõ íàñòàé õàìààðàëòàé ýñýõèéã ñóäàëëàà.

Ìàòåðèàë àðãà ç¿é

Ñóäëàãäàõóóí: Ñóäàëãààã ÓÍÒÝ-èéí áººðíèé ìýñ çàñëûí òàñàã áîëîí êàáèíåòûã ò¿øèãëýí ÿâóóëñàí. Äàâñàãíû õàâäàðòàé ãýæ îíîøëîãäñîí, îíîø íü ýìãýã ñóäëàëûí øèíæèëãýýãýýð áàòëàãäñàí

18 áîëîí ò¿¿íýýñ äýýø íàñíû 44 ºâ÷òºí áîëîí íàñ õ¿éñèéí õóâüä ýäãýýð ºâ÷òºíòýé èæèëõýí 44 õàðüöàíãóé ýð¿¿ë õ¿ì¿¿ñèéã ñîíãîí íèéò 88 õ¿íèéã ñóäàëãààíä õàìðóóëëàà. Òîõèîëäëûí áîëîí õÿíàëòûí á¿ëãèéí õ¿ì¿¿ñèéí õóðààãóóð ñóäàñíààñ 3 ìë öóñ àâ÷, ÄÍÕ-ã ÿëãàæ àâàõ õ¿ðòýë 40Ñ õýìä õàäãàëàâ. Óã ñóäàëãààã ÀØÓ¯ÈÑ-èéí Ñóäàëãààíû ¸ñ ç¿éí õÿíàëòûí õîðîîíû çºâøººðëèéí äàãóó ÿâóóëñàí áîëíî.

ÄÍÕ ÿëãàõ: Qiagen mini blood DNA extraction kit (Qiagen Inc.,Valencia, CA) èæ á¿ðäýë áîëîí 96% ýòèëèéí ñïèðòèéã (Duk San Co. Korea) àøèãëàí äàãàëäàõ ïðîòîêîëûí äàãóó öóñíààñ ÄÍÕ-èéã ÿëãàí àâëàà. ßëãàæ àâñàí ÄÍÕ-èéã -200Ñ õýìä õàäãàëæ áàéâ.

MDM2 SNP309, PCR- RFLP: Áèä MDM2 SNP309 ïîëèìîðôèçìûã Ying-Fang Sun íàðûí ïðîòîêîëûí äàãóó PCR-RFLP àðãààð õèéñýí [12].

PCR: MDM2 SNP309-èéí ïîëèìîð-ôèç ìûã MDM2SNP309-èéí F (5’-CGGGAGTTCAGGGTAAAGGT-3’) áîëîí R (5’-AGCAAGTCGGTGCTTACCTG-3’) ïðàéìåð¿¿äèéã àøèãëàí ïîëèìåðàçûí ãèíæèí óðâàëààð îëøðóóëàâ. Ïîëèìåðàçûí ãèíæèí óðâàëûí íèéò õîëèìãèéí õýìæýý 50 ìêë áàéõààð òîîöîæ, õîëèìîãò 100 íã ÄÍÕ, 0.2 μM ïðàéìåð, 200 μM dNTP, 1.5 mM MgCl2, 20 mM Tris-HCl (pH 8.4), 50 mM KCl áîëîí íýã íýãæ Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA) òóñ òóñ àãóóëàãäàæ áàéâ. ÏÃÓ-ûã àíõäàã÷ äåíàòóðàöè 940C-ä 1 ìèíóò, äàðàà íü 940C-ä 30 ñåêóíä äåíàòóðàöè, 580C-ä 30 ñåêóíä àííýàëèíã, 720C-ä 30 ñåêóíä ýêñòýíøí á¿õèé 40 öèêë, òºãñãºëèéí ýêñòýíøí 720C-ä 10 ìèíóò áàéõ íºõöºëä ÿâóóëàâ.

RFLP: ¯¿íèé äàðàà áèä 10 μl PCR-ûí îëøðóóëñàí á¿òýýãäýõ¿¿íèéã íýã íýãæ MspA1l (New England Biolabs, Ibswich, MA) ðåñòðèêöèéí ýíçèì àøèãëàí 37°C-ò 60 ìèíóò áîëîâñðóóëàëò õèéñýí. Èíãýýä 3% NuSieve àãàðîçûí ãåëüä ã¿éëãýæ ãåëèéã ýòèäèóì áðîìèäàä 20 ìèíóò áóäàæ ãåëèéí ä¿ðñ áóóëãàã÷èä çóðàã àâ÷ä¿ãíýâ. MDM2 SNP309 ïî ëè ìîðô õýëáýðøèëèéã MspA1l ðåñòðèêöèéí ýíçèìýýð ç¿ñýãäñýí áàéäëààð òîäîðõîéëîâ. ¯¿íä: T/Ò wild-type õî¸ð õýð÷èì (233bp, 88bp), G/Ghomozygotes õî¸ð õýð÷èì (187bp, 88bp), õàðèí T/Gheterozygotes ãóðâàí õýð÷èì (233bp, 187bp, 88bp) áàéíà.

Ñòàòèñòèê áîëîâñðóóëàëò: Òîõèîëäëûí áî-ëîí õÿíàëòûí á¿ëãèéí õ¿ì¿¿ñèéí õîîðîíä õàðüöóóëàëò õèéõäýý SPSS 16 ïðîãðàìì, Binary Logistic regression analysis ¿éëäëèéã àøèãëàí Odds ratio (OR), 95% (CI) èòãýõ èíòåðâàë, P óòãûã òîîöîâ.


¯ð ä¿í

Áèäíèé ñóäàëãààíä òîõèîëäîë áà õÿíàëòûí á¿ëãèéí íèéò 88 õ¿í õàìðàãäàâ.

PCR-RFLP àðãààð MDM2 SNP309 ïîëèìîðô õýëáýð øèëèéã òîäîðõîéëñîí ¿ð ä¿íã Çóðàã 1-ò ¿ç¿¿ëýâ.

M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

233bp 187bp 88bp

Figure1. PCR-RFLP analysis of the MDM2 SNP309 polymorphism using MspA1l. Wild-type T allele produces two fragments (233bp, 88bp), TG heterozygotes three fragments (233bp, 187bp, 88bp), and GG homozygotes two fragments (187bp, 88bp).

MDM2 SNP309 ïîëèìîðô õýëáýðøèëèéã òîõèîëäëûí áîëîí õÿíàëòûí á¿ëýãò õ¿éñ áà äóíäàæ íàñíû ¿ç¿¿ëýëòýýð àíãèëàí õ¿ñíýãòýýð õàðóóëàâ (Õ¿ñíýãò1).

Table 1. Genotype distribution by sex and mean age in study subjects

TT TG GGControl group 44 13 (29.5%) 22 (50%) 9 (20.5%)Case group 44 12 (27.3%) 17 (38.6%) 15 (34.1%)Gender (M/F) Control group Case group

35/935/9

10/38/4

19/316/1

6/311/4

Mean age+-SD

Control group Case group

54±12.555±12.6

59.9±16.158.8±1.68

51.5±10.658.8±8.9

54.8±9.51.2±1.3

MDM2 SNP309 íýã íóêëåîòèäûí ïîëèìîðôèçìûí äàâòàìæèéã òîõèîëäëûí áîëîí õÿíàëòûí õ¿ì¿¿ñò íàñíû á¿ë ãýýð àíãèëñíûã õ¿ñíýãò 2-ò õàðóóëàâ. TG ãåíîòèï õÿíàëòûí áîëîí òîõèîëäëûí àëü ÷ á¿ëýãò õàìãèéí èõ òî äîð õîé ëîãäîæ áàéõàä GG ãåíîòèï õàâäàðòàé á¿ëýãò, TT ãåíîòèï ýð¿¿ë á¿ëýãò èõ òîõèîëäîæ áàéíà (Õ¿ñíýãò 2).

Table 2. Genotype frequencies of MDM2 SNP309 by age group

Age group Bladder cancer Control group

man female TT TG GG TT TG GG20-30 1 0 1 0 0 1 0 031-40 3 1 0 1 3 1 3 041-50 6 3 3 2 4 2 3 451-60 15 2 3 8 4 2 11 261-70 5 0 0 4 2 0 3 371-80 5 3 5 2 2 7 2 0Total 35 9 12 17 15 13 22 9

MDM2 SNP309 íýã íóêëåîòèäûí ïîëèìîðôèçì áîëîí äàâñàãíû õàâäðûí õàìààðëûã ñóäëàõàä äàâñàãíû õàâäàðòàé õ¿ì¿¿ñèéí GG ãåíîòèï íü õàâäàð ¿¿ñãýõ ýðñäýëò õ¿÷èí ç¿éë áîëîõ ìàãàäëàëòàé áàéíà. Ìºí G àëëåëèéí äàâòàìæ íü õàâäàðòàé õ¿ì¿¿ñò 53.4%, õÿíàëòûí á¿ëãèéí õ¿ì¿¿ñò 45.4% áàéëàà (Õ¿ñíýãò 3).

Table 3. Risk evaluation of MDM2 SNP309 genotypes on the development of bladder cancer in Mongolian people

Genotype Patient group Control group OR (95%CI) P-value N=44 N=44 (100%) (100%)TT 12 (27.3%) 13 (29.5%) 0,89(1,07-1.69) 0,813TG 17 (38.6%) 22 (50%) 0,62(1.27-1.72) 0,284GG 15 (34.1%) 9 (20.5%) 2.0(1.03-1.84) 0,154TG+GG 32 (72.7%) 31 (70.5%) 1.1(1.00-1.25) 0,813


AlleleT 0.466 0.545

G 0.534 0.454

MDM2 SNP309 íýã íóêëåîòèäûí ïîëèìîðôèçì áîëîí äàâñàãíû õàâäàðòàé õ¿ì¿¿ñèéí îíîøëîãäñîí äóíäàæ íàñíû õàìààðëûã ñóäëàõàä GG ãåíîòèïòýé õ¿ì¿¿ñèéí äóíäàæ íàñ íü 41 áàéõàä TT áîëîí TG ãåíîòèï¿¿äèéí äóíäàæ íàñ íü 50 áà 60 íàñ áàéíà (Çóðàã 2).

Age at diagnosis of bladder cancer

GGvsTG P=0.0001 GGvsTT P=0.003

Figure 2. Association between MDM2 SNP309 polymorphisms with an earlier age onset of bladder cancer cases in Mongolian.

ÕýëöýìæÁèä ýíý ñóäàëãààãààð ìîíãîëä àíõ óäàà MDM2SNP309 ãåíèéí íýã íóêëåîòèäèéí ïîëèìîðôèçìûã ìîíãîë õ¿ì¿¿ñò òîõèîëäîæ áóé äàâñàãíû õàâäàðòàé õàìààðàëòàé ýñýõèéã ñóäàëëàà. ßïîí, Òóðê, Èñïàíèä ýíýõ¿¿ ïîëèìîðôèçìûã äàâñàãíû õàâäàðòàé õîëáîí ñóäàëæ, õýâëýãäñýí ñóäàëãààíû àæëóóäòàé ººðñäèéí ñóäàëãààãàà õàðüöóóëëàà [9-11].

Ìîíãîë äàâñàãíû õàâäàðòàé õ¿ì¿¿ñò òîõèîëäîæ áàéãàà MDM2 SNP309 ãåíèéí íýã íóêëåîòèäèéí ïîëèìîðôèçìûí äàâòàìæèéí õóâüä ãåòåðîçèãîò áóþó TG ãåíîòèïèéí äàâòàìæ õàìãèéí îëîí (38.6%) òîõèîëäñîí íü áóñàä îðíû ñóäàëãààòàé (ßïîí-51.1%, Òóðê-48%, Èñïàíè-51.8%) èæèë áàéíà. Áèäíèé ñóäàëãààãààð GG ãåíîòèïèéí äàâòàìæ (34,1%) íü ßïîí (29.5%), Òóðê (34.6%)-èéíõòàé èæèë, Èñïàíèé (11.3%) ñóäëàà÷äûíõààñ ººð áàéëàà. Õàðèí TT ãåíîòèïèéí äàâòàìæ áèäíèé (27,3%) áîëîí ßïîí (19.4%), Òóðê (17.3%)-èéí ñóäàëãààãààð õàìãèéí áàãà áàéõàä Èñïàíèéí ñóäàëãààãààð 36.9% òîõèîëäîæ áàéíà.

Ñóäàëãààãààð äàâñàãíû õàâäàðòàé ìîíãîë õ¿ì¿¿ñò MDM2 SNP309 ãåíèéí íýã íóêëåîòèäèéí GG ïîëè ìîðôèçì íü õÿíàëòûí á¿ëãèéí õ¿ì¿¿ñòýé õàðüöóóëàõàä èõ òîõèîëäîæ áàéãàà íü GG ãåíîòèï íü õàâäàð ¿¿ñýõ ýðñäýëò õ¿÷èí ç¿éëñ (OR-2.0) áîëæ áîëîõûã õàðóóëæ áàéíà. Ýíý ¿ç¿¿ëýëò íü ßïîí, Òóðêèéí ñóäàëãààãààð 1.06 áîëîí 2.68 áàéëàà. ßïîí áîëîí Èñïàíèéí ñóäëàà÷äûíõààð G àëëåëü íü èíâàçèâ (Invasive) áîëîí õàâäðûí ºíäºð çýðýãòýé (high grade) äàâñàãíû õàâäàðò èõ òîõèîëäîæ áàéãàà íü G àëëåëü íü õîðóó ÿâöòàé õàâäàð ¿¿ñãýõ ýðñäýëòýé áîëîõûã õàðóóëæ áàéíà.

MDM2 SNP309-èéí ïîëèìîðôèçìûí õýëáýðøèë áîëîí äàâñàãíû õàâäàðòàé ãýæ îíîøëîãäñîí õ¿ì¿¿-ñèéí íàñ õîîðîíäûí õàìààðëûã ñóäàëñàí ãàäààäûí ñóäàëãààíóóäûí ¿ð ä¿í íü õàâäðûí òºðºë, õàìðàãäñàí õ¿í àì, ñóäàëãààíû àðãà çýðãýýñýý õàìààðàí ººð ººð áàéíà. Òóõàéëáàë õºõíèé õàâäàðòàé Àôðèê ãàðàë òàé Àìåðèê÷¿¿ä áîëîí öàãààí àðüñò [13] õ¿ì¿¿ñò õàâäàð áîëîí íàñíû õîîðîíä õàìààðàëã¿é áàéõàä Õÿòàä õ¿ì¿¿ñò õàìààðàëòàé áàéíà [14]. Ìºí G àëëåëü íü á¿ä¿¿í, øóëóóí ãýäýñíèé áîëîí öóñíû õàâäàðòàé õ¿ì¿¿ñèéí íàñòàé õàìààðàëòàé áàéíà [15]. Áèäíèé ñóäàëãààãààð MDM2 SNP309 ãåíèéí GG ïîëèìîðôèçìòýé äàâñàãíû õàâäàðòàé õ¿ì¿¿ñèéí äóíäàæ íàñûã (41)TG ïîëèìîðôèçìòýé õ¿ì¿¿ñèéí äóíäàæ íàñòàé (60) õàðüöóóëàõàä ñòàòèñòèê ¿íýí ìàãàäëàë á¿õèé ÿëãààòàé (P=0,0001) áàéëàà. Ìºí GG ïîëèìîðôèçìûã TT ïîëèìîðôèçì òîäîðõîéëîãäñîí õ¿ì¿¿ñèéí äóíäàæ (50) íàñòàé õàðüöóóëàõàä ìºí ÿëãààòàé áàéëàà (P=0.003) (Çóðàã2). Èéìýýñ GG ïîëèìîðôèçì íü äàâñàãíû õàâäðààð ýðò íàñàíäàà ºâäºõ ýðñäëèéã áèé áîëãîäîã áàéíà.

Áèäíèé ýíý ñóäàëãààíä õàìðàãäñàí õ¿ì¿¿ñèéí òîî ßïîí, Òóðê, Èñïàíè çýðýã îðíû ñóäëàà÷äûíõòàé õàðüöóóëàõàä öººí áàéãàà áîëîâ÷ èõýíõ ¿ð ä¿íã¿¿ä íü îéðîëöîî áàéíà.

Ä¿ãíýëò:

1. MDM2 SNP309 íýã íóêëåîòèäèéí ïîëèìîð-ôèçìûí TG ãåíîòèï íü ñóäàëãààíä õàìðàãäñàí õ¿ ì¿¿ñò õàìãèéí èõ òîõèîëäîæ áàéíà. GG ãåíî òèï íü äàâñàãíû õàâäàðòàé ìîíãîë õ¿-ì¿¿ñò õàâäàð ¿¿ñãýõ ýðñäýëò õ¿÷èí ç¿éë áàéõ ìàãàäëàëòàé áàéíà.

2. MDM2 SNP309 íýã íóêëåîòèäèéí ïîëèìîð ôèç-ìûí GG ãåíîòèïòýé õ¿ì¿¿ñ äàâñàãíû õàâäðààð ýðò çàëóó íàñàíäàà ºâäºõ ìàãàäëàë íü ñòàòèñòèê à÷ õîëáîãäîë á¿õèé õàìààðàëòàé áàéíà.

Áèä öààøèä ñóäàëãààíä õàìðàãäàãñäûã ºðãºæ¿¿-ëýí äýýðõ ¿ð ä¿íã áàòàëãààæóóëàõ çîðèëò òàâèí àæèëëàæ áàéíà. Öààøèëáàë MDM2 SNP309 ãåíèéí íýã íóêëåîòèäèéí ïîëèìîðôèçìûã ìîíãîë õ¿ì¿¿ñò òîõèîëääîã ººð áóñàä õàâäðóóäàä ñóäëàõ øààðäëàãàòàé þì.


Íîì ç¿é

1. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69: 1237-45.

2. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119:591-602.

3. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX,Kawabe T, Omata M. MDM2 pro-moter SNP309 is associatedwith the risk of hepatocellular carcinoma in patients withchronic hepatitis C. Clin Cancer Res 2006; 12: 4867-4871.

4. Ezzikouri S, El Feydi AE, Afifi R, El Kihal L, BenazzouzM, Hassar M, Marchio A, Pineau P, Benjelloun S. MDM2SNP309T>G polymorphism and risk of hepatocellularcarcinoma: a case-control analysis in a Moroccan population.Cancer Detect Prev2009; 32: 380-385.

5. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, KangDR, Park JY, Myoung SM, Kim DY, Chon CY, Han KH.MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients withchronic hepatitis B virus infection. Carcinogenesis 2008; 29:1192-1196.

6. American Cancer Society.Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013.

7. Ýð¿¿ë ìýíäèéí ¿ç¿¿ëýëò. Ýð¿¿ë ìýíäèéí õºãæëèéí òºâ; ÓÁ.2012.õ.3,11-12.

8. Ferlay J, Shen HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008; GLOBOCAN 2008. Int J Cancer. 2010 Dec 15; 127(12):2893-2917.

9. Onat OE, Tez M, Ozcelik T, Toruner GA.MDM2 T309G polymorphism is associated with bladder cancer.Anticancer Res. 2006 Sep-Oct;26(5A):3473-3475.

10. Horikawa Y, Nadaoka J, Saito M, Kumazawa T, Inoue T, Yuasa T, Tsuchiya N, Nishiyama H, Ogawa O, Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.Oncol Rep. 2008 Jul;20(1):49-55.

11. Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, Cordon-Cardo C. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.Clin Cancer Res. 2007 Jun 1;13(11):3215-3220.

12. Ying-Fang Sun, Jyh-Der-Leu, Su-Mei_Chen, I-Feng-Lin and Yi-Jang Lee Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 2009, 9:13.

13. Millikan RC, Heard K, Winkel S, Hill EJ, Heard K, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR. No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):175-7.

14. Lum SS1, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z, Sabapathy K. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis. 2008 Apr;29(4):754-61.

15. Alhopuro, P et al. The MDM2 promoter polymorphism SNP309T-G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med. Genet. 2005; 42, 694-698.

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Aíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð Á.Ìºíõáàò


¯íäýñëýë

Íàíîòåõíîëîãè íü ýäèéí çàñàã, òåõíèê òåõíî ëîãè, øèíæëýõ óõààíû ñàëáàðò ¿ñðýíã¿é õºãæëèéã àâ÷ðàõ, XXI çóóíû îíöëîõ àìæèëòûí íýã þì [1]. Íàíîìàòåðèàë ãýäýã îéëãîëòîä íýã áóþó ò¿¿íýýñ äýýø õýìæýýñò îðîí çàéä 100íì–ýýñ äîòîãø õýìæèãäýõ, çºâõºí ¿éëäâýðëýëèéí àðãààð ãàðãàí àâñàí á¿òýýãäýõ¿¿íèéã (ìåòàëëûí îêñèä, êàðáîí íàíî-òþáà, ôóëëåðåí ã.ì) õàìðóóëäàã [2]. Õàðèí áàéãàëèéí áîëîí ¿éëäâýðëýëèéí ÿâ-öàä ¿¿ññýí çàâñðûí á¿òýýãäýõ¿¿í áîëîõ ãàë

áîëîí ãàãíóóðûí óòàà, í¿¿ðñíèé õºº çýðãèéã ýíý îéëãîëòîä õàìðóóëàõã¿é [3]. Íàíîìàòåðèàë íü ìàø æèæèã õýìæýýòýé (1-100íì) òóë ýñèéí ìåìáðàíààð ÷ºëººòýé íýâòýð÷, ýñýä õóðèìò-ëàãäàõààñ ãàäíà [4], ãàäàðãóóãèéí òàëáàé èõ òýé-ãýýñ áèîõèìèéí óðâàëä èäýâõòýé îðæ, áîäèñûí ñîëèëöîîã àëäàãäóóëñíààð õ¿í áî ëîí áàéãàëü îð÷èíä ñºðºã íºëºº ¿ç¿¿ëæ áîëîõûã ýðäýìòýí ñóäëàà÷èä ¿ã¿éñãýäýãã¿é þì [5]. Áèäíèé àìüäðàëä õàãàñ äàìæóóëàã÷, óñ ø¿¿ã÷, áèî ìýäðýã÷ çýðýã íàíî á¿òýýãäýõ¿¿í ºðãºí õýðýãëýãäýõ áîëñíîîð

Ýìíýëãèéí íàíî-á¿òýýãäýõ¿¿íèé õîðóó ÷àíàðûã

in vitro îð÷èíä ñóäàëñàí ä¿í

Ã.Õóëàí, Á.Õóëàí, Í.Ýíõòóÿà, Ñ.ªíºðñàéõàíÍèéãìèéí ýð¿¿ë ìýíäèéí õ¿ðýýëýí

E-mail: [email protected]

Abstract

Results of toxicity for medical nanomaterialsin vitro

Khulan.G, Khulan.B, Enkhtuya.N, Unursaikhan.SPublic Health Institute


Background

Nano is a key technology to bring accelerated development in science, economy and business in 21st century. Besides lots of advantages contained in nanoproducts, cytotoxic effects on human and environment may occur due to their extreme small size and large surface area and it promotes chemical reaction and activates reactive oxygen species in the cell. In the last few decades, human and environment exposure of nanomaterials have been increasing, but research papers related to nanomaterial toxicity have been poor.

Goal: Determination of nanomaterial toxicity in medical application

Materials and Methods

Totally 21 nanomaterials collected in this study including imported nano-medicines, disinfectant spray, cleaning solution and experimental nanomaterial produced in Mongolia. The particle sizes of nanomaterialswere determined by Cross correlation analysis and X-Ray diffraction analysis, and mutagenicity was determined by Ames test.

Results

The particle sizes of nanomaterials in 5 of 21 were measured at the range of 1 – 100nm and 5 of 21 nanomaterials were determined as mutagenic by Ames test.

Conclusion

Ingredients and production methods can be one of causes of nanomaterial toxicity. Therefore, more specific methods are needed to reveal cytotoxicity of nanomaterials in the future.

Key words: Nanomaterial, nanoparticle, Ames test, Cross correlation analysis, X-Ray Diffraction analysis

Pp. 9-12, Table 1, Figures 2, References 11


íàíîìàòåðèàëä ñà íàì ñàðã¿é ºðòºõ òîõèîëäëûí òîî ñ¿¿ëèéí 10 æèëä ìýäýãäýõ¿éö ºññºí áîë, íàíî òîñ, ýì, áèî áýëäìýëèéã çîðèóäààð ò¿ðõýõ, óóõ áîëîí òàðüæ õýðýãëýñíýýð ò¿¿íä øóóä ºðòºõ çàìûã áàñ íýìýãä¿¿ëæ áàéíà [6]. Íàíî ìàòåðèàëûí õîðóó ÷àíàð, ò¿¿íèé êèíåòèê ¿éë÷ëýëèéã in vivo îð÷èíä ñóäëàõààñ [7] ãàäíà ýñýä ¿éë÷ëýõ ìåõàíèçì [8], òýäãýýðèéí àþóëã¿é áàéäëûí òàëààð öîãö ìýäýý-ëýëòýé áîëîõ çîðèëãîîð in vitro îð÷èíä ñóäàëãàà [9] õèéõ áà ¿íý õÿìä, õóãàöàà áàãà çàðöóóëäãààðàà äàâóó òàëòàé þì.

Çîðèëãî

Ìîíãîë óëñàä èìïîðòëîãäñîí áîëîí òóðøèëòààð ãàðãàí àâñàí ýìíýëãèéí íàíî á¿òýýãäýõ¿¿íèé õîðóó ÷àíàðûã òîäîðõîéëîõ

Çîðèëò:

1. Á¿òýýãäýõ¿¿íèé äýýæèí äýõ íàíî øèðõýãëýãèéí õýìæýýã òîäîðõîéëîõ

2. Íàíî-á¿òýýãäýõ¿¿íèé ýñýä ìóòàöè ¿¿ñãýõ íºëººã èëð¿¿ëýõ

Ìàòåðèàë, àðãà ç¿é

Ñóäàëãààíä íàíî òîäîòãîëòîé èìïîðòûí 7 ýì, àðèóòãàëûí 4, àõóéí öýâýðëýãýýíèé 2 á¿òýýãäýõ¿¿íèé äýýæ, Ìîíãîëä òóðøèëòààð ãàðãàí àâñàí àðèóòãàë áîëîí öýâýðëýãýýíèé 5 äýýæ, áèîëîãèéí íýìýëò 3 á¿òýýãäýõ¿¿í íèéò 21 äýýæèéã õàìðóóëñàí. Íàíî øèðõýãëýëèéí õýìæýýã òîäîðõîéëîõûí òóëä Ðåíòãåí òóÿàíû àíàëèç, Ôîòîíû õºíäëºí êîððåëÿöèéí àðãààð Philips PW1800, NANOPHOX (NX0061) òºõººðºìæ¿¿äýýð õýìæèëò õèéñýí. Ìºí Salmonella Typhimurium TA1537 áàêòåðèéí øòàìûã àøèãëàí Àìåñ òåñòèéí àðãààð íèéò 21 äýýæíä ìóòàöè ¿¿ñãýõ íºëººã èëð¿¿ëñýí.

¯ð ä¿í

Ñóäàëãààíä õàìðóóëñàí íèéò 21 äýýæèéã ôè-çèêèéí òºëºâ áàéäëààð íü 2 àíãèëàí, íóíòàã 10 äýýæèíä Ðåíòãåí òóÿàíû äèôôðàêöèéí àíàëèçûí àðãààð (Çóðàã 1) õýìæèëò õèéõýä á¿õ äýýæèí äýõ íàíî øèðõýãëýãèéí õýìæýý 100íì-ýýñ èõ áàéâ.

Fig. 1 X-Ray Diffraction pattern (XRD) of nano powders

(a) XRD pattern of Em8(695.5nm), (b) XRD pattern of Em10 (301.9nm),

(c) XRD pattern of Em11 (405.1nm), (d) XRD pattern of Em12 (226.6nm),

(e) XRD pattern of Em13 (416.3nm), (f) XRD pattern of Em14 (140.5nm),

(g) XRD pattern of Em15 (182.9nm), (h) XRD pattern of Em3 (120nm),

(i) XRD pattern of Em7 (385.3nm), (j) XRD pattern of Em1 (213.1nm).

Õàðèí øèíãýí 11 äýýæèí äýõ íàíî øèðõýãëýãèéã Ôîòîíû õºíäëºí êîððåëÿöèéí àðãààð õýìæèõýä Ìîíãîëä òóðøèëòààð ãàðãàí àâñàí 1 äýýæ (R.S-2), èìïîðòûí àðèóòãàëûí 3 (DS-1, DS-2, DS-4), àõóéí öýâýðëýãýýíèé 1 äýýæèí äýõ(CS-2) íàíî øèðõýãëýãèéí õýìæýý 100íì-ýýñ áàãà áàéñàí (Õ¿ñíýãò 1).


Table 1.The Nanoparticle size of liquid samples

Nanoproducts

Parameter

Nano silver solution Research Nano disinfectant Nano cleaning

1 2 3 4 5 6 7 8 9 10 11

Ag-1 Ag-2 Ag-3 RS-1 RS-2 DS-1 DS-2 DS-3 DS-4 CS-1 CS-2

X10(nm)

360.5 3343 158.3 89.16 28.15 32.91 46.67 415.2 43.62 90.19 67.09X

16(nm)372.6 3497 163.5 93.21 29.4 34.08 48.7 430.2 45.42 93.87 69.99

X50(nm)

414.8 4024 182.2 107.2 33.87 38.19 55.72 481.3 51.74 106.8 79.97

X84(nm)

461.4 4639 202.9 123.4 38.93 42.93 63.89 539.8 59.09 121.9 91.62X

90(nm)478.3 4852 208.6 129 40.76 44.32 66.58 558.2 61.34 126.4 95.37

X99(nm)

527.2 5617 233.2 149 47.14 49.68 76.19 620.8 69.46 143.2 108.7

SMD (nm)

412.7 3964 181.1 106.2 33.55 37.97 55.26 478.2 51.34 106 79.32

Sv (m2/cm2)

14.54 1.51 33.14 56.51 178.9 158 108.6 12.55 116.9 56.6 75.64

VMD (nm)

417.3 4067 183.1 108.3 34.21 38.45 56.27 484.5 52.21 107.8 80.74

Fig 2. Mutagenic nanoproducts

Ñóäàëãààíä õàìðóóëñàí íèéò 21 äýýæèéí ìóòàöè ¿¿ñãýõ íºëººã Salmonella Typhimurium TA1537 áàêòåðèéí øòàìûã àøèãëàí Àìåñ òåñòèéí àðãààð òîäîðõîéëñîí áºãººä òýæýýëò îð÷èíä óðãàñàí áàêòåðèéí òîî ≥10±1 áîë ýåðýã, áàêòåðèéí òîî ≤10±1 áîë ñºðºã ãýæ ¿íýëñýí (Çóðàã 2).

Ñóäàëãààíû ¿ð ä¿íãýýð ìóòàöè ¿¿ñãýõ íºëººòýé íü òîãòîîãäñîí Ìîíãîëûí 3 äýýæèéí 1 íü 1-100íì õýìæýýòýé, 2 íü 100íì-ýýñ äýýø õýìæýýòýé áàéñàí áîë ¿ëäñýí 18 äýýæ ìóòàöè ¿¿ñãýõ íºëººã¿é áàéâ.

Õýëöýìæ

Áèäíèé ñóäàëãààíä õýðýãëýñýí 21 òºðëèéí ýìíýë-ãèéí íàíî äýýæèéí 1-100íì õýìæýýòýé Ìîíãîëûí 1, 100íì-ýýñ äýýø õýìæýýòýé Ìîíãîëûí 2, íèéò 3 äýýæ ìóòàöè ¿¿ñãýõ íºëººòýé áàéñàí íü íàíî-á¿òýýãäýõ¿¿íèé õîðóó ÷àíàð ãàðãàí àâàõ àðãààñ õàìààðäàã áîëîõûã õàðóóëàõààñ ãàäíà Anda R

Gliga áîëîí Sara Skoglund íàðûí õ¿íèé óóøãèíû ýñýä ìºíãºíèé íàíî øèðõýãëýãèéí ¿ç¿¿ëýõ õîðóó ÷àíàðûã òîäîðõîéëñîí ñóäàëãààíû ¿ð ä¿íãýýð íàíî øèðõýãëýãèéí õîðóó ÷àíàð ò¿¿íèé õýìæýýíýýñ õàìààðäàã [10] áîëîõûã òîãòîîñîí áàéñàí íü áèäíèé ñóäàëãààíû ¿ð ä¿íòýé èæèë áàéíà.

Íàíî øèðõýãëýãèéí õýìæýý áîëîí õîðóó ÷àíàðûã Åâðîïûí õîëáîîíîîñ ãàðãàñàí çºâëºìæèéí äàãóó [11] Ðåíòãåí òóÿàíû àíàëèç, Àìåñ òåñòèéí àðãóóäààð òîäîðõîéëñîí íü áèäíèé ñóäàëãààíû ¿ð ä¿íã áàòàëãààæóóëæ áàéíà [11].

Ä¿ãíýëò

Áèäíèé ýíýõ¿¿ àæèë Ìîíãîë óëñàä õèéãäýæ áàéãàà ñóäàëãààíû ýõëýë áºãººä íàíî-á¿òýýãäýõ¿¿íèé õîðóó ÷àíàð íü ò¿¿íèé íàéðëàãà, ãàðãàí àâàõ àðãà çýðãýýñ õàìààðàõ òóë ò¿¿íèé õîðóó ÷àíàðûã öààøèä èë¿¿ íàðèéâ÷ëàí ñóäàëæ òîãòîîñíû äàðàà õýðýãëýýíä íýâòð¿¿ëýõ øààðäëàãàòàé áîëîõûã õàðóóëæ áàéíà.

Íîì ç¿é

1. Sumit Arora, Jyutika M. Rajwade, Kishore M. Paknikar, Nanotoxicology and in vitro studies: The need of the hour review, Toxicology and Applied Pharmacology 258 (2012) 151–165

2. Hoyt, V.W., Mason, E., 2008. Nanotechnology: emerging health issues. J. Chem. HealthSaf.15, 10–15

3. Andreas M. Nyström a, Bengt Fadeel, Review, Safety assessment of nanomaterials: Implications for nanomedicine, Journal of Controlled Release 161 (2012) 403–408

4. Sara Mostafalou, Hamidreza Mohammadi, Ali Ramazani and Mohammad Abdollahi, Different biokinetics of nanomedicines linking to their


toxicity; an overview, Mostafalou et al. DARU Journal of Pharmaceutical Sciences 2013, 21:14

5. Daniela De Stefano,Rosa Carnuccio andMaria ChiaraMaiuri,Review Article, Nanoproducts Toxicity and Cell DeathModalities, Journal of Drug Delivery Volume 2012, Article ID 167896, 14 pages

6. Oberdorster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J., Ausman, K.,Carter, J., Karn, B., Kreyling, W., Lai, D., Olin, S., Monteiro-Riviere, N., Warheit, D.,Yang, H., 2005a. Principles for characterizing the potential human health effectsfrom exposure to nanoproducts: elements of a screening strategy. Part. FibreToxicol.2, 8–43

7. Lewinski, N., Colvin, V., Drezek, R., 2008. Cytotoxicity of nanoparticles. Small 4, 26–49

8. Nel, A., Xia, T., Madler, L., Li, N., 2006.

Toxic potential of materials at the nanolevel. Science311, 622–627

9. Oberdorster, G., Oberdorster, E., Oberdorster, J., 2005b. Nanotoxicology: an emergingdiscipline evolving from studies of ultrafine particles. Environ. Health Perspect.113, 823–839

10. Anda R Gliga, Sara Skoglund, Inger Odnevall Wallinder, BengtFadeel and Hanna L Karlsson, Size-dependent cytotoxicity of silver nanoparticles in human lung cells: the role of cellular uptake, agglomeration and Ag release, Particle and Fibre Toxicology 2014, 11:11

11. S2 (R1) Genotoxicity testing and Data interpretation for Pharmaceuticals Intended for human use, U.S. Department of Health and Human Services, June 2012

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Àêàäåìè÷ Ë.Ëõàãâà


ÝÌÍÝËÇ¯É

Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä öºñíèé

õ¿¿äèéã äóðàíãààð àâàõ àñóóäàëä

Í.Áààñàíæàâ1,2, Ä.Àëòàíãýðýë2, Ì.Ãàíáààòàð2, Ö.Ëî÷èí2, Ä.Ýðäýíýáîëä2

1“À÷” Àíàãààõ óõààíû äýýä ñóðãóóëü, 2Óëñûí ãóðàâäóãààð òºâ ýìíýëýã, 3Õîâä àéìãèéí ìýñ çàñëûí òàñàã

Laparoscopic cholecystectomy in surgical treatment of

acute cholecystitis

N.Baasanjav1, 2, B.Batbold1, Bastuya1, D.Altangerel2, M.Ganbaatar2, Ts.Lochin2, D.Erdenebold2 J.Gankhuyg3

1”Ach” Medical University, 2State Third Central Hospital, 3Department of Surgery, Khovd aimag

Background

Acute inflamed process in gallbladder stand no more in the list of contraindication for its laparoscopic removal, although specifity of operational technics need to be elaborated in details.

Purpose

The purpose of the study to determine feasibility and specifity of laparoscopic cholecystectomy.

Methods and Materials

Based on standard instructions three holes were punched on the front wall of the abdominal cavity for insertion of fibroscopic instrument, Olympus-2008, Model-Uni 3, input-120/240V, 50/60Hz, 150VA. Patient selection included 108 individuals hospitalized during 2009-2013 in the department of urgent surgery, III Shastin Clinical Hospital.

Results

Average ages of the patients were 38. Clinical diagnosis based on signs and symptoms revealed at the physical examination confirmed by echosonographic investigation for final diagnosis. Specificity of surgical technics were incision and infusion of large amount of antibiotic solution into the inflamed gallbladder at the inoculation; use blunt edge for inoculation of the duct and artery of gallbladder; switching to open surgery in case of revealed massive enzymatic infiltration and adhesive scars.

Conclusion: Laparoscopic cholecystoectomy is feasibility operative procedure having advantages and disadvantages, requiring necessary preventive measures of the complications.

Key words: Laparoscopic cholecystoectomes, surgical treatment

Pp. 13-15, References 7

Îðøèë

Öºñ ÷óëóóæèõ ºâ÷íèé õàìãèéí àþóëòàé õ¿íäðýë íü íîéð áóë÷èðõàéí ¿õæèë, öºñíèé õ¿¿äèéí èäýýëñýí öî÷ìîã ¿ðýâñýë, ìåõàíèê øàðëàëò þì. Ä.Ë.Ïèêîâñêèéí ñóäàëãààãààð öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí øàëòãààíû 90% íü öºñ ÷óëóóæèõ ºâ÷èí þì [1]. Öºñíèé õ¿¿äèéí èäýýëñýí öî÷ìîã ¿ðýâñëèéí ýì÷èëãýýíèé ìýñ çàñëûí òàêòèêèéí áàðàã çóóí æèë ¿ðãýëæèëñýí ìàðãààíû äàðàà ºâ÷èí ýõýëñíýýñ õîéø áàðàã 72 öàãò ìýñ çàñëûí ýì÷èëãýýã õèéõ íü çºâ ãýäýã

íü òîãòîîãäñîí. Òåõíèêèéí äýâøëèéí íºëººãººð ¿¿ññýí ýì÷èëãýýíèé òåõíîëîãèéí õºãæèë íü îëîí òàðõìàë ºâ÷íèé ýì÷èëãýýíèé óëàìæëàëò àðãûã ººð÷èëñºí. Ò¿¿íèé òîäîðõîé æèøýý íü öºñ ÷óëóóæèõ ºâ÷íèé ýì÷èëãýýíä äóðàíãèéí ýì÷èëãýýã õýðýãëýñýí ÿâäàë þì.

Öºñíèé õ¿¿äèéã äóðàíãààð àâàõ àðãûã áîëîâñðîíãóé áîëãîæ äóðàíãèéí òåõíîëîãèéí àíõäàã÷èä òóðøëàãà õóðèìòëóóëàõ ¿å øàòàíä öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñýë íü äóðàíãààð öºñ àâàõ õàãàëãààíû ýñðýã çààëò áîëæ áàéâ [2].


Òóðøëàãà õóðèìòëàãäàí òåõíèê ñàéæèðñíààð öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ýì÷èëãýýíä ÷ äóðàíãààð öºñ àâàõ àðãûã õýðýãëýõ áîëñîí [3].

Ìîíãîë óëñàä àíõíû äóðàíãààð öºñ àâàõ õàãàëãààã Ã.Íÿìõ¿¿, À.Îòãîíäàëàé, Ñ.Íýðã¿é íàð 1994 îíä õèéñýí áàéíà.

Çîðèëãî:

Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä õ¿¿äèéã äóðàíãààð àâàõ àðãûí îíöëîãèéã ñóäëàõ

Çîðèëò:1. Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéã äóðàíãèéí

òóñëàìæòàé àâàõ áîëîìæèéã ñóäëàõ

2. Öºñíèé õ¿¿äèéí àðõàã áà öî÷ìîã ¿ðýâñëèéí ¿åèéí äóðàíãèéí õàãàëãààã õàðüöóóëàí ñóäëàõ

3. Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åèéí äóðàíãèéí õàãàëãààíû îíöëîãèéã òîäîðõîéëîõ

Ìàòåðèàë, àðãàç¿é

2009-2013 îíä ØÓÃÒÝ-èéí ÿàðàëòàé ìýñ çàñëûí òàñàãò ýì÷ëýãäñýí 108 ºâ÷òºíä ñóäàëãàà ÿâóóëàâ. Ýðýãòýé 50, ýìýãòýé 58. Äóíäàæ íàñ 48.

Õàãàëãààã Olympus-2009, Model-Uni-3 input100-240v 50/60 HZ 150 VA ôèðìèéí äóðàíãààð õýâëèéí óðä õàíàíä 3 í¿õ ãàðãàæ îëîí óëñàä õýðýãëýäýã ñòàíäàðòààð ã¿éöýòãýâ.

¯ð ä¿íÖºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñýëòýé ºâ÷òºíèé îíîøëîãîîíû ýìíýëç¿éí øàëãóóð íü áàðóóí õàâèðãàíû íóìàí äîð õ¿÷òýé ºâäºõ, ºâäºëòòýé òîìîðñîí öºñíèé õ¿¿äèé òýìòðýãäýõ, õàëóóðàõ, çàõûí öóñàíä ëåéêîöèò èõýññýí áàéâ. Òºãñãºëèéí îíîøèéã ýõîñîíîãðàôèéí øèíæèëãýýãýýð 100% íîòëîæ áàéâ.

Á¿õ ºâ÷òºíä õàãàëãààíû ¿åä àíòèáèîòèê õýðýã-ëýñýí. Õàãàëãààíû äàðààõ ýõíèé õîíîãèéí òºãñãºëä á¿õ ºâ÷òºí áîñ÷ ºðººí äîòðîî ÿâæ ýõýëñýí. Ýìíýëýãò áàéñàí õóãàöàà 2-5 õîíîã ¿ðãýëæèëæ, äóíäàæààð 3.5 õîíîã áàéâ. Õºäºëìºðèéí ÷àä-âàð àëäàëò ¿ðãýëæèëñýí õóãàöàà 8-10 õîíîã, äóíäàæààð 9 õîíîã áàéâ.

ªâ÷òºí öºñíèé öî÷ìîã ¿ðýâñëèéí øàíàëãàà, ýìíýëç¿éí áà ëàáîðàòîðèéí øèíæ òýìäýãã¿é áàéñàí. 18 (16.6%) ºâ÷òºíä äóðàíãèéí õàãàëãààíû ¿åä öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñýë èëýðñýí.

Á¿õ ºâ÷òºíä ñòàíäàðòûí äàãóó õàãàëãààíû ºìíºõ øèíæèëãýý áà õàãàëãààíû ºìíºõ áýëòãýëèéã õèéñýí. Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ýìíýëç¿éí áà ýõîñîíîãðàôèéí èëò øèíæ èëýðñýí ºâ÷òºí¿¿äýä 24-48 öàãèéí äîòîð àðãà÷ëàëä äóðäñàí àðãààð õàãàëãààã õèéâ. Õàãàëãàà

¿ðãýëæëýõ õóãàöàà 45-65 ìèíóò, äóíäàæ íü 55 ìèíóò áàéëàà. Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä õàãàëãàà õèéõ íü öººí òîõèîëäîëä òåõíèêèéí õ¿íäðýëèéã äàãóóëæ áàéíà. Òóõàéëáàë: Õàâàí, ýäèéí öóñ ãîîæèëò, öºñíèé õ¿¿äèéí áà öºñíèé åðºíõèé ñóâãèéí ãýìòýë, õàëäâàð áàéãàà çýðýã íü õ¿íäðýë áà ò¿¿íèé çýðýã èõñýõ áîëîìæèéã èõýñãýæ áàéíà. Õ¿íäðýëýýñ õàìãààëàõàä ÷èãëýñýí äîîðõ àðãóóäûã õýðýãëýâýë öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä äóðàíãààð öºñ àâàõ íü àþóëã¿é áàéõ áîëîìæòîé áàéíà.

¯¿íä:- Õàãàëãààã öºñíèé õ¿¿äèéí õàòãàëòààð ýõýëæ,

õàëäâàð á¿õèé öºñèéã ãàðãàí öºñíèé õ¿¿äèé ð¿¿ ºðãºí ¿éë÷èëãýýòýé àíòèáèîòèêèéí óóñìàë õèéõ õýðýãòýé.

- Õ¿¿äèéí öîðãî áà õ¿¿äèéí àðòåðèéã ÿëãàõ ¿åä ìîõîî àðãûã õýðýãëýõ íü ç¿éòýé.

- Öºñíèé õ¿¿äèéã ÿëãàõ ¿åä èõýâ÷ëýí ìîõîî àðãûã õýðýãëýæ, öóñ ñàéí òîãòîîõ õýðýãòýé.

- Ýëýã, àðâàí õî¸ð íóãàëàà ãýäýñíèé õîëáîîñûí ýñëýãèéí ¿ðýâñëèéí íýâ÷äýñ, ñîðâèæèëò èõ èëýðñýí ¿åä íýýëòòýé õàãàëãàà ðóó øèëæèõ íü ç¿éòýé.

Ýäãýýð ¿éëäëèéã àìæèëòàé õýðýãëýñíýýð èõýíõ òîõèîëäîëäöºñíèé õ¿¿äèéí ¿ðýâñëèéí ¿åä õ¿íäðýë ãàðãàõã¿éãýýð öºñ àâàõ äóðàíãèéí õàãàëãààã àìæèëòòàé õèéâ.

Õàãàëãààíû ¿åä äîîðõ õ¿íäðýë¿¿ä ãàðñàí áàéíà.- Öºñíèé õ¿¿äèéí àðòåðèéí ñóäàñíààñ öóñ

àëäàõ 1 (0.92%)- Öºñíèé õ¿¿äèé áàéñàí ãàçðààñ öóñ àëäàõ 1

(0.92%)- ßëãàõ ¿åä öºñíèé õ¿¿äèé ãýìòýõ 3(2.7%)

Õàãàëãààíû àðãûã ñîíãîõäîî äàðààõ çàð÷èìûã áàðèìòàëñàí: õàãàëãàà ýõëýýä 30 ìèíóòûí äîòîð Êàëîãèéí ãóðâàëæèíãèéí àíàòîìèéí á¿òöèéã ÿëãàæ ÷àäàõã¿é áîë íýýëòòýé õàãàëãàà ðóó øèëæñýí. Èéì òîõèîëäîë 6 (5.5%) ãàðñàí. ¯¿íèé øàëòãààí íü 1 ºâ÷òºíä öºñíèé àðòåðèàñ öóñ àëäñàí, öºñ áàéñàí ãàçðààñ öóñ àëäñàí òîõèîëäîë 1, ýëýã, àðâàí õî¸ð õóðóó íóãàëààíû õîëáîîñûí ýñëýãèéí ñîðâèæèëò ¿ðýâñëèéí èëýðõèé ººð÷ëºëò 4 ºâ÷òºíä ãàðñàí áàéíà.

Õàãàëãààíû äàðàà ãàðñàí õ¿íäðýë¿¿ä:- Õàãàëãààíû øàðõíû èäýýëýëò 4 (3.7%)- Öºñíèé õ¿¿äèé áàéñàí ãàçðûí ¿ðýâñëèéí

íýâ÷äýñ 1 (0.92%)- Óóøèãíû õàòãàà 1 (0.92%)- Íàñ áàðàëò áàéãààã¿é.


Ä¿ãíýëò:

1. Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä öºñíèé õ¿¿äèéã äóðàíãààð àâàõ áîëîìæòîé íü íîòëîãäîâ.

2. Öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä äóðàíãèéí õàãàëãààã õýðýãëýõ íü íýýëòòýé õàãàëãààíààñ îëîí òàëààð äàâóó òàëòàé, áàñ äóòàãäàëòàé òàëòàé áàéíà.

3. Öºñíèé õ¿¿äèéí àðõàã ¿ðýâñýëòýé õàðü-öóóëàõàä öºñíèé õ¿¿äèéí öî÷ìîã ¿ðýâñëèéí ¿åä õèéõ äóðàíãèéí õàãàëãàà íü èë¿¿ òºâºãòýé, õàãàëãààíû ¿åèéí áà õàãàëãààíû äàðààõ õ¿íäðýë èë¿¿ ãàðäàã òóë äîîðõ íºõöºëèéã çààâàë øààðäàæ áàéíà.

à. Ìýñ çàñàë÷ õàíãàëòòàé òóðøëàãàòàé áàéõ (öºñíèé õ¿¿äèéí àðõàã ¿ðýâñëèéí ¿åä 80-100 äóðàíãèéí õàãàëãàà õèéñýí áàéõ)

á. Õ¿íäðýëýýñ ñýðãèéëýõýä ÷èãëýñýí àðãà, ä¿ðìèéã õàòóó ìºðäºõ.

Íîì ç¿é

1. Ïèêîâñêèé Ä.Ë. Îñòðûé õîëåöèñòèò 2012

2. Cushiery A. Laparoscopic biliary surgery, lackwell med. Publications. London, 1990

3. Zucker K. Surgical laparoscopy up-date. Quality med. Publishers. St.Louis, 1993

4. Áîáîåâ Á.Ä. Ðåçóëüòàòû îäíîìîìåíòíîãî ëàïàðîñêîïè÷åñêîãîëå÷åíèÿ áîëüíûõ õîëåöèñòîõîëåäîõîëèòèàçîì // Àííàëû õèðóðãè÷åñêîé ãåïàòîëîãèè. -2014. -17(4). -80-85.24. Êàëèíè÷åíêî À.À, Êëèïà÷ Ñ.Ã, Áóáëåéíèê À.À.

5. Îïûò âûïîëíåíèÿ îäíîïîðòîâûõ ëàïàðîñ-êîïè÷åñêèõ õîëåöèñòýêòîìèé. // Àëüìàíàõ Èíñòèòóòà õèðóðãèè èì. À.Â.Âèøíåâñêîãî, №1 2014 ãîä, ñòð. 43.

6. Êàëèíè÷åíêî À.À, À.Ã.Ìóðàõîâñêèé, Êëè ïà÷ Ñ.Ã., Áóáëåéíèê À.À.Îäíî ïîð òîâàÿ ëàïàðîñêîïè÷åñêàÿ õîëåöèñ-òýêòî ìèÿ â óñëîâèÿõ îò äåëåíèÿ íå îòëîæíîé õè ðóðãèè // Ñîâðåìåííûå òåõíîëîãèè â õè ðóð ãèè»: Ñáîðíèê íàó÷íûõ òðóäîâ ìåæðåãèîíàëüíîé íàó÷íî-ïðàêòè÷åñêîé êîíôåðåíöèè, ïîñâÿùåííîé 90-ëåòèþ êàôåäðû ãîñïèòàëüíîé õèðóðãèè, ñ. 136, Îìñê 2013

7. Trerotola S.O., Savader S.J., Lund G.B. et al. Biliary tract complications following laparoscopic cholecystectomy: imaging and intervention//Radiology. – 2014. – Vol. 184. – P. 195 – 200.

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð

Î.Ñýðãýëýí


Á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýýíèé áýëòãýëä áóðãóéäàõ áîëîí óóñìàë óóõ àðãûí õàðüöóóëñàí ñóäàëãàà

Í.Áîðõ¿¿, Ò.Öýíäñ¿ðýíÓëñûí õî¸ðäóãààð òºâ ýìíýëýã


Abstract

Prospective, randomized trial comparing a salt laxative solution with use water enema for colonoscopy preparation

N.Borkhuu, T.TsendsurenState Second Central Hospital

IntroductionColonoscopy is the current standard method for evaluation of the colon. Diagnostic accuracy and therapeutic safety of colonoscopy depends on the quality of the colonic cleansing or preparation.The preparation also would not cause any patient discomfort and would be inexpensive.

GoalTo compare two bowel preparation regimens for colonoscopy in terms of result of preparation.

Materials and MethodsA total 100 patients underwent colonoscopy were randomized to two bowel preparation regimens: A salt laxative solution (n=50) oruse water enema (n=50). In group A, patients were consuming up to 5 L of salt laxative solution at 8:00 an examination.Second groupB, patient received 6-9 L water enema the evening before the colonoscopy, and the morning of the examination. Associated with the bowel preparation such as duration of examination, used volume of fluid, quality of bowel preparation was good (availability detection of polyps greater than 5 mm), poor (inadequate cleansing).

Data were entered into computer database using SPSS 20.0. The one simple test was used for analysis of categorical and ordinal variables. A Ð value of less than 0.05 was considered statistically significant.

Results Using oral salt laxatives andwater enema preparation were decreased duration of examination, patient satisfaction, successful cleaning of colon mucosa for both diasnostic and treatment procedure, decreased time for patient preparation.

Conclusion This randomized trial, salt laxative solution achieved better bowel preparation for colonoscopy than water enema.

Key words: Laxative, enema, bowel preparation, colonoscopy

Pp.16-20, Tables 5, Figures 2, References 11

Îðøèë

1969 îíä Shinya, Wolff íàð á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýý (ÁÃÄØ) õèéñýí òóõàé òýìäýãëýñíýýñ õîéø á¿ä¿¿í ãýäýñíèé ýìãýãèéí îíîøëîãîî, ýì÷èëãýýíä øèíý ýðèí ¿å íýýãäýæ á¿ä¿¿í ãýäýñíèé õàâäðûí îíîøëîãîî áîëîí óðüä÷èëàí ñýðãèéëýëòýä äóðàíãèéí øèíæèëãýý “Àëòàí ñòàíäàðò” áîëæ ÷àäñàí áèëýý [1-3].

ÁÃÄØ íü øèíæë¿¿ëýã÷äýä õ¿íäðýë áàãàòàé, õóðäàí àìàð õÿëáàð áàéõ íü òîõèðîìæòîé [4] áà ¿¿íèéã äàãààä ÁÃÄØ-íèé áýëòãýë íü ÿìàð ÷

ºâ÷òºíä áýðõøýýëòýé áóñ, ¿ð ä¿íòýé, àþóëã¿é áàéõ øààðäëàãàòàé. Õàðàìñàëòàé íü îäîîãèéí áàéäëààð ÁÃÄØ-íèé áýëòãýëèéí àëü ÷ àðãà íü äýýðõ øààðäëàãûã õàíãàæ ÷àääàãã¿é áàéíà [5-6]. Õÿòàä, Îðîñ, Ãåðìàí, Èõ Áðèòàíè, ÀÍÓ, ßïîí çýðýã ºíäºð õºãæèëòýé îðíóóäàä äàâñàí òóóëãà áóþó ïîëèýòèëåí ãëèêîýëåêòðîëèò óóñìàë [7-8], NaCl, NaHCO3, KCl–í äàâñàí òóóëãà [8-9] çýðãèéã ãîëëîí õýðýãëýæ á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèë ãýýíèé áýëòãýë õèéäýã áàéíà.

Õàðèí Ìîíãîë óëñàä äýýðõ ýðäýñò óóñìàëóóä


íü ýìèéí á¿ðòãýëä äºíãºæ îðæ áàéãàà áºãººä òºäèéëºí ºðãºí õýðýãëýæ äàäààã¿é øàëòãààíààð õýðýãëýãäýõã¿é áàéãàà áà óëàìæëàëò áóðãóéãààð ãýäýñ öýâýðëýõ àðãà ò¿ãýýìýë õýâýýð áàéíà.

Ñ¿¿ëèéí æèë¿¿äýä á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýý õèéëãýõ òîõèîëäîë íýìýãäñýýð áàéãàà áºãººä ¿¿íòýé õàìò øèíæèëãýýíèé øààðäëàãàä íèéöñýí áýëòãýëèéí àðãûã õýðýãëýæ ïðàêòèêò íýâòð¿¿ëæ äóðàíãèéí øèíæèëãýýã ã¿éöýä ÷àíàðòàé õèéõ øààðäëàãà òóëãàð÷ áàéíà.

Èéìýýñ áèä îëîí óëñàä ºðãºí õýðýãëýãääýã àðãàä ¿íäýñëýí Ìîíãîë õ¿íèé îíöëîãò òîõèðñîí äàâñíû õîëèìîã óóñìàëûã á¿ä¿¿í ãýäýñíèé äóðàíãèéí áýëòãýëä õýðýãëýí, áóðãóéäàõ àðãàòàé õàðüöóóëàí ñóäëàõ çîðèëãûã àæëûí ãîë ¿íäýñëýë áîëãîëîî.

Õýðýãëýãäýõ¿¿í, àðãàç¿é

2012-2014 îíä ÓÕÒÝ-èéí óÿí äóðàíãèéí êàáè-íåòàä á¿ä¿¿í ãýäýñ äóðàíäóóëàõ çààëòòàé èðñýí õàðüöàíãóé ýð¿¿ë áîëîâ÷ îíîøëîãîî õèéëãýõ øààðäëàãàòàé íàñàíä õ¿ðñýí 101 ¿éë÷ë¿¿ëýã÷äýýñ ñàíàìñàðã¿é ñîíãîëòîîð ãýäýñ öýâýðëýõ óóñìàë õýðýãëýõ (Á¿ëýã A) 50, áóðãóéãààð öýâýðëýõ àðãààð áýëä¿¿ëýõ (Á¿ëýã B) 50 òîõèîëäëûã ñîíãîí õàðüöóóëñàí,ýìíýë ç¿éí ñóäàëãàà ÿâóóëàâ.

À Á¿ëãèéí ¿éë÷ë¿¿ëýã÷äýä òàíèóëñàí çºâ øºº ðºë õèéæ, øèíæèëãýýíèé ºãëºº íýã ëèòð óñàíä NaCl2- 6.5 ãð, KCl-0.75 ãð, NaHCO3-2.5 ãð õýìæýýòýé óðüä÷èëàí áýëòãýñýí õóóðàé äàâñíû õîëèìãèéã 4-5 ëèòð óñàíä íàéðóóëàí, ºëºí ¿åä 5-10 ìèíóòûí çàéòàé óóëãàæ áýëòãýë õèéñýí.

Â á¿ëãèéí ¿éë÷ë¿¿ëýã÷äýä òàíèóëñàí çºâ øººðºë àâ÷, øèíæèëãýýíýýñ õî¸ð õîíîãèéí ºìíººñ õîîëûã íü õÿçãààðëàí, øèíæèëãýýíýýñ íýã õîíîãèéí ºìíººñ 1.5-2 ëèòð óñààð øèíæèëãýý õèéõ õ¿ðòýë 5-6 óäàà øóëóóí ãýäñýýð áóðãóéäàæ á¿ä¿¿í ãýäñèéã öýâýðëýñýí. Áýëòãýñýí ¿ð ä¿íã ¿éë÷ë¿¿ëýã÷èéí øèíæèëãýýíèé áýëòãýëä õýðýãëýãäñýí òóóëãûí õýìæýý ëèòðýýð òîîöîõ, øèíæèëãýýíèé ¿ðãýëæèëñýí õóãàöààã øèíæèëãýý ýõýëñíýýñ ìóõàð ãýäýñ õ¿ðòýë äóðàíäñàí õóãà öààãààð òîîöîõ, ãýäýñíèé ñàëñò õýðõýí öýâýðëýãäñýí ¿ç¿¿ëýëòèéã ñàéí áîë 0.5 ìì õýìæýýòýé óðãàöàã õàðàãäàõ áîëîìæòîé, ìóó áîë ñàëñò øèíæëýõ áîëîìæã¿é ºòãºíèé àãóóëàìæòàé áàéõ ãýñýí øàëãóóðààð ¿íýëýí öóãëóóëñàí ìýäýýëýëä ä¿í øèíæèëãýý õèéæ ñòàòèñòèê áîëîâñ ðóóëàëòûã SPSS 20.0 ïðîãðàììààð õèéâ.

¨ñ ç¿é

ÝÌØÓÈÑ-èéí Àíàãààõ Óõààíû ¨ñ Ç¿éí Õÿíàëòûí ñàëáàð õîðîîíû 2013.10.25 ºäðèéí 13-01/1À òîîò õóðëûí øèéäâýðýýð ñóäàëãàà ÿâóóëàõ çºâøººðºë àâñàí. Ãýäýñ öýâýðëýõ óóñìàëûã ÝÌß-íû Õ¿íèé ýìèéí õîðîîíû 2013 îíû 7 äóãààð ñàðûí 02-íû õóðëààñ ãàðñàí çºâøººðëèéí äàãóó ñóäàëãààíä õýðýãëýñýí áîëíî.

¯ð ä¿í

Ñóäàëãààíä 19-87 íàñíû íèéò 100 ¿éë÷ë¿¿ëýã÷ õàìðàãäëàà (Table 1).

Ñóäàëãààíä õàìðàãäñäûí íàñ, æèíãèéí ¿ç¿¿ëýëò

Table 1. Age and weight data of the study population

N Lower Upper Mean Std. Deviation

Age (year) 100 19 87 52.42 15.104

Weight(kg) 100 45 97 65.68 13.041

Õ¿ñíýãò 1-ýýñ õàðàõàä ºíäºð íàñòàé õ¿í õàìðàãäñàí áàéãàà íü øèíæèëãýý õèéëãýõ õýðýãöýý èõ áàéæ áîëîõûã õàðóóëæ áàéíà.¯¿íýýñ ýìýãòýé 57, ýðýãòýé 43 áàéëàà (Table 2).

Table 2. Gender data of the study population

N Percent Valid Percent Cumulative Percent

Validmale 43 43.0 43.0 43.0female 57 57.0 57.0 100.0total 100 100.0 100.0

Õ¿ñíýãò 2-îîñ õàðàõàä áèäíèé ñóäàëãààíä õàìðàãäàãñàä õ¿éñèéí ÿëãàà áàðàã ¿ã¿é áàéíà.


Table 3. Data of the group A consumed salt laxative solution for colonoscopy preparation


Examination duration (Minute) 50 5.0 36.0 11.68 6.41Used volume of fluid (liter) 50 3.0 5.0 3.70 .646Quality of bowel preparation (good-1, poor -2) 50 1.0 2.0 1.08 .274

Õ¿ñíýãò 3-ààñ ¿çýõýä óóñìàë óóæ áýëòãýõ ¿åèéí äóðàí øèíæèëãýý õàìãèéí áàãà íü 5 ìèíóò, õàìãèéí èõ íü 36 ìèíóò ¿ðãýëæèëñýí áàéíà. Äóðàíãèéí øèíæèëãýýíèé áýëòãýëä äóíäæààð 3.7 ëèòð óóñìàë õýðýãëýãäñýí áàéëàà.

Table 4. Data of group B prepared by enema for colonoscopy


Examination duration (Minute) 50 15.0 80.0 52.26 14.07242Used volume of fluid (liter) 50 6.0 9.0 7.48 .88617Quality of bowel preparation (good-1, poor -2) 50 1.0 2. 1.82 .38809

Õ¿ñíýãò 4-ººñ ¿çýõýä áóðãóéäàæ áýëòãýõ ¿åèéí äóðàí øèíæèëãýý õàìãèéí áàãà íü 15 ìèíóò, õàìãèéí èõ íü 80 ìèíóò ¿ðãýëæèëñýí áàéíà. Äóðàíãèéí øèíæèëãýýíèé áýëòãýëä äóíäæààð 7.48 ëèòð óñ õýðýãëýãäñýí áàéëàà.

Table 5. Comparison of timing of the examination group À and group B

Comparison of Timing of the examination t N Sig. (2-tailed)

Mean 95% Confidence Interval of the Difference

Lower Upper

Timing of the examination group À 12.88 50 .000 11.680 9.86 13.50

Timing of the examination group B 26.25 50 .000 52.260 48.26 56.26

Group A: use salt laxative solutionfor colonoscopy preparation, group B: use enema for colonoscopy preparation

Õ¿ñíýãò 5-ààñ ¿çýõýä óóñìàë óóæ áýëòãýõ ¿åèéí øèíæèëãýýíèé äóíäàæ õóãàöàà 11.68 ìèíóò áóþó áóðãóéí àðãààð áýëòãýñýí ¿åèéí øèíæèëãýýíèé õóãàöààíààñ (52.26 ìèíóò) áàãà áàéãàà íü ñòàòèñòèê ¿íýí ìàãàäòàé ¿ð ä¿í þì. Øèíæèëãýýíèé áýëòãýëä çàðöóóëàãäñàí øèíãýíèé õýìæýýã õàðüöóóëàí ¿çýõýä óóñìàë óóæ áýëòãýñýí ¿åèéí óóñàí øèíãýíèé õýìæýý õàìãèéí áàãàäàà 3 ëèòð óóõàä ãýäýñ ñàéí öýâýðëýãäýæ øèíæèëãýý õèéãäñýí áîë áóðãóéí àðãààð áýëòãýñýí ¿åèéí çàðöóóëàãäñàí øèíãýíèé õýìæýý áóðãóéäàõàä õàìãèéí áàãàäàà 6 ëèòð (P= 0.001) áàéëàà (Figure 1).

Figure 1.Comparison of use fluid for colonoscopy preparation

3

65

9

use enema

Lower liter Upper liter

Used fluid volume for colonoscopy preparation


Ãýäýñíèé ñàëñòûí áàéäàë õàíãàëòòàé öýâýðëýãäñýí áàéäëûã ¿íýëýõýä óóñìàë óóæ áýëòãýõ ¿åä 46 (92%) òîõèîëäîë íü ñàéí öýâýðëýãäñýí áàéñàí áîë áóðãóéí àðãààð áýëòãýñýí òîõèîëäëûí 9 (18%) íü ñàéí öýâýðëýãäñýí ¿ç¿¿ëýëò ãàðñàí áàéíà (Figure 2).

Figure 2. Comparison of quality of preparation

Õýëöýìæ

Áèäíèé ñóäàëãààíû ¿ð ä¿í íü á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýýíèé áýëòãýëä óóñìàë óóõ àðãààð ãýäñèéã öýâýðëýõ íü áóðãóéí àðãààð öýâýðëýõýýñ øèíæèëãýýíèé õóãàöàà áàãà çàðöóó-ëàãä äàã (õàìãèéí áàãà õóãàöàà 5 ìèíóò áîë áóð-ãóé äàõ áýëòãýëèéí õóâüä 15 ìèíóò) àìàð õÿëáàð (äóíäæààð 3.7 ëèòð óóñìàë óóõ, áóðãóé àðãààð 7.48 ëèòð øèíãýí õýðýãëýõ) áàéãàà íü øèíæèëãýýíèé øààðäëàãàä íèéöñýí ãýäýñ öýâýðëýõ àðãà áîëæ áîëîõ þì ãýæ ¿çýõ áîëîìæ ãàð÷ áàéíà.

2014 îíä ÀÍÓ-ûí ãàñòðîýíòåðîëîãèéí òºâèéí ñóäàëãààíààñ ãàðñàí óäèðäàìæààð 0.5 ñì õýìæýý-òýé óðãàöàã õàðàãäàõ áîëîìæòîé ñàëñòûí áàéäëûã õàíãàëòòàé öýâýðëýãäñýí ãýæ ¿çíý ãýñýí áàéíà [10]. Áèäíèé ñóäàëãààãààð äýýðõ óäèðäàìæèéí äàãóó ¿íýëæ ¿çýõýä óðãàöàã õàðàãäàõ íü óóñìàë óóæ öýâýðëýãäñýí òîõèîëäîëä õàíãàëòòàé ñàéí áàéñàí áºãººä á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýýíèé ÿâöàä øààðäëàãàòàé ýì÷èëãýý, ìýñ àæèëáàð, õàãàëãàà õèéõ íºõöºëèéã äýýðõ áýëòãýëèéí àðãà íü á¿ðä¿¿ëñýí áàéâ. Ýíý íü Ãåðìàíû ñóäëàà÷ Æ.Æ.Ãîíâåðñ, Ô.Ôðîíõëèù íàðûí 2005 îíä õèéñýí ñóäàëãààãààð ïîëèïýêòîìè õèéñýí òîî ãýäýñ ñàéí áýëòãýãäñýí ¿åä èõýññýí áàéâ [11] ãýñýí ä¿ãíýëòòýé òîõèð÷ áàéíà.

Ñóäàëãààíû ¿ð ä¿íãýýñ á¿ä¿¿í ãýäýñíèé äóðàíãèéí øèíæèëãýýíä óóñìàë óóëãàæ ãýäýñ öýâýðëýí øèíæèëãýýíä áýëòãýõ íü îäîî ¿åä ïðàêòèê à÷ õîëáîãäîë ºíäºðòýé áîëîõ íü õàðàãäàæ áàéãàà áîëîâ÷ öààøèä á¿ä¿¿í ãýäýñíèé äóðàíãèéí áýëò -ãýëèéã óëàì ñàéí áîëãîõ àðãà, óóõ øèíãýíèé õýì -æýýã áàãàñãàõ ãýõ ìýò àñóóäëûã ñóäëàõ øààðä-ëàãàòàé þì.

Ä¿ãíýëò:

Ãýäýñ öýâýðëýõ óóñìàëûã á¿ä¿¿í ãýäýñíèé äóðàí-ãèéí áýëòãýëä õýðýãëýõýä øèíæèëãýýíèé õóãàöàà õýìíýñýí, ¿éë÷ë¿¿ëýã÷èéí áèåä ¿¿ñýõ øèíãýíèé à÷ààëàë áàãàññàí, á¿ä¿¿í ãýäýñ õàíãàëòòàé ñàéí öýâýðëýãäýõ áîëîìæòîé ¿ç¿¿ëýëò íü ñòàòèñòèê ¿íýí ìàãàäëàëòàé áàéâ (p<0.05).

Íîì ç¿é

1. Wolf WI, Shinya H. Fibrocolonoscopy. JAMA 1971; 30: 252-9

2. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansal H, Waye JD. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Eng J Med 2000; 3042: 1766-72

3. U.S. Preventive Task Force. Screening for colorectal cancer: U.S. Preventive Task Force recommendation statement. Ann Inter Med 2008; 149:1-44

4. Â.È.Ìàñëîâ, Íàðìàíäàõ Á, Íàðàíöýöýã Á, Ãàí-Îðøèõ Ë. Õîäîîä ãýäýñíèé ýíäîñêîïè.ÓÁ õîò;2010.õ.208-209.

5. DiPalma JA, Brady CE. Colon cleansing for diagnostic and surgicalprocedures: polyethylene glycol-electrolyte lavage solution. Am JGastroenterol 1989;84:1008-16.

6. Tooson JD, Gates LK Jr. Bowel preparation before colonoscopy. Choosing the best lavage regimen. Postr grad Med 1996;100:203-14.

7. U.S. Preventive Task Force. Screening for colorectal cancer: U.S. Preventive Task Force recommendation statement. Ann Inter Med 2008; 149:1-44.

46

9 4

41

use enema

good poor

Quality of preparation


8. Áàòòóëãà À. Õîîë áîëîâñðóóëàõ áà àìüñãàëûí ýðõòíèé äóðàíãèéí øèíæèëãýýíèé óäèðäàìæ.Àíõäóãààð õýâëýë ÓÁ õîò; 2006. õ.48-50.

9. Meinhard Glassen, Guida NJ Tytgat, Charles J Lithdale. Gastroenterological Endoscopy. Second edition; 2010. p.133-149.

10. David A. Johnson, Alan N. Barkun. Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Forceon Colorectal Cancer. Gastroenterology 2014;147:903–924

11. Froehlich F, Wietlisbach V. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastroin test Endosc. 2005;61:378–384.

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Àíàãààõ óõààíû äîêòîð, ïðîôåññîð Ã.×îéæàìö


Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöààíû ñóäàëãàà

Ã.Ñàðàíöýöýã1, Ñ.Ò¿âøèíãýðýë2

1Äîðíîä àéìàã äàõü ÁÎÝÒºâ2Õàâäàð ñóäëàëûí ¿íäýñíèé òºâ

[email protected]/

Abstracts

Study on survival time of breast cancer patients

G.Sarantsetseg1, S.Tuvshingerel21Dornod Medical Center2National Cancer [email protected]/

Introduction

Breast cancer is one of the most common cancers in the world. According to the WHO report, over 14.1 million new cases were registered every year. 6% of all cancers of Mongolian women were indicated as a breast cancer. This is the 2.5% of cancer cases of whole Mongolian population.

Goal

Identify observed 5 year survival rate and mean of survived time of patients with breast cancers in Mongolian population, and some risk factors of survival.


The study design was retrospective and a total of 195 patients were selected which are registered by breast cancer in National Cancer Registry of Mongolia, 2007-2008 years. Average of survival time calculated by median and mean, observed 1, 3, 5 year survival rate calculated by percent. Data analyses were performed using SPSS 19.0 software.

Result

Totally 195 people involved in research, 5 year after diagnosed 59 (30.3%) people died from cancer, 136 (69.7%) people was alive.

Breast cancer patients observed 1, 3, 5 year survival rate was correlated to age group, level of education, stage of diagnosis and get involved cancer treatment.

Breast (Wald (3) =26.30, P<0.0001) cancer patients survival was correlated to stage of diagnosis and get involved cancer treatment.

Conclusion:

1. Mean of survived time of patients with breast cancer was 50.4 months and observed 5 year survival rate 69.7%.

2. Breast cancer patient’s survival was correlated to age group and level of education.

3. Breast cancer patient’s survival was correlated to stage of diagnosis and get involved cancer treatment.



¯íäýñëýë

ÄÝÌÁ-ûí 2012 îíû ìýäýýãýýð æèë òóòàìä 14.1 ñàÿ õîðò õàâäðûí øèíý òîõèîëäîë á¿ðòãýãäýæ, 8.2 ñàÿ õ¿í õîðò õàâäðûí óëìààñ íàñ áàðæ áàéíà.

XX çóóíû ñ¿¿ë÷ýýñ äýëõèéí óëñ îðíóóäàä õºõíèé ºìºíãèéí ºâ÷ëºë íýìýãäýæ, 2008 îíîîñ õîéø õºõíèé ºìºíãèéí ºâ÷ëºë 20 õóâü, íàñ áàðàëò 14 õóâèàð ºññºí áàéíà. ÄÝÌÁ-ûí ìýäýýëñíýýð æèëäýý 1.7 ñàÿ õºõíèé ºìºíãèéí ºâ÷ëºë á¿ðòãýãäýæ, 522 000 ýìýãòýé õºõíèé ºìºíãèéí óëìààñ íàñ áàðæ áàéãàà áà îíîøëîãäñîíîîñ õîéø 6.3 ñàÿ ýìýãòýé ýõíèé 5 æèëäýý àìüäàð÷ áàéíà. 2014 îíû áàéäëààð ýìýãòýé÷¿¿äèéí íàñ áàðàëòûí 1 ä¿ãýýðò õºõíèé ºìºíãèéí íàñ áàðàëò îðæ áàéíà.1

Ìàíàé óëñàä õºõíèé ºìºí íèéò õîðò õàâäðûí òîõèîëäëûí 6 äóãààðò, ýìýãòýé õ¿éñýíä ýëýã, óìàéí õ¿ç¿¿, õîäîîä, óëààí õîîëîéí ºìºíãèéí äàðàà 5 äóãààðò òîõèîëäîæ áàéíà.

ÕÑ¯Ò-èéí ìýäýýãýýð ýìýãòýé õ¿éñýíä òîõèîëäîõ õîðò õàâäðûí ºâ÷ëºëä õºõíèé ºìºíãèéí ýçëýõ õóâü 2000-2004 îíû äóíäæààð 2.04 õóâü, 2006-2010 îíû äóíäæààð 4.9 õóâü áàéñàí áîë 2008-2012 îíû äóíäæààð 6 õóâü áîëæ ºññºí áàéíà. Õºõíèé ºìºíãèéí íàñ áàðàëò ýìýãòýé õ¿éñýíä 3 õóâèéã ýçëýõ áºãººä íàñ áàðàëòûí ñòàíäàðò÷èëñàí ò¿âøèí íèéò õ¿í àìä 1.6, ýìýãòýé õ¿éñýíä 3.3 áàéíà [1].

Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöààã ñóäàëñàíààð öààøèä õºõíèé ºìºíãèéí ¿åä ¿ç¿¿ëýõ òóñëàìæèéã íîòîëãîîíä òóëãóóðëàí õºãæ¿¿ëýõ, êëèíèêèéí òóðøèëò ñóäàëãààíû ¿ð ä¿íã õÿíàõ, îäîîãèéí ¿ç¿¿ëæ áóé õàâäðûí òóñëàìæ ¿éë÷èëãýýã ¿íýëýõ, ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäðàõ õóãàöààã óðòàñãàõ ñóóðü ìýäýýëýë á¿ðä¿¿ëýõ, íºãºº òàëààð õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöààã ñóäàëñàí õ¿í àìä ñóóðèëñàí ñóäàëãààíû àæèë õîâîð çýðýã íü ýíýõ¿¿ ñóäàëãààã õèéõ ¿íäýñëýë áîëñîí þì.

Çîðèëãî

Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöààã òîîöîõ, ò¿¿íä íºëººëæ áóé çàðèì õ¿÷èí ç¿éëñèéã ñóäëàõ

Çîðèëò:

1. Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöààã ñóäëàõ

2. Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷

áàéãàà õóãàöààã íàñíû á¿ëýã, áîëîâñðîëûí ò¿âøèíãýýð õàðüöóóëàí ãàðãàõ

3. ªâ÷òºíèé íàñíû á¿ëýã, õîðò õàâäðûí ¿å øàò, ýì÷èëãýýíèé òºðëèéã àìüäàð÷ áàéãàà õóãàöààòàé óÿëäóóëàí ñóäëàõ

Ìàòåðèàë, àðãàç¿é

Áàðèìò ò¿øèãëýí ýðãýìæ ÷èãëýë á¿õèé Êîãîðò çàãâàðààð ñóäëàâ. 2007, 2008 îíóóäàä Õºõíèé ºìºíãººð ºâ÷èëñºí íèéò 204 õ¿í á¿ðòãýãäñýí áîëîâ÷ òóõàéí õàðúÿà àéìàã, ä¿¿ðãèéí Õàâäàð ñóäëàëûí êàáèíåòûí “Õîðò õàâäðûí õÿíàëòûí áààç”-ä áàéõã¿é, Óëñûí èðãýíèé á¿ðòãýëýýñ õàñàãäààã¿é àìüä, íàñ áàðñàí ýñýõ íü òîäîðõîéã¿é 2 õ¿í, Ìîíãîë óëñûí èðãýíøèëýýñ õàñàãäñàí 1 õ¿í, íàñ áàðàëòûí îãíîîãîîð á¿ðòãýãäñýí 6 õ¿í, íèéò 9 õ¿íèéã õàñàæ òîîöîí, ýíýõ¿¿ ñóäàëãààíä 195 õ¿íèéã õàìðóóëàâ.

Ñóäàëãààíû ìýäýýã îðóóëàõ, øèíæèëãýý õèéõäýý SPSS-19.0 ïðîãðàìì àøèãëàâ [1]. Àìüäàð÷ áàéãàà õóãàöààã mean-ààð, 95% èòãýõ èíòåðâàëûí ñòàíäàðò àëäààíû äóíäàæòàé õàìò Kaplan-Meier-ûí àðãààð, àæèãëàëòûí 1, 3, 5 æèë àìüäàðñàí õóâèéã Actuarial life-table àðãààð, àìüäàð÷ áàéãàà õóãàöààíä íºëººëºõ ýðñäýëò õ¿÷èí ç¿éëèéã Cox regression àðãóóäààð òîîöñîí áîëíî [1, 2].

¯ð ä¿í, õýëöýìæÑóäàëãààíä õàìðàãäñàí íèéò 195 ºâ÷òºíººñ îíîøëîãäñîíîîñ õîéø 5 æèëèéí äàðàà 136 õ¿í áóþó íèéò õàìðàãäàãñäûí 69.7% íü àìüä, 59 õ¿í áóþó íèéò õàìðàãäàã÷äûí 30.3% íü íàñ áàðñàí (Çóðàã 1) áà íàñ áàðñàí õ¿ì¿¿ñèéí àìüäàðñàí äóíäàæ õóãàöàà 6 ñàð áàéíà. Íèéò ñóäàëãààíä õàìðàãäàã÷äûí àìüäàð÷ áàéãàà õóãàöàà mean-ààð 50.4 ñàð, ñòàíäàðò õýëáýëçýë 1.3 áàéâ.

Àæèãëàëòûí 1, 3, 5 æèë àìüäàð÷ áàéãàà õóâèéã 2-ð çóðãààð ¿ç¿¿ëáýë 1 æèë àìüäàðñàí õóâü 87%±0.2, 3 æèë àìüäàðñàí õóâü 72%±0.3, 5 æèë àìüäàðñàí õóâü 69%±0.3 áàéíà.

Àæèãëàëòûí 1, 3, 5 æèë àìüäàðñàí õóâü íü íàñíû á¿ëýã, áîëîâñðîëûí ò¿âøèí, õîðò õàâäðûí ¿å øàò, õèéãäñýí ýì÷èëãýýíèé òºðºë òóñ á¿ðýýñ õàìààðàí ÿëãààòàé áàéãààã 1-ð õ¿ñíýãòýýð ¿ç¿¿ëýâ.

Àìüäàð÷ áàéãàà õóãàöàà íàñíû á¿ëã¿¿äèéí õîîðîíä ÿëãààòàé áàéñàí áºãººä 60< íàñíû ýìýãòýé÷¿¿äýä íàñ áàðàëò ýëáýã, 0-29 íàñíû ýìýãòýé÷¿¿äèéí äóíä õàìãèéí áàãà òîõèîëäîæ áàéíà. Àæèãëàëòûí 5 æèëä àìüäàðñàí õóâü 0-29 íàñàíä 100 õóâü, 30-39 íàñàíä 57.1 õóâü, 40-

1 http://www.ncri.ie/tags/globocan ¿çñýí, 2014.8.152 “Õîðò õàâäðûí ¿ç¿¿ëýëò¿¿ä 2006-1010 îí” òàéëàí, ÕÑ¯Ò, ÓÁ, 2012 3 ×èìãýý Ä., “SPSS õýðýãëýã÷èéí ãàðûí àâëàãà”, ÓÁ., 2008 4 ×èìãýý Ä., “SPSS ñòàòèñòèêèéí øèíæèëãýýíèé ¿ð ä¿íã òàéëáàðëàõ íü”, ÓÁ., 20105 Chan Y H., Singapore Medical Association, “Biostatistics 203. Survival analysis” basic statistics for doctors, Singapore, 2004


49 íàñàíä 74 õóâü, 50-59 íàñàíä 75.8 õóâü, 60< íàñàíä 53.6 õóâü áóþó íàñíààñ õàìààðàí ÿëãààòàé áàéâ (p<0.033).

Figure 1. Survived rate of patients with breast cancer observed 1, 3, 5 year

Figure 2. Survived rate of patients with breast cancer 5 year after

Àìüäàð÷ áàéãàà õóãàöààã áîëîâñðîëûí ò¿âøèíãýýð íü àâ÷ ¿çýõýä äýýä áîëîâñðîëòîé ýìýãòýé÷¿¿äýä mean-ààð 52.4 ñàð áóþó õàìãèéí óðò, ìýðãýæëèéí áîëîâñðîëòîéä 51.4 ñàð, äóíä áîëîâñðîëòîéä 50.4 ñàð, áàãà áîëîâñðîëòîéä 41.8 ñàð, áîëîâñðîëã¿é ýìýãòýé÷¿¿äýä 37.0 ñàð áàéñàí áºãººä median-ààð (ãîë÷) áàãà áîëîâñðîëòîé ýìýãòýé÷¿¿äýä 45.9 ñàð, áîëîâñðîëã¿é ýìýãòýé÷¿¿äýä 35.7 ñàð

áóþó õàìãèéí áîãèíî áàéâ. Àæèãëàëòûí 5 æèëä àìüäàðñàí õóâü áîëîâñðîëã¿é ýìýãòýé÷¿¿äýä 20 õóâü, áàãà áîëîâñðîëòîé ýìýãòýé÷¿¿äýä 45.5 õóâü, äóíä áîëîâñðîëòîé ýìýãòýé÷¿¿äýä 70.7 õóâü, ìýðãýæëèéí áîëîâñðîëòîé ýìýãòýé÷¿¿äýä 71.9 õóâü, äýýä áîëîâñðîëòîé ýìýãòýé÷¿¿äýä 75.4 õóâü áóþó áîëîâñðîëûí ò¿âøèíãýýñ õàìààðàí àìüäàð÷ áàéãàà õóãàöàà ÿëãààòàé áàéíà (p<0.027).

Àìüäàð÷ áàéãàà õóãàöàà îíîøëîãäîõ ¿åèéí õîðò õàâäðûí ¿å øàòààðàà ÿëãààòàé áàéñàí áºãººä 1-ð ¿åä îíîøëîãäñîí 2 õ¿í àìüä, 2-ð ¿åä îíîøëîãäñîí 32 õ¿íèé 28 õ¿í íü àìüä, 3-ð ¿åä îíîøëîãäñîí 107 õ¿íèé 87 õ¿í íü àìüä, 4-ð ¿åä îíîøëîãäñîí 54 õ¿íèé 19 õ¿í íü àìüä áàéíà. Õîðò õàâäðûí ¿å øàòààñ õàìààðàí àæèãëàëòûí 5 æèë àìüäàðñàí õóâü õàðèëöàí àäèëã¿é áàéñàí áºãººä 1–ð ¿åäýý îíîøëîãäñîí ýìýãòýé÷¿¿ä õàìãèéí èõ áóþó 100 õóâü, 4–ð ¿åäýý îíîøëîãäñîí ýìýãòýé÷¿¿äèéíõ õàìãèéí áàãà áóþó 35.2 õóâü áàéâ (p<0.0001).

Õèéãäñýí ýì÷èëãýýíýýñ õàìààðàí àìüäàð÷ áàéãàà õóãàöàà ÿëãààòàé áàéñàí áºãººä äàí ìýñ çàñàë ýì÷èëãýýíèé äàðàà àìüäàð÷ áàéãàà õóãàöàà mean-ààð õàìãèéí óðò 58.4±2.4 ñàð, ìýñ çàñàë, õèìè, òóÿà õàâñàðñàí ýì÷èëãýýíèé äàðàà 51.6±1.3 ñàð, ìýñ çàñëûí áóñ õàâäðûí ýñðýã ºâºðìºö ýì÷èëãýý áîëîõ õèìè, òóÿà ýì÷èëãýýíèé äàðàà 29.5±11.6 ñàð áóþó median-ààð 10.1±19.2 ñàð, õºíãºâ÷ëºõ ýì÷èëãýýíèé äàðàà 24.5±7.9 ñàð áóþó median-ààð 12.3±2.5 ñàð õàìãèéí áîãèíî áàéíà (p<0.0001).

Êîêñ ðåãðåññèéí àðãààð õºõíèé õîðò õàâäðûí ýì÷èëãýýíèé äàðàà àìüäàð÷ áàéãàà õóãàöààíä ÿìàð õ¿÷èí ç¿éë äàâõàð íºëººëæ áàéãààã äýýðõ ÿëãààòàé ãàðñàí ¿ç¿¿ëýëò¿¿äèéã (íàñíû á¿ëýã, áîëîâñðîëûí ò¿âøèí, õîðò õàâäðûí ¿å øàò) íýãòãýí îðóóëæ øàëãàõàä çºâõºí õîðò õàâäðûí ¿å øàòíààñ èë¿¿ èõ õàìààðàëòàé (Wald(3)=26.30, P<0.0001) áóþó õýäèé÷èíýý ýðò ¿å øàòàíäàà îíîøëîãäîíî òºäèé÷èíýý àìüäðàõ õóãàöàà óðò áàéãàà íü òîãòîîãäîæ áàéíà.

Table 1. Survived rate of patients with breast cancer observed years

1 year 3 years 5 years

P value rate 95% CI rate 95% CI rate 95% CI

Age group n=195 0.033

0-29 n=4 100 100 100 100 100 100

30-39 n=28 79 78.2-79.8 64 63.1-64.9 56 55-57

40-49 n=73 93 92.7-93.3 77 76.5-77.5 73 72.5-73.5

50-59 n=62 87 86.6-87.4 76 75.5-76.5 76 75.5-76.5

60-69 n=28 75 74.2-75.8 54 53.1-54.9 54 53.1-54.9


Ñóäëàà÷ Ñ.Ò¿âøèíãýðýëèéíõýýð 2003 îíä õºõíèé ºìºíãººð îíîøëîãäñîí 47 õ¿íèé 38% íü îíîøëîãäñîíîîñ õîéø 5 æèëèéí äàðàà àìüä, äóíäàæ àìüäàðñàí õóãàöàà 39.6 ñàð áàéñàí áîë áèäíèé õèéñýí ýíý óäààãèéí ñóäàëãààíä 195 õ¿íä õàìðàãäñàíààñ îíîøëîãäñîíîîñ õîéø 5

æèëèéí äàðàà 69.7% íü àìüä, íèéò ñóäàëãààíä õàìðàãäàã÷äûí àìüäàð÷ áàéãàà äóíäàæ õóãàöàà 50.4 ñàð áàéãàà íü ìàíàé óëñûí õºõíèé ºìºíãèéí ¿åèéí òóñëàìæ ¿éë÷èëãýýíèé ÷àíàð ñàéæèð÷ áóéí èëðýë ãýæ ¿çýæ áîëîõîîð áàéíà.

Education n=195 0.027

Unlearned n=5 80 78.2-81.8 20 18.2-21.8 20 18.2-21.8

Less n=11 82 80.8-83.2 45 43.5-46.5 45 43.5-46.5

Middle n=82 88 87.6-88.4 72 71.5-72.5 70 69.5-70.5

Professional n=32 84 83.4-84.6 78 77.3-78.7 69 68.1-69.9

Higher n=65 88 87.6-88.4 77 76.5-77.5 75 74.5-75.5

Stage n=195 0.0001

Stage 1 n=2 100 100 100 100 100 100

Stage 2 n=32 97 96.7-97.3 88 87.4-88.6 88 87.4-88.6

Stage 3 n=107 94 93.8-94.2 83 82.6-83.4 81 80.6-81.4

Stage 4 n=54 65 64.4-65.6 39 38.3-39.7 34 33.3-34.7

Treatment n=195 0.0001

Surgical n=10 100 100 90 89.1-90.9 90 89.1-90.9

Surgery+combined n=173 89 88.8-89.2 74 73.7-74.3 71 70.6-71.4

Unsurgical n=4 50 47.5-52.5 25 22.8-27.2 25 22.8-27.2

Palliative care n=8 38 36.3-39.7 25 23.5-26.5 25 23.5-26.5

Ä¿ãíýëò:

1. Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí îíîøëîãäñîíîîñ õîéø àìüäàð÷ áàéãàà äóíäàæ õóãàöàà 50.4 ñàð áºãººä àæèãëàëòûí 5 æèëèéí äàðàà 69.7 õóâü íü àìüä áàéíà.

2. Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöàà íü íàñíû á¿ëýã, áîëîâñðîëûí ò¿âøèí çýðýã õ¿í àì ç¿éí çàðèì ¿ç¿¿ëýëòýýñ õàìààðàí ÿëãààòàé áàéíà.

3. Õºõíèé ºìºíãººð ºâ÷èëñºí õ¿ì¿¿ñèéí àìüäàð÷ áàéãàà õóãàöàà íü õîðò õàâäðûí ¿å øàò, õàâñàðñàí ýì÷èëãýýíèé òºðºëòýé õ¿÷òýé õàìààðàëòàé áàéíà. Ýíý íü õýäèé÷èíýý ýðò ¿å øàòàíäàà îíîøëîãäîæ õàâäðûí ýñðýã ºâºðìºö ýì÷èëãýý ìýñ çàñàë, õàâñàðñàí ýì÷èëãýýíä õàìðàãäàíà òºäèé÷èíýý àìüäðàõ õóãàöàà íü óðòñàæ áàéãààã èëýðõèéëæ áàéíà.

Íîì ç¿é

1. Íÿìäàâàà Í., Îþóí÷èìýã Ä., ßãààí Ä., Ò¿âøèíãýðýë Ñ., “Ìîíãîëûí ýìýãòýé÷¿¿äèéí äóíäàõ õºõíèé ºìºíãèéí òàðõâàð ç¿éí

áàéäàë”, Ìîíãîëûí Àíàãààõ óõààí ñýòã¿¿ë, ÓÁ., 2006, №1, õ.8-11

2. “Õîðò õàâäðûí ¿ç¿¿ëýëò¿¿ä 2006-1010 îí”, ÓÁ., 2012

3. ×èìãýý Ä., “SPSS õýðýãëýã÷èéí ãàðûí àâëàãà”, ÓÁ., 2008

4. ×èìãýý Ä., “SPSS ñòàòèñòèêèéí øèíæèëãýýíèé ¿ð ä¿íã òàéëáàðëàõ íü”, ÓÁ., 2010

5. Chan Y H., Singapore Medical Association, “Biostatistics 203. Survival analysis” basic statistics for doctors, Singapore, 2004

6. http://www.ncri.ie/tags/globocan ¿çñýí, 2014.8.15

7. http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/breast/survival/breast-cancer-survival-statistics ¿çñýí, 2014.8.15

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí:Àíàãààõ óõààíû äîêòîð Ä.Àâèðìýä


ÍÈÉÃÌÈÉÍ ÝÐ¯¯Ë ÌÝÍÄ

Õàðàà, Îðõîí ãîëûí óñíû ÷àíàðûã ñóäàëñàí ä¿í

Ý.Òóÿà1, Ë.Íÿìñ¿ðýí1, Á.Õîíãîðçóë1, Ï.Óíäàðìàà1, Í.Àìàðäóëàì1,Æ.Õèøèãò1

, Á.Áóðìààæàâ2, È.Áîëîðìàà1

1Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñíèé òºâ2Ìîíãîëûí àíàãààõ óõààíû àêàäåìè

Water quality analysis of Kharaa and Orkhon river

E.Tuya1, L. Nyamsuren1, B.Khongorzul1, P.Undarmaa1, N.Amardulam1,J.Khishigt1, B.Burmaajav2, I.Bolormaa1

1National Center of Public Health2Mongolian Academy of Medical Sciences

Introduction

According to the report from 2010, Mongolian water consumption was 550 million cubic meter and approximately 9.1% of the total Mongolian population obtain their water from inadequate hygiene water resources - springs and rivers. Due to non-hygiene water usage has caused water-born communicable and non communicable diseases among the population. In the last years there has been issue of pollution of one of the Mongolia’s more representative river Selenge and its following rivers -Kharaa, Orkhon and it is necessary to evaluate water pollution of these rivers.

Goal

To determine water chemical and biological pollution of Kharaa and Orkhon river and to evaluate water quality


We collected water, sediments and macro invertebrates sample from three points of river -upstream, midstream, downstream and for Kharaa river the samples were collected from Tunkhel, Mandal and Bayangol soum, fo Orkhon river the sequence was Orkhontuul, Orkhon, Khushaat soum. Samples were collected June, August, October of 2011, 2013.

In water sample, we determined physic-chemical 15 parameters including temperature, pH, total dissolved solids, conductivity, smell, color, hardness, sulfate, chloride, nitrate, nitrite, ammonia, dissolved oxygen, biological oxygen demand and mercury using their standard methods. Macro invertebrate samples were collected to evaluate water quality and we determined mercury in sediments and macroinvertebrate samples to evaluate mercury contamination.

Result Physic-chemical results of the water showed that water of Kharaa, Orkhon rivers were classified low mineralized, soft water and nutrient pollution indicators for ‘slightly polluted’category. For dissolved and biochemical oxygen, they were belong to the category of ‘pure water’.

There were no correlation between 2012 and 2013 results and mercury in water, sediments and macro invertebrates were qualified standard value.

Conclusion

According to research results water quality of Kharaa, Orkhon river was good and have less pollution and it is possible to use in household consumption after proper cleaning and disinfection.

Key word: Water quality, chemical and liological pollution

Pp. 25-29, Table 1, Figures 8, References 6


Îðøèë

Ñ¿¿ëèéí æèë¿¿äýä Ìîíãîë îðîíä òºäèéã¿é äýëõèé äàõèíàà õ¿í àìûí õóðäàöòàé õºãæèë, ¿éëäâýðæèëò, íèéãýì ýäèéí çàñãèéí áàéäàë çýðãýýñ ¿¿äýí óíäíû óñíû õ¿ðòýýìæ, ÷àíàð, àþóëã¿é áàéäëûí àñóóäàë õóðöààð òàâèãäàæ áàéíà. Ìàíàé îðíû õ¿í àìûí óñíû íèéò õýðýãëýý æèëä 550 ñàÿ øîî ìåòð (2010 îíû áàéäëààð) áàéãàà áºãººä íèéò õ¿í àìûí 9.1% íü ýð¿¿ë àõóéí øààðäëàãà õàíãààã¿é áóëàã øàíä, ãîë ãîðõèíû óñ õýðýãëýæ áàéãàà íü óñíààñ ¿¿äýëòýé õàëäâàðò, õàëäâàðò áóñ ºâ÷ëºëèéí ýõ ¿¿ñâýð áîëæ áàéíà [1]. ßëàíãóÿà ñ¿¿ëèéí æèë¿¿äýä Ìîíãîë îðíû íóòàã äýâñãýðèéí 28%-èéã õàìàðäàã Ñýëýíãý ìºðíèé àé ñàâ, ò¿¿íèé öóòãàë ãîëóóäûí áîõèðäëûí àñóóäàë õºíäºãäºæ, ¿¿íòýé õîëáîîòîé ñóäàëãàà, øèíæèëãýýíèé àæèë ºðãºí õ¿ðýýòýéãýýð õèéãäýæ áàéíà.

Çîðèëãî

Ýíý ñóäàëãààãààð Ñýëýíãý ìºðíèé òîìîîõîí öóòãàë ãîëóóä áîëîõ Îðõîí, Õàðàà ãîëóóäûí õèìè, áèîëîãèéí áîõèðäîëòûí ò¿âøèíã òîäîðõîéëæ, ¿íýëýõèéã çîðüñîí áîëíî.

Ñýëýíãý ìºðºíä Èäýð, Äýëãýð, Õàíóé, Ýã çýðýã æèæèã ãîëóóä öóòãàõ áîëîâ÷ õàìãèéí òîì öóòãàë íü Îðõîí ãîë þì. Îðõîí ãîë Ñýëýíãý ìºðºíä öóòãàõûí ºìíº Äàðõàí-Óóë àéìãèéí ºìíº õýñãýýð Õàðàà ãîëòîé íèéëäýã. Îðõîí ãîë íü äàíãààðàà Îðõîí àéìãèéí 3, ªâºðõàíãàé àéìãèéí 1 áîëîí Áàÿíõîíãîð àéìãèéí 3 ñóìäûí íóòãèéã õàìàðñàí áàéäàã áîë Õàðàà ãîë íü Äàðõàí-Óóë àéìãèéí Äàðõàí, Îðõîí, Õîíãîð ñóìûí íóòàã, Ñýëýíãý àéìãèéí Áàÿíãîë, Ìàíäàë, Ñàéõàí ñóìûí íóòàã, Òºâ àéìãèéí Áàòñ¿ìáýð, Áîðíóóð, Áàÿí÷àíäìàíü, Ñ¿ìáýð ñóìûí íóòãèéã õàìàð÷, ýäãýýð íèéò ñóìäûí õ¿í àìûí óíäíû óñíû ýõ ¿¿ñâýð áîëäîã [2].


Îðõîí, Õàðàà ãîëûí óñíû ÷àíàð, áîõèðäîëòûí ò¿âøèíã òîäîðõîéëîõûí òóëä ãîëûí ýõýí, äóíä, àäàã õýñãèéã ñîíãîí äýýæ àâñàí áà Îðõîí ãîëûí ýõíèé öýãýýð Îðõîíòóóë ñóì, äóíä öýãýýð Îðõîí ñóì, àäàã öýãýýð Õóøààò ñóìûí íóòãààð äàéðàí óðñàõ ãîëûí öýã¿¿äèéã ñîíãîí àâñàí. Õàðèí Õàðàà ãîëûí õóâüä Ò¿íõýë òîñãîí, Ìàíäàë ñóì (Ç¿¿íõàðàà), Áàÿíãîë ñóì (Áàðóóí õàðàà) ãýñýí äàðààëàëòàéãààð öýã¿¿äèéã ñîíãîí àâ÷, äýýæëýëòèéã 2012, 2013 îíû 6, 8, 10 äóãààð ñàðóóäàä áóþó íýã öýãýýñ íèéò 6 óäàà äýýæ àâ÷, øèíæèëãýý õèéñýí áîëíî.

Ãàäàðãûí óñíû äýýæèéã àâàõäàà ãîëûí óðñàö ñàéòàé äóíä õýñýã áîëîí óðñàö ìóó, áîõèðäîë òºâëºðºõ ìàãàäëàëòàé çàõûí öýãýýñ äýýæëýëò õèéæ, ¿ð ä¿íã õàðüöóóëàí ñóäàëëàà.

Figure 1. Location of water sampling points

Ãàäàðãûí óñíû äýýæ àâàõ öýãèéã ñîíãîõ, äýýæëýëò õèéõ àðãà÷ëàëûã Áàéãàëü îð÷èí. Óñíû ÷àíàð äýýæëýëò 6-ð õýñýã Ãîë ãîðõèíû óñíààñ äýýæ àâàõ çààâàð MNS ISO 5667-6:2001 ñòàíäàðòûí äàãóó ÿâóóëñàí. Ãîëûí óñíû äýýæèíä åðºíõèé, øèì áîõèðäîëò, õ¿÷èëòºðºã÷èéí ãîðèìûí ¿ç¿¿ëýëò¿¿äèéã Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñíèé òºâèéí Íèéãìèéí ýð¿¿ë ìýíäèéí ëàâëàãàà ëàáîðàòîðèä, ìºíãºí óñíû õýìæýýã óã òºâèéí Õîð Ñóäëàëûí ñåêòîðä Ìîíãîë óëñûí ñòàíäàðò àðãà, àðãà÷ëàëûí äàãóó òîäîðõîéëëîî.Ãîëûí óñíû ÷àíàðûã ¿íýëýõäýý ãàäàðãûí óñíû öýâðèéí çýðãèéí àíãèëëûí íîðì (Áàéãàëü îð÷íû ñàéä, Ýð¿¿ë ìýíä, íèéãìèéí õàìãààëëûí ñàéäûí 1997 îíû 143/A/352 òîîò òóøààëûí 3-ð õàâñðàëò)-ûã àøèãëàí ¿íýëëýý.

Ãîëûí óñíû ÷àíàðûã èëýðõèéëýã÷ áàñ íýãýí ¿ç¿¿ëýëò áîëîõ ìàêðîñýýðíóðóóã¿éòíèé òºðºë ç¿éëèéí íèéëìýë ñîðüöûã Àìåðèêèéí Íýãäñýí óëñûí Áýðêëýé Èõ Ñóðãóóëèéí ñîðüö öóãëóóëàõ àðãà÷ëàëûí äàãóó öóãëóóëàí ãîëûí óñíû ÷àíàð ñàéí ¿åä àìüäàðäàã “ìýäðýã îðãàíèçì”, áàãà çýðýã áîõèðäîëòîé óñàíä àìüäàð÷ ÷àääàã “äóíä çýðýã ìýäðýã îðãàíèçì” áîëîí áîõèðäîëò èõòýé óñàíä àìüäðàõ ÷àäâàðòàé “òýñâýðòýé îðãàíèçì” ãýñýí àíãèëëûí äàãóó òîîëæ, òóñãàé àðãà÷ëàëûí äàãóó á¿ëãèéí èíäåêñèéã òîîöîîëæ, óã èíäåêñèéí òîîãîîð óñíû ÷àíàðûã äàðààõ õ¿ñíýãòèéí äàãóó ¿íýëëýý.

Table 1. Benthic macroinvertebrate index

Benthic macroinvertebrate index Water quality

> 2521-2515-20<15

ExcellentGoodModeratePoor

Ãîëûí óñíû ìºíãºí óñíû áîõèðäîëòûã ¿íýëýõ çîðèëãîîð ¸ðîîëûí òóíàäàñíû äýýæèéã MNS


(ISO) 4867:1999 – Óñíû ÷àíàð – Äýýæ àâàõ Õýñýã 12: ¨ðîîëûí òóíàäàñíû äýýæ àâàõ çºâëºìæèéí äàãóó öóãëóóëæ, ìºíãºí óñíû õýìæýýã ìàêðîñýýðíóðóóã¿éòíèé ñîðüöûí õàìò Óëñûí ìàë ýìíýëýã, àðèóí öýâðèéí òºâ ëàáîðàòîðèä àòîì øèíãýýëòèéí ñïåêòðîìåòðèéí àðãààð òîäîðõîéëëîî.

¯ð ä¿í

Õàðàà ãîëûí óñíû øèíæèëãýýíèé ä¿í

Õàðàà ãîëûí óñíû äýýæèä õèéñýí ñóäàëãààíû ä¿íãýýð óñíû òåìïåðàòóð 6, 8, 10-ð ñàðûí äóíäæààð 11.6îÑ, ºíãº áîëîí áóëèíãàðûí õóâüä õóð òóíàäàñíû áàéäëààñ øàëòãààëàí òóñ á¿ð 5.2-30.0 ãðàäóñ, 0.1- 6.7 ìã/ë-èéí õîîðîíä õýëáýëçýæ áàéíà.

Õàðàà ãîëûí óñíû ðH óëèðàë áîëîí áàéðøëààñ ¿ë õàìààðàí 7.26-7.71, ýðäýñæèëò 96-134 ìã/ë, õàòóóëàã 1.3-2.5 ìã-ýêâ/ë áàéãàà áà ýðäýñæèëòèéí õóâüä À. Ì. Îâ÷èííèêîâûí àíãèëàë (1948)-ààð íýí öýíãýã áóþó ÿëèìã¿é ýðäýñæèëòòýé, õàòóóëãèéí õóâüä Î.À.Àëåêèíû àíãèëàë (1953)-ààð çººëºí óñíû àíãèëàëä áàãòàæ áàéíà.

0

20

40

60

80

100

120

140

160

180

Tota

l dis

solv

ed s

olid

s, m

g/l

Time

TunkhelMandalBayangol

Figure 2. Total dissolved solids in water of Kharaa river

0

0.5

1

1.5

2

2.5

Har

dnes

s, m

g/l

Time

TunkhelMandalBayangol

Figure 3. Water hardness of Kharaa river

Çóðàã 2, 3-ààñ õàðàõàä óñíû õàòóóëàã áîëîí ýðäýñæèëòèéí ò¿âøèí 6, 10 ñàðä íýìýãäýæ, 8

äóãààð ñàðä áóóðñàí òºëºâ àæèãëàãäàæ áàéíà. Ýíý íü 8 äóãààð ñàðä îðñîí èõ õýìæýýíèé õóð òóíàäàñíû óëìààñ óñíû ò¿âøèí íýìýãäýí, íýãæ ýçýëõ¿¿íä íîîãäîõ íèéò óóññàí áîäèñûí õýìæýý áàãàññàíòàé õîëáîîòîé áàéíà.

Äýýðõ çóðãààñ Ò¿íõýë, Ìàíäàë, Áàÿíãîë ñóìäûí äàãóó õàòóóëàã, ýðäýñæèëòèéí õýìæýý íýìýãäñýí áàéãàà íü ãîëûí óñíû ýõíèé öýãýýñ ýõëýí íèéò óóññàí áîäèñûí ò¿âøèí íýìýãäñýýð áàéãààã õàðóóëæ áàéíà.

Ãîëûí óñíû ñóëüôàòûí àãóóëàìæ 9.5-74.5 ìã/ë, õëîð 5.1- 11.3 ìã/ë, øèì áîõèðäîëòûí ¿ç¿¿ëýëò áîëîõ íèòðàò, íèòðèò, àììèàêèéí àãóóëàìæ òóñ á¿ð 0.01-4.02ìã/ë, 0.005-0.011 ìã/ë, 0.01-0.30 ìã/ë áàéãàà íü óñíû öýâðèéí çýðãèéí àíãèëëààð áàãà áîõèðäîëòîé áóþó 3 äóãààð çýðãèéí àíãèëàëä õàìààðàãäàæ áàéíà. Ýäãýýð ¿ç¿¿ëýëò¿¿ä íü ãîëûí óðñãàëûí äàãóó áóþó äýýðõ 3 ñóìäûí äàãóó èõýññýí ç¿é òîãòîë àæèãëàãäààã¿é áîëíî (Çóðàã 4).

0

0.05

0.1

0.15

0.2

0.25

0.3

0.35

June.2012 August.2012 October.2012 June.2013 August.2013 October.2013

Аm

mon

ium

, мg/

l

Time

Tunkhel

Mandal

Bayangol

Figure 4. Ammonium of water of Kharaa river

Çóðàã 4-ººñ õàðàõàä Ò¿íõýë, Ìàíäàë, Áàÿíãîë ñóìäûí äàãóóõ ãîëûí óñíû àììèàêèéí àãóóëàìæ õàðèëöàí àäèëã¿é áàéãàà áºãººä 8 äóãààð ñàðä õàìãèéí èõ, 10 äóãààð ñàðä õàìãèéí áàãà áàéíà.

Õ¿÷èëòºðºã÷èéí ãîðèìûí ¿ç¿¿ëýëòèéí íýã áîëîõ óóññàí õ¿÷èëòºðºã÷èéí àãóóëàìæ Ò¿íõýë, Ìàíäàë, Áàÿíãîë ñóìäûí äàãóó áàãàñ÷ 11.3-11.82 ìã/ë, áèîõèìèéí õýðýãöýýò õ¿÷èëòºðºã÷èéí àãóóëàìæ (ÁÕÕ) 1.43-1.87 ìã/ë-èéí õîîðîíä áàéãàà íü ãàäàðãûí óñíû öýâðèéí çýðãèéí àíãèëëààð “ìàø öýâýð” óñíû àíãèëàëä õàìààðàãäàæ áàéíà.

Ãîëûí óñíû çàõ, äóíä õýñãèéí óñíû ¿ç¿¿ëýëò¿¿äèéí õîîðîíä ÿëãàà àæèãëàãäààã¿é áà äýýæ àâñàí ñàðóóäûí õóâüä öàã àãààðûí íºõöºë áàéäàë áóþó õóð òóíàäàñíààñ øàëòãààëàí çàðèì ¿ç¿¿ëýëò èõñýæ, áàãàññàí áàéäàë àæèãëàãäñàí. Òóõàéëáàë èõ õýìæýýíèé áîðîî îðñîí ¿åä óñíû óðñàö èõýññýí ¿åä ò¿¿íä àãóóëàãäàõ åðºíõèé ¿ç¿¿ëýëò¿¿ä áóóðñàí áàéäàë àæèãëàãäñàí áà íºãººòýéã¿¿ð óñíû ò¿âøèí èõñýí ýðýã ð¿¿ äàâñíû óëìààñ çàðèì øèì áîõèðäîëòûí õýìæýý èõýññýí ç¿é òîãòîë àæèãëàãäëàà.

2012, 2013 îíû Õàðàà ãîëûí óñíû øèíæèëãýýíèé ä¿íã õàðüöóóëàõàä çàðèì ¿ç¿¿ëýëò ¿ë ÿëèã


èõýññýí áàéäàë àæèãëàãäñàí ÷ ñòàòèñòèêèéí õàìààðàë á¿õèé ÿëãàà àæèãëàãäààã¿é (p<0.01).

Õàðàà ãîëûí óñíû áîõèðäîëòûã òîäîðõîéëîõûí òóëä áîõèðäëîîñ øóóä õàìààðàëòàé ¿ç¿¿ëýëò áîëîõ ¸ðîîëûí ìàêðîñýýðíóðóóã¿éòíèé òºðºë áîëîí òîîã òîäîðõîéëæ, óñíû ÷àíàðûã ¿íýëýõýä ìàø ñàéí (ìàêðîñýýðíóðóóã¿éòíèé óñíû ÷àíàðûí èíäåêñ >25) áàéëàà. ßëàíãóÿà 8 äóãààð ñàðä ìàêðîñýýðíóðóóã¿éòíèé òîî èõñýæ, 10 äóãààð ñàðä áóóðàõ õàíäëàãàòàé áàéãàà íü àæèãëàãäñàí áà ýíý íü 6 äóãààð ñàðä ¿ðæëèéí õóãàöàà ÿâàãäàæ, 8 äóãààð ñàðä íàñ áèå ã¿éöýí, 10 äóãààð ñàðä óñíû òåìïåðàòóð áóóðñàíòàé õîëáîîòîéãîîð àìüäðàõ ÷àäâàð íü áóóðñàí áàéíà.

Õàðàà ãîëûí óñ, ¸ðîîëûí øàâàðëàã áîëîí ìàêðîñýýðíóðóóã¿éòýíä õèéñýí øèíæèëãýýíèé ä¿íãýýð ìºíãºí óñíû àãóóëàìæ ñòàíäàðò õýìæýý (óñ- 1ìêã/ë-ààñ èõã¿é, øàâàðëàã-1 ìêã/êã-ààñ èõã¿é, ìàêðîñýýðíóðóóã¿éòýí-1 ìêã/êã-ààñ èõã¿é)-íä áàé-ëàà.

0

5

10

15

20

25

30

35

40

45

0

5

10

15

20

25

Tunkhel Mandal Bayangol

Mer

cury

in s

edim

ent a

nd

mac

roin

verte

brat

e, μ

g/kg

in macroinvertebreain sedimentin water

Mer

cury

in w

ater

, ng/

l

Figure 5. Mercury determination results of water, macroinvertebrea and sediment of Kharaa river

Ìºí ãîëûí öýã¿¿ä äýõ óñ, ìàêðîñýýðíóðóóã¿éòýí áîëîí ̧ ðîîëûí øàâàðëàãèéí òóíàäàñ äàõü ìºíãºí óñíû àãóóëàìæèéí ä¿íã õîîðîíä íü õàðüöóóëæ çóðàã 5-ä õàðóóëàâ.

Ýíäýýñ õàðàõàä ãîëûí ýõýí, äóíä, àäàã õýñýã äýõ ìºíãºí óñíû õýìæýý áîëîí óñ, ̧ ðîîëûí øàâàðëàã, ìàêðîñýýðíóðóóã¿éòýíä àãóóëàãäàõ ìºíãºí óñíû õýìæýýíä ÿìàð íýãýí õàìààðàë àæèãëàãäààã¿é (p<0.01) áîëíî.

Îðõîí ãîëûí óñíû øèíæèëãýýíèé ä¿í

Îðõîí ãîëûí óñíû äýýæèíä õèéñýí ñóäàëãààíû ä¿íãýýð óñíû òåìïåðàòóð 6, 8, 10 äóãààð ñàðûí äóíäàæ òåìïåðàòóð 11.1îÑ, ºíãº áîëîí áóëèíãàðûí õóâüä õóð òóíàäàñíû áàéäëààñ øàëòãààí òóñ á¿ð 9.8-32.4 ãðàäóñ, 0.2-3.6 ìã/ë õîîðîíä äóíä õýëáýëçýæ áàéãàà íü Õàðàà ãîëòîé õàðüöóóëàõàä áàãà çýðýã èõ áàéíà.

Îðõîí ãîëûí óñíû ðH óëèðàë áîëîí áàéðøëààñ ¿ë õàìààðàí 7.42-7.85, ýðäýñæèëò 103-176 ìã/ë, õàòóóëàã 1.4-2.65 ìã-ýêâ/ë íü áàéãàà íü óñíû

ýðäýñæèëòèéã À.Ì.Îâ÷èííèêîâûí àíãèëëààð àâ÷ ¿çýõýä íýí öýíãýã áóþó ÿëèìã¿é ýðäýñæèëòýé óñíû àíãèëàëä õàìààðàãäàõ áà õàòóóëãèéí õóâüä ìºí çººëºí óñíû àíãèëàë (Î.À.Àëåêèíû àíãèëàë)-ä áàãòàæ áàéíà.

80

100

120

140

160

180

200

Tota

l dis

solv

ed s

olid

s, m

g/l

Time

OrkhontuulOrkhonKhushaat

Figure 6. Total dissolved solids in water of Orkhon river

0.5

1

1.5

2

2.5

3

Hard

ness

, mg-

ekv/l

Time

Orkhontuul

Orkhon

Khushaat

Figure 7. Water hardness of Orkhon river

Çóðàã 5, 6-ààñ õàðàõàä Îðõîíòóóë, Îðõîí, Õóøààò ñóìäûí îð÷èì ãîëûí óñíû ýðäýñæèëò, õàòóóëãèéí õýìæýý õàðèëöàí àäèëã¿é áàéãàà áà ýðäýñæèëòèéí õýìæýý 8 äóãààð ñàðä õàðüöàíãóé áàãàññàí áàéíà.

Ñóëüôàòûí àãóóëàìæ 14.8-66.1ìã/ë, õëîðûí õýìæýý 8.7-22.0ìã/ë, øèì áîõèðäîëòûí ¿ç¿¿ëýëò áîëîõ íèòðàò, íèòðèò, àììèàêèéí àãóóëàìæ òóñ á¿ð 0.01-13.52ìã/ë, 0.005-0.013 ìã/ë, 0. 01-0.91 ìã/ë áóþó Õóøààò ãîëûí øèì áîõèðäîëò 6 äóãààð ñàðä õàðüöàíãóé èõ áàéñàí õýäèé ÷ íèòðàò, íèòðèòèéí õóâüä ýäãýýð ¿ç¿¿ëýëò íü óñíû ÷àíàðûí ñòàíäàðòûí øààðäëàãûí õýìæýýíä áàéíà.

Õ¿÷èëòºðºã÷èéí ãîðèìûí ¿ç¿¿ëýëòèéí íýã áîëîõ óóññàí õ¿÷èëòºðºã÷èéí àãóóëàìæ 6 äóãààð ñàðä õàìãèéí èõ áóþó 12.9- 12.44 ìã/ë, ÁÕÕ5 1.88-2.45 ìã/ë-èéí õîîðîíä áàéíà.

Îðõîí ãîëûí õóâüä Õàðàà ãîëòîé àäèë çàõ áîëîí äóíä õýñãèéí óñíû ÷àíàðûí ¿ç¿¿ëýëò¿¿ä áîëîí 2012, 2013 îíû øèíæèëãýýíèé ä¿íãèéí õîîðîíä ñòàòèñòèê


à÷ õîëáîãäîë á¿õèé ÿëãàà àæèãëàãäààã¿é áîëíî (p<0.01).

Îðõîí ãîëûí óñíû ¸ðîîëûí ìàêðîñýýðíóðóóã¿éòíèé òºðºë áîëîí òîîã òîäîðõîéëæ, ãîëûí óñíû ÷àíàðûã ¿íýëýõýä á¿ëãèéí èíäåêñèéí òîî>25 áóþó óñíû ÷àíàð “ìàø ñàéí” áàéëàà. Ìàêðîñýýðíóðóóã¿éòíèé òîî, òºðºë óëèðëààñ õàìààðñàí ººð÷ëºëò Îðõîí ãîëûí õóâüä àæèãëàãäààã¿é áîëíî.

Ìºíãºí óñíû øèíæèëãýýíèé ä¿íãýýð Îðõîí ãîëûí óñ, åðîîëûí øàâàðëàã áîëîí ìàêðîñýýðíóðóóã¿éòýíä àãóóëàãäàõ ìºíãºíóñíû õýìæýý ñòàíäàðò õýìæýý (óñ- 1ìêã/ë-ààñ èõã¿é, øàâàðëàã – 1 ìêã/êã-ààñ èõã¿é, ìàêðî-ñýýðíóðóóã¿éòýí –1 ìêã/êã-ààñ èõã¿é)-íä áàéëàà.

Figure 8. Mercury determination results of water, macroinvertebrea and sediment of Kharaa river

Mer

cury

in w

ater

, ng/

l

0

5

10

15

20

25

30

35

40

45

50

0

1

2

3

4

5

6

7

8

9

Orkhontuul Orkhon Khushaat

Mer

cury

in s

edim

ents

and

m

acro

inve

rteb

rate

, μg/

kg

Location

in macroinvertebreain sedimentin water

Mer

cury

in w

ater

, ng/

l

Ìºí ãîëûí óñíû äýýæ àâñàí öýã¿¿ä äýõ óñ, ìàêðîñýýðíóðóóã¿éòýí, ¸ðîîëûí øàâàðëàã äàõü ìºíãºí óñíû õýìæýýã õîîðîíä íü õàðüöóóëæ Çóðàã 6-ä õàðóóëàâ.

Çóðãààñ õàðàõàä ãîëûí ýõýí, äóíä, àäàã õýñýã äýõ ìºíãºíóñíû õýìæýý áîëîí óñ, ¸ðîîëûí øàâàðëàã, ìàêðîñýýðíóðóóã¿éòýíä àãóóëàãäàõ ìºíãºí óñíû õýìæýýíä ÿìàð íýãýí õàìààðàë àæèãëàãäààã¿é áîëíî (p<0.01).

ÕýëöýìæÎðõîí ãîëûí óñíû øèíæèëãýýíèé ä¿íã ñ¿¿ëèéí æèë¿¿äýä õèéñýí áóñàä ñóäàëãàà (Óñ ñóâãèéí óäèðäàõ ãàçàð (2010-2011), Ãåîýêîëîãèéí õ¿ðýýëýí (2011))-íû ä¿íòýé õàðüöóóëàõàä ýðäýñæèëò áîëîí õàòóóëàã óðñãàëûí äàãóó èõýñ÷, áîðîîíû óëèðàëä òóñ á¿ð 110-240 ìã/ë, 1-2.00 ìã ýêâ/ë áàéãàà íü ìàíàé ñóäàëãààíû ä¿íòýé àäèë áàéãàà áºãººä ìºí øèì áîõèðäîëòûí áóþó àììîíè, íèòðèò, íèòðàò áîëîí õ¿÷èëòºðºã÷èéí ãîðèìûí ¿ç¿¿ëýëò¿¿äèéí õóâüä ÿëãààã¿é áóþó óñíû ÷àíàðò îíöûí ººð÷ëºëò ãàðààã¿é ãýæ ¿çýæ áàéíà.

Õàðàà ãîëûí õóâüä ìºí ýðäýñæèëò áîëîí õàòóóëãèéí õýìæýý áóñàä ñóäàëãààíû ¿ð ä¿íòýé (ýðäýñæèëò 280-300 ìã/ë, õàòóóëàã 2,4 ìã-ýêâ/ë)-òýé õàðüöóóëàõàä áàãà áàéãàà íü áîðîîíû ¿å òààð÷, óñíû ò¿âøèí íýìýãäñýíòýé õîëáîí ¿çýæ áîëîõ áºãººä õ¿÷èëòºðºã÷èéí ãîðèìûí ¿ç¿¿ëýëò¿¿äèéí õóâüä îíöûí ÿëãàà àæèãëàãäààã¿é áîëíî. Õàðàà ãîëûí øèì áîõèðäîëòûí õóâüä ñ¿¿ëèéí æèë¿¿äýä

íýìýãäýõ õàíäëàãàòàé õýäèé ÷ áîðîîíû óëèðàëä õýâèéí õýìæýýíä áàéäàã áàéíà.

Ä¿ãíýëò:

1. Õàðàà ãîëûí óñíû ðH 7.26-7.71 õîîðîíä õýë-áýëçýæ, óñíû ýðäýñæèëòèéí õóâüä íýí öýíãýã áóþó àëèìã¿é ýðäýñæèëòýé óñ, õàðèí õàòóóëãèéí õóâüä çººëºí óñíû àíãèëàë (Î.À.Àëåêèíû àíãèëàë)-ä áàãòàæ áàéíà. Òèéìäýý ÷ áóñàä àíèîí, êàòèîíóóäûí õýìæýý áàãà øèì áîõèðäîëòûí ¿ç¿¿ëýëò (íèòðàò, íèòðèò, àììèàê) áàãà áàéãàà íü óñíû öýâðèéí çýðãèéí àíãèëëààð áàãà áîõèðäîëòîé àíãèëàëä õàìààðàãäàæ áàéãàà áºãººä ìàêðîñýýðíóðóóã¿éòíèé ä¿íãýýð óñíû ÷àíà ðûí ¿íýëãýý “ìàø ñàéí” ãýñýí ä¿í ãàðñàí íü óñíû ÷àíàð ñàéí, áîõèðäîëò áàãà áàéãààã õàðóóëæ áàéíà.

2. Îðõîí ãîëûí óñíû ºíãº, áóëèíãàð (9.8-32.4 ãðàäóñ, 0.2-3.6 ìã/ë) áàãà çýðýã èõ áà ýðäýñæèëò õàòóóëãèéí õóâüä íýí öýíãýã áóþó ÿëèìã¿é ýðäýñæèëòýé, çººëºí óñíû àíãèëàë áàãòàæ áàéãàà áà ýäãýýð ¿ç¿¿ëýëò íü Õàðàà ãîëûíõòîé õàðüöóóëàõàä ÿëèìã¿é èõ áàéíà. Øèì áîõèð-äîëòûí ¿ç¿¿ëýëò áîëîí íèòðàò, íèòðèò, àììèàêûí áàãà áàéãàà íü óñíû àíãèëëààð áàãà áîõèðäîëòîé áóþó óñíû ÷àíàðûí ñòàíäàðò õýìæýýíä áàéãàà áà öàã àãààðûí íºõöºë áàéäàë áîëîí áóñàä õ¿÷èí ç¿éëèéí íºëººãººð áîõèðäîëò íýìýãäýõ ìàãàäëàëòàé áàéãàà íü 6, 8,10-ð ñàðóóäûí øèíæèëãýýíèé ¿ð ä¿íã¿¿äèéí ÿëãààòàé áàéäëààñ àæèãëàãäàæ áàéíà.

3. Ñýëýíãý ìºðíèé öóòãàë ãîë áîëîõ Õàðàà, Îðõîí ãîëûí óñíû ÷àíàð ñàéí, áàãà áîõèðäîëòòîé áà àðèóí öýâðèéí õàìãààëàëòûí àðãà õýìæýýã ÷àíä õýðýãæ¿¿ëýí, çîõèõ öýâýðëýãýý, õàëäâàðã¿éòãýë õèéñíèé äàðàà ãîëûí óñûã ìàëûí óíä, õ¿í àìûí àõóéí õýðýãöýýíä àøèãëàæ áîëîõ þì.

Íîì ç¿é1. Ä.Áàòìºíõ, Ìîíãîë îðíû óñíû íººö àøèãëàëò,

óñ õýðýãëýý, Mongolian mining Journal, ÓÁ, 2014, õ 25

2. Îðõîí ãîëûí ñàâ ãàçðûí óñíû íººöèéí íýãäñýí ìåíåæìåíòèéí òºëºâëºãºº, ÓÁ, 2012, õ-50-61

3. Îðõîí ãîëûí ñàâ ãàçðûí óñíû íººöèéí íýãäñýí ìåíåæìåíòèéí òºëºâëºãººíä õèéñýí øèíæèëãýýíèé ä¿í, ÓÁ, 2013, õ 9-13

4. Ñýëýíãý-Õèë õÿçãààðã¿é ìºðºí, ýðäýì øèíæèë-ãýýíèé õóðëûí ýìõýòãýë, ÓÁ, 2014, õ-91-98

5. MNS ISO 5667-6:2001-Áàéãàëü îð÷èí. Óñíû ÷àíàð äýýæëýëò 6-ð õýñýã Ãîë ãîðõèíû óñíààñ äýýæ àâàõ çààâàð

6. MNS (ISO) 4867:1999-Óñíû ÷àíàð-Äýýæ àâàõ Õýñýã 12: ¨ðîîëûí òóíàäàñíû äýýæ àâàõ çºâëºìæ

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð Í.Ñàéæàà


Ñýëýíãý ìºðíèé ñàâ ãàçðûí îéðîëöîîõ ñóìäûí õ¿í àìûí äóíäàõ ãýäýñíèé õàëäâàðûí ºâ÷ëºëèéã ñóäàëñàí ä¿íãýýñ

Ë.Íÿìñ¿ðýí1, Î.Îþóí-Ýðäýíý1, Ý.Òóÿà1,Á.Äîðæõàíä1, Ý.Ýðäýíý÷èìýã2, Á.Áóðìààæàâ3, È.Áîëîðìàà1,

1Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñíèé òºâ2Àíàãààõûí øèíæëýõ óõààíû ¿íäýñíèé èõ ñóðãóóëü-ÍÝÌÑ

3Ìîíãîëûí àíàãààõ óõààíû àêàäåìèe-mail: [email protected]

Abstract

Some results of the study on morbidity of gastrointestinal infectious diseases among population of soums in Selenge River Basin

Nyamsuren.L1, Oyun-Erdene.O1, Tuya.E1,Dorjkhand.B1, Erdenechimeg.E2, Burmaajav.B3, Bolormaa.I1

1National Center for Public Health2Mongolian National University of Medical Science

3Mongolian Academy of Medical Sciences

IntroductionWaterborne diseases, especially diarrhea, related to water quality and safety, personal sanitation and hygiene have been still reported very high in developing countries. Globally, there are an estimated 1.4 million cases of hepatitis A every year. The hepatitis A virus is transmitted through ingestion of contaminated food and water or through direct contact with an infectious person. Hepatitis A is associated with a lack of safe water and poor sanitation [2].

Dysentery is bloody diarrhea, i.e. any diarrheal episode in which the loose or watery stools contain visible red blood. Dysentery is most often caused byShigella species (bacillary dysentery) or Entamoeba histolytica (amoebic dysentery) [3].

Kharaa and Orkhon River are tributaries of the Selenge River-basin, in which many mining and other industries, agriculture, and residential areas reside. It has become a one pollutant factor for water of the Kharaa and Orkhon rivers. As a result, water of the Tuul, Kharaa and Orkhon River was reported to be highly contaminated (Mongolian Human Development Report 2010: Water and Development report) [4].

Goal

The aim of the research was to study incidence of gastrointestinal infectious diseases among population of soums are located in Selenge River Basin.

Materials and MethodsData on health statistics 2009-2013 years of gastrointestinal infectious diseases, including dysentery, diarrhea, hepatitis A virus and others, were collected and analyzed.

ResultsIncidence of dysentery was registered highly among people who live in Mandal soums in 2009-2013 years. But incidence of dysentery (per 10 000 population 2.82) among population ofMandal soum lower than the Selenge province and National average. Incidence of hepatitis A virus was registered highly among people who live in Orkhon (74.46), Orkhontuul (48.86) soums and it was greater than 1.3-2 times than the Selenge province average. Incidence of diarrhea was registered highly among people who live in Khushaat soum and it was greater than 2.18-3.8 times the than Selenge province average

ConclusionIncidences of diarrhea and hepatitis A virus were registered highly in Orkhon, Orkhotuul and Khushaat soums compared to other target soums and it was greater than 1.3-3.8 times than the Selenge province average. Especially, these diseases were registered highly among 0-16 aged children.

Key words: Gastrointestinal infectious diseases, Selenge River Basin, Water borne diseases



Îðøèë

Óñààð äàìæèõ õàëäâàð òýðäóíäàà ñóóëãàëò õàëäâàðûã óíäíû óñíû ÷àíàð, àþóëã¿é áàéäàë, õóâü õ¿íèé áîëîí ºðõèéí àðèóí öýâýð, ýð¿¿ë àõóéí áàéäàë, óñíû õýðýãëýý, õ¿ðýëöýý, õàíãàìæèéí áàéäàëòàé õàðüöóóëàí ñóäàëñàí ñóäàëãààíû àæëóóä õºãæèæ áóé îðíóóäàä íèëýýä õèéãäýæ áàéíà. Áàòàëãààã¿é óíäíû óñíü õ¿í àìûí ýð¿¿ë ìýíäýä íºëººëäºã õàëãààò õ¿÷èí ç¿éëèéí íýã áºãººä ýìãýãòºðºã÷ íÿí, âèðóñ, ýãýëáèåòýí, øèìýã÷ àãóóëñàí óñíü õàëäâàð äàìæóóëàã÷ ãîë çàì áîëäîã áàéíà. Èõýíõ õàëäâàð ¿¿ñãýã÷ áè÷èë áèåòýí íü ýð¿¿ë àõóéí øààðäëàãà õàíãààã¿é óñ óóõ, õ¿ðýëöýõ, àìüñãàëàõ ¿åä äàìæèí õàëäâàðëàäàã. Óñààð äàìæèí õàëäâàðëà õºâ÷èíä õºíãºí, õ¿íä ÿâöòàé õîäîîä ãýäýñíèé ¿ðýâñýë, õåïàòèò, àðüñíû ¿ðýâñë¿¿ä, èäýýò õàëäâàð, ¿åìº÷, àìüñãàëûí çàìûí ºâ÷èí îðíî [1]. Âèðóñò õåïàòèòÀ íü äýëõèé äàÿàð ¿å ¿å áà òàõàë, äýãäýëò áàéäëààð òîõèîëääîã õàíäëàãàòàé áàéãàà áà æèë á¿ð õåïàòèò À-èéí 1.4 ñàÿ òîõèîëäîë á¿ðòãýãäýæ áàéíà. Õåïàòèò À âèð¿ñèéí õàëäâàð áîõèðäñîí õîîë õ¿íñ, óñààð äàìæäàã [2]. Öóñàí ñóóëãà íü ñóë, ýñâýë öî÷ìîã õýëáýðýýð óñàðõàã, öóñàãóóëñàí áàéäàã. Öóñàí ñóóëãà èõýâ÷ëýí Shigella ç¿éëèéí (íÿíãèéí öóñàí ñóóëãà) ýñâýë Entamoeba òåñòhistolytica (àì¸áûí ãàðàëòàé öóñàí ñóóëãà) ¿¿äýëòýé áàéäàã [3].

Ìîíãîë óëñûí òîìîîõîí õîò ñóóðèí, ¿éëäâýðëýëèéí òºâ¿¿ä Ñýëýíãý ìºðíèé àé ñàâ ãàçðûí óñíû íººöººñ õàíãàãääàã. Òóõàéëáàë, Äàðõàí õîòûí ºìíº òàëààð Õàðàà ãîë óðñàæ Îðõîí ãîëä öóòãàäàã. Õàðàà ãîë íü Äàðõàí õîò, Õîíãîð ñóì, Ñàëõèò ºðòºº, Áàðóóí õàðàà, Ç¿¿í õàðàà çýðýã îëîí õîò ñóóðèíû óñàí õàíãàìæèéí (ãàäàðãûí áîëîí ã¿íèé õýëáýðýýð) øóóä áà øóóä áóñ ýõ ¿¿ñâýð áîëäîã.Ñýëýíãý ìºðíèé òîìîîõîí öóòãàë ãîëûí ýðýã, ñàâ äàãóó ¿éëäâýð, àæ àõóé, õîò ñóóðèí ãàçàð, àéìàã, ñóìóóäûí òºâ áàéðëàäàã íü òóõàéí ãîë ìºðíèé óñíû õèìèéí íàéðëàãà ººð÷ëºãäºõ, óëìààð áîõèðäîõ íýã õ¿÷èí ç¿éë áîëæ áàéãàà áºãººä Òóóë, Õàðàà, Îðõîí ãîëóóäûí óñ áîõèðäîë èõòýé áàéíà. Íèéò õ¿í àìûí óñíûõ¿ðòýýìæ, ýõ ¿¿ñâýðèéã íü àâ÷ ¿çýõýä 30.8 õóâü íü òºâëºðñºí óñ ò¿ãýýã¿¿ðèéí ñ¿ëæýýíýýñ, 24.8 õóâü íü çººâðèéí óñ òýýâðèéí ¿éë÷èëãýýíýýñ, 35.3 õóâü óñ ò¿ãýýõ áàéð, õóäãààñ, 9.1 õóâü íü áóëàã, øàíä, ãîë ãîðõèíû óñûã óíä, àõóéäàà õýðýãëýæ áàéíà [4].

2000 îíä ªâºðõàíãàé àéìàãò óñòàé õîëáîîòîé âèðóñò õåïàòèò À äýãäýëò õýëáýðýýð á¿ðòãýãäýæ, Àðâàéõýýð õîòîä ºâ÷ëºëèéí òîõèîëäîë 291-ä õ¿ðñýí áºãººä óã äýãäýëòèéí ¿åýð íºëººëñºí õ¿÷èí ç¿éëèéã òîãòîîõ çîðèëãîîð 96 ºâ÷òºíººñ àñóóìæ ñóäàëãàà àâàõàä 70% íü ò¿¿õèé óñ, 58.3% íü óñ ò¿ãýýõ öýãýýñ, 35.5% íü èë çàäãàé

óñíû ýõ áóëãààñ óñ õýðýãëýñýí íü òîãòîîãäñîí áàéíà [5]. Èéìä Ìîíãîë óëñûí òîìîîõîí õîò ñóóðèíãèéí óñíû íººö áîëñîí Ñýëýíãý ìºðíèé àé ñàâ äàãóó îðøèí áàéõ ñóóðèí ãàçðûí õ¿í àìûí äóíä á¿ðòãýãäýæ áóé óñòàé õîëáîîòîé õàëäâàðûí ºâ÷ëºëèéí ºíººãèéí áàéäëûã ñóäëàí òîãòîîõ øààðäëàãàòàé áàéíà.

Çîðèëãî: Ñýëýíãý ìºðíèé ñàâ ãàçðûí îéðîëöîîõ ñóìäûí õ¿í àìûí äóíäàõ ãýäýñíèé õàëäâàðûí ºâ÷ëºëèéã òîäîðõîéëîõ

Màòåðèàë, àðãà ç¿éÑýëýíãèéí ñàâ ãàçðûí òîìîîõîí öóòãàë áîëîõ Õàðàà ãîëûí ýðýã äàãóó áàéðëàäàã Ñýëýíãý àéìãèéí Ìàíäàë (Ò¿íõýë òîñãîí), Áàÿíãîë ñóìäóóä, Îðõîí ãîëûí äàãóó áàéðëàñàí Îðõîí, Îðõîíòóóë, Õóøààò çýðýã íèéò 6 ñóìûã ñóäàëãààíä õàìðóóëñàí áºãººä ñóìäûí õ¿í àìûí äóíäàõ óñòàé õîëáîîòîé õàëäâàðò ºâ÷íèéã ñóäëàõäàà áè÷èãëýëèéí ñóäàëãààíû àðãààð 2009-2013 îíóóäàä ÕªÑ¯Ò-èéí ñòàòèñòèêèéí àëáàíä áîëîí ñóìûí ýìíýëãèéí Health-Info ïðîãðàììä á¿ðòãýãäñýí ãýäýñíèé õàëäâàðò (öóñàí ñóóëãà, áàëíàä, ñàëüìîíåëë¸ç, âèðóñò õåïàòèò À, ñóóëãàëò õàëäâàð) ºâ÷íèé òîîí ìýäýýëýëä ä¿í øèíæèëãýýã õèéëýý. Õ¿í àìûí ºâ÷ëºëèéí ò¿âøèíã 10000 õ¿í àìä òîîöîîëæ, ºâ÷íèé õºäëºë ç¿éã æèëèéí èíòåðâàëòàéãààð, òàðõàëòûã ñóìûí áàéðøëààð òóñ òóñ òîîöîîëîâ.

¯ð ä¿íÂèðóñò õåïàòèò À-ãèéí ºâ÷ëºë: Âèðóñò õåïàòèò À íü óëñûí õýìæýýíä 2009-2013 îíû áàéäëààð 2011 îíä õàìãèéí îëîí òîõèîëäîë á¿ðòãýãäñýí áºãººä 10000 õ¿í àìä ºâ÷ëºë 49 áàéñàí áîë 2012 îíîîñ áóóð÷ 2013 îíû áàéäëààð 10000 õ¿í àìä ºâ÷ëºë 5.7 áîëæ áóóðñàí áàéíà. Ñýëýíãý àéìãèéí õýìæýýíä ñ¿¿ëèéí 5 æèëèéí áàéäëààð 10000 õ¿í àìä âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë óëñûí ºâ÷ëºëòýé àäèë 2011 îíä õàìãèéí îëîí òîõèîëäîë (36.84) á¿ðòãýãäýæ 2013 îíä ºâ÷ëºë 12.73 áîëæ áóóðñàí áàéíà. Ãýõäýý òóñ àéìãèéí õýìæýýíä 2012-2013 îíä âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë óëñûí äóíäæààñ ºíäºð áàéíà (Figure 1).

Figure 1. Hepatitis A per 10000 pop, Selenge aimag, (2009-2013)


ªâ÷ëºëèéí áàéäëûã àâ÷ ¿çâýë âèðóñò õåïàòèò À-ãèéí ºâ÷ëºëèéí îðãèë ¿å íü 10-ààñ 2 äóãààð ñàðûí õîîðîíä áàéãààãààñ 11 ä¿ãýýð ñàðä õàìãèéí èõ áàéíà (Figure 2).

Figure 2. Hepatitis A cases by month, Selenge aimag, (2009-2013 years average)

Ñóäàëãààíä ñîíãîãäñîí ñóìäûí õ¿í àìûí äóíä âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë 2009-2013 îíû áàéäëààð 2011 îíä õàìãèéí èõ á¿ðòãýãäýæ, 2013 îíä áóóðñàí áàéíà. Âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë Ñýëýíãý àéìãèéí õýìæýýíä 2011 îíû áàéäëààð 10000 õ¿í àìä 36.84 áàéõàä Îðõîí (74.46), Îðõîíòóóë (48.86) ñóìäàä àéìãèéí äóíäæààñ 1.3-2 äàõèí íýìýãäñýí áàéíà. Îðõîíòóóë ñóìàíä âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë 2010-2012 îíä àéìãèéí äóíäæààñ ºíäºð áàéñàí áîë 2013 îíä ºâ÷ëºë á¿ðòãýãäýýã¿é áàéíà. Ìàíäàë, Áàÿíãîë, Õóøààò ñóìäàä âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë ñ¿¿ëèéí 5 æèëèéí áàéäëààð àéìãèéí äóíäæààñ äîîãóóð áºãººä ºâ÷ëºë àéìãèéí ò¿âøèíòýé èæèë áàéíà. Îðõîí ñóìàíä 2009-2013 îíä âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë õàðüöàíãóé öººí á¿ðòãýãäýæ, õàðèí 2011 îíä õàìãèéí îëîí(10000 õ¿í àìä 74.46) òîõèîëäîë á¿ðòãýãäñýí áàéíà (Figure 3).

Figure 3. Hepatitis A per 10000 pop, selected soums of Selenge aimag, (2009-2013)

Çîðèëòîò ñóìäûí õ¿í àìûí äóíäàõ âèðóñò õåïàòèò À-ãèéí ºâ÷ëºëèéã íàñíû á¿òöýýð àâ÷ ¿çâýë íèéò ºâ÷ëºëèéí 89.9%-èéã õ¿¿õýä, 10.1%-èéã íàñàíä õ¿ðýã÷èä ýçýëæ áàéíà. Õ¿¿õäèéí äóíä ãîë òºëºâ 3-4 íàñíûõàí ºâ÷èëñºí áîë òýäãýýðèéí 50% íü ñóðãóóëüä, 32.7% íü öýöýðëýãò, 17.2% íü ãýðòýý áàéäàã áàéíà. Âèðóñò õåïàòèò À-ààð ºâ÷èëñºí íàñàíä õ¿ðýã÷äèéã íàñíû á¿òöýýð àâ÷ ¿çâýë 80.7% íü 17-35 íàñíûõàí ýçýëæ, ¿¿íýýñ 19-20 íàñíûõàí õàìãèéí èõ ºâ÷èëñºí áàéíà.Õ¿ñíýãò 1-ä âèðóñò õåïàòèò À-ãèéí òàðõàëòûã 10000 õ¿íä àìä òîîöîí õ¿í àì ç¿éí ¿ç¿¿ëýëòýýð õàðóóëàâ.


Öóñàí ñóóëãà: Óëñûí õýìæýýíä öóñàí ñóóëãà ºâ÷íèé òîõèîëäîë 2009-2013 îíä åðºíõèéäºº áóóðàõ õàíäëàãàòàé áîëæ,10000 õ¿í àìä íîãäîõ ºâ÷ëºë íü 2009 îíä óëñûí õýìæýýíä 11.7, 2013 îíû áàéäëààð 7 áîëæ 1.67 äàõèí áóóðñàí áàéíà. Ñýëýíãý àéìàãò ìºí àäèë ñ¿¿ëèéí 5 æèëä öóñàí ñóóëãûí ºâ÷ëºë áóóð÷ áàéãàà íü àæèãëàãäñàí. Òóõàéëáàë 2009 îíä Ñýëýíãý àéìàãò 10000 õ¿í àìä íîãäîõ öóñàí ñóóëãûí ºâ÷ëºë 11.27 áàéñàí áîë ýíý ¿ç¿¿ëýëò æèëýýñ æèëä áóóð÷ 2013 îíû áàéäëààð 0.76 áîëæ ýðñ áóóðñàí áàéíà. Ñýëýíãý àéìàãò ñ¿¿ëèéí 5 æèëèéí áàéäëààð öóñàí ñóóëãûí ºâ÷ëºë óëñûí äóíäæààñ áàãà áàéíà (Figure 4).

Figure 4. Dysentery cases per 10000 pop. Selenge aimag (2009-2013)

Ñóìäààð ºâ÷ëºëèéã àâ÷ ¿çâýë ñ¿¿ëèéí 5 æèëèéí áàéäëààð Ìàíäàë ñóìûí ºâ÷ëºëèéí ò¿âøèí (10000 õ¿í àìä 2.82) àéìàã, óëñûí äóíäæààñ áàãà áàéíà. 2010 îíä öóñàí ñóóëãûí òîõèîëäîë Áàÿíãîë ñóìàíä 1, Îðõîí ñóìàíä 2, 2011 îíä Îðõîí ñóìàíä 1 òîõèîëäîë òóñ òóñ á¿ðòãýãäñýí áàéíà.

ªâ÷ëºëèéí áàéäëûã àâ÷ ¿çâýë öóñàí ñóóëãà ºâ÷èí äóëààíû óëèðàë áóþó 5-8 äóãààð ñàðä çîíõèëîí á¿ðòãýãäñýí áàéíà (Figure 5).

Figure 5. Dysentery cases by month, Selenge aimag (2009-2013)

Öóñàí ñóóëãààð ºâ÷ëºãñäèéí 67.4%-èéã 0-5 íàñíû õ¿¿õýä ýçýëæ áàéíà. ªâ÷ëºëèéã õ¿éñýýð àâ÷ ¿çâýë 45.4% íü ýðýãòýé, 54.6% íü ýìýãòýé÷¿¿ä ýçýëæ áàéíà. Õ¿ñíýãò 2-ä öóñàí ñóóëãà ºâ÷íèé òàðõàëòûã 10000 õ¿íä àìä òîîöîí õ¿í àì ç¿éí ¿ç¿¿ëýëòýýð õàðóóëàâ.

Table 2. Demographic of Dysentery per 10000 pop, selected soms of Selenge aimag (2009-

2013)

Case Average

population (2009-2013)

Per 10000 pop.

Gender

Male 13 19202 6.8

Female 18 19532 9.2

Age group

0-4 23 9923 23.2

5-14 4 17499 2.3

15-24 1 21981 .5

55< 3 9250 3.2

Table 1. Demographic of Hepatitis A per 10000 pop, selected soms of Selenge aimag (2009-2013)

Case Average population (2009-2013) Per 10000 pop.

Gender

Male 142 19202 74.0

Female 106 19532 54.3

Age group

0-4 80 9923 80.65-14 135 17499 77.1

15-24 24 21981 10.925-34 4 17815 2.235-44 3 15337 2.0

45-54 2 11893 1.755< - - -


Öóñàí ñóóëãà ºâ÷íººð ºâ÷ëºãñäèéí íèéãìèéí áàéäëûã òîäîðõîéëîõîä ºâ÷èëñºí õ¿¿õäèéí äèéëýíõ íü áóþó 67.1% ãýðòýý áàéäàã áàéíà (Figure 6).

Figure 6. Social status of dysentery patients, Selenge aimag

Ñóóëãàëò õàëäâàð: Ñýëýíãý àéìàãò 2012-2013 îíä ñóóëãàëò õàëäâàðûí òîõèîëäîë 10000 õ¿í àìä 57.14 áàéãàà íü óëñûí äóíäæààñ (0,3) õàðüöàíãóé ºíäºð áàéíà. Çîðèëòîò ñóìäààñ Õóøààò ñóìàíä ñóóëãàëò õàëäâàðûí ºâ÷ëºë õàìãèéí èõ (àéìãèéí äóíäæààñ 2.18-3.8 äàõèí èõ) áàéíà. Ãîë òºëºâ 0-4 íàñíûõàí ºâ÷èëñºí áàéíà.

Õýëöýìæ:

Ñóäëàà÷ Ø.Ýíõöýöýã, Á.Áóðìàà íàðûí “Óñààð äàìæèõ õàëäâàðò ºâ÷íèé ñóäàëãààíû àæëûí òàéëàí (2005)-ä Óëààíáààòàð õîòîä âèðóñò õåïàòèò À-ààð ºâ÷ëºãñäèéí 85.7%-èéã 0-14 íàñíû õ¿¿õýä ýçýëæ, ºâ÷ëºë õ¿¿õäèéí öýöýðëýã, ñóðãóóëü, çóíû àìðàëòûí ãàçàðò ãîëîìòëîí ãàð÷ áàéíà ãýñýí áîë áèäíèé ñóäàëãààíû ¿ð ä¿íä âèðóñò õåïàòèò À-ãèéí íèéò ºâ÷ëºëèéí 89.9%-èéã õ¿¿õýä ýçýëæ áàéãàà áºãººä äýýðõ ñóäàëãààíû ä¿íòýé àäèë ñóðãóóëü (50%), öýöýðëýãò (32.7%) ãîëîìòëîí ãàð÷ áàéíà.

Ñóäëàà÷ È.Áîëîðìàà, Ø.Ýíõöýöýã íàðûí “Õ¿í àìûí ãýäýñíèé õàëäâàðò ºâ÷íèé õºäëºë ç¿éã ñóäàëñàí ä¿í” (2006-2009)-ãýýð Ñýëýíãý àéìàãò ãýäýñíèé õàëäâàðûí ºâ÷ëºë 2004-2008 îíä ºññºí áîë áèäíèé ñóäàëãààãààð 2009-2013 îíä áóóðñàí áàéíà. Ìºí ýíýõ¿¿ ñóäàëãààãààð âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë 9 ä¿ãýýð ñàðààñ 1-ä¿ãýýð ñàðûí õîîðîíä õàìãèéí èõ á¿ðòãýãäýæ áàéñàí áà ãýäýñíèé áóñàä õàëäâàðûí ºâ÷ëºë 5-10 äóãààð ñàðä îðãèë öýãòýý õ¿ð÷ áàéíà ãýñýí áîë áèäíèé ñóäàëãààíû ä¿íä Ñýëýíãý àéìãèéí çîðèëòîò 6 ñóìûí õ¿í àìûí äóíäàõ âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë 10 äóãààð ñàðààñ 1 ä¿ãýýð ñàðä õàìãèéí èõ, õàðèí ñóóëãàëò õàëäâàð, öóñàí ñóóëãà çýðýã áóñàä ãýäýñíèé õàëäâàðûí ºâ÷ëºë íü 6-9 ä¿ãýýð ñàðä èõ á¿ðòãýãäñýí áàéãàà íü àäèëõàí áàéíà. Ãýâ÷ áèäíèé ñóäàëãàà Ñýëýíãý àéìãèéã á¿õýëä íü õàìðóóëæ ÷àäààã¿é, çºâõºí Õàðàà, Îðõîí ãîëûí äàãóó áàéðëàäàã 6 ñóìäûã õàìðóóëñíààðàà õÿçãààðëàãäìàë áàéíà.

ÍÝÌ¯Ò-èéí ñóäëàà÷äûí 2012-2014 îíä õèéñýí “Óñ õàíãàìæèéí àþóëã¿é áàéäàë, ãàäàðãûí óñíû õèìè, áèîëîãèéí áîõèðäîëòûí ò¿âøèí, õ¿í àìûí ýð¿¿ë ìýíäýä ¿ç¿¿ëýõ íºëºº” ñýäýâò ñóäàëãààãààð Õàðàà, Îðõîí ãîëûí óñíû ÷àíàð íü ôèçèê, õèìèéí ¿ç¿¿ëýëòýýð çººëºí óñíû àíãèëàëä îðæ áàéñàí áîë íÿí ñóäëàëûí øèíæèëãýýãýýð çóíû óëèðàëä óñàí äàõü íÿíãèéí åðºíõèé òîî èõ, ãýäýñíèé á¿ëãèéí ýìãýã òºðºã÷ èëýð÷ áîõèðäîëòòîé áàéñàí áîë ýäãýýð ãîëûí óñíû øèì áîõèðäëûí çàðèì ¿ç¿¿ëýëò íü îéðîëöîîõ ñóìäûí õ¿í àìûí äóíäàõ ãýäýñíèé õàëäâàðûí ºâ÷ëºëòýé øóóä õàìààðàëòàé áàéãàà íü òîãòîîãäæýý. Òóõàéëáàë ãîëûí óñíû íèòðèòèéí àãóóëàìæ íü ñóìäûí õ¿í àìûí äóíäàõ öóñàí ñóóëãà, ñóóëãàëò õàëäâàðûí ºâ÷ëºëòýé øóóä ñóë (r=0.38, p=0.022; r=0.291, p=0.005), ãîëûí óñíû íÿíãèéí åðºíõèé òîî íü õ¿í àìûí âèðóñò õåïàòèò À-ãèéí ºâ÷ëºëòýé øóóä äóíä çýðãèéí (r=0.403, p=0.015) õàìààðàëòàé áàéãàà íü òîãòîîãäæýý.

Ä¿ãíýëò:

Çîðèëòîò ñóìäûí áàãà íàñíû õ¿¿õäèéí äóíä ãýäýñíèé õàëäâàðûí ºâ÷ëºë èõ áàéíà. ßëàíãóÿà Îðõîí, Îðõîíòóóë, Õóøààò ñóìäûí õ¿í àìûí äóíä áîëîí áàãà íàñíû õ¿¿õäèéí äóíä âèðóñò õåïàòèò À, ñóóëãàëò õàëäâàðûí ºâ÷ëºë àéìãèéí äóíäæààñ 1.3-3.8 äàõèí ºíäºð áàéíà.Ýäãýýð ñóìäûí áàãà íàñíû õ¿¿õäèéí äóíäàõ âèðóñò õåïàòèò À-ãèéí ºâ÷ëºë ñóðãóóëü, öýöýðëýãò ãîëîìòëîí ãàð÷ áàéãàà áîë ñóóëãàëò õàëäâàð, öóñàí ñóóëãûí ºâ÷ëºë àõóéí íºõöºëä çîíõèëîí òîõèîëäñîí áàéíà.

Íîì ç¿é:1. ChristonJ.Hurst, Guy R.Knudsen, Michael

J.McInerney, Linda D.Stetzenbach, Michael V. Walter. Manual of Environmental microbiology; 1997.

2. World Health Organization [Internet]. [Place unknown]: Hepatitis A, Fact sheet N°328, [updated June 2014;].

Available from: http://www.who.int/mediacentre/factsheets/fs328/en/

3. World Health Organization [Internet]. [Place unknown]: Dysentery, Available from:

http://www.who.int/topics/dysentery/en/

4. Áàñàíäîðæ Á. Ìîíãîë óëñûí õ¿íèé õºãæëèéí èëòãýë: Óñ áà õ¿íèé õºãæèë; 2010.

5. Õàëäâàðò ºâ÷èí ñóäëàëñýòã¿¿ë; 2004. №1,2,3

6. Áîëîðìàà È.,ªðõèéí óñíû ÷àíàð, àðèóí öýâýð ýð¿¿ë àõóéí áàéäàë, õ¿í àìûí ìýäëýã, äàäàë, õàíäëàãà. Ñóäàëãààíû àæëûí òàéëàí. ÓÁ. 2011


7. Íÿìðàã÷àà ×., Àíàíä Ñ., Íàðàíòóÿà Ë. áà áóñàä. Óíäíû óñíû øèì áîõèðäîëò, óñààð äàìæèõ õàëäâàðààñ ñýðãèéëýõ ýïèäåìèîëîãèéí õÿíàëòûí òîãòîëöîî, óðüä÷èëàí ñýðãèéëýëò. Íèéãìèéí ýð¿¿ë ìýíäèéí õ¿ðýýëýí-Ýðäýì øèíæèëãýýíèé á¿òýýëèéí ýìõýòãýë; 2005.

8. Äýëõèéí ýð¿¿ë ìýíäèéí áàéãóóëëàãà. Õ¿í àìûí óñàí õàíãàìæ, àðèóí öýâðèéí áàéãóóëàìæèéí õ¿ðòýýìæ; 2004.

9. Ýíõöýöýã Ø., Áóðìàà Á., íàð. Óñààð äàìæèõ õàëäâàðò ºâ÷íèé ñóäàëãààíû àæ ëûí òàéëàí; 2005.

http://www.moh.mn/.../water%20survey%20report-%20mongol%20last.doc

10. Íèéãìèéí ýð¿¿ë ìýíäèéí õ¿ðýýëýí. Ýðäýì øèíæèëãýýíèé á¿òýýëèéí ýìõýòãýë- IX; 2011.

11. Íèéãìèéí ýð¿¿ë ìýíäèéí õ¿ðýýëýí. Ýðäýì øèíæèëãýýíèé á¿òýýëèéí ýìõýòãýë-IV; 2005.

12. Ýð¿¿ë ìýíäèéí ÿàì áà áóñàä. Õºäººãèéí õ¿í àìûí óñ õàíãàìæ, àðèóí öýâýð, ýð¿¿ë àõóé; 2007.

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð Í.Ñàéæàà


Ìîíãîë÷óóäûí íèéòëýã õýðýãëýäýã õîîëíû äàâñíû

àãóóëàìæèéã ñóäàëñàí ä¿í

Á.Ýíõòóíãàëàã1,Á.Öîãçîëìàà2, Æàêóé Âåáñòåð4, Î.×èìýäñ¿ðýí3, Æ.Áàòæàðãàë1

e-mail:[email protected]Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñíèé òºâ,

2Äýëõèé ýð¿¿ë ìýíäèéí áàéãóóëëàãûí Ìîíãîë äàõü ñóóðèí òºëººëºã÷èéí ãàçàð3Àíàãààõûí øèíæëýõ óõààíû ¿íäýñíèé èõ ñóðãóóëü

4Àâñòðàëèéí Äýëõèé äàõèíû ýð¿¿ë ìýíäèéí Æîðæ èíñòèòóò

Abstract

Study on salt content in commonly consumed

meals of Mongolians

Batsaikhan Enkhtungalag1, Bayandorj Tsogzolmaa2, Jacqui Webster3, OchirChimedsuren4, JamayanBatjargal1

e-mail:[email protected]

1National Center for Public Health, Mongolia2Office of the WHO Representative in Mongolia,

3The George Institute for Global Health, Australia4 School of Public Health of the Mongolian National University of Medical Sciences

IntroductionExcessive use of salt lead to development of noncommunicable diseases, especially to hypertension [1, 2, 3, 4, 5].The WHO Global Action Plan for the Prevention and Control of NCDs 2013-2020 (Geneva, 2012) called for a reduction of population salt intake by 30 percent by 2025 [13, 14, 15, 15, 16, 17]. There was no any data on salt content collected under the fourth National Survey on Nutrition 2010 and the STEPS survey on the prevalence of noncommunicable disease risk factors 2005, 2009 and 2013. Thus, this is first time ever, the detailed data on salt content was collected and analysed.

Materials and MethodsFifty two food production and food handling organizations were enrolled during 2011-2012 through cross-sectional survey. In total, 251 samples from 43 types of meals were tested NaCI ion by titer method in the laboratory of National Center of Public Health and statistical analysis were done by running SPSS package, Version 19. The ethical approval has been obtained from the Ethics Committee of the Ministry of Health in 2011 (Resolution No. 14).

ResultsAn average content of salt was 0.94 g/100 g (SD 0.42, 95%CI 0.90-1.00) in the commonly used meals from mass catering services. For example, soup has content of 0.86 g/100 ml (SD 0.23, 95%CI 0.81-0.91) of salt; fried meal has 1.03 g (SD 0.41, 95% CI 0.95-1.12); buuz – meat dumpling, khuushuur- fried meat dumpling, buns, pirojki –russian fried dumpling, fried sausage, hot dog, hamburger, pizza and other fast food -1.12 g/100 g (SD 0.34, 95%CI 0.93-1.14); vegetable salad and meat snacks 0.90 g/100 g (SD 0.62, 95%CI 0.77-1.18); tea -0.69 g/100 ml (SD 0.50, 95%CI 0.49-0.92) of salt.

Conclusions Eighty five percent of Mongolian commonly consumed food were classified as ”high salt” content. Mongolian meal recipes for mass catering services that 1 portion of meal contains 1 g salt. The study results will serve as an evidence-based recommendations to further revision of the current recipes. Thus, it is important to renew a salt content in 100 g of foods based on international recommendations.

Keywords: fast food,fried meals, meat snacks, salt, soup, tea, vegetable salad

Pp.36-42, Tables 5, Figures 2, References 22


Îðøèë

Õàëäâàðò áóñ ºâ÷èí (ÕÁª) íü äýëõèéí õ¿í àìûí ºâ÷ëºë, íàñ áàðàëòûí ãîë øàëòãààí áîëæ áàéíà, ÕÁª-íèé íàñ áàðàëòûí øàëòãààíä ç¿ðõ ñóäàñíû ºâ÷èí (48%), õàâäàð (21%)-ûí ºâ÷ëºë äàâàìãàéëæ áàéíà. ÄÝÌÁ-ûí òîîöîîãîîð 2030 îí ãýõýä ÕÁª-íèé íèéò íàñ áàðàëò 55 ñàÿä õ¿ðýõ ìàãàäëàëòàé áàéíà. Äàâñíû èë¿¿äýë õýðýãëýý íü ÕÁª, ÿëàíãóÿà àðòåðèéí äàðàëò èõñýõ ýðñäëèéã íýìýãä¿¿ëæ, àðòåðèéí äàðàëò èõñýëò íü äýëõèéí õ¿í àìûí íàñ áàðàëòûí øàëòãààíû 13%, òàðõèíû öóñ õàðâàëòûí íàñ áàðàëòûí øàëòãààíû 51%, ç¿ðõíèé øèãäýýñèéí íàñ áàðàëòûí øàëòãààíû 49%-èéã òóñ òóñ ýçýëæ áàéíà [1, 2, 3, 4, 5].

Ìîíãîë óëñûí õ¿í àì 2014 îíû æèëèéí ýöñèéí áàéäëààð 2 ñàÿ 930.3 ìÿíãà (ýðýãòýé÷¿¿ä 48.7%, ýìýãòýé÷¿¿ä 51.3%) áàéíà. Íèéò õ¿í àìûí 68.1% íü õîò ñóóðèí ãàçàð, 31.9% íü õºäºº àìüäàð÷ áàéíà. Íàñíû á¿òöýýð àâ÷ ¿çâýë 15- 64 íàñíû õ¿í àì 68.8%, 65-ààñ äýýø íàñíû õ¿í àì 3.8%-èéã òóñ òóñ ýçýëæ áàéíà. Õ¿í àìûí äóíäàæ íàñëàëò 69.11 æèë (ýìýãòýé 75.01, ýðýãòýé 65.42) áàéíà. 2013 îíû áàéäëààð äýëõèéí óëñ îðíóóäûí õ¿í àìûí äóíäàæ íàñëàëòààñ õàðàõàä Ìîíãîë óëñ 157-ðò áè÷èãäñýí áàéíà.

Ìîíãîë óëñûí õ¿í àìûí äóíä õàëäâàðò áóñ ºâ÷ëºëèéí òýðã¿¿ëýõ øàëòãààí áîëæ áàéãàà áà 2013 îíû áàéäëààð 10 000 õ¿í àìä 7091.8 íîãäîæ, 2003 îíòîé õàðüöóóëàõàä 10 000 õ¿í àìä 1-2.5 äàõèí íýìýãäñýí áàéíà.

2013 îíä õ¿í àìûí íàñ áàðàëòûí íèéò øàëòãààíû 35.1%-èéã ç¿ðõ-ñóäàñíû òîãòîëöîîíû ºâ÷èí, 23.4%-èéã õàâäàð, 17.2%-èéã ãýìòýë õîðäëîãî, íàñ áàðàëòûí ãàäíû øàëòãààí, 8.4%-èéã õîîë áîëîâñðóóëàõ òîãòîëöîîíû ºâ÷èí, 3.4%-èéã àìüñãàëûí òîãòîëöîîíû ºâ÷èí ýçýëæ áàéíà.

1995 îíîîñ õîéø õ¿í àìûí íàñ áàðàëòûí òýðã¿¿ëýõ øàëòãààíä ç¿ðõ-ñóäàñíû òîãòîëöîîíû ºâ÷èí, õàâäàð, ãýìòýë õîðäëîãî, íàñ áàðàëòûí ãàäíû øàëòãààí îðæ æèë èðýõ òóòàì ýäãýýð ºâ÷íèé óëìààñ íàñ áàðñàí õ¿íèé òîî íýìýãäñýýð áàéíà. Òóõàéëáàë, 2013 îíä ç¿ðõ-ñóäàñíû òîãòîëöîîíû ºâ÷íººð 5500-6000 õ¿í (íàñ áàðñàí 3 õ¿íèé íýã), õàâäðààð 3500 ãàðóé õ¿í (5 õ¿íèé íýã) íàñ áàðñàí áàéíà.

Ìîíãîë óëñûí 15-64 íàñíû õ¿í àìûí 27.3% (ýðýãòýé÷¿¿äèéí 30.5%, ýìýãòýé÷¿¿äèéí 24.5%) àðòåðèéí äàðàëò èõñýëòòýé; íèéò õ¿í àìûí 36.9% ÕÁª-ººð ºâ÷ëºõ ýðñäýë ºíäºðòýé (3-5 ýðñäýë õàâñàðñàí) áàéíà [6].

Õîîë, õ¿íñíèé á¿òýýãäýõ¿¿íèé äàâñíû àãóóëàì-æèéã ñóäëàõ íü õ¿í àìûí äàâñíû õýðýãëýýíèé ýõ ¿¿ñâýðèéã òîãòîîõ, áóóðóóëàõ àðãà çàìûã òîäîðõîéëîõ øèíæëýõ óõààíû íîòîëãîî áîëæ ºãäºã. Ìîíãîë óëñàä 1992, 1999, 2004, 2010 îíóóäàä õèéãäñýí õîîë òýæýýëèéí ¿íäýñíèé ñóäàëãàà; 2005, 2009, 2013 îíä õèéãäñýí õàëäâàðò áóñ ºâ÷íèé ýðñäýëò õ¿÷èí ç¿éëñèéí òàðõàëòûí ò¿âøèíòîãòîîõ ¿íäýñíèé ñóäàëãààíä õ¿íñíèé á¿òýýãäýõ¿¿íèé äàâñíû àãóóëàìæèéí òàëààð òóñãàãäààã¿é þì [6, 7, 8, 9, 10, 11, 12].

Õ¿í àìûí äàâñíû õýðýãëýýã áóóðóóëàõ íü ÕÁª-íººñ ñýðãèéëýõ èõýýõýí ¿ð ä¿íòýé àðãà õýìæýý áîëîõûã äýëõèéí óëñ îðíóóäûí òóðøëàãà õàðóóëæ áàéíà. ÄÝÌÁ-ààñ 2025 îí ãýõýä äýëõèéí õ¿í àìûí äàâñíû õýðýãëýýã 30% áóóðóóëàõ çîðèëò äýâø¿¿ëæ, áîëîâñðóóëñàí õ¿íñíèé á¿òýýãäýõ¿¿íèé äàâñíû àãóóëàìæèéã ñóäëàõ, áóóðóóëàõ àðãà õýìæýý àâ÷ õýðýãæ¿¿ëýõèéã ãèø¿¿í îðíóóäûí çàñãèéí ãàçàðò çºâëºìæ áîëãîñîí [13, 14, 15, 15, 16, 17].

Ìîíãîë÷óóäûí íèéòëýã õýðýãëýäýã õîîëíû äàâñíû àãóóëàìæèéã ñóäàëæ, îëîí óëñûí ñòàíäàðòòàé õàðüöóóëàí ¿íýëãýý ºãºõºä ñóäàëãààíû àæëûí çîðèëãî îðøèæ áàéâ.


Ñóäàëãààã àíàëèòèê ñóäàëãààíû àãøèíãèéí ñóäàëãààíû çàãâàðààð 2011-2012 îíä õèéñýí. Óëààíáààòàð õîòîä íèéòèéí õîîë ¿éëäâýðëýë ¿éë÷èëãýý ýðõýëäýã 52 áàéãóóëëàãûã ýíãèéí ñàíàìñàðã¿é ò¿¿âðèéí àðãààð ñîíãîí àâ÷ ñóäàëãààíä õàìðóóëñàí. Ñóäàëãàà íü òîîí ìýäýýëýë öóãëóóëàõ àðãàä ¿íäýñëýãäñýí áà äàâñíû àãóóëàìæèéã ëàáîðàòîðèéí øèíæèëãýýíèé àðãààð òîãòîîñîí. Ñóäàëãààíû àæëûí õ¿ðýýíä õîîëíû íèéò 251 äýýæ (øºëòýé õîîë 64, II õîîë 89, ò¿ðãýí õîîë 40, öàé 19, ìàõ áîëîí íîãîîíû çóóø 35, áóñàä 4) öóãëóóëæ, äàâñíû õëîðûí èîíûã òèòðèéí àðãààð ÍÝÌ¯Ò-èéí Ýð¿¿ë ìýíäèéí ëàáîðàòîðèä òîäîðõîéëñîí áºãººä àðãûí ìýäðýìæ ÷àíàð 0.2 ìã/ã áàéñàí [18, 19]. Ñòàòèñòèê áîëîâñðóóëàëòûã IBM SPSS Statistics 19 ïðîãðàìì äýýð ã¿éöýòãýæ, äóíäàæ ¿ç¿¿ëýëò¿¿äèéã òîîöîæ, õîëáîãäîõ ñòàíäàðò, òåõíèêèéí øààðäëàãóóäòàé õàðüöóóëàâ [20, 21, 22]. Ñóäàëãààíû ¸ñ ç¿éí àñóóäëûã ÝÌß-íû Äýðãýäýõ Àíàãààõ óõààíû ¨ñ ç¿éí õÿíàëòûí õîðîîíû õóðëààð 2011 îíû 7 äóãààð ñàðä õýëýëö¿¿ëæ, (õóðëûí òîãòîîë №14) ñóäàëãàà õèéõ çºâøººðëèéã àâñàí.

¯ð ä¿í

Íèéòèéí õîîëíû ãàçðóóäàä õóäàëäàí áîðëóóëæ áóé õîîëíû äàâñíû àãóóëàìæèéã (n=251, òóñ á¿ð 100ã) ñóäëàõàä äóíäæààð 0.94ã/100ã (Ñò.õàç 0.42,


95% ÈÌ 0.90-1.00) äàâñ àãóóëàãäàæ áàéíà (Çóðàã 1). Óã ¿ç¿¿ëýëòèéã îëîí óëñûí ñòàíäàðò (0.3ã/100ã, “äàâñíû çýðãèéí äàâñòàé”)-òàé õàðüöóóëæ, íýã òºâèéí õàìààðàëò “t” òåñòýýð øàëãàõàä

ìîíãîë÷óóäûí íèéòëýã õýðýãëýäýã õîîëíû äàâñ ñòàíäàðòàä çààñàí õýìæýýíýýñ 0.65ã-ààð èõ (95% 0.60-0.70, ð=0.001) áàéíà.

Figure 1. Average salt content in commonly consumed meals of Mongolians

Table 1. Mean salt content in soups (g/100ml)

Meals type & nameMean

(g/100ml)St.Dev

95% CI

Lower UpperNoodles & meat soup 0.79 0.18 0.65 0.92

Vegetable & meat soup 0.99 0.27 0.86 1.20

Dumpling soup 0.80 0.23 0.63 0.99

Meat soup 0.71 0.27 0.55 0.87

Rice & meat soup 0.89 0.16 0.75 1.12

Broth with meat balls soup 0.98 0.12 0.86 1.08

Rib soup 0.80 0.24 0.60 1.03

Fired vegetables & meat soup (huitsaa) 0.94 0.12 0.84 1.05

Mulligan soup 0.93 0.23 0.74 1.10

Bantan (meat soup with flour) 0.83 0.22 0.71 1.02

Total 0.86 0.23 0.81 0.91

Õ¿ñíýãò 1-ýýñ õàðàõàä á¿õ òºðëèéí øºëòýé õîîë, ÿëàíãóÿà íîãîîòîé øºë, áººðºíõèé ìàõòàé øºë õàìãèéí èõ äàâñòàé (0.99ã/100ìë; 0.98ã/100ìë) áàéíà. Õóóðñàí, øàðñàí 16 òºðëèéí 89 õîîëîíä õèéñýí

ñóäàëãààãààð äóíäæààð 1.03ã (Ñò.Õàç 0.41, 95% ÈÌ 0.95-1.12) äàâñ àãóóëàãäàæ áàéíà. Äàâñíû àãóóëàìæ íü õîîëíû íýð òºðëººñ õàìààðàí ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààòàé áàéíà (ð=0.001, Õ¿ñíýãò 2).

Tables 2. Mean salt content in fired meals (g/100g)


(g/100ml)St.Dev

95% CI

Lower UpperFired rice & meat 0.89 0.33 0.67 1.13

Goulash 0.87 0.22 0.73 1.05

Fired vegetables & meat 0.91 0.08 0.86 1.01

Potato casserole 1.06 0.26 0.90 1.46


Tsuivan (meat, vegetables & flour) 1.04 0.28 0.86 1.25

Fired meat 0.79 0.17 0.65 0.94

Fired mushroom & meat 1.62 0.21 1.44 1.85

Fired egg & meat 0.85 0.12 0.67 0.96

Fired pepper & meat 0.88 0.18 0.73 1.03

Spaghetti 1.11 0.32 0.84 1.35

Teftel 1.10 0.33 0.86 1.29

Fired fish 1.82 0.50 1.45 2.19

Fired chicken 0.96 0.20 0.77 1.17

Fired dumpling 0.90 0.27 0.69 1.13

Fired liver 0.60 0.13 0.51 0.70

Fired rib 0.99 0.65 0.53 1.54

Total 1.03 0.41 0.95 1.12

Õ¿ñíýãò 2-ò äóðüäñàí øàðñàí, õóóðñàí 100ã õîî ëîíä àãóóëàãäàæ áóé äàâñíû äóíäàæ õýìæýý (1.03ã, Ñò.Õàç 0.41, 95%ÈÌ 0.95-1.12)-ã ñòàíäàðò(0.3ã/100ã)-òàé õàðüöóóëæ, íýã òºâèéí õàìààðàëò “t” òåñòýýð øàëãàõàä ñòàíäàðòàä çààñàí õýìæýýíýýñ 0.73ã (95%ÈÌ 0.65-0.83)-ààð èõ äàâñòàé áàéíà (t=16.9, ð=0.001). Øàðñàí çàãàñ, ìººãòýé õóóðãà áóñàä õîîëòîé õàðüöóóëàõàä

õàìãèéí èõ äàâñòàé (1.82ã/100ã; 1.62ã/100ã) áàéíà.

Áóóç, õóóøóóð, ìàíòóóí áóóç, ïèðîøêè, øàðñàí çàéäàñ, õîòäîã, ãàìáóðãåð, ïèööà (n=40) çýðýã ò¿ðãýí õîîëîíä õèéñýí ñóäàëãààãààð äóíäæààð 1.12ã/100ã (Ñò.õàç 0.34, 95% ÈÌ 0.93-1.14) äàâñ àãóóëàãäàæ áàéíà (ð=0.03, Õ¿ñíýãò 3).

Table 3. Mean salt content in fast food (g/100g)


(g/100ml)St.Dev

95% CI

Lower UpperBuuz 0.92 0.26 0.71 1.13Mantuun buuz 0.92 0.27 0.72 1.14khuushuur 0.86 0.30 0.61 1.16Peroski 0.90 0.16 0.76 1.03Fired sausage 1.17 0.47 0.80 1.58Pizza 1.42 0.36 1.11 1.72Hotdog, cheeseburger and hamburger

1.27 0.05 1.10 1.18

Total 1.12 0.34 0.93 1.14

Õ¿ñíýãò 3-ò äóðüäñàí 100ã ò¿ðãýí õîîëîíä àãóóëàãäàæ áóé äàâñíû äóíäàæ õýìæýý (1.12ã, Ñò.Õàç 0.34, 95%ÈÌ 0.93-1.124)-ã ñòàíäàðò ¿ç¿¿ëýëò (0.3ã/100ã)–òýé õàðüöóóëæ, íýã òºâèéí õàìààðàëò “t” òåñòýýð øàëãàõàä ñòàíäàðòàä çààñàí õýìæýýíýýñ 0.73ã (95%ÈÌ 0.63-0.84)-ààð èõ áàéíà (t=16.6, ð=0.0001). Ìºí ïèööà, õîòäîã, ÷åñáóðãåð, ãàìáóðãåð çýðýã ò¿ðãýí õîîë õàìãèéí èõ äàâñòàé áàéíà.

Öàéíû 19 äýýæèä õèéñýí ñóäàëãààãààð äàâñíû äóíäàæ àãóóëàìæ 0.69ã/100ìë (Ñò.õàç 0.50, 95%ÈÌ

0.49-0.92) áàéíà. Óã ¿ç¿¿ëýëòèéã îëîí óëñûí ñòàíäàðò (0.3ã/100ìë)-òàé õàðüöóóëæ, íýã òºâèéí õàìààðàëò “t” òåñòýýð øàëãàõàä ñòàíäàðòàä çààñàí õýìæýýíýýñ 0.39ã (95%ÈÌ 0.15-0.64)-ààð èõ äàâñ àãóóëàãäàæ áàéâ (t=3.38, ð=0.003). Áàíøòàé öàéíä 0.88ã/100ìë (Ñò.õàç 0.26, 95% ÈÌ 0.71-1.10); ñ¿¿òýé öàéíä 0.68ã/100ìë (Ñò.õàç 0.61, 95% ÈÌ 0.34-1.20); õàð öàéíä 0.43ã/100ìë (95%ÈÌ 0.22-1.0) äàâñ òóñ òóñ àãóóëàãäàæ áàéíà (Çóðàã 2).


Òºðºë á¿ðèéí íîãîîíû ñàëàò, ìàõàí çóóø (n=35)-íû äàâñíû äóíäàæ àãóóëàìæ 0.90ã/100ã (Ñò.õàç 0.62, 95%ÈÌ 0.77-1.18) áàéíà. Á¿òýýãäýõ¿¿íèé

íýð òºðëèéí õóâüä äàâñíû àãóóëàìæèä ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãàà àæèãëàãäàõã¿é áàéíà (ð=0.58, Õ¿ñíýãò 4).

Figure 2. Mean salt content in tea (g/100ml)

Table 4. Mean salt content in saladand meat snacks (g/100g)


(g/100ml)St.Dev

95% CI

Lower UpperFresh vegetables salad 0.68 0.37 0.40 1.11Potato’s salad 0.90 0.22 0.70 1.11Carrot salad 1.03 0.36 0.72 1.42Cabbage salad 1.07 0.95 0.46 2.08Eggs salad 0.56 0.16 0.41 0.69Meat snacks 1.12 0.29 0.86 1.34Khanchan’s 1.29 1.22 0.42 2.58

Total 0.90 0.62 0.77 1.18

Õ¿ñíýãò 4-ä äóðüäñàí äóíäàæ ¿ç¿¿ëýëò (0.90ã, Ñò.õàç0.62, 95%ÈÌ 0.77-1.18)-ã ñòàíäàðò (0.3ã/100ã)-òàé õàðüöóóëæ, íýã òºâèéí õàìààðàëò “t” òåñòýýð øàëãàõàä ñòàíäàðòàä çààñàí õýìæýýíýýñ 0.65ã (95%ÈÌ 0.43-0.86)-ààð èõ äàâñ àãóóëàãäàæ áàéíà (t=6.17, ð=0.000).

Õýëöýìæ

Ìîíãîë óëñûí õ¿íñíèé ñòàíäàðòóóäàä òóõàéí á¿òýýãäýõ¿¿íèé 100ã-ä àãóóëàãäàõ äàâñíû õýìæýý òîäîðõîé òóñãàãäààã¿é, ìºí íèéòèéí õîîëíû æîð, òåõíîëîãèä äàâñíû îðö õýìæýýã 1 ïîðöîä 1ãáàéõààð ºíäºð òîãòîîãäñîí áàéíà. Í¯Á-ûí ÕÕÀÀÁ, ÄÝÌÁ-ûí õàìòàðñàí Õ¿íñíèé Ýðõ Ç¿éí Êîìèññ (ÕÝÇÊ)-îîñ óëñ îðíóóäàä çºâëºìæ áîëãîæ áóé Codex Standard for Food Grade Salt.

CODEX STAN 150 (1985, 1997, 2006); Guidelines for Use of Nutrition Health Claims.CAC/GL23(1997, 2004, 2013) çýðýã ñòàíäàðòàä çààñíààð 100ã-ä àãóóëàãäàõ äàâñíû õýìæýýãýýð íü õîîë õ¿íñíèé á¿òýýãäýõ¿¿íèéã “äàâñã¿é” (0.005ã/100ã); “ìàø áàãà äàâñòàé” (0.04ã/100ã); “áàãà äàâñòàé” (0.12ã/100ã); “äóíä çýðãèéí äàâñòàé” (0.13ã-0.6ã/100ã); “èõ äàâñòàé” (>0.6ã/100ã) ãýæ 5 àíãèëñàí áàéäàã [18, 20]. Áèäíèé ñóäàëãààíû ¿ð ä¿íã êîäåêñèéí äýýðõ 2 ñòàíäàðòòàé õàðüöóóëàõàä ñóäàëãààíä õàìðàãäñàí íèéò õîîëíû äºíãºæ 0.8 õóâü (95% ÈÌ 0.0-2.0) íü “áàãà äàâñòàé”; 14.3 õóâü (95%ÈÌ 10.0-18.7) íü “äóíä çýðãèéí äàâñòàé”, äèéëýíõ áóþó 84.9 õóâü (95% ÈÌ 80.5-89.67) íü “èõ äàâñòàé” áàéíà (ð=0.001, Õ¿ñíýãò 5).

0.88

0.68

0.54

0

0.2

0.4

0.6

0.8

1

1.2

Milk tea with dumpling Milk tea Black tea

Salt

(g)

Tea type

1.2

1

0.8

0.6

0.4

0.2

0

0.88

0.68

0.54


Table 5. Classification by salt content of commonly consumed meals of Mongolians

Meals type N Low salty(%, 95% ÈÌ)

Medium salty(%,95% ÈÌ)

High salty(%,95% ÈÌ)

Soups 64 - 12.5(4.7-20.3) 87.5(79.7-95.3)Fired meals 89 - 6.7(2.2-12.4) 93.3(89.6-97.8)

Tea 19 10.5(0.0-26.3) 42.1(21.1-63.2) 47.4(26.3-68.4)

Salads 35 - 25.7(11.7-40.0) 74.3(60.0-88.6)

Fast foods 40 - 7.5 (0.7-17.5) 92.5(82.5-100.0)

Others 4 - 2.0(50.0-50.0) 2.0(50.0-50.0)

Total 251 0.8(0.0-2.0) 14.3(10.4-19.1) 84.9(80.5-88.8)

Íèéòèéí õîîëíû ãàçðààð ¿éëë÷ë¿¿ëýã÷äèéí õóâüä ÄÝÌÁ-ûí çºâëºìæèéí äàãóó äàâñ èõòýé õîîë õýðýãëýõã¿é áàéõ áîëîìæ õÿçãààðëàãäìàë áàéíà. Òóõàéëáàë, íèéòèéí õîîëíû ãàçðóóäàä ò¿ãýýìýë õýðýãëýãääýã 10 íýð òºðëèéí 62 øºëòýé õîîëíû äºíãºæ 1.1 õóâü (95% ÈÌ 0.9-1.2) íü “äàâñ áàãàòàé”, 15.0 õóâü (95%ÈÌ 0.9-1.2) íü “äóíä çýðãèéí äàâñòàé”, õàðèí äèéëýíõ íü áóþó 84.0 õóâü (95%ÈÌ 82.4-85.4) íü “äàâñ èõòýé” áàéíà.

Ä¿ãíýëò:

1. Ìîíãîë÷óóäûí íèéòëýã õýðýãëýäýã øºëòýé õîîëíû äàâñíû àãóóëàìæ 0.86ã/100ìë, øàðñàí áîëîí õóóðñàí õîîëíû äàâñíû àãóóëàìæ 1.03ã/100ã; áóóç, õóóøóóð, ìàíòóóí áóóç, ïèðîøêè, øàðñàí çàéäàñ, õîòäîã, ãàìáóðãåð, ïèööà çýðýã ò¿ðãýí õîîëíû äàâñíû àãóóëàìæ 1.12ã/100ã; òºðºë á¿ðèéí öàéíû äàâñíû àãóóëàìæ 0.69ã/100ìë; íîãîîíû ñàëàò, ìàõàí çóóøíû äàâñíû àãóóëàìæ 0.90ã/100ã òóñ òóñ áàéíà.

2. Îëîí óëñûí ñòàíäàðòòàé õàðüöóóëàõàä Ìîíãîë÷óóäûí íèéòëýã õýðýãëýäýã õîîëíû äèéëýíõ áóþó 84.9 õóâü íü “äàâñ èõòýé” ººðººð õýëáýë, ÄÝÌÁ-ûí çºâëºìæººð õýðýãëýõýýñ òàòãàëç ãýñýí àíãèëàëä áàãòàæ áàéíà.

3. Ìîíãîë óëñàä îäîîãîîð õ¿÷èí òºãºëäºð ìºðäºæ áóé íèéòèéí õîîëíû æîð òåõíîëîãèä äàâñíû õýìæýý ºíäºð òóñãàãäñàí íü äàâñ èõòýé õîîë ¿éëäâýðëýë ¿éë÷èëãýý ÿâóóëàõ íýã íºõöºë áîëæ áàéãàà òóë íèéòèéí õîîëíû æîð òåõíîëîãèéã øèíý÷ëýõ, 100ã-ä àãóóëàãäàõ äàâñíû õýìæýýã îëîí óëñûí ñòàíäàðòàä íèéö¿¿ëýí øèíýýð òîãòîîõ øààðäëàãàòàé áàéíà.

Íîì ç¿é

1. WHO. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization (WHO); 2009; 3:17-8 p.

2. WHO. Global Status Report on Non-communicable Diseases.Italy: World Health Organization (WHO); 2011:9-15 p.

3. WHO. Global Action Plan for the Prevention and Control of Non communicable Diseases 2013-2020.Geneva: World Health Organization (WHO); 2013:7 p.

4. WHO. Guidilene on Sodium Intake for Adults and Children. Geneva: World Health Organization (WHO); 2012:7p.

5. WHO.Salt Reduction: Key Facts [Internet]. Fact sheet N°393.Geneva: World Health Organization; September 2014 [cited 2015 Feb 03]. Available from: http://www.who.int/mediacentre/factsheets/fs393/en/

6. ÝÌß, ÍÝÌ¯Ò, ÄÝÌÁ, ÌÌÑÑ. Õàëäâàðò áóñ ºâ÷èí, îñîë ãýìòëèéí øàëòãààí, ýðñäýëò õ¿÷èí ç¿éëñèéí òàðõàëòûí øàòàëñàí ñóäàëãàà. Ìîíãîë óëñ-2013. Æåíåâ: Äýëõèéí ýð¿¿ë ìýíäèéí áàéãóóëëàãà (ÄÝÌÁ); 2014;31-32, 42-68 õ.

7. ÝÌÍÕß, ÕÑÒ, Í¯ÁÕÑ. Õ¿¿õäèéí õîîë òýæýýëèéí áàéäàë. ¯íäýñíèé ñóäàëãàà, Óëààíáààòàð: Ýð¿¿ë ìýíäèéí ÿàì (ÝÌß); 2002.94-106 õ.

8. ÝÌß, ÍÝÌÕ, Í¯ÁÕÑ. Õ¿í àìûí õîîë òýæýýëèéí áàéäàë. ¯íäýñíèé õî¸ðäóãààð ñóäàëãàà. Óëààíáààòàð: Íèéãìèéí Ýð¿¿ë Ìýíäèéí Õ¿ðýýëýí (ÍÝÌÕ); 2002:

9. ÝÌß, ÍÝÌÕ, Í¯ÁÕÑ. Ìîíãîëûí õ¿¿õýä, ýìýãòýé÷¿¿äèéí õîîë òýæýýëèéí áàéäàë. ¯íäýñíèé ãóðàâäóãààð ñóäàëãàà. Óëààíáààòàð: Íèéãìèéí ýð¿¿ë ìýíäèéí õ¿ðýýëýí (ÍÝÌÕ); 2006:94-106 x.

10. ÝÌß, ÕÕÀÀÕ¯ß, ÍÝÌÕ, Í¯ÁÕÑ, Äýëõèéí Çºí Ìîíãîë, ÄÝÌÁ. Ìîíãîëûí õ¿í àìûí õîîë òýæýýëèéí áàéäàë. ¯íäýñíèé IV ñóäàëãààíû


òàéëàí. Óëààíáààòàð: Íèéãìèéí Ýð¿¿ë Ìýí-äèéí õ¿ðýýëýí (ÍÝÌÕ); 2011.p103-104, 109-110, 131-132, 151, 162-164 x.

11. ÝÌß, ÍÝÌÕ, ÄÝÌÁ. Õàëäâàðò áóñ ºâ÷èí, îñîë ãýìòëèéí øàëòãààí, ýðñäýëò õ¿÷èí ç¿éëñèéí òàðõàëòûí ¿íäýñíèé ñóäàëãàà-2005. Æåíåâ: Äýëõèéí Ýð¿¿ë Ìýíäèéí Áàéãóóëëàãà (ÄÝÌÁ); 2006;31-32, 42-68p.

12. ÝÌß, ÍÝÌÕ, ÄÝÌÁ, ÌÌÑÑ. Õàëäâàðò áóñ ºâ÷èí, îñîë ãýìòëèéí øàëòãààí, ýðñäýëò õ¿÷èí ç¿éëñèéí òàðõàëòûí ¿íäýñíèé ñóäàëãàà-2009. Æåíåâ: Äýëõèéí Ýð¿¿ë Ìýíäèéí Áàéãóóëëàãà (ÄÝÌÁ); 2010;31-32, 42-68 p.

13. Nicole Li, John Prescott, Yangfeng Wu. The effects of a reduced sodium, high- potassium salt substitute on food taste and acceptability in rural northern China, British Journal of Nutrition (2009) 101:1088-1093 p.

14. Jacqueline L, Webster, Elizabeth K, Salt reduction initiatives around the world, Journal of Hypertension 2011, 29:1043-1050 p.

15. WHO. Reducing Salt Intake in Populations, Report of a WHO Forum and Technical Meeting, 5-7 October 2006, Paris: France; 2006:3 p.

16. WPRO. Meeting Report Regional Consultation on Strategies to Reduce Salt Intake. World Health Organization, Western Pacific Region. Singapore 2-3 June.2010. Manila: World Health Organization, Western Pacific Region (WPRO); 2010;1-3 p.

17. WHO. Policy Brief: Reducing the Use of Salt in the Food Industry to Lower Sodium Consumption. Geneva: World Health Organization (WHO); December;2014

18. CAC. Codex Standard for Food Grade Salt. CODEX STAN 150-1985, Rev.1-1997, Amended in 2001, 2006. Rome, Codex Alimentarius Commission (CAC);2006;3 p.

19. Ìîíãîë óëñûí ñòàíäàðò. Õ¿íñíèé äàâñ:Òåõíèêèéí øààðäëàãà. NNS ÑÀÑ 150:2007. Óëàààíáààòàð: Ñòàíäàðò Õýìæèë Ç¿éí Ãàçàð (ÑÕÇÃ);2007

20. Joint FAO/WHO Food Standards Programme. Guidelines for Use of Nutrition Health Claims.CAC/GL 23-1997, Revised in 2004, Amended in 2011. Rome: Codex Alimentarius Commission (CAC);2013:3p.

21. Joint FAO/WHO Food Standards Programme. Standard for Salted Fish and Dried salted Fish of the Gadidae Family of Fished. CODEX STAN 167-1989, Amendments 2011. Rome: Codex Alimentarius Commission(CAC);2013:3 p.

22. Ìîíãîë óëñûí ñòàíäàðò. Ñàâëàñàí õ¿íñíèé á¿òýýãäýõ¿¿íèé øîøãîëîòîä òàâèãäàõ åðºí õèé øààðäëàãà, NNS ÑÀÑ 150:2007.Óëàààíáààòàð: Ñòàíäàðò Õýìæèë Ç¿éí Ãàçàð (ÑÕÇÃ);2007;3 p

Òàëàðõàë

Ýíýõ¿¿ ñóäàëãààã ÿâóóëàõàä äýìæëýã ¿ç¿¿ëñýí Íèéãìèéí Ýð¿¿ë Ìýíäèéí ¯íäýñíèé Òºâ, Äýëõèéí Ýð¿¿ë Ìýíäèéí Áàéãóóëëàãûí õàìò îëîí; ØÓÒÈÑ, Îòãîí òýíãýð ÄÑ, Îð÷ëîí äýýä ñóðãóóëèéí îþóòíû çîîãèéí ãàçàð; ÍÝÌÃ, ÑÁÄ-èéí ÝÌÍ, “Ìàõ èìïåêñ” ÕÊ, “Òàëõ ÷èõýð” ÕÊ, “Ãî¸î” ÕÊ-èéí àæèë÷äûí öàéíû ãàçàð; “BBQ Chicken”, “Áýýæèí”, “Ben Joe”“Jin Hi and I”, “Íàíäèí” çýðýã ðåñòîðàí; “Óêðàéí Ìîíãîë Çîîã”, “Òîõèëîã Çîîã”, “Íàðëàã Çîîã”, “Àëòàé òîîðîé”, “Æàðãàëàí”, “Õààí áóóç” çýðýã çîîãèéí ãàçàð; “Øèìò áóóç”, “Òàëñò”, “Íèéñëýë”, “Äºë”, “Íàðàíòóóë”, “Öýöãýí áóóç”, “Ramon”, “Freedom”, “Õîíãîð”, “Çóí öàã”, “Áàÿëàã áóóç”, “Ìîíãîë õààí” çýðýã êàôåéíû õàìò îëîíä ÷èí ñýòãýëèéí òàëàðõàë èëýðõèéëæ, àæëûí ºíäºð àìæèëò õ¿ñüå!

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí:Àíàãààõûí øèíæëýõ óõààíû äîêòîð,

ïðîôåññîð Á.Áóðìààæàâ


Áè÷èë óóðõàé ýðõëýã÷äèéí ìºíãºí óñíû ýð¿¿ë ìýíäèéí íºëººëºë, àðõàã

õîðäëîãîòîé çàðèì ºâ÷òºíèéã èëð¿¿ëñýí òóõàé

Ð.Äàâààäîðæ, Ä.Áààòàðöîë, Ñ.Îþóíòóíãàëàã, Ä.Ñóâä, Ã.Î÷, Ã.Óÿíãà, Ã.Õóëàí, Á.Õóëàí, Á.Ãîâüãýðýë, Ñ.ªíºðñàéõàí

Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñíèé òºâÅ-ìàéë: [email protected]

Abstract

The health impact assessment of mercury on artisanal and small scale miners and revealed chronic mercury intoxicated patients

R.Davaadorj, D.Baatartsol, S.Ouyntungalag, D.Suvd, G.Och, G.Uyanga, G.Khulan, B.Khulan, B.Govigere, S.Unursaikhan

National Center of the Public Health, Mongolia,

IntroductionIn connection with request and financial assistance of Swiss Development Agency ‘’Mercury exposure and health impact assessment study among small scale miners in mercury free technology, was conducted by researchers of Toxicology division of NCPH.

GoalTo determine mercury exposure level in biological samples of local small scale miners from mercury free technology introduced area. To reveal chronic mercury intoxicated patients,

Materials and MethodsTotally 147 artisanal miners from 33 cooperatives for small scale mining from Bayan-Îvoo soum of Bayankhongor, Bornuur sum of Tuv, Bayangol, Mandal and Tunkhel sum of Selenge province are participated in this study and the study was performed by cross sectional study methods during April to December, 2014.

Over all 147 participants were in the first part of study, 60.5% out of 147 (89 participants) were in second parts, and another 35.4% (52 people) were participated to the third parts of study. The participants were undergone in to toxicological, dermatological and neurological examinations and the WHO guidance for mercury exposure determination was followed in this study.

ResultsOn the results of all testing we revealed that there were 2 cases of chronic mercury intoxicated patients from each Bayangol Bornuur soum, 2 from Mandal soum, and 3 from Bayanovoo soum.Overall 7 patients were diagnosed as chronic mercury intoxicated and it comprised 4.7%of (n=147) all involved participants.We have observed that average height of total medical examination number was (2.9) in Bornuur soum. It indicated that there will have higher number of patients would exist in Bornuur soum than others.Our study result has shown that neurological symptoms like tremor and imbalance were more diagnosed among participants from Mandal and Bayngol soums. It implies that the health of the small scale miners from this soum more affected and needed to be investigating further.

ConclusionsMercury is still being used among artisanal gold miners even thoughit is still illegal. Further medical evaluation and assistance needed to be taken for newly diagnosed 7 patients.

Key words: gold mining, artisanal miners,chronic mercury intoxication, tremor, lost balance

Pp. 43-48 , Tables 5, Figure 1, References 5


¯íäýñëýë

Ìîíãîë Óëñûí Çàñãèéí Ãàçðààñ áè÷èë óóðõàéí ñàëáàðûã òºðººñ çîõèöóóëàõ àðãà õýìæýýíèé õ¿ðýýíä Çàñãèéí ãàçðûí 2010 îíû 308 äóãààð òîãòîîëîîð “Áè÷èë óóðõàéãààð àøèãò ìàëòìàë îëáîðëîõ æóðàì”-ûã áàòàëñàí. Õóâèàðàà àøèãò ìàëòìàë îëáîðëîã÷äûí ýð¿¿ë ìýíä, àõóé àìüäðàë, îðîí íóòãèéí ýäèéí çàñãèéí õºãæèë, îð÷íû ýð¿¿ë ìýíäèéã äýìæèõ çîðèëãîîð Óóë óóðõàé ÿàì Øâåéöàðèéí õºãæëèéí àãåíòëàãòàé õàìòðàí 2008 îíä Òºâ àéìãèéí Áîðíóóð ñóìàíä áè÷èë óóðõàé÷äûí ñàíàà÷èëãààð ìºíãºí óñ õýðýãëýõã¿éãýýð àëòíû õ¿äýð áîëîâñðóóëàõ öåõèéã áàéãóóëæ, ñàíõ¿¿ãèéí áîëîí òåõíîëîãèéí äýìæëýã ¿ç¿¿ëñýí. Îäîîãèéí áàéäëààð Ìîí-ãîë óëñàä àëò îëáîðëîõ ¿éë àæèëëàãààíä îðîëöîã÷ íèéò 10.5 ìÿíãàí èðãýíèé 75.8 õóâü íü õóâèàðàà àëò îëáîðëîã÷ áóþó ãýð á¿ëèéíõýý àëò îëáîðëîëòûí ¿éë àæèëëàãààíä îðîëöîæ, ¿ëäñýí 24.2 õóâü íü íºõºðëºëèéí çîõèîí áàéãóóëàëòàíä îðæ, ¿éë àæèëëàãàà ýðõýëæ áàéíà (Áè÷èë óóðõàé ýðõëýã÷äèéí ñóäàëãààíû íýãäñýí òàéëàí, 2012 îí).

Øâåéöàðèéí õºãæëèéí àãåíòëàãèéí çàõèàëãààð ìºíãºí óñã¿é òåõíîëîãè ýðõýëäýã áè÷èë óóðõàé ýðõëýã÷äèéí äóíä ìºíãºí óñíû ºðòºëò áîëîí ýð¿¿ë ìýíäèéí íºëººëëèéí òàëààðõ ñóäàëãààã õýðýãæ¿¿ëýõ õ¿ñýëò ãàðãàñíû äàãóó ÍÝÌ¯Ò-èéí Õîð ñóäëàëûí ñåêòîðûí ìýðãýæèëòí¿¿ä ÕßÒ¯Ò, ÝÕÝÌ¯Ò, ÀªÑ¯Ò-èéí ýì÷ ìýðãýæèëòí¿¿äòýé õàìòðàí ýíýõ¿¿ ñóäàëãààã 2014 îíû 4-12 ñàðûí õîîðîíä õèéæ ã¿éöýòãýâ.

Çîðèëãî

Ìºíãºí óñã¿é òåõíîëîãè íýâòð¿¿ëñýí îðîí íóòãèéí áè÷èë óóðõàé ýðõëýã÷äèéí äóíä ìºíãºí óñíû ºðòºëòèéí ¿åèéí ýð¿¿ë ìýíäèéí íºëººëëèéã òîãòîîõ, àðõàã õîðäëîãûí øèíæ á¿õèé ºâ÷òºíèéã èëð¿¿ëýõ


Ñóäàëãààíä áè÷èë óóðõàéí íºõºðëºëèéí õýë-áýðýýð àëò îëáîðëîõ ¿éë àæèëëàãààíä îðîëöîæ áàéãàà Áàÿíõîíãîð àéìãèéí Áàÿí-Îâîî, Òºâ àéìãèéí Áîðíóóð, Ñýëýíãý àéìãèéí Áàÿíãîë, Ìàíäàë ñóìä áîëîí Ò¿íõýë òîñãîíû íèéò 33 áè÷èë óóðõàéí íºõºðëºëèéí 147 áè÷èë óóðõàé ýðõëýã÷èä õàìðàãäñàí áà ñóäàëãààã íýã àãøèíãèéí ñóäàëãààíû çàãâàðààð 3 ¿å øàòòàé 2014 îíû 04-12 ñàðä õèéæ ã¿éöýòãýâ. “Ýð¿¿ë ìýíäèéã õàìãààëàõ òåõíîëîãè–Ìºíãºí óñ, ò¿¿íèé íýãäë¿¿äèéí õîðä-ëîãûí îíîøèëãîî, ýì÷èëãýý” MNS 6450:2014 ñòàíäàðòûí äàãóó ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé ýðõëýã÷äýýñ ºðòºëòèéí ìýäýýëëèéã

öóãëóóëæ, ìýäðýëèéí ¿çëýã õèéí, ¿íýëãýý ºãñàí. Ìºíãºí óñíû õîðäëîãûí ¿íäñýí øèíæ áîëîõ ÿâàõ òýíöâýð àëäàãäàõ, õî¸ð õºëèéí æèéõ õºäºëãººíä ýâñýë àëäàãäàõ, õ¿÷äýëèéí ñàëãàíàë ¿¿ñýõ, çîâõè ÷è÷ðýõ, õºë ñàëãàëàõ çýðýã øèíæ¿¿äèéã èëð¿¿ëýõèéí òóëä äèñäèàäîõîêèíåç õàì øèíæèéã èëð¿¿ëäýã ñòàíäàðò ¿çëýãèéí òóñëàìæòàéãààð õºäºëãººíèé ýâñýë çîõè-öóóëãà øàëãàõ, õºäºëãººíèé Ìýäðýõ¿éí Öþðè-õèéí ¿íýëãýý (ZNA)-íä òóñãàãäñàí íýìýãäýë òåñòèéí äàãóó äèñäèàäîõîêèíåçèéã èëð¿¿ëýõ çýðýã ñîðèëòóóäûã àøèãëàñàí. Ñóäàëãààíû ¿ð ä¿íãèéí ìýäýýëëèéí ºãºãäëèéã êîäëîõ, øèâýõ, àëäààã øàëãàñíû äàðàà “SPSS 17.0” ïðîãðàìì àøèãëàí áîëîâñðóóëàëò õèéâ.

¯ð ä¿í

Ñóäàëãààíä îðîëöîã÷äûí ýð¿¿ë ìýíäèéí áàéäëûã àñóóìæààð ¿íýëýõýä 85.7% íü ýð¿¿ë, 6.1% íü îäîî õàëóóíòàé, 16.3% íü ñ¿¿ëèéí 1 æèëä òóðñàí, 22.4% íü ñ¿¿ëèéí íýã æèëä 3 áà ò¿¿íýýñ äýýø óäàà õàíèàä õ¿ðñýí, 12.2% íü ÿìàð íýãýí õàëäâàðò ºâ÷íººð ºâäºæ áàéñàí, 34.7% íü øýýñíèé çàìûí õàëäâàðààñ ãàäíà áººðíèé çàìûí ºâ÷íººð ºâäºæ áàéñàí, 17% íü ýëýãíèé ºâ÷íººð ºâäºæ áàéñàí, 18.4% íü àìüñãàëûí çàìûí ºâ÷íººð õ¿íäýýð ºâ÷èëæ áàéñàí, 6.1% íü ñ¿ðüåýãýýð ºâäºæ áàéñàí, 6.8% íü ìýäðýëèéí áîëîí ñýòãýöèéí ãàðàëòàé ÿìàð íýã ºâ÷íººð ºâäºæ áàéñàí ãýæ õàðèóëñàí.

Áè÷èë óóðõàé ýðõëýã÷äèéí ñóáüåêòèâ çîâèóðóóäûã 21 àñóóëòûí äàãóó ÿðèëöàæ èëýð÷ áóé øèíæ òýìäã¿¿äèéã ìºíãºí óñíû íºëººëºëòýé õîë-áîí ¿çýæ áàéãàà ýñýõèéã òîäðóóëàâ. Àñóóìæ ñóäàëãààíû ä¿íãýýñ õàðàõàä ñóäàëãààíä õàìðàãä-ñàí áè÷èë óóðõàé ýðõëýã÷äèéí 2.7% íü õîîëîíä ìóó, 25.2%-ä íü ñ¿¿ëèéí íýã æèë ¿ñ óíàëò íü èõýññýí, 8.2% íü íîéðîíäîî ìóó, 13.6%-ä íü àìàíä ìåòàëëûí àìò àìòàãääàã, 15.6%-ä íü ø¿ëñ ÿëãàðàëò èõýññýí, 21.1% íü ñàëãàíàõ çîâèóðòàé, 34.7% íü àìàðõàí ÿäàðäàã, 23.8%-ä íîéðìîã, óíòàà øèíæ èëýðäýã, 29.3%-ä íü òàìèð òýíõýý äóòàãäàæ áàéäàã, 24.5%-ä íü àíõààðàë òºâëºðºëò áóóðñàí, 34.7%-ä íü øàëãààíã¿é óóðëàõ, 25.2%-ä íü ãóíèãëàõ, ñýòãýëýýð óíàõ, 47.6% íü òîëãîé ºâääºã ãýæ õàðèóëñàí.

Ìºíãºí óñíû íºëººëºëä ºðòñºí ýñýõ òàëààð àñóóõàä ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé ýðõëýã÷äèéí 61.9% íü ìºíãºí óñíû íºëººëºëä ºðòººã¿é, 26.5% íü ìºíãºí óñíû íºëººëºëä ºðòñºí áîëîâ÷ ýð¿¿ë ìýíäýä íºëººëººã¿é ãýæ ñóäàëãààíä îðîëöîãñîä õàðèóëñàí áºãººä 11.6% (n=17) íü ìºíãºí óñòàé àæèëëàñíààñ õîéø ýð¿¿ë ìýíäèéí áàéäàë ìóóäñàí ãýæ ººðñäèéãºº ¿çñýí áàéíà. Ìºíãºí óñòàé àæèëëàñíààñ õîéø ýð¿¿ë ìýíä ìóóäñàí ãýæ õàðèóëñàí õ¿ì¿¿ñ (n=17)-èéí


äèéëýíõ íü áóþó 64.7% (n=11) íü Áîðíóóð ñóìûí áè÷èë óóðõàé ýðõëýã÷èä áàéâ. Ò¿¿í÷ëýí Ìàíäàë ñóìààñ ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé

ýðõëýã÷èä (n=15)-èéí õóâüä 26.7% (n=4) íü ìºíãºí óñòàé àæèëëàñíààñ õîéø ýð¿¿ë ìýíäèéí áàéäàë ìóóäñàí ãýæ õàðèóëñàí áàéíà (Çóðàã 1).

75% 61.50%

40%

6.70%

87.70%

20.80% 38.50%

33.30%

56.70%

10.80% 4.20%

26.70% 36.70%

1.50%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Yes, their exposure tomercury had negativelyaffected their health

Yes, but did not relate it totheir health symptoms

They hadn't been exposed

Pe

rce

nta

ge

of

exp

osu

re

sta

tus

to

me

rcu

ry

Figure1. Percentage of exposure status to mercury by soums

Àëõàëòûí òýíöâýðèéã øàëãàõ ñîðèëûí ã¿éöýòãýë íü ñóäàëãààíä õàìðàãäñàí ñóìäààð ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààòàé áàéâ (p<0.05). Òóõàéëáàë: Áîðíóóð, Áàÿí-Îâîî ñóìäóóäòàé õàðüöóóëàõàä Áàÿíãîë, Ìàíäàë, Ò¿íõýë ñóìûí áè÷èë óóðõàé ýðõëýã÷äèéí äóíä ÿâàõàä òýíöâýð àëäàãäàõ õàì øèíæ èë¿¿ èõ áóþó 62.5-69.2%-ä íü èëýðñýí. Ñàëãàíàëòûã øàëãàõ õóðóóã õàìðûí ¿ç¿¿ðò õ¿ðãýõ ñîðèëûí ã¿éöýòãýë íü ñóäàëãààíä õàìðàãäñàí ñóìäààð ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààòàé áàéâ (p<0.05). Òóõàéëáàë: Ìàíäàë ñóìûí áè÷èë óóðõàé ýðõëýã÷èä (n=15) ýíý ñîðèëûã

ìóó ã¿éöýòãýæ áàéñàí áóþó òýäãýýðèéí 53.3%-ä íü ñàëãàíàëò èëýð÷ áàéñàí áàéíà.

Ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé ýðõëýã ÷èä (n=147)-èéí 21.8%-ä íü õºäºëãººíèé êîîðäèíàöè àëäàãäàõ õàì øèíæ èëýðñýí áà ýíýõ¿¿ õàì øèíæ íü ñóäàëãààíä õàìðàãäñàí ñóìäààð ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààã¿é áàéâ (p>0.05). Ñóäàëãààíä õàìðàãñäûí ìýäðýëèéí ¿çëýãèéí ¿ð ä¿íã ìºíãºí óñòàé õàðüöàæ àæèëëàæ áàéñàí ýñýõýýñ õàìààðóóëàí ñóäàëæ, ¿ð ä¿íã Õ¿ñíýãò 1-ä õàðóóëàâ.

Òable1. Neurological examination results (exposed with mercury)

Neurological examination Handling with mercury TotalYes No

N % N % N %Gait ataxia * Yes 31 47.7 46 56.1 77 52.4

No 34 52.3 36 43.9 70 47.6Total 65 100.0 82 100.0 147 100.0

Imbalanceof finger-nose tremor *

Yes 49 75.4 67 81.7 116 78.9No 16 24.6 15 18.3 31 21.1Total 65 100.0 82 100.0 147 100.0

Disdiachokinesia Yes 53 81.5 62 75.6 115 78.2No 12 18.5 20 24.4 32 21.8Total 65 100.0 82 100.0 147 100.0

Heel - knee tremor, n.s Yes 62 95.4 80 97.6 142 96.6No 3 4.6 2 2.4 5 3.4Total 65 100.0 82 100.0 147 100.0

Pearson Chi-square: n.s. = not significant, p<0.05=*, p<0.01**, p<0.001***Ìàãàäëàë

Áè÷èë óóðõàé ýðõëýã÷èä ºñãèéã ºâäãºíä õ¿ðãýõ àòàê ñèéí ñîðèëûã 96.6% íü ìýäðýëèéí áóñàä ñîðè-ëóóäòàé õàðüöóóëàõàä ñàéí ã¿éöýòãýæ áàé ñàí áà ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé ýðõ ëýã÷èä

(n=147)-èéí 3.4%-ä íü àòàêñè èëýðñýí (Õ¿ñíýãò 1). Ìýäðýëèéí ñîðèëûí ã¿éöýòãýë¿¿ä íü ìºíãºí óñòàé õàðüöàí àæèëëàæ áàéñàí ýñýõýýð ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààã¿é áàéâ (p>0.05).


Ìýäðýë-ñýòãýõ¿éí ¿çëýãèéã ø¿äýíçíèé õàéðöàã áîëîí ¿çãýýð öýã òàâèõ ñîðèëîîð ã¿éöýòãýæ, ¿ð

ä¿íã ñóìäààð Õ¿ñíýãò 2-ä õàðóóëàâ.

Table 2. Neuropsychological examination result by soums

Name of test Time, sec Study soums TotalBayangol Tunkhel Mandal Bornuur Bayan-Ovoo

N % N % N % N % N % N %Match box test***

0-17 4 16.7 1 7.7 1 6.7 3 10.0 27 41.5 36 24.5

17< 20 83.3 12 92.3 14 93.3 27 90.0 38 58.5 111 75.5Total 24 100.0 13 100.0 15 100.0 30 100.0 65 100.0 147 100.0

Pencil tapping test, n.s

0-45 1 4.2 1 7.7 2 13.3 4 13.3 10 15.4 18 12.2

45< 23 95.8 12 92.3 13 86.7 26 86.7 55 84.6 129 87.8Total 24 100.0 13 100.0 15 100.0 30 100.0 65 100.0 147 100.0

Pearson Chi-square: n.s. = not significant, p<0.05=*, p<0.01**, p<0.001***

Ø¿äýíçíèé õàéðöàãíû áîëîí ¿çãýýð öýã òàâèõ ñîðèëûã ìºíãºí óñòàé õàðüöàæ àæèëëàæ áàéñàí

ýñýõýýñ íü õàìààðóóëàí ñóäàëæ, ¿ð ä¿íã Õ¿ñíýãò 3-ä õàðóóëàâ.

Table 3. Neuropsychological examination results by handling with mercury

Name of test Time, second Handling with mercury TotalYes No

N % N % N %Match box test*** 0-17 7 10.8 29 35.4 36 24.5

17< 58 89.2 53 64.6 111 75.5Íèéò 65 100.0 82 100.0 147 100.0

Pencil tapping test, n.s 0-45 6 9.2 12 14.6 18 12.2

45< 59 90.8 70 85.4 129 87.8Íèéò 65 100.0 82 100.0 147 100.0


Ìºíãºí óñòàé õàðüöàí àæèëëàæ áàéñàí áè÷èë óóðõàé ýðõëýã÷èä (n=65)-èéí 89.2% (n=58), õàðüöàí àæèëëàæ áàéãààã¿é áè÷èë óóðõàé ýðõëýã÷èä (n=82)-èéí 64.6% íü ø¿äýíçíèé õàéðöàãíû ñîðèëûã 17-îîñ äýýø ñåêóíäýä ã¿éöýòãýæ áàéñàí áóþó ø¿äýíçíèé õàéðöàãíû ñîðèëûí ã¿éöýòãýë íü ìºíãºí óñòàé õàðüöàí àæèëëàæ áàéñàí ýñýõýýð ñòàòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààòàé áàéâ (p<0.001). ¯çãýýð öýã òàâèõ ñîðèëûí ã¿éöýòãýë íü ìºíãºí óñòàé õàðüöàí àæèëëàæ áàéñàí ýñýõýýð ñòàòèñòèêèéí õóâüä à÷ õîëáîãäîë á¿õèé ÿëãààã¿é

áàéâ (p>0.05).

Ñóäàëãààíä îðîëöîãñäûí 38.1% (n=56) íü àðüñíû òàëààñ ÿìàð íýãýí çîâèóðòàé, 40.8% íü àðüñàíä òóóðàëòòàé ãýæ õàðèóëñàí áàéíà. Àðüñàí äýýð òóóðàëò ãàðäàã 60 áè÷èë óóðõàé ýðõëýã÷èéí 38.3% (n=23) íü 1-3 æèë ãàð àðãààð àëò îëáîðëîñîí õ¿ì¿¿ñ áàéâ. Àðüñàí äýýðõ òóóðàëò íü ìºíãºí óñòàé õàðüöàæ àæèëëàæ áàéñàí ýñýõýýð àâ÷ ¿çýõýä ñòàòèñòèêèéí õóâüä à÷ õîëáîãäîë á¿õèé ÿëãààòàé áàéâ (p<0.001) (Õ¿ñíýãò 4).

Table 4. Dermatological questionnaire related with mercury usage

Indicators Frequency Have you worked with mercury? TotalYes No

N % N % N %Have you had skin problems***

Yes 16 24.6 40 48.8 56 38.1No 49 75.4 42 51.2 91 61.9Total 65 100 82 100 147 100

Have you had skin rashes **

Yes 20 30.8 40 48.8 60 40.8No 45 69.2 42 51.2 87 59.2Total 65 100 82 100 147 100



Ýð¿¿ë ìýíäèéí ¿çëýãèéí íèéëáýð îíîîíû äóíäæèéã ñóìäààð àâ÷ ¿çâýë Áàÿíãîëä 2.1, Ò¿íõýë ñóìàíä 2.3, Ìàíäàë ñóìàíä 3.3, Áîðíóóðò 2.9, Áàÿí-Îâîîä 1.7 áàéâ. Ýð¿¿ë ìýíäèéí ¿çëýãèéí íèéëáýð îíîî Ìàíäàë ñóìàíä õàìãèéí ºíäºð (3.3) áàéãàà íü òóñ ñóìàíä îäîîãèéí áàéäëààð ìºíãºí óñíû õýðýãëýý ºíäºð áàéãààòàé õîëáîîòîé.

Áîðíóóð ñóìàíä ýð¿¿ë ìýíäèéí ¿çëýãèéí íèéëáýð îíîîíû äóíäàæ ºíäºð (2.9) áàéãàà íü òóñ ñóìûí áè÷èë óóðõàé ýðõëýã÷äèéí äóíä àðõàã õîðäëîãîîñ ¿¿äýëòýé ìºíãºí óñíû ýð¿¿ë ìýíäèéí íºëººëºë áàéñààð áàéãààã õàðóóëæ áàéíà.

Ýð¿¿ë ìýíäèéí ¿çëýãèéí íèéëáýð îíîîíû ä¿íãýýð ìºíãºí óñíû àðõàã õîðäëîãûí òîõèîëäîë Áàÿíãîë, Áîðíóóð ñóì òóñ á¿ðä 1, Ìàíäàë ñóìàíä 2, Áàÿí-Îâîî ñóìàíä 3 áóþó íèéò 7 áè÷èë óóðõàé ýðõëýã÷èä ìºíãºí óñíû àðõàã õîðäëîãîòîé áàéñàí áºãººä ýíý íü ìàíàé ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé ýðõëýã÷èä (n=147)-èéí 4.7%-èéã ýçýëæ áàéíà. Ýíý íü Stephan Bose-O’Reilly íàðûí Òàíçàíä õèé ñýí ìºíãºí óñíû ñóäàëãààòàé õàðüöóóëàõàä õàðüöàíãóé ºíäºð ¿ç¿¿ëýëò áºãººä òýäíèé ñóäàë-ãààãààð àðõàã õîðäëîãîòîé òîõèîëäîë 26 èëýðñýí áà ýíý íü ñóäàëãààíä îðîëöîã÷èä (n=221)-èéí 11.8%-èéã ýçýëæ áàéñàí áàéíà.

2008 îíä ÍÝÌ¯Ò-èéí Òºâ àéìãèéí Æàðãàëàíò, Áîðíóóð ñóìäûí õ¿í àìûí ýð¿¿ë ìýíäýä ¿ç¿¿ëñýí ìºíãºí óñíû íºëººëëèéí ñóäàëãààãààð ìºíãºí óñíû àðõàã õîðäëîãîòîé òîõèîëäîë 1 èëýðñýí áóþó ýíý íü ñóäàëãààíä îðîëöîã÷èä (n=197)-ûí 0.51%-èéã ýçýëæ áàéñíûã áèäíèé ñóäàëãàà (4.7%)-òàé õàðüöóóëàõàä äîîãóóð ¿ç¿¿ëýëò áàéíà. Ýäãýýðýýñ ¿çýõýä Ìîíãîëä àëò îëáîðëîäîã õ¿ì¿¿ñ ìºíãºí óñ õýðýãëýñýýð áàéãàà áºãººä ìºíãºí óñààð áàðèóëàõ àëò áóþó àìàëüãàì õàéëóóëàõ ¿éë àæèëëàãààíä áóñàä èæèë òºñòýé ¿éë àæèëëàãàà ýðõýëäýã îðíû õ¿ì¿¿ñýýñ áàãà îðîëöäîãòîé õîëáîîòîé áàéõ ìàãàäëàëòàé þì.

Stephan Bose-O’Reilly áà áóñàä ñóäëàà÷äûí Èíäîíåçýä õèéñýí ñóäàëãààãààð ìºíãºí óñíû

àðõàã õîðäëîãîòîé òîõèîëäîë Òàíçàí áîëîí áèä íèé ñóäàëãààíû ä¿íòýé õàðüöóóëàõàä ýðñ ºíäºð áàéâ. Òóõàéëáàë: Õîéä Ñóëàâåñè, Òºâ Êàëèìàíòàíû áîõèðäîëòîé á¿ñ íóòàãò àìüäàðäàã õ¿ì¿¿ñèéí 17%(n=3), 32%(n=21)-ä íü, ìºíãºí óñòàé õàðüöàí àæèëëàäàã áîëîâ÷ àìàëüãàì õàéëóóëäàãã¿é õ¿ì¿¿ñèéí 24% (n=4), 43%b(n=13)-ä íü, ìºíãºí óñòàé õàðüöäàã, àìàëüãàì õàéëóóëäàã õ¿ì¿¿ñèéí 55% (n=33), 62% (n=43)-ä íü òóñ òóñ ìºíãºí óñíû àðõàã õîðäëîãûí òîõèîëäîë èëýðñýí áóþó ñóäàëãààíä îðîëöîã÷èä (n=281)-ûí 41.6% (n=117)-èéã ýçýëæ áàéâ.

Áèäíèé ñóäàëãààãààð ìºíãºí óñíû àðõàã õîðäëîãûí ¿åä ìýäðýëèéí òîãòîëöîîíû òàëààñ ò¿ãýýìýë èëýðäýã ñàëãàíàëòûí õàì øèíæ Ìàíäàë ñóìûí áè÷èë óóðõàé ýðõëýã÷èä (n=15)-èéí 53.3%-ä áóþó õàìãèéí èõ õóâèéã ýçýëæ áàéâ. 2008 îíä ìºíãºí óñíû íºëººëºëä ºðòñºí áîëîõ íü ñóäàëãààãààð òîãòîîãäñîí Æàðãàëàíò ñóì (n=79)-ûí 23%-ä, Áîðíóóð ñóì (n=76)-ûí 31.6%-ä íü ñàëãàíàëò èëýð÷ áàéñàíòàé õàðüöóóëáàë Ìàíäàë ñóìûí áè÷èë óóðõàé ýðõëýã÷èä ìºíãºí óñíû íºëººëºëä èõýýð ºðòñºíèéã õàðóóëæ áàéíà. Ýíý ¿ç¿¿ëýëòèéã áóñàä ñóìäààð àâ÷ ¿çâýë Áàÿíãîëûí 12.5% (n=3), Ò¿íõýëèéí 15.4% (n=2), Áîðíóóðûí 23.3% (n=7), Áàÿí-Îâîîãèéí 16.9%-ä íü òóñ òóñ ñàëãàíàëòûí õàì øèíæ èëýð÷ áàéâ.

Ìºíãºí óñíû íºëººëºëä ºðòºõºä ìýäðýëèéí òîãòîëöîîíä èëýðäýã õàì øèíæ áîëîõ àëõàõàä òýíöâýð àëäàãäàõ òîõèîëäîë Áîðíóóð, Æàðãàëàíò ñóìäààñ îðîëöîãñäûí 31.6%, 37.3%-ä íü èëýðñýí áîë áèäíèé ñóäàëãààãààð Áàÿíãîë (62.5%), Ìàíäàë (66.7%), Ò¿íõýë (69.2%) ñóìäûí áè÷èë óóðõàé ýðõëýã÷äèéí äóíä õàðüöàíãóé ºíäºð áàéâ.

Ýíýõ¿¿ ñóäàëãààíä õàìðàãäñàí Áàÿíãîë (25%), Ò¿íõýë (23.1%), Ìàíäàë (20%), Áîðíóóð (26.7%), Áàÿí-Îâîî (18.5%) ñóìäûí áè÷èë óóðõàé ýðõëýã÷äýä èëýðñýí õºäºëãººíèé çîõèöóóëãà àëäàãäàõ õàì øèíæ íü 2008 îíû ñóäàëãààíä õàìðóóëñàí Æàðãàëàíò (45.9%), Áîðíóóð (36.7%) ñóìäûí îðîëöîã÷äûíõîîñ áàãà áàéñàí.

Ìýäðýëèéí ¿çëýã áîëîí ìýäðýë-ñýòãýõ¿éí ñîðèë, àñóóìæ ñóäàëãààíû ä¿íä ¿íäýñëýæ, ýð¿¿ë ìýíäèéí ¿çëýãèéí îíîîíû íèéëáýðèéã ãàðãàâ (Õ¿ñíýãò 5).

Ýð¿¿ë ìýíäèéí ¿çëýãèéí îíîîíû íèéëáýð ñóäàë ãààíä õàìðàãäñàí ñóìäààð ñòàòòèñòèê à÷ õîëáîãäîë á¿õèé ÿëãààòàé áàéâ (p<0.001).

Table 5. Total score for medical examination

Soum name N Min score Mean Max score AverageBayangol 24 0 2 5 2.1Tunkhel 13 1 2 6 2.3Mandal 15 1 3 6 3.3Bornuur 30 0 3 7 2.9Bayan-Ovoo 65 0 1 7 1.7Kruskal Wallis test, p<0.001


Ä¿ãíýëò:

1. Ýð¿¿ë ìýíäèéí ¿çëýãèéí íèéëáýð îíîîíû ä¿íãýýð ìºíãºí óñíû àðõàã õîðäëîãûí òîõèîëäîë Áàÿíãîë, Áîðíóóð ñóì òóñ á¿ðä 1, Ìàíäàë ñóìàíä 2, Áàÿí-Îâîî ñóìàíä 3 áóþó íèéò 7 áè÷èë óóðõàé ýðõëýã÷èä ìºíãºí óñíû àðõàã õîðäëîãîòîé áàéñàí áºãººä ýíý íü ìàíàé ñóäàëãààíä õàìðàãäñàí áè÷èë óóðõàé ýðõëýã÷èä (n=147)-èéí 4.7%-èéã ýçýëæ áàéíà.

2. Ìºíãºí óñíû àðõàã õîðäëîãûí ¿åä ìýäðýëèéí òîãòîëöîîíû òàëààñ ò¿ãýýìýë èëýðäýã ñàëãàíàëò, àëõàõàä òýíöâýð àëäàãäàõ çýðýã ìºíãºí óñíû íºëººëºëä èõýýð ºðòñºíèéã èëýðõèéëýõ õàì øèíæ Ìàíäàë, Áàÿíãîë ñóìûí áè÷èë óóðõàé ýðõëýã÷äèéí äóíä ò¿ãýýìýë èëýð÷ áàéíà.

3. Àðõàã õîðäëîãîä ºðòñºí 7 ºâ÷òºíèéã ýì÷ëýõ,õÿíàëòàä àâàõ, äàâòàí ¿çýõ, äàõèí òàíäàëò, èëð¿¿ëýëò, óðü÷èëàí ñýðãèéëýõ öîãö àðãà õýìæýýã îðîã íóòãèéí ýìíýëýã, Õîðäëîãûí ÿàðàëòàé òóñëàìæèéí òºâèéã ò¿øèãëýí õèéõ øààðäëàãàòàé áàéíà.

Íîì ç¿é:1. Ñòåôàí Áîéñå Î Ðåëëè, Ø.Ýíõöýöýã,

Á.Öýöýã ñàéõàí, Á.Áóðìàà, À.Ýíõæàðãàë, Ôèëèï Ôåðñòë, Ãàáðèýëü Ðîéäåð, Á.È÷èí-õîðëîî, Ñ.ªíºðñàéõàí, Êåðñòåí Ãóòø-ìèäò. Òºâ àéìãèéí Æàðãàëàíò, Áîðíóóð ñóì äûí õ¿í àìûí ýð¿¿ë ìýíäýä ¿ç¿¿ëñýí ìºíãºí óñíû íºëººëëèéã ñóäëàõ ñóäàëãààíû òàéëàí, 2008

2. Ewers U, Krause C, Schulz C, Wilhelm M. Reference values and human biological monitoring values for environmental toxins. Report on the work and recommendations of the Commission on Human Biological Monitoring of the German Federal Environmental Agency. Int Arch Occup Environ Health 1999;72(4):255-60.

3. Bose-O’Reilly S, Dahlmann F, Lettmeier B, Drasch G. Removal of barriers to the introduction of cleaner artisanal gold mining and extraction technologies in Kadoma, Zimbabwe- Final report, part B Health assessment. UNIDO Project EG/GLO/01/G34 No.03/089. BRGM Project Nr 822657-3. In. Orleans, France: BRGM (Bureau de Recherches Géologiques et Minières); 2004.

4. Boese-O`Reilly S, Lettmeier B, Drasch G. Final report of the pilot study: Mercury exposure in Temirtau / Kazakhstan and health effects. In: EUOR W, editor. WHO Eur0; 2007. p. 65.

5. Bose-O’Reilly S, Lettmeier B, Matteucci Gothe R, Beinhoff C, Siebert U, Drasch G. Mercury as a serious health hazard for children in gold mining areas. Environ Res 2008.

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí:Àíàãààõûí øèíæëýõ óõààíû äîêòîð,

ïðîôåññîð Í.Ñàéæàà


Ïåðèíàòàëü øàëòãààíòàé ýíäýãäëèéã ýðãýìæ ñóäëàãààíû

àðãààð ñóäàëñàí íü, Ìîíãîë óëñ

Ö.Ñîëîíãî1, Á.Ñóâä1, Ç.Ãýðýëìàà2, Á.Áóðìààæàâ3

1ÀØÓ¯ÈÑ-èéí äîêòîðàíò, 2ÀØÓ¯ÈÑ3Ìîíãîëûí àíàãààõ óõààíû àêàäåìè,

Ýëåêòðîí øóóäàí: [email protected]

Abstract:

Infant mortality rates in Ìongolia caused by “certain conditions originating in

the perinatal period” (ICD code p00-p96)

Ts.Solongo1, B.Suvd1, Z.Gerelmaa2, B.Burmaajav3

1PhD (c) MNUMS, 2MNUMS3Mongolian Academy of Medical Sciences,

e-mail: [email protected]

Justification

According to the World Health Organization (WHO), 6.6 million children under the age of five died in 2012 - more than 750 every hour. Most of these children could survive and thrive with access to simple, affordable interventions. The loss of a child is a tragedy - families suffer and human potential is wasted. WHO is improving child health by helping countries deliver integrated, effective care in a continuum, starting with a healthy pregnancy for the mother, through birth and care up to five years of age. Investing in health systems is important to delivering this essential care [1, 2].

Goal

To study perinatal mortality, this is the most important reason of infant mortality in Mongolia.

Material and MethodsA retrospective cohort study was conducted reviewing data from 2007-2011 using the ICD code P00-P96 [4] listing “certain conditions originating in the perinatal period”. Data was analyzed using Epi-Info 2000 and GIS software.

Results

Data from 2007-2011 showed that 3091 neonates died from conditions originating in the perinatal period and of these 58.7% (1814) were males. Furthermore, the results of this study showed that the leading causes of death were “respiratory and cardiovascular disorders during the perinatal period” (ICD code P20-P29). More specifically, the causes were:- Birth asphyxia (P21)- Respiratory distress of newborn (P22)- Congenital pneumonia (P23)

Conclusion

National average deaths per 1,000 live births in Mongolia are 9.5—with the highest rates reported in Dornogovi, Uvurkhangai, Bayankhongor, Gobi Altai, Uvs, Zavkhan and Khovsgol.

Key words: perinatal mortality, Mongolia, infant

Pp. 49-53 , Tables 2, Figures 5, References 6


Table 1. Infant mortality by certain conditions originating in the perinatal period (P00-P96), Mongolia, 2007-2011

Study time

Male Female Total

Nu

mb

er

10

00

live

b

irth

Pe

rce

nta

ge

Nu

mb

er

10

00

live

b

irth

Pe

rce

nta

ge

Nu

mb

er

10

00

live

b

irth

Pe

rce

nta

ge

2007 291 10.2 16.0 203 7.4 15.9 494 8.9 16.0

2008 396 12.1 21.8 248 8.1 19.4 644 10.2 20.8

2009 430 12.2 23.7 297 8.9 23.3 727 10.6 23.5

2010 379 11.2 20.9 273 8.5 21.4 652 9.9 21.1

2011 318 8.8 17.5 256 7.5 20.0 574 8.1 18.6

Total 1814 10.9 100.0 1277 8.1 100.0 3091 9.5 100.0

Reference: Health statistics & NSO, 2007-2011

¯íäýñëýë

Äýëõèé äýýð æèë á¿ð 3 ñàÿ îð÷èì õ¿¿õýä ýíäýæ áàéãààãèéí 75 õóâü íü àìüäðàëûíõàà ýõíèé 7 õîíîãò ýíäñýí áàéíà. Ýíäýãäëèéí øàëòãààíä äóòóó òºðºëòèéí áîëîí àìüñãàëûí ýìãýã çîíõèëæ áàéãàà áºãººä ýäãýýðèéí äèéëýíõ íü ñýðãèéëæ, ýì÷èëæ áîëîõóéö øàëòãààíòàé áàéäàã àæýý [1, 2]. Ñ¿¿ëèéí æèë¿¿äýä Mîíãîë óëñàä íÿëõñûí ýíäýãäëèéí òýðã¿¿ëýõ øàëòãààíä ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýã òýðã¿¿ëñýýð áàéíà. Ìîíãîë óëñûí íÿëõñûí ýíäýãäëèéí ò¿âøèí 1000 àìüä òºðñºí õ¿¿õäýä 1990 îíä 63.4 áàéñàí áîë 1990 îíîîñ õîéø ýð÷èìòýé áóóð÷ 2012 îíä 15.3 áîëæ 4.1 äàõèí áóóð÷ýý. 2015 îí ãýõýä íÿëõñûí ýíäýãäëèéã 15.0-ä õ¿ðãýõ ÌÕÇ-ûã äýâø¿¿ëñýí áàéíà. 2012 îíû ýð¿¿ë ìýíäèéí ñòàòèñòèê ìýäýýãýýð íÿëõñûí ýíäýãäëèéí 53.5 õóâü íü íÿðàéí ýðò ¿åä, 12.6 õóâü íü íÿðàéí õîæóó ¿åäýý ýíäñýí áàéíà [3].

Çîðèëãî

Ìàíàé óëñûí íÿëõñûí ýíäýãäëèéí òýðã¿¿ëýõ øàëòãààí áîëæ áóé ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí íÿðàéí ýíäýãäëèéã ñóäëàõ


Tàðõâàð ç¿éí ýðãýìæ ñóäàëãààíû àðãààð

2007-2011 îíä ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí íÿðàéí (0-28 õîíîãòîé) ýíäýãäëèéí ñòàòèñòèê ìýäýýã àøèãëàí ä¿í øèíæèëãýý õèéñýí. Ñóäàëãààíä Epi-Info 2000, GIS ïðîãðàììûã àøèãëàëàà. ÎÓ-ûí ºâ÷íèé àíãèëëààð [4] ïåðèíàòàëü ýìãýãèéí óëìààñ ýíäñýí íÿðàéí ñòàòèñòèê ìýäýýëýëä ä¿í øèíæèëãýý õèéæ áè÷èãëýë (äåñêðèïòèâ) ñóäàëãààíû àðãààð òàéëàãíàëàà.

¯ð ä¿í2007-2011 îíû ñòàòèñòèê ìýäýýëëýýñ 0-5 õ¿ðòýëõ íàñíû õ¿¿õäèéí íàñ áàðàëòûí òýðã¿¿ëýõ øàëòãààíä: • ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýã (P00-P96)• àìüñãàëûí òîãòîëöîîíû ºâ÷èí (J00-J99)• ºâ÷ëºë áà íàñ áàðàëòûí ãàäíû øàëòãààí

(V01-Y98)• òºðºëõèéí ãàæèã, õðîìîñîìûí ýìãýã (Q00-

Q99) òóñ òóñ òýðã¿¿ëæ áàéíà.

2007-2011 îíä íèéò 3091 íÿðàé ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí áºãººä 58.7 õóâü (1814) íü ýðýãòýé áàéíà. 2007 îíä 1000 àìüä òºðºëòèéí 8.9 íü ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí áîë 2009 îíä 10.6 áîëæ íýìýãäýýä 2011 îíä 8.1 áîëñîí áàéíà (Õ¿ñíýãò 1).

2007-2011 îíä ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí íèéò òîõèîëäëûí 58.2 õóâü (1798) íü ïåðèíàòàëü ¿åèéí àìüñãàë áà ç¿ðõ ñóäàñíû òîãòîëöîîíû ºâºðìºö ýìãýãèéí (P20-P29) øàëòãààíòàé áàéëàà. Ñóäëàãäñàí 5 æèëèéí

äóíäæààð 1000 àìüä òºðºëòºä ïåðèíàòàëü ¿åèéí àìüñãàë áà ç¿ðõ ñóäàñíû òîãòîëöîîíû ºâºðìºö ýìãýãýýð (P20-P29)5.5 íü ýíäñýí áºãººä ýíý ¿ç¿¿ëýëò ýðýãòýé õ¿¿õäýä èë¿¿ áàéíà (Õ¿ñíýãò 2).


Table 2. Infant mortality by certain conditions originating in the perinatal period (P00-P96), Mongolia, 2007-2011

Certain conditions originating in the perinatal period (P00-P96), ICD-10

Male Female Total

Num

ber

of

mort

alit

y

1000 li

ve

birth

%

Num

ber

of

mort

alit

y

1000 li

ve

birth

%

Num

ber

of

mort

alit

y

1000 li

ve

birth

%

Fetus and newborn affected by maternal factors and by complications of pregnancy, labor and delivery (P00-P04)

3 0.02 0.2 4 0.03 0.3 7 0.02 0.2

Disorders related to length of gestation and fetal growth (P05-P08)

130 0.78 7.2 72 0.46 5.6 202 0.62 6.5

Birth trauma (P10-P15) 104 0.62 5.7 82 0.52 6.4 186 0.57 6.0Respiratory and cardiovascular disorders specific to the perinatal period (P20-P29)

1052 6.32 58.0 746 4.73 58.4 1798 5.54 58.2

Infections specific to the perinatal period (P35-P39)

140 0.84 7.7 108 0.68 8.5 248 0.76 8.0

Haemorrhagic and haematological disorders of fetus and newborn (P50-P61)

54 0.32 3.0 47 0.30 3.7 101 0.31 3.3

Transitory endocrine and metabolic disorders specific to fetus and newborn (P70-P74)

1 0.01 0.1 2 0.01 0.2 3 0.01 0.1

Digestive system disorders of fetus and newborn (P75-P78)

34 0.20 1.9 17 0.11 1.3 51 0.16 1.6

Conditions involving the integument and temperature regulation of fetus and newborn (P80-P83)

1 0.01 0.1 0 0.00 0.0 1 0.00 0.0

Other disorders originating in the perinatal period (P90-P96)

295 1.77 16.3 199 1.26 15.6 494 1.52 16.0

Total 1814 10.9 100.0 1277 8.09 100.0 3091 9.53 100.0

Reference: Health statistics, 2007-2011

Ïåðèíàòàëü ¿åèéí àìüñãàë áà ç¿ðõ ñóäàñíû òîãòîëöîîíû ºâºðìºö ýìãýãèéí (P20-P29) óëìààñ ýíäñýí øàëòãààíä:

• Òºðºõ ¿åèéí õ¿íä á¿òýëò (P21)(á¿ãä 850, ýðýãòýé-490, ýìýãòýé-360)

• Íÿðàéí àìüñãàëûí ãà÷ààë (P22)(á¿ãä 610, ýðýãòýé-347, ýìýãòýé-263)

• Òºðºëõ õàòãàà (P23)(á¿ãä 98, ýðýãòýé-65, ýìýãòýé-33) òóñ òóñ òýðã¿¿ëæ áàéíà.

Ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí íÿðàéí òîîã 1000 àìüä òºðºëòºä òîîöîîëîõîä óëñûí äóíäàæ 9.5 áàéñàí áºãººä ¿¿íýýñ Äîðíîãîâü (1000 àìüä òºðºëòºä 14.8), ªâºðõàíãàé (1000 àìüä òºðºëòºä 14.4), Áàÿíõîíãîð (1000 àìüä òºðºëòºä 12.9), Ãîâü-Àëòàé (1000 àìüä òºðºëòºä 11.9), Óâñ (1000 àìüä òºðºëòºä 11.7), Çàâõàí (1000 àìüä òºðºëòºä 11.4), Õºâñãºë (1000 àìüä òºðºëòºä 11.0) àéìàãò òóñ òóñ óëñûí äóíäæààñ èõ áàéíà.

Figure 1. Infant mortality by certain conditions originating in the perinatal period, 1000 live births, Mongolia, 2007


Figure 2. Infant mortality by certain conditions originating in the perinatal period,

1000 live births, Mongolia, 2008








Õýëöýìæ

2007-2011 îíû ñòàòèñòèê ìýäýýëëýýñ íàñ áàðàëòûí òýðã¿¿ëýõ øàëòãààíä ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýã (P00-P96), àìüñãàëûí òîãòîëöîîíû ºâ÷èí (J00-J99), ºâ÷ëºë áà íàñ áàðàëòûí ãàäíû øàëòãààí (V01-Y98), òºðºëõèéí ãàæèã, õðîìîñîìûí ýìãýã (Q00-Q99) òóñ òóñ òýðã¿¿ëæ áàéíà. Èéìä ïåðèíàòàëü ¿åä ¿¿ññýí çàðèì ýìãýãèéí óëìààñ ýíäñýí íÿðàéí ñòàòèñòèê ìýäýýëýëä ä¿í øèíæèëãýý õèéæ áè÷èãëýë ñóäàëãààíû àðãààð òàéëàãíàëàà. Íÿðàéí ýíäýãäëèéí òýðã¿¿ëýõ øàëòãààí áîëæ áóé ïåðèíàòàëü ¿åèéí ýìãýã íü çàðèì àéìãóóäàä óëñûí äóíäæààñ ºíäºð áàéãàà àéìãóóäûí ýìíýëãèéí òóñëàìæ ¿éë÷èëãýýíèé áàéäëûã öîãöîîð íü ñóäàëæ, ñàéæðóóëàõ øààðäëàãàòàéã õàðóóëæ áàéíà. Ìºí àíõàí øàòíû ýð¿¿ë ìýíäèéí áàéãóóëëàãûí íèéãìèéí ýð¿¿ë ìýíäèéí òóñëàìæ ¿éë÷èëãýýíèé ÷àíàð, õ¿ðòýýìæ, ¿ð íºëººã ñàéæðóóëàõ àæëûã ýð÷èìæ¿¿ëýõ íü ç¿éòýé õýìýýí ¿çëýý. Ýð¿¿ë ìýíäèéí ñòàòèñòèê ìýäýýíä îíîøèéã ÎÓ-ûí æèøãýýð [4] íàðèéâ÷ëàí òýìäýãëýýã¿é íü øàëòãààíûã òîäîðõîé ãàðãàõàä õÿçãààðëàãäìàë áàéëàà.

Ä¿ãíýëò

Íÿðàéí ýíäýãäëèéí òýðã¿¿ëýõ øàëòãààíä ïåðèíàòàëü ¿åèéí àìüñãàë áà ç¿ðõ ñóäàñíû

òîãòîëöîîíû ºâºðìºö ýìãýã äàâàìãàéëæ, ýðýãòýé õ¿éñýíä èë¿¿ òîõèîëäîæ áàéíà. Íÿðàéí ýíäýãäëèéí òýðã¿¿ëýõ øàëòãààí áîëæ áóé ïåðèíàòàëü ¿åèéí ýìãýã íü çàðèì àéìãóóäàä óëñûí äóíäæààñ ºíäºð áàéíà.

Àøèãëàñàí íîì

1. http://www.who.int/mediacentre/factsheets/fs290/en/, January 5, 2015

2. World Health Organization. WHO Mortality database. http://www3.who.int/whosis, Geneva, World Health Organization, 2003.

3. Ýð¿¿ë ìýíäèéí õºãæëèéí òºâ, ÝÌß, Ýð¿¿ë ìýíäèéí ñòàòèñòèê ìýäýý, 2007-2011

4. http://apps.who.int/classifications/icd10/browse/2015/en#/P20-P29, January 3, 2015

5. WHO. The WHO Application ofICD-10 to deaths during pregnancy, childbirth and the puerperium: ICD-MM

6. Daniels J, et al. The WHO analysis of causes of maternal death, in preparation, 2011

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Ïðîô.Ò.Ýðõýìáààòàð


ÝÌÇ¯É, ÓËÀÌÆËÀËÒ ÀÍÀÃÀÀÕ ÓÕÀÀÍ

Òóðøèëòûí àìüòàíä ¿¿ñãýñýí ýòèëèéí ñïèðòèéí äóðøèëä

×àííàäñýëøè æîðûí ¿ç¿¿ëýõ íºëºº

Æ.Áàò-Ýðäýíý1, Ì.Óóãàíöýöýã2, Ò.Àëèìàà2, ×.×èìýäðàã÷àà1

1Óëàìæëàëò Àíàãààõ Óõààí, Òåõíîëîãèéí Õ¿ðýýëýí,2ÀØÓ¯ÈÑ-ÀÓÑ-Óëàìæëàëò Àíàãààõ Óõààíû Èíñòèòóò

E-mail: [email protected], 99069649

Abstract

Effect of Channadselshi on voluntary alcoholic wistar rats

J.Bat-Erdene1, M.Uugantsetseg2, T.Alimaa2, Ch.Chimedragchaa1

1Institute of Traditional Medicine and Technology2Mongolian National University of Medical Sciences – Traditional Medical Institute


Introduction

Alcohol (EtOH) use disorders (AUDs) represent a substantial public health problem worldwide. Over 76 million people present with AUDs 2.5 million deaths were attributed to alcohol (World Health Organization, 2010). Channadshelshi has been used for treatment of alcohol-related, liver disease and intoxication in traditional medicine.

Goal

To determine effect of channadshelshi on voluntary alcoholic wistar rats.

Material and Methods

To examine acute toxicity of Channadselshi were used V.P.Prozorovsky express method (1978) and OECD (2001).

Voluntary EtoH consumption measurement (two-bottle choice, intermittent access to EtOH paradigm in wistar rats). Water and 20% ethanol were presented in 200 mlgraduated plastic cylinders with stainless-steel drinking spouts.The experiment period was 10 weeks total. EtOH consumption was expressed as grams of EtOH consumed per kilogram of body weight/day.

Elevated plus maze. Anxiety associated with EtoH withdrawalwas measured on EPM The maze waselevated 1 m above the floor and contained four 50 cm long, 10 cmwidearms arranged at right angles. The closed arms had opaque walls 30cm high, extending the length of the arm. At the time of the test, eachanimal was placed in the center of the maze facing an open arm andallowed to explore for a 5 min session. During this 5 min test session, theanimal’s number of arm entries and time spent in each arm per entry was recorded on a camera.

Pentylenetetrazol (PTZ) 100 mg/kg dose used in this study was determined as the dose that induced seizures and protection against mortality in mice

The experimental protocol was approved by the Ethics Committee of the MNUMS. (№ 14-11/1À)

Results

LD50 of Channadselshi extract was found to be LD50=2.58 (2.1-3.2) gr/kg by V.P.Prozorovsky express method (1978). Channadselshi was no acute toxic by OECD (2001).


¯íäýñëýë

Äýëõèéí ýð¿¿ë ìýíäèéí áàéãóóëëàãààñ 2002 îíä ãàðãàñàí óðèàëãàä óëàìæëàëò àíàãààõ óõààíä õýðýãëýæ áóé ýì òàí, ýì÷èëãýýíèé àðãóóäûã íîòîëãîîæóóëàõ çàéëøã¿é øààðäëàãàòàéã çààæýý. Ìîíãîë óëñûí øèíæëýõ óõààí òåõíîëîãèéã õºãæ¿¿ëýõ ìàñòåð òºëºâëºãººíä çààñíààð àíàãààõ óõààíû ñàëáàðûí òýðã¿¿ëýõ ÷èãëýë íü ýì ç¿é, ýì ñóäëàë, òåõíîëîãè, ñòàíäàðòûí ñóäàëãàà, áàòàëãààæóóëñàí ýì áýëäìýë, õ¿íñíèé íýìýëò á¿òýýãäýõ¿¿í çîõèîí á¿òýýõ ÿâäàë ãýæýý.

Ìîíãîë óëñûí 15-64 íàñíû íèéò õ¿í àìûí 65,8% íü ÿìàð íýã õýìæýýãýýð àðõè, ñîãòóóðóóëàõ óíäààã õýðýãëýæ áàéíà. Ýðýãòýé÷¿¿äèéí 39,7% ýìýãòýé÷¿¿äèéí 15,1% íü àðõèéã õýòð¿¿ëýí õýðýãëýæ áàéãàà áºãººä ýðýãòýé÷¿¿äèéí 4,3% ýìýãòýé÷¿¿äèéí 1,8% íü ñîãòóóðóóëàõ óíäààíû àþóëòàé õýðýãëýýòýé áàéíà. Ìºí íàñàíä õ¿ðýã÷äèéí 13,8 % íü àðõèíä äîíòîõ ýìãýãèéí øàëãóóðûã õàíãàñàí áàéãààã ñóäàëãààãààð èëð¿¿ëæýý [1, 2].

Ñ¿¿ëèéí æèë¿¿äýä àðõèíû øàëòãààíò ýëýã, íîéð áóë÷èðõàé, õîîë áîëîâñðóóëàõ çàìûí ýìãýã¿¿ä èõñýæ áàéãàà áºãººä ºäºðò 50 ãð-ààð 2-3 æèë àðõè óóõàä íîéð áóë÷èðõàéí àðõàã ¿ðýâñýë ¿¿ñäýã áîëîõ íü òîãòîîãäæýý. Àðõèíû øàëòãààíò ýëýãíèé õàòóóðëààð íàñ áàðñàí ºâ÷òºí¿¿äèéí 70-100%-ä íîéð áóë÷èðõàéí ¿ðýâñýë èëýð÷ áàéñàí áàéíà. Ìºí Àíãëèéí ñóäëàà÷èä àðõè áà ýìèéí áîäèñ íü ºâ÷íèé øàëòãààíû 29%-èéã ýçýëäýã ãýæ áàòàëæýý [3].

Óëàìæëàëò ×àííàäñýëøè æîðûí íàéðëàãàíä ñîðìóóñò äýãä (Gentiana Barbata Froel), àð¿ð (Terminalia Chebula Ret/), ã¿ðã¿ì (Carthamus

Tinctorius L.), ñýâèìýäîã (Rosa Acicularis Lindl.) îðäîã [4-6]. Ñîðìóóñò äýãä óðãàìàëä luteolin, diosmetin, diosmin çýðýã ôëàâíîèä àãóóëàãääàã [7]. 2012 îíä ÀÍÓ-ä õèéãäñýí ñóäàëãààãààð Dihydromyricetin ôëàâíîèä íü ÃÀÌÊ-ä íºëººëæ ýòèëèéí ñïèðòèéí äóðøèë áóóðóóëæ áàéãààã òîãòîîñîí áàéíà [8].

Èéìýýñ óëàìæëàëò àíàãààõ óõààíä øàðûí õàëóóíûã àðèëãàõ, àðõèíû ºâ÷íèéã àíàãààõ ¿éëäýëòýé õýìýýí áè÷èãäñýí ×àííàäñýëøè æîðûí ôàðìàêîëîãèéí òàëààð ñóäëàõààð çîðèëîî.

Çîðèëãî

Òóðøèëòûí àìüòàíä ýòèëèéí ñïèðòýýð ¿¿ñãýñýí ýìãýã çàãâàðò ×àííàäñýëøè æîðûí ¿ç¿¿ëýõ íºëººã òîãòîîõ

Çîðèëò:

1. ×àííàäñýëøèæîðûí õóðö õîðîí ÷àíàðûã òîäîðõîéëîõ

2. Òóðøèëòûí àìüòàíä ¿¿ñãýñýí ýòèëèéí ñïèðòèéí äóðøëûã áóóðóóëàõ íºëººã ñóäëàõ

3. Ýòèëèéí ñïèðòèéí íºëººãººð ¿¿ññýí àéäàñ ò¿ãø¿¿ðò ×àííàäñýëøè æîðûí ¿ç¿¿ëýõ íºëººã ñóäëàõ

4. Ïåíòèëåòåòðàçîëîîð ºäººñºí òàòàëòàíä ×àííàäñýëøè æîðûí ¿ç¿¿ëýõ íºëººã ñóäëàõ


Áèä ñóäàëãààíû àæëàà ÓÀÓÒ Õ¿ðýýëýíãèéí ýðäýì øèíæèëãýýíèé òºâèéã ò¿øèãëýí ã¿éöýòãýñýí áºãººä ×àííàäñýëøè æîðûã òóñ õ¿ðýýëýíãèéí Óëàìæëàëò Ýìèéí ¯éëäâýðýýñ àâñàí ñîðìóóñò äýãä (Gentiana Barbata Froel), àð¿ð (Terminalia Chebula Ret), ã¿ðã¿ì (CarthamusTinctorius L.),

Ten and four weeks oral administration of Channadselshi (200 mg/kg) significantly (P<0.01) decreased the consumption of ethanol and significantly (P<0.01) increased time spent in open arm (EPM) in voluntary alcoholic wistar rat compare to control.

The time (sec) of latency the generalized convulsion were significantly (P<0.01) increased of Channadselshi compare to control. The percent of protection against mortality were 80% in PTZ induced seizure in mice.

Conclusions:

1. Our study showed that Channadselshi hasreduced consumption of ethanol in voluntary alcoholic wistar rat.

2. Channadselshi has central nervous system protection effect against PTZ induced seizure in mice.

Key words: Ethanol consumption, Elevated plus maze, Pentylenetetrazol, SeizurePp. 54-60, Table 1, Figures 4, References14


ñýâèìýäîã (Rosa AcicularisLindl.) ò¿¿õèé ýä¿¿äèéã õóâü òýíö¿¿ íàéðóóëàí æîðûã áýëòãýñýí.

Ñóäàëãààíä ×àííàäñýëøè æîðûí èäýýøìýë, Ìàòåðèà-Ìåäèêà êîìïàíèä ¿éëäâýðëýñýí Ïðîïðîòåí-100 ýì, òºâèéí ÃÀÌÊà àíòàãîíèñò Ïåíòèëåòåòðàçîë (PTZ) òóñ òóñ àøèãëàñàí.

Ñóäàëãààã 50 òîëãîé wistar ¿¿ëäðèéí õàðõ, 30 òîëãîé öàãààí õóëãàíà àøèãëàí ÿâóóëàâ.Òóðøèëòûí õóãàöààíä àìüòäûã âèâàðûí õýâèéí íºõöºëä (20±2C) áàéëãàí, åðäèéí òýæýýëýýð õîîëëîæ áàéâ.

Õóðö õîðîí ÷àíàð òîäîðõîéëîõ àðãàç¿é:

1. Â.Ï.Ïðîçîðîâñêèé (1978) àðãààð 27-33,5 ãð æèíòýé öàãààí õóëãàíû õýâëèéí õºíäèéä ×àííàäñýëøè æîðûí 25%-èéí èäýýøìýë òàðèõ çàìààð ¿õýëä õ¿ðãýæ áóé äóíäàæ òóíã òîäîðõîéëæ È.Â.Áåðåçîâñêàÿ (2003) àíãèëëààð ¿íýëýâ [9, 10]

2. OECD (2001) óäèðäàìæèéí äàãóó 50-2000, 5000 ìã/êã õ¿ðòýë àìààð ºã÷ GHS àíãèëëààð ¿íýëíý.

Ýòèëèéí ñïèðòèéí äóðøèë áóóðóóëàõ íºëººã ñóäëàõ àðãà ç¿é: Íèéò 50 òîëãîé wistar ¿¿ëäðèéí õàðõûã ýð¿¿ë, õÿíàëò, ×àííàäñýëøè I, ×àííàäñýëøè II, ïðîïðîòåí-100 ãýñýí 5 á¿ëýãò õóâààñàí. Ýòèëèéí ñïèðòèéí äóðøëûã Yi Shen, A. Kerstin Lindemeyer et al (2012) àðãààð 20%-ûí ýòèëèéí ñïèðò 10õ7 õîíîã ÷ºëººò ñîíãîëòîîð óóëãàõ çàìààð ¿¿ñãýâ [8]. Òóðøèëòûí ýõíèé ºäðººñ ýõëýí õÿíàëò, ×àííàäñýëøèI, ×àííàäñýëøè II, ïðîïðîòåí-100á¿ëýã òóñ á¿ð 200 ìë á¿õèé õî¸ð çîðèóëàëòûí óãæ áàéõ áà íýã óãæèíä íü íýðìýë óñ, íºãºº óãæèíä 20% ýòèëèéí ñïèðò õèéæ ÷ºëººò ñîíãîëòîîð óóõààð ¿ëäýýíý.×àííàäñýëøè I á¿ëýãò 6 äàõü 7 õîíîãîîñ ýõëýí æîðûí èäýýøìýë 200ìã/êã òóíãààð àìààð ºãíº. ×àííàäñýëøè II á¿ëýãò òóðøèëòûí ýõíèé ºäðººñ ýõëýí æîðûí èäýýøìýë 200 ìã/êã òóíãààð àìààðºãíº. Ïðîïðîòåí-100 á¿ëýãò 6 äàõü 7 õîíîãîîñ Ïðîïðîòåí-100 ýìèéã 30 ìã/êã òóíãààð àìààðºãíº. Òóðøèëòûí õóãàöààíä á¿ëýã òóñ á¿ðèéí 20% ýòèëèéí ñïèðòèéí õýìæýýã

ºäºð á¿ð õýìæèæ, óóñàí õýìæýýãýýð äóðøèë áóóðñàí ýñýõèéã ¿íýëíý.

Àéäàñ ò¿ãø¿¿ðò ¿ç¿¿ëýõ íºëººã ñóäëàõ àðãà ç¿é: Yi Shen, A. Kerstin Lindemeyer et al (2012) àðãààð 20% ýòèëèéí ñïèðò 10x7õîíîã ÷ºëººò ñîíãîëòîîð óóëãàõ çàìààð ýòèëèéí ñïèðòèéí äóðøèë ¿¿ñãýñýí òóðøèëòûí àìüòäàä 6 áîëîí 10 äàõü äîëîî õîíîãò íýìýõ õýëáýðòýé ºðãºãäñºí ëàáèðèíò (Elevated Plus Maze) àøèãëàí ¿íýëíý [8, 11].

Ïåíòèëåòåòðàçîëîîðºäººñºí òàòàëòàíä ¿ç¿¿ëýõ íºëººã ñóäëàõ àðãà ç¿é: Íèéò 10 òîëãîé 21 ãð æèíòýé öàãààí õóëãàíà àâ÷ 2 á¿ëýãò õóâààíà. Õÿíàëòûí á¿ëýãò Ïåíòèëåòåòðàçîë (PTZ)-100 ìã/êã òóíãààð àðüñàí äîð òàðüæ òàòàëòûí íóóö ¿å áà ¿ðãýæëýõ õóãàöààã á¿ðòãýíý. Òóðøèëòûí á¿ëýãò ×àííàäñýëøè æîðûã 400 ìã/êã òóíãààð óóëãàñíààñ õîéø 60 ìèí äàðàà Ïåíòèëåòåòðàçîë (PTZ)-100 ìã/êã òóíãààð àðüñàí äîð òàðüæ òàòàëòûí íóóö ¿å áà ¿ðãýæëýõ õóãàöààã á¿ðòãýæ ¿íýëíý [12].

Ñòàòèñòàê áîëîâñðóóëàëò

Ñóäàëãààíû àæëûí ¿ð ä¿íã SPSS-20, Prism-5 ïðîãðàìì äýýð, one way ANOVA, two way RM ANOVA post hoc (Bonferroni) àíàëèç àøèãëàí ¿íýëëýý. Á¿ëýã õîîðîíäûí ÿëãàà (P<0.05; P<0.01) áàéõàä ¿íýí ìàãàäëàëòàé ãýæ ¿çýâ.

¨ñ ç¿é

Ñóäàëãààíû àæëûí ¸ñ ç¿éí çºâøººðëèéã ÝÌØÓÈÑ-èéí 2014 îíû 5 äóãààð ñàðûí 09-íèé ºäðèéí Áèî-Àíàãààõûí ¨ñ Ç¿éí Ñàëáàð Õîðîîíû õóðëààð áàòëóóëñàí (№ 14-11/1À).

¯ð ä¿í

Õóðö õîðîí ÷àíàð òîäîðõîéëñîí ä¿í

1. Â.Ï.Ïðîçîðîâñêèé (1978) àðãààð ×àííàäñýëøè æîðûí 25%-èéí áýëäìýëèéí LD50=2.58 (2.1-3.2) ãð/êã áºãººä È.Â.Áåðåçîâñêàÿ (2003) àíãèëàëààð áàãà õîðòîé áàéíà.

2. OECD (2001) àðãààð òîäîðõîéëîõîä:

- 50, 300, 500, 2000, 5000 ìã/êã õ¿ðòýë ºãºõºä 1 ÷ àìüòàí ¿õýýã¿é.

- GHS àíãèëàëààð õîðã¿é áàéíà.

Òóðøèëòûí 1-6 äàõü 7 õîíîãò õÿíàëòûí á¿ëãèéí ÷ºëººò ñîíãîëòîîð óóñàí ýòèëèéí ñïèðòèéí õýìæýý áîëîí ã/êã/õîíîãò òîîöñîí õýìæýýã ×àííàäñýëøèI áà Ïðîïðîòåí-100 á¿ëýãòýé õàðüöóóëàõàä ñòà-òèñòàê à÷ õîëáîãäîë á¿õèé ÿëãààã¿é áàéíà.

Õàðèí ×àííàäñýëøè II á¿ëãèéã õÿíàëòûí á¿ëýãòýé õàðüöóóëàõàä 1-6 äàõü 7 õîíîãò ñòàòèñòàê à÷ õîëáîãäîë á¿õèé (**P<0.01) ÿëãààòàé áóóðñàí áàéíà (Figure 1.A, 2).

Ýòèëèéí ñïèðòèéí äóðøèë áóóðóóëàõ íºëººã ñóäàëñàí ä¿í


Figure 1. Result ofEtoH consumption average in the voluntary intermittent two-bottle (20% EtoH/water) choice paradigm in rats. A. 1-6 week.B. 7-10 week.(n=9-10 rats per group) **P<0.01 vs control, Two way RM-ANOVA

Òóðøèëòûí 7-10 äàõü 7 õîíîãò ×àííàäñýëøè I, ×àííàäñýëøè II, ïðîïðîòåí-100 á¿ëã¿¿äèéí ÷ºëººò ñîí ãîëòîîð óóñàí ýòèëèéí ñïèðòèéí õýìæýý áîëîí ã/êã/õîíîãò òîîöñîí õýìæýýã õÿíàëòûí á¿ ëýã-òýé õàðüöóóëàõàä ñòàòèñòàê à÷ õîëáîãäîë á¿õèé (**P<0.01) ÿëãààòàé áóóðñàí áàéíà (Figure 1.B, 2).

10õ7 äîëîî õîíîãèéí õóãàöààíä õÿíàëòûí á¿ëýã 4560 ìë 20% ýòèëèéí ñïèðò óóñàí áàéíà. ×àííàäñýëøè I, II, ïðîïðîòåí-100 á¿ëãèéí óóñàí 20% ýòèëèéí ñïèðòèéí õýìæýýã õÿíàëòûí á¿ëýãòýé õàðüöóóëàõàä 33,89%, 67,7%, 22,15% òóñ òóñ áàãà áàéíà (Figure 3).

Figure 2. Result of EtoH consumption in the voluntary intermittent two-bottle (20% EtoH/water) choice paradigm

in rats. (n=9-10 rats per group) **P<0.01 vs control, Two way RM-ANOVA

Figure 3. Total amount of drank 20% alcohol during 10 week.(n=9-10 rats per group)

A

Alcohol intake average (1-6 week)

B

Alcohol intake average (7-10 week)

EtoH intake

Time (week)

Alcohol


Àéäàñ, ò¿ãø¿¿ðò ¿ç¿¿ëýõ íºëººã ñóäàëñàí ä¿í

Òóðøèëòûí 6 äàõü 7 õîíîãò ×àííàäñýëøè II á¿ë-ãèéí àìüòäûí íýýëòòýé òàëáàéä áàéñàí õóãà-öàà, òàëáàéä ãàðñàí òîîã õÿíàëòûí á¿ëýãòýé õàðüöóóëàõàä ñòàòèñòàê à÷ õîëáîãäîë á¿õèé (**P<0.01) ÿëãààòàé èë¿¿ áàéñàí áºãººä ýð¿¿ë á¿ ëýãòýé îéðîëöîî áàéíà. Õàðèí õÿ íàëò, ×àííàäñýëøè I, ïðîïðîòåí-100 á¿ëã¿¿ä õîîðîíäîî ñòàòèñòàê à÷ õîëáîãäîë á¿õèé ÿëãààã¿é

áàéëàà(Figure 4.À, B).

10 äàõü 7 õîíîãò ×àííàäñýëøèI, ×àííàäñýëøè II, ïðîïðîòåí-100 á¿ëãèéí àìüäûí íýýëòòýé òàëáàéä áàéñàí õóãàöàà, òàëáàéä ãàðñàí òîîã õÿíàëòûí á¿ëýãòýé õàðüöóóëàõàäñòàòèñòàê à÷ õîëáîãäîë á¿õèé (**P<0.01) ÿëãààòàé èë¿¿ áàéñàí áºãººä ýð¿¿ë á¿ëýãòýé îéðîëöîî áàéíà (Figure 4.Ñ, D).

Figure 4. A,B. Entry times andtime spent in the open arms of EPM by rats group in 6th week(**P<0.01 vs control One way ANOVA). C, D. Entry times and time spent in the open arms of EPM by rats group in 10th week. (n=8-10 rats per group) *P<0.05, **P<0.01 vs control One way ANOVA.

Ïåíòèëåòåòðàçîëîîð ºäººñºí òàòàëòàä ¿ç¿¿-ëýõ íºëººã ñóäàëñàí ä¿í×àííàäñýëøè á¿ëãèéí òàòàëòûí íóóö ¿åèéã õÿíàëòûí á¿ëýãòýé õàðüöóóëàõàä ñòàòèñòàê à÷ õîëáîãäîë á¿õèé (**P<0.01) ÿëãààòàé èë¿¿ áàéíà. Õÿíàëòûí á¿ëýã òàòàëòûí äàðàà 0% àìüä áàéñàí áîë òóðøèëòûí á¿ëýã 80% õàìãààëàõ íºëºº ¿ç¿¿ëæ áàéíà (Table 1).

Table 1. Effect of Channadselshi on PTZ inducedseizure in rat

Groups

Latency for the 1st generalized

convulsion (sec) mean±SD

Duration of convulsion(sec)

mean±SD

Number of mice having convulsion

Number of deaths

Protection against mortality

(%)

Control(n=5) 33.80±4.438 23.20±4.087 5/5 5/5 0

Channadselshi400 mg/kg oral (n=5)

67.00±4.123** 20.00±3.808 5/5 4/5 80

**P<0.01 vs control, unpaired T-test.

A

Elevated plus maze (6 th week)

C

Elevated plus maze (10 th week)

DB


Õýëöýìæ

Hong Zou, Ke Wang et al (2014) íàðûí ñóäàëãààãààð òóðøèëòûí àìüòàíä ÷ºëººò ñîíãîëòîîð óóõààð óñ áîëîí ýòèëèéí ñïèðò ºãºõºä òóðøèëòûí ýõíèé äîëîî õîíîãò 1-2 ãð/êã/õîíîã òóíãààð ýòèëèéí ñïèðò óóæ áàéñàí áîë 6 äàõü 7 õîíîãò 2-4 ãð/êã/õîíîã, 8 äàõü 7 õîíîãò 3-5 ãð/êã/õîíîã òóñ òóñ ýòèëèéí ñïèðò óóñàí áàéíà [13].

Ñóäëàà÷ Yi Shen, A. Kerstin Lindemeyer et al (2012) íàð Hoveniadulcis ìîäîíä àãóóëàãäàõ dihydromyricetin (DHM)ôëàâíîéäûã òóðøèëòûí àìüòàíä ÷ºëººò ñîíãîëòîîð ¿¿ñãýñýí ýòèëèéí ñïèðòèéí äóðøèëä ¿ç¿¿ëýõ íºëººã ñóäàëñàí áàéíà. Óã ôëàâíîéä íü ÃÀÌÊà ðåöåïòîðò àíòàãîíèñò ¿éë÷èëãýýòýé áàéñàí áà òóðøèëò ñóäàëãààãààð 7-10 äàõü 7 õîíîãò õÿíàëòûí á¿ëýãò 6-8 ãð/êã/õîíîã, òóðøèëòûí á¿ëýãò 1-3 ãð/êã/õîíîã ýòèëèéí ñïèðò õýðýãëýñýí íü ñòàòèñòàê à÷ õîëáîãäîë á¿õèé (P<0.01) ÿëãààòàé äóðøèë áóóðóóëñàí áàéíà. Ìºí Dihydromyricetin íü ïåíòèëåòåòðàçîë (PTZ)-îîð ºäººñºí òàòàëòûí ¿ðãýëæëýõ õóãàöààã áóóðóóëæ, íýìýõ õýëáýðòýé ºðãºãäñºí ëàáèðèíò (EPM) òåñòýä íýýëòòýé òàëáàéä áàéõ õóãàöààã 30% óðòàñãàñàí áàéíà [8].

Muhammad Imran Naseer, Li Shupeng (2009) íàðûí ñóäàëãààãààð ïåíòèëåòåòðàçîë (PTZ)-îîð òàòàëò ¿¿ñãýõýä ìýäðýëèéí ýñ áîëîí ãèïîêàìïûí õýñýãò àïîïòèê äåãåíðàöèä îðóóëæ áàéãààã òîãòîîñîí áàéíà [14].

Áèäíèé ñóäàëãààãààð õÿíàëòûí á¿ëãèéí àìüòàä ýõíèé 7 õîíîãò 2,5-6 ãð/êã/õîíîã òóíãààð ýòèëèéí ñïèðò óóæ áàéñàí áîë 6 äàõü äîëîî õîíîãò 3-5 ãð/êã/õîíîã, 10 äàõü 7 õîíîãò 4 ãð/êã/õîíîã òóñ òóñ ýòèëèéí ñïèðò óóæ áàéñàí. Ýíý íü äýýðõ ñóäëàà÷äûí ñóäàëãààòàé îéðîëöîî áºãººä ýòèëèéí ñïèðòèéí äóðøèë ¿¿ññýí áîëîõûã èëòãýæ áàéíà. Õàðèí ×àííàäñýëøè æîðûã ºã÷ áàéñàí á¿ëãèéí ýòèëèéí ñïèðòèéí õýìæýý õÿíàëòûí á¿ëãýýñ ñòàòèñòàê à÷ õîëáîãäîë (P<0.01) á¿õèé ÿëãààòàéãààð áóóðñàí íü ×àííàäñýëøè æîð ýòèëèéí ñïèðòèéí äóðøèë áóóðóóëäàã áîëîõûã õàðóóëæ áàéíà.

Ìºí ×àííàäñýëøè íü íýìýõ õýëáýðòýé ºðãºãäñºí ëàáèðèíò (EPM) òåñòýä íýýëòòýé òàëáàéä áàéõ õóãàöààã óðòàñãàæ, ýòèëèéí ñïèðòèéí íºëººãººð ¿¿ññýí àéäàñ, ò¿ãø¿¿ðèéã áóóðóóëæ áàéíà.

Áèäíèé ñóäàëãààãààð ×àííàäñýëøè æîð íü ïåíòèëåòåòðàçîë (PTZ)-îîð ºäººñºí òàòàëòûí ¿ðãýëæëýõ õóãàöààíä íºëººëººã¿é áîëîâ÷ íóóö ¿åèéã ñòàòèñòàê à÷ õîëáîãäîë (P<0.01) á¿õèé ÿëãààòàé óðòàñãàñàí íü ÃÀÌÊà ðåöåïòîðò íºëººëæ áàéãààã õàðóóëæ áàéíà. Ìºí PTZ-ýýð ºäººñºí òàòàëòûí ¿õëýýñ 80% õàìãààëæ áàéíà.

Ä¿ãíýëò:

1. ×àííàäñýëøè æîðûí õóðö õîðîí ÷àíàð íüLD50=2.58 (2.1-3.2) ãð/êã áàéíà.

2. Òóðøèëòûí àìüòàíä ¿¿ñãýñýí ýòèëèéí ñïèðòèéí äóðøëûã ×àííàäñýëøè æîð áóóðóóëàõ íºëººòýé áàéíà.

3. Óã æîð íü òóðøèëòûí àìüòàíä ýòèëèéí ñïèðòèéí íºëººãººð ¿¿ññýí àéäàñ, ò¿ãø¿¿ðèéã áóóðóóëæ áàéíà.

4. ×àííàäñýëøè æîð íü ïåíòèëåòåòðàçîë (PTZ)-îîð ºäººñºí òàòàëòûí íóóö ¿åèéã óðòàñãàæ, òºâ ìýäðýëèéí ñèñòåìèéã õàìãààëàõ íºëººã ¿ç¿¿ëæ áàéíà.

Íîì ç¿é

1. Ýðäýíýáàÿð.Ë Àðõèíä äîíòîõ ºâ÷èí. Óëààíáààòàð õîò, ªíãºò õýâëýë ÕÕÊ, 2009 îí, õ.15, 33-38, 93

2. È.Áîëîðìàà, Í.Áîëîðìàà, Á.Öîãçîëìàà áà áóñàä. Õàëäâàðò áóñ ºâ÷íèé ýðñäýëò õ¿÷èí ç¿éëñèéí òàðõàëòûí ò¿âøèí òîãòîîõ ñóäàëãàà – 2006, òàéëàí. ÄÝÌÁ, ÍÝÌÕ. 2007 îí, õ.49-51

3. Øàãäàðñ¿ðýí.Ì, Áàÿðìàãíàé.Á, Òóíãàëàã. Ä Ýëýã íèé ºâ÷èí. Óëààíáààòàðõîò, 2010 îí,õ.261-272

4. ß.Ãàíáàÿð “Ìîíãîë ýìèéí æîðûí õóâèëáàð íýðèéí ò¿¿âýð” Óëààíáààòàð õîò 2010. x.327

5. Æ.Æàìñðàí “Ýëãýý õàéðëàæ, õàìãààëæ ñóðöãààÿ” Óëààíáààòàð õîò 2008 îí.

6. Õ.Íàðñ “Ìîíãîë ýìèéí 1200 æîð” Óëààíáààòàð õîò 2007. Õ.338

7. À.Ãàíñ¿õ, Ñ.Ï¿ðýâñ¿ðýí, Sabine Glasl “Ñîð-ìóóñò äýãäèéí ôëàâíîèäûí àãóóëàìæèéí ñóäàëãàà” Ýìç¿é ñýòã¿¿ë №1,2 (32,33) Óëààíáààòàð õîò, 2011 îí. õ.21-25

8. Yi Shen, A.Kerstin Lindemeyer, Claudia Gonzalez, Xuesi M. Shao, Igor Spigelman, Richard W. Olsen, Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medicationü, Neurobiology of Disease, The Journal of Neuroscience, January 4, 2012. 32(1):390–401

9. Â.Ï.Ïðîçîðîâñêèé, Ì.Ï. Ïðîçîðîâñêàÿ, Â.Ì.Äåì÷åíêî. Ýêñïðåññ ìåòîäî ïðåäåëåíèÿ ñðåäíåé ýôôåêòèâíîé äîçû è åå îáèøêè. Ôàðìà è Òîêñèêîëîãèÿ 1978, òîì 4, ñ.497

10. È.Â.Áåðåçîâñêàÿ. Êëàññèôèêàöèÿ õèìè÷åñêèõ âåùåñòâ ïî ïàðàìåòðîì îñòðîé òîêñè÷íîñòè ïðè ïàðåíòðàëüíûõ ñïîñîáàõ ââåäåíèÿ.


Õèìèêî-ôàðìàöåâòè÷åñêèé æóðíàë. Òîì 37, №3, 2003

11. Stefka Valcheva-Kuzmanova, MiroslavEftimov, KrasimirKuzmanov, an experimental model of alcohol induced anxiety and depressive behaviour in rats, ScriptaScientificaMedica, vol. 45, No 3, 2013, pp. 48-52

12. Raines A, Henderson TR, Swinyard EA, Dretchen KL.Comparison of midazolam and diazepam by the intramuscular route for the control of seizures in a mouse model of status epilepticus. Epilepsia. 1990 May-Jun 31 (3): 313-7.

13. Hong Zou, QinglianXie, Manfang Zhang,

Chenghao Zhang, Guoping Zhao, Meilei Jin, and Lei Yu. Chronic alcohol consumption from adolescence to adulthood in mice-effect on growth and social behavior. Drug Alcohol Depend. 2009 September 1; 104(1-2): 119–125.

14. Muhammad Imran Naseer, Li Shupeng and Myeong Ok Kim. Maternal epileptic seizure induced by Pentylenetetrazol: Apoptotic neurodegeneration and decreased GABAB1 receptor expression in prenatal rat brain. Molecular Brain 2009, 2:20

Òàíèëöàæ, íèéòëýõ ñàíàë ºãñºí: Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð

Á.Ñàðàíöýöýã


ËÅÊÖ, ÒÎÉÌ, ÇªÂËªÃªª

Ýïèëåïñèòýé õ¿ì¿¿ñèéí ñýòãýë ç¿é-íèéãìèéí àñóóäàë

Ä.Áàÿñãàëàí, Â.Äýëãýðìàà, À.ÒîâóóäîðæÀíàãààõûí Øèíæëýõ Óõààíû ¯íäýñíèé Èõ Ñóðãóóëü

Èìýéë õàÿã: [email protected]Óòàñ:88190889

Abstract

Psychosocial problem of people with epilepsy

D.Bayasgalan, V.Delgermaa, A.TovuudorjMongolian National University of Medical Sciences

Email:[email protected] number: 88190889

Many studies have demonstrated psychosocial problem of people with epilepsy that who has depression and anxiety symptoms, ashamed, worried, guilt or feelings of worthlessness, poor self-esteem and social side which includes education, employment issues, marriage, pregnancy, quality of life and stigma. These are related to the knowledge of the social, duration of epilepsy and seizure types.

People with epilepsy are coexisting that seizure relatedissues such as behavioral and psychosocial problems and comorbid psychiatric disorders that are prone to develop in patients with this disorder. Therefore hidden psychosocial problems stigmatizing and negative attitude are arisen from the social. The reason of that is demanded improve the quality of life for people with epilepsy and also is required to solve problem, completely. Not only medicine is treatment of people with epilepsy, but coping with epilepsy may also associate with psychosocial problemsfacing patients with epilepsy.

According to this, hospital and social positive factors need to initiate for the people with epilepsy without seizure and help to live normally. Furthermore, it is necessary to establish national program and recommendation.

Key word: epilepsy, psychosocial problem, seizure


Óäèðòãàë

Ýïèëåïñè íü õ¿ì¿¿ñèéí ñóð÷, áîëîâñðîõ, õºäºëìºðëºõ ÷àäâàðò òîäîðõîé õýìæýýãýýð ñºðºã íºëºº ¿ç¿¿ëäýã ìýäðýëèéí òîãòîëöîîíû ò¿ãýýìýë ºâ÷í¿¿äèéí íýã áºãººä óã ýìãýãèéí ýìíýëç¿éí ÿâö, òàâèëàí òºäèéëºí òîäîðõîé áóñ, çîíõèëîí ýðýãòýé÷¿¿äýä òîõèîëäîæ áàéíà [1, 2, 3].

Äýëõèéí óëñ îðíóóäàä 50 ãàðóé ñàÿ ýïèëåïñèòýé õ¿ì¿¿ñ àìüäàð÷ áóéãààñ õºãæèíã¿é óëñ îðîíä 1000-ä 4-7, õºãæèæ áóé îðíóóäàä 5-74 òîõèîëäîë íîîãäîæ, æèëä 10 ãàðóé ñàÿ õ¿ì¿¿ñ õºäºëìºðèéí ÷àäâàðàà àëäàæ, òýäíèé îéð äîòíû 500 ãàðóé ñàÿ õ¿ì¿¿ñ ýïèëåïñèéí óëìààñ ¿¿ñýõ àñóóäàë, áýðõøýýë¿¿äèéã øóóä áóñààð ìýäýðäýã áàéíà. Ýäãýýð òîî áàðèìòóóä ýïèëåïñè ºâ÷èí íèéãýì, ýäèéí çàñàã, ýð¿¿ë ìýíäèéí òîãòîëöîîíû òîìîîõîí àñóóäëûí íýã ãýäãèéã èëýðõèéëæ áàéíà [1, 4, 5, 6].

Ýïèëåïñèòýé õ¿ì¿¿ñò ýð¿¿ë ìýíä, íèéãìèéí òóñëàìæ ¿éë÷èëãýýíèé îëîí áýðõøýýë¿¿ä öàã ÿìàãò òóëãàð÷, òàòàëòã¿é áàéõ ¿åä ÷ ñýòãýë ò¿ãøèë, ñýòãýë ãóòðàë, öààøëààä àìèà õîðëîõ çýðýã ñýòãýöèéí ýìãýã¿¿ä áîëîîä çàí òºðõèéí ººð÷ëºëòèéí õàâñàðñàí øèíæ òýìäã¿¿ä èëðýõ, ò¿¿í÷ëýí óíàëòòàé õîëáîîòîé íèéãìèéí áóðóó, òàøàà ¿çýë áàðèìòëàë, ñºðºã õàíäëàãà, õºäºëìºðèéí ÷àäâàð àëäàëò çýðýã ñýòãýëç¿é-íèéãìèéí òóëãàìäñàí àñóóäëóóä áàéíãà ¿¿ñ÷ áàéäàã [7, 8, 9].

Ýïèëåïñèéí óëìààñ ¿¿ññýí ñýòãýë ç¿éí õ¿íä äàðàìò íü àìüäðàõ ÷àäàìæèéí õóâüä áóñäààñ äîîãóóð ãýñýí îéëãîëòûã ººðòºº ¿¿ñãýõ, ººðèéãºº áóñäààñ, íèéãìýýñ òóñãààðëàäàã íü àìüäðàëûí ÷àíàð áóóðàõ íýãýí øàëòãààí áîëíî [10]. Ìºí òàòàëò ºãºõ àãøíààñ áóñàä ¿åä ýïèëåïñè øèíæ òýìäýãã¿é, ýð¿¿ë ìýò õàðàãäàõ òóë “äàëä áàéäëûí”


õºäºëìºðèéí ÷àäâàð àëäàëòàíä õ¿ðãýäýã ýìãýã þì. Óíàëò òàòàëò ººðòºº èòãýõ èòãýë àëäðàõ, ººðèéí ¿íýëýìæ áóóðàõàä õ¿ðãýæ íèéãìèéí äóíäàõ áóðóó îéëãîëò, ñòèãì, ñòðåññ ¿¿ñýõ íýìýëò øàëòãààí áîëäîã. Ýäãýýðýýñ ¿¿äýëòýé ñòðåññ íü èõýíõ õ¿ì¿¿ñèéã ñýòãýë ò¿ãøèëä îðóóëæ óëìààð ñýòãýë ãóòðàë, õóâü õ¿íèé çàí òºðõèéí ººð÷ëºëòèéã ¿¿ñýõýä íºëººëäºã [7, 11, 12].

¯¿íèé ýìãýã ôèçèîëîãèéí íàðèéí ìåõàíèçìûã ñåðîòîíèí, íîðàäðåíàëèí, äîôàìèí, ÃÀÌÊ, ãëóòàìàò çýðýã íåéðîòðàíñìèòåð¿¿äèéí ººð÷-ëºëò, ãèïîòàëàìóñ-ºí÷èí òàðõè-áººðíèé äýýä áóë÷èðõàéí òîãòîëöîîíû ¿éë àæèëëàãààíû àëäàã-äàëòàé õîëáîí òàéëáàðëàäàã.

Ýïèëåïñèéí ýìãýã æàìûí ãîë ìåõàíèçì íü îëîí òºðëèéí ãåíèéí ººð÷ëºëòººð íºõöºëäñºí áèîöàõèëãààí çîõèöóóëãàò èîíû ñóâãèéí ººð÷ëºëò, ìåìáðàíû á¿òöèéí ººð÷ëºëò, ñýðãýýõ áà ñààòóóëàõ òîãòîëöîîíû òýíöâýðò áàéäëûí àëäàãäàë çýðýãò ñåðîòîíèíä ìýäðýã ðåöåïòîðóóäûí èäýâõò ÷àíàðûí ººð÷ëºëòòýé õîëáîîòîé [13-17].

Ýïèëåïñèéí ñýòãýë ç¿éí àñóóäàë

Õ¿í áîë íèéãìèéí áîëîí õóâèéí ¿éë àæèëëàãààíä èäýâõòýé îðîëöäîã ººðèéí ãýñýí ñýòãýë ç¿éí á¿òöèéã àãóóëæ, áèåý äààñàí áàéäëàà õàäãàëñàí áóñäààñ òóñãààð òîãòíîñîí áîäüãàë þì. Õàðèí ýïèëåïñèòýé õ¿ì¿¿ñèéí àìüäðàë òîäîðõîé õýìæýýãýýð áóñäààñ õàìààðàëòàé áàéäàã íü àìüäðàõ ÷àäàìæààð ýíãèéí õ¿ì¿¿ñýýñ äîîãóóð õýìýýí ººðèéíõºº ¿íýëýìæèéã áóóðóóëæ, ººðºº ººðòºº ñòèãìèéã ¿¿ñãýäýã îíöëîãòîé.Ýïèëåïñè íü õóâü õ¿íä ñýòãýë ç¿éí èõýýõýí õ¿íä äàðàìòûã áèé áîëãîæ ºâ÷íºº ¿ã¿éñãýõ, ñýòãýë ò¿ãøèë, ñýòãýë ãóòðàë, áóõèìäàë ¿¿ñ÷ ýöýñò íü ýíý á¿õíèéã õ¿ëýýí çºâøººðºõ ñýòãýë ç¿éí õàðèó óðâàëóóä ÿâàãäàæ òóõàéí õ¿í ººðèéãºº õºäºëìºðèéí ÷àäâàð àëäàãäñàí áàéäëààð ìýäýðäýã [11,18].

Ñóäëàà÷èä ýïèëåïñèòýé õ¿ì¿¿ñèéí 75-ààñ äýýø õóâü íü ñýòãýë ç¿é-íèéãìèéí àñóóäàëòàé, 50-ààñ èë¿¿ õóâü íü ñýòãýöèéí ÿìàð íýãýí ýìãýã, òàíèí ìýäýõ¿éí ººð÷ëºëòòýé áàéäãèéã òýìäýãëýñýí. [19, 20] Jones íàðûí õèéñýí êîãîðò ñóäàëãààãààð óíàëò òàòàëò ýõýëñíýýñ 4 æèëýýñ öààø çàí òºðõ, ñýòãýöèéí ÿìàð íýãýí ººð÷ëºëò èëýðäãèéã òîäîðõîéëæýý. [21, 22, 23] Õýë ÿðèà, îé òîãòîîëòûí ººð÷ëºëò, ñýòãýöèéí õàâñàðñàí ýìãýãèéí øèíæ¿¿ä ààæìààð ¿¿ñýõ íü òàòàëò, ýìèéí íºëººëºë, ñýòãýë ç¿é-íèéãìèéí õ¿÷èí ç¿éë¿¿äýýñ øàëòãààëäàã. [24, 25, 26] Ýïèëåïñèéí ¿åä ò¿ãýýìýë èëýðäýã ýäãýýð õàâñàðñàí ýìãýã¿¿äýýñ ñýòãýë ãóòðàë, ñýòãýë ò¿ãøèë çîíõèëîí òîõèîëäîæ ¿¿íèéã îëîí æèëèéí òóðøèä ýì÷ íàð ýïèëåïñèéí óëìààñ íèéãìèéí îëîí áýðõøýýë¿¿äýä ¿ç¿¿ëæ áóé õóâü õ¿íèé çàí

÷àíàðûí õýâèéí õàðèó óðâàë õýìýýí áóðóóãààð òàéëáàðëàæ áàéæýý [12, 27]. ¯íýí õýðýãòýý ñýòãýë ãóòðàë íü ýïèëåïñèòýé ºâ÷òºí¿¿äèéí àæèë ýðõëýõ, áîëîâñðîõîä áýðõøýýë ó÷ðóóëàõ, íèéãìèéí ç¿ãýýñ ¿ç¿¿ëýõ ñòèãì çýðýã ýïèëåïñèéí íèéãýì ñýòãýëç¿éí òààã¿é áàéäàëä ¿ç¿¿ëæ áóé õàðèó óðâàë áºãººä ¿¿íèéã íåéðîòðàíñìèòðèéí ººð÷ëºëòººð òàéëáàðëàäàã [13,14]. Ñýòãýë ãóòðàë íü òóõàéí õ¿íèé çîðèã, ýðìýëçëýë ñîíèðõîë àëäàãäàõ, ººðèéãºº áóðóóòãàõ, àíõààðàë òºâëºðºëò àëäàãäàõ, àëèâàà ç¿éëä èòãýëã¿é áîëîõ, ¿õëèéí òóõàé áîäîõ óëìààð àìèà õîðëîëòîíä õ¿ðãýæ áîëîõ íºõöºë þì. 28 Ñýòãýë ãóòðàëûí òàðõàëò ýð¿¿ë õ¿ì¿¿ñò 1,5%-19% áîë ýïèëåïñèòýé õ¿ì¿¿ñèéí 20%-80%-ä òîõèîëäîõ áºãººä àìüäðàëûí ÷àíàðò èë¿¿ õîð íºëººòýé [12, 27]. Ýïèëåïñèòýé ºâ÷òºí¿¿äýä ñýòãýë ãóòðàëûí òàðõàëòûí ò¿âøèí 19-65%, ¿¿íýýñ äóõ, ÷àìàðõàéí áàéðøèëòàé ýïèëåïñèòýé õ¿÷ëýí-÷è÷èðõèéëýõ òàòàëòòàé õ¿ì¿¿ñò èë¿¿ èõ áàéíà.12 Çàðèì ñóäàëãààãààð ñýòãýë ãóòðàë ¿¿ñýõ íü ÷àìàðõàéí äóíä õàòèíãàðøèëûí ¿åä èë¿¿ òîõèîëäîæ, ¿¿íèé 40%-50% íü óäàìøëûí ãàðàëòàé ãýæýý [13, 24, 29]. Ñóäëàà÷èä ýïèëåïñèòýé ºâ÷òºí¿¿äèéí 10-25% ñýòãýë ò¿ãøèëòòýé, ººðèé ãºº õÿíàõ ÷àäâàð ñóëòàé áàéäãèéã òîäîðõîéëñîí. 30 Ñýòãýë ò¿ãøèë, ñýòãýë ãóòðàë, òàíèí ìýäýõ¿é, çàí òºðõèéí ººð÷ëºëò çýðýã ýïèëåïñèéí ¿åèéí õàâñàðñàí ýìãýã¿¿ä äàí áîëîí õàâñàð÷ ýïèëåïñèéí ñòèãì, íèéãìèéí òóñãààðëàëòûã ¿¿ñãýäýã ãîë øàëòãààí áîëäîã. Ýïèëåïñèéí òàòàëò õóâü õ¿íèé äîòîîä õ¿÷èí ç¿éë¿¿ä áîëîõ ñýòãýëèéí ãýíýòèéí öî÷ðîëóóä, ñòðåññ, óóð áóõèìäàë, ñýòãýë ò¿ãøèë, õýòýðõèé èõ ñýòãýë õºäëºë çýðãýýð ºäººãäºõ áîëîìæòîé. Ýïèëåïñèéíýì÷èëãýýíä çàí òºðõèéí ººð÷ëºëò, ñýòãýë ãóòðàë, ñýòãýë ò¿ãøëèéã çàñàõ ýì÷èëãýýã õèéõ íü òàòàëòûí äàâòàìæèéã áóóðóóëäàã [12, 24, 27].

Ýïèëåïñèéí íèéãìèéí àñóóäàëÝïèëåïñèòýé õ¿ì¿¿ñèéííèéãìèéí àñóóäàëä òýä-íèé õàìãèéí îéðûí õàðèëöàà áîëîõ ãýð á¿ëèéí ãèø¿¿äèéí õàíäëàãà èõýýõýí íºëººòýé õ¿÷èí ç¿éë þì [31]. ßëàíãóÿà õ¿¿õä¿¿äýä ýöýã, ýõèéí õýò èõ àíõààðàë õàëàìæ, àéäñààñ ¿¿äñýí ýïèëåïñèéí òóõàé áóðóó îéëãîëò ãýð á¿ë, àõ ä¿¿ñèéí äîòîð ¿¿ñýõ íüòýäíèéã íèéãìýýñ òóñãààðëàõ, áóñàäòàé õàðüöàõ ñºðºã õàíäëàãà áèé áîëîõ íºõöëèéã ¿¿ñãýõ óëìààðòóõàéí õ¿¿õäèéí óõàìñàðò ººðèéãºº òóñãààðëàõ òºñººëºëèéã áèé áîëãîõ íºõöºë áîëäîã. Èéìýýñ ýïèëåïñèòýé õ¿¿õäèéí ýì÷èëãýýíèé õºòºëáºðèéí ÷óõàë õýñýã íü ãýð á¿ëèéí îéëãîëò õàíäëàãûã çàñàõ ñóðãàëò þì [12, 24]. Ýöýã, ýõ÷¿¿äýä õ¿¿õäýýýïèëåïñèòýé ãýæ ñîíñîõ íü ñýòãýë ç¿éí äàðàìòûã ¿¿ñãýõ áºãººä áîëîâñðîë,


èðýýä¿éí àìüäðàëûí òóõàé òºñººëëººñ 22.6%-ä ñýòãýë ãóòðàë ¿¿ñäýã [32].

¯íýí õýðýãòýé ÷ ýïèëåïñèòýé ºâ÷òºí¿¿äèéí áîëîâñðîëûí ò¿âøèí åðºíõèéäºº äîîãóóð áàéãàà íü ìàðãààíã¿é ¿íýí áîëîâ÷ óëñ, îðîí íèéãýì, õàìò îëíîîñ øàëòãààëàí ýíý ¿ç¿¿ëýëò ÿëãààòàé áàéíà.5,6Ìºí ýïèëåïñèòýé õ¿¿õä¿¿äèéí äîòîð ñóðãóóëèéí íàñíûõàí 1000-ä 4-7 òîõèîëäîë á¿ðòãýãäýæ, 3 õ¿¿õýä òóòìûí íýãíèé èðýýä¿éí àìüäðàëä ÿìàð íýãýí áàéäëààð ñºðºã íºëºº ¿ç¿¿ëäãèéã ñóäëàà÷èä òîãòîîñîí [2, 33].

Ýïèëåïñèéí ¿åä òàðõèíû ãèïïîêàìïûí ìýäðýëèéí ýäèéí ñºíºðëèéí óëìààñ ñóðàõ ÷àäâàð, òàíèí ìýäýõ¿é áóóðàõ,óíàëòûí ýñðýã ýìèéí íºëººëºë çýðýã íü õ¿¿õäèéí ñóðàõ ¿éë ÿâöàä ñºðãººð íºëººëäºã. Óëìààð ýïèëåïñèòýé õ¿¿õýä ñóðãóóëü çàâñàðäàõ,ººðòºº èëòãýëã¿é áîëîõ, ãàíöààðäìàë, çîæèãðîõ çýðýã ñýòãýë ç¿é-íèéãìèéí õ¿÷èí ç¿éëèéã áèé áîëãîæ ñòðåññ áóõèìäàë ¿¿ñãýõ íýã øàëòãààí áîëíî [16, 17, 24].

Óíàëò, òàòàëò á¿ðýí õÿíàãäààã¿é íºõöºëä ýïèëåïñèòýé õ¿ì¿¿ñò àæèëã¿éäýë õºãæèæ áóé îðîíä 100% õ¿ðòýë, õºãæèíã¿é îðîíä 50% õ¿ðòýë áàéíà. [11, 12] Ýïèëåïñèòýé õ¿ì¿¿ñ ìýðãýæèë ýçýìøèõ íü öººí, àæèëã¿éäëèéí ò¿âøèí ýíãèéí õ¿ì¿¿ñòýé õàðüöóóëàõàä 30%-ààð èë¿¿ áàéãàà íü àæèë îëãîã÷èéí õàíäëàãààñ øàëòãààëäàã áîë íºãºº òàëààñ òýä íèéãìèéí õàðèëöààíä îðîõäîî ººðòºº èòãýëã¿é áàéõ, àìüäðàëûí èäýâõã¿é õýâ ìàÿã, ñòèãì, ÿëãàâàðëàí ãàäóóðõàëò çýðýã ñýòãýë ç¿é-íèéãìèéí á¿ðäýë îéëãîëòóóäààñ ¿¿ñäýã. [24] Àæèë ýðõëýýã¿é ýïèëåïñèòýé õ¿ì¿¿ñ àæèë õèéæ áóé ýïèëåïñèòýé õ¿ì¿¿ñýýñ àìüäðàëûí ÷àíàðûí õóâüä ÿìàãò äîîãóóð, ñýòãýë ç¿é-íèéãìèéí àñóóäàëòàé èõ òóëãàðäàã [34, 35]. Àæèë ýðõëýëò ýäèéí çàñãèéí õóâüä à÷ õîëáîãäîëòîé òºäèéã¿é õóâü õ¿íèé íèéãìèéí ºìíº õ¿ëýýõ ¿¿ðýã, õàðèóöëàãàà ìýäðýõ, ººðòºº èòãýõ, ººðèéí ¿íýëýìæýý äýýøë¿¿ëýõ, àìüäðàëààñ ñàéí ñàéõíûã ìýäðýõ, àìüäðàëûí ÷àíàðûã äýýøë¿¿ëýõ ÷óõàë õ¿÷èí ç¿éë áîëíî [11, 24]. ÀÍÓ-ä õèéãäñýí ñóäàëãààãààð íèéò ºâ÷òºí¿¿äýä ýðõýëæ áóé àæëûí à÷ õîëáîãäëûã ºíäðººð ¿íýëýõ àæëûí áàéðíû ÿëãàâàðëàí ãàäóóðõàëòûí àéäñûã áóóðóóëàõ íü ýïèëåïñèòýé ºâ÷òºí¿¿äèéí àæèë ýðõëýëòèéí ò¿âøèíã íýìýãä¿¿ëýõ ÷óõàë ¿¿ðýãòýé áàéíà [36]. Èéìä ýïèëåïñèòýé ºâ÷òºí¿¿äèéã àæëûí áàéðààð õàíãàõ, õàäãàëàõ, òóñãàé íºõºí ñýðãýýõ õºòºëáºð øààðäëàãàòàé áàéíà. Õºãæèæ áóé îðíóóä óã õºòºëáºðèéã áèé áîëãîõ, ýì÷ ìýðãýæèëòí¿¿ä óíàëòûã õÿíàëòàíäàà àâàõ àðãà õýìæýýã õýðýãæ¿¿ëýõ íü ç¿éòýé. Óíàëòûí äàâòàìæ îéð áàéäãààñ àæèëã¿éäëèéí ò¿âøèí èõ áàéíà [34, 36, 37]. Àæèëã¿éäýë, ãýð á¿ëèéíõíèé

õýò àíõààðàë íü ñýòãýë ò¿ãøëèéã ¿¿ñãýõ, ãýð á¿ëèéí õàðèëöààíààñ ãàäóóð èäýâõòýé ¿éë àæèëëàãààíä îðîëöîõûã õÿçãààðëàõ, íèéãìýýñ àíãèä áàéõ íºõöëèéã á¿ðýëä¿¿ëäýã. Ýïèëåïñèéí òóõàé íèéãìèéí äóíäàõ áóðóó õàíäëàãà ºâ÷íèé ÿâö, òàâèëàíä ñºðãººð íºëººëæ, ýì÷èëãýýíèé çºâ ìåíåæìåíò õèéõýä õ¿íäðýë ó÷ðóóëäàã [11, 24].

Õ¿í àìä ñóóðèëñàí ñóäàëãààíû ¿ð ä¿íãýýñ íèéãìèéí äýìæëýã õÿçãààðòàé áàéõ íü ýïèëåïñèòýé õ¿ì¿¿ñèéã õàìãèéí èõ ñóëüäàëä îðóóëäàã ãýäãèéã òîãòîîñîí [38, 39]. Ýïèëåïñèòýé õ¿ì¿¿ñò òîõèîëäîõ ººð íýã àñóóäàë íü îëîí íèéò ýïèëåïñèéí òóõàé ìýäýýëýë õàíãàëòã¿éãýýñ òýäíýýñ õîë áàéõ, óíàëòûí ¿åä àéæ ñàíäðàõ ¿éëäë¿¿ä ãàðäãèéã àðèëãàõ, çºâ îéëãîëòûã áèé áîëãîõ íü íèéãìèéí òóñãààðëàëòààñ ñýðãèéëýõ ýíãèéí àðãà þì [11, 27, 40]. Èéìä òºðºëæñºí ìýðãýæëèéí ñýòãýë çàñàë, ñýðãýýí çàñàë, ººðèéí ¿íýëýìæ, èäýâõòýé àìüäðàëûí äàäëûã ñàéæðóóëàõ çºâëºìæ ºãºõ, õ¿í àìûí äóíäàõ îéëãîëòûã äýýøë¿¿ëýõýä ãîë àíõààðëàà õàíäóóëàõ, íèéãýì, õàìò îëîíä òóëãóóðëàñàí ñýòãýë ç¿éí ñýðãýýí çàñàë ýì÷èëãýýã ýìèéí ýì÷èëãýýòýé õàâñðàõ íü ýïèëåïñèéí ýì÷èëãýýíèé ¿ð ä¿íòýéàðãà çàì áîëíî [24].

Ýïèëåïñèòýé õ¿íèé àìüäðàëûí ÷àíàðò óíàë-òûí äàâòàìæ, óíàëòûí ¿ðãýëæèëñýí õóãàöàà, ýïèëåïñèéí ¿ðãýëæèëñýí òàòàëòàíä îðîõ, ñýòãýë ç¿é, òàíèí ìýäýõ¿éí ººð÷ëºëò, ñýòãýöèéí ýð¿¿ë ìýíäèéí áàéäàë,íèéãìèéí õàðèëöàà, ýïèëåïñèéí óëìààñ ¿¿ññýí ñòèãì çýðýã íü øóóä íºëººëíº [41, 42]. Áèåèéí ýð¿¿ë ìýíäèéí õóâüä óíàëòûí äàâòàìæ èõ, îñîë ãýìòëèéí çýðýã, óíàëòûí ýñðýã ýìèéí ãàæ íºëºº,áýëãèéí àìüäðàëûí ñýòãýë õàíàìæã¿é áàéäàë, íèéãìèéí ç¿ãýýñ ÿäóóðàë, áîëîâñðîëã¿é, àæèëã¿éäýë èõ áàéõ, íèéãìèéí òóñãààðëàëòçýðãýýñ õàìààð÷ àìüäðàëûí ÷àíàð áóó-ðà õàä íºëººëíº [11, 24]. Ýïèëåïñèòýé ºâ÷òºíèé ãýðëýëòèéí ¿ç¿¿ëýëò íèéò õ¿í àìòàé õàðüöóóëàõàä äîîãóóð áºãººä õàðèí Cameroon óëñàä õèéãäñýí ñóäàëãààãààð ãýðëýëòèéí ò¿âøèí 58.9% áàéãàà íü õàìãèéí ºíäºð ¿ç¿¿ëýëò þì [43]. Ýïèëåïñèòýé õ¿ì¿¿ñèéí àìüäðàëûí ÷àíàðûã ¿íýëýõýäàõìàä íàñíûõàí áà ýìýãòýé÷¿¿ä, óíàëòûí õýëáýðèéí õóâüä ýíãèéí õýñýã÷èëñýí óíàëòòàé õ¿ì¿¿ñ èë¿¿ áàãà îíîî àâäàã îíöëîãòîé.34Ìºí àìüäðàëûí ÷àíàðûí ººð÷ëºëò 30-35%-ä ñýòãýë ç¿éí õ¿÷èí ç¿éëòýé õîëáîîòîé [40].

Ñòèãì

Ñòèãì íü òóõàéí õóâü õ¿íèé ç¿ãýýñ áóñäàä õ¿ëýýí çºâøººðºãäºõ áàéäàë àëäàãäàõ, ÿëãàâàðëàëòàíä ºðòºãäºõ, ººðèéãºº íèéãýìä õ¿ëýýí çºâøººðºõã¿é áîëîõ, ººðèéãºº ¿íýëýõ ¿íýëýìæ áóóðñíààñ áóñäààñ òàòãàëçàõ, èòãýëã¿é áîëîõ, íºãººòýéã¿¿ð


áóñäûã ÿëãàâàðëàí ãàäóóðõàõ, ¿ë òîîìñîðëîõ, áóðóóòãàõ, äîðä ¿çýõ çýðýã àãóóëãûã áàãòààñàí íèéãìèéí ç¿ãýýñ ¿ç¿¿ëýõ õàðèó óðâàë þì [24, 44, 45]. Ýïèëåïñèéí ñòèãìèéí¿åä áèå ìàõáîäü, ñýòãýë ç¿éä ¿¿ññýí íºëººëºë íü ºâ÷òºíèé íèéãýìä àìüäàð÷, àæèëëàõàä ñºðãººð íºëººëæ, àìüäðàëûí ÷àíàðûã áóóðóóëäàã [44].

Ýïèëåïñèòýé õ¿ì¿¿ñ íèéãìèéí õàðèëöààíä îðîëöîõ ÿâöäàà ãýíýòèéí óíàëòàíä ºðòºæ ººðò òàâèõ õÿíàëòàà àëääàã ó÷ðààñ óíàëòûí ¿åä ¿¿ñýõ òºðõ áàéäàë íü ýð¿¿ë õ¿ì¿¿ñò àþóëòàé ìýò ñýòãýãäëèéã òºð¿¿ëýõýýñ ýìçýãëýæ, íèéãìèéí ç¿ãýýñ äàðàìòòàé áàéäëûã áàéíãà ìýäýð÷ áàéäàã [46, 47].

Ýïèëåïñèòýé ºâ÷òºí¿¿äèéí 50-ààñ èë¿¿ õóâü íü íèéãìèéí õàðèëöààíä îðîõ ÿâöäàà ñòèãìèéã ìýäýðäýã òºäèéã¿é, óíàëò òàòàëòã¿é ¿åäýý ÷ ò¿¿íèéã áàéíãà ººðòºº ¿¿ñãýæ áàéäàã [43, 45, 48]. Îëîí ñóäàëãààíààñ ¿çýõýä çàëóó íàñàíä óíàëò ýõëýõ, óíàëòûí äàâòàìæ îéð, ¿ðãýëæëýõ õóãàöàà èõ, áîëîâñðîëûí ò¿âøèí áàãà, óíàëò ãýìòëèéí øàëòãààíòàé, åðºíõèé õ¿÷ëýõ ÷è÷èðõèéëýõ òàòàëò òàé çýðýã õ¿÷èí ç¿éë¿¿ä íü ýïèëåïñèéí ñòèãìèéí òóõàé ¿çýë ñàíààíä õ¿÷òýé íºëºº ¿ç¿¿ëäýã ãýäãèéã õàðóóëñàí [44]. Ñ¿¿ëèéí ¿åèéí ñóäàëãààãààð áîäèòîé ÿëãàâàðëàí ãàäóóðõàëòàé òóëãàðàõ äîòîãøîî ÷èãëýñýí õóâü õ¿íèé ÷àíàð, àñóóäëûã øèéäâýðëýõ ÷àäàâõè, ñýòãýëèéí õºäºë-ãººíèéã õÿíàõ çýðýã áàéäëóóä íü ñýòãýöèéí ¿éëèéí àëäàãäëààñ õàìààðàõã¿éãýýð ýïèëåïñèéí ñòèãìèéí òàëààðõè ìýäðýìæèíä íºëººëäãèéã õàðóóëæ áàéíà [37].

Ýïèëåïñèéí ¿åä ¿¿ñýõ ñòèãìèéã ãóðâàí õýëáýðò õóâààõ áà íýãä¿ãýýðò ººðººñ õàìààðàëòàé ñòèãì áóþó ýïèëåïñèéí óëìààñ è÷èõ, áóñäûí ç¿ãýýñ ¿ç¿¿ëýõ ñºðºã õàíäëàãààñ ýìýýõ áàéäëûã èëýðõèéëäýã. Ýïèëåïñèòýé ºâ÷òºí¿¿ä áóñäàä ¿ë òîîìñîðëîãäîí ÿëãàâàðëàí ãàäóóðõàãäàõ àéäàñòàé áàéäàã. Ýíý áîäëîîñ òýä íèéãìèéí èäýâõèòýé àìüäðàëààñ çóãàòàí, íóóãäàæ, àìüäðàëûí ÷àíàðàà äîðîéòóóëàí ñòèãìèéã ¿¿ñãýäýã. Õî¸ðäóãààðò íèéãìèéí õàìààðàëòàé ñòèãì áóþó ýïèëåïñèòýé ºâ÷òºí¿¿äýä îëîí íèéòèéí ç¿ãýýñ ¿ç¿¿ëæ áóé ÿëãàâàðëàí ãàäóóðõàõ èëðýë þì. Ýíý ¿çýë íü ýïèëåïñèéí ¿íäñýí øàëòãààíûã áóðóó îéëãîñîíòîé õîëáîîòîéãîîð ò¿¿íèéã ãàäíû õ¿÷èí ç¿éëèéí óëìààñ ¿¿ñäýã ãýæ ¿çäýã. Ãóðàâäóãààðò ãýð á¿ëèéí õàìààðàëòàé ñòèãì áóþó çàðèì ñóäàëãààíààñ õàðàõàä ýïèëåïñèòýé õ¿¿õä¿¿äèéí ýöýã ýõ÷¿¿ä è÷ã¿¿ðòýé ãýñýí ãóðâàí õýëáýðò õóâààæ áîëíî [43, 45, 49]. Äýýðõè ãóðâàí òºðëèéí ýïèëåïñèéí ñòèãì áèå áèåíäýý õàðèëöàí óÿëäààòàé íýã õ¿÷èí ç¿éë

íü íºãºº õ¿÷èí ç¿éëýý íºõöºëä¿¿ëýí ýïèëåïñèéí ýì÷èëãýý, òóñëàìæèíä èõýýõýí ñààä ó÷ðóóëäàã.

Áîëîâñðîë ýçýìøèõýä ýïèëåïñèéí ñòèãìûí íºëººëºë õºãæèæ áóé îðíóóäàä èë¿¿ ò¿ãø¿¿ðòýé, ýïèëåïñèòýé õ¿¿õäèéã îþóí óõààíû ÷àäàâõèã¿é ãýæ ¿çýõ, òýäíèé ýöýã, ýõ÷¿¿ä õ¿¿õä¿¿äýý óíàëòààñ áîëîîä õ¿íä ãýìòýë àâàõ, ãýðýýñýý ãàäóóð ÿâæ áàéãààä çîëã¿é òîõèîëäëîîð àìü ýðñäýõ àéäñûí óëìààñ ñóðãóóëüä ÿâàõûã íü õîðèãëîäîã. [50] Ñóðãóóëèéí îð÷èíä óíàæ òàòàõ íü òóõàéí õ¿¿õäèéí ãýð á¿ëèéí ãèø¿¿äýä ¿¿ñýõ ñòèãìèéã óëàì ã¿íçãèéð¿¿ëýõýýñ ãàäíà õ¿¿õäèéí ººðèéí ¿íýëýìæ áóóð÷, íèéãìèéí õàðèëöààíä îðîõ íü áàãàñäàã [51].

Ìºí àæèë ýðõýëäýãã¿é õ¿ì¿¿ñ ýïèëåïñèéí ñòèãìä èë¿¿ èõ ºðòäºã. ªíºº õ¿ðòýë àæèë îëãîã÷èä ýïèëåïñèòýé õ¿ì¿¿ñòýé àæèëëàõàä òààã¿é õàíääàãààñ ºâ÷òºí¿¿äèéí íèëýýä õóâü íü ºâ÷íºº íóóäàã áàéíà [36, 51].

Òèéìýýñ ñòèãì áîëîí ò¿¿íýýñ ñýðãèéëýõ ìåíåæìåíòèéã ñóäëàõ íèéòèéí ìýäëýãèéã äýýøë¿¿ëýõ ñóðãàëòûí õºòºëáºð, ¿éë àæèëëàãààã ýð÷èìæ¿¿ëýõ, íýí øààðäëàãàòàé. Ò¿¿í÷ëýí ýð¿¿ë ìýíäèéí á¿õ øàòëàëûí ìýðãýæèëòí¿¿ä ýïèëåïñèéí ñòèãìèéí òàëààð îéëãîëòòîé áàéõ øààðäëàãà ç¿é ¸ñîîð òàâèãäàæ áàéíà.

Ä¿ãíýëò:

Ýïèëåïñèéí ºðãºí õ¿ðýýíèé îéëãîëòîîñ õàìãèéí àíõààðàõ íü îþóí ñàíàà, ñýòãýí áîäîõ ¿éëèéí õÿìðàë, ìºí ñýòãýë ç¿éí ººð÷ëºëò þì. Ñýòãýë ç¿éí ñºðºã õàðèó óðâàëóóä, ñýòãýë ò¿ãøèë íü áóðóó, äóòìàã ìýäýýëýëòýé áóñàä õ¿ì¿¿ñèéí ç¿ãýýñ ãàð÷ áóé õàíäëàãûí óëìààñ ¿¿ñýõ ó÷èð ýïèëåïñèòýé õ¿ì¿¿ñ, òýäíèé ãýð á¿ë, íèéãýì, õàìò îëíûã çºâ ìýäýýëýëýýð õàíãàõ, ñýòãýë ç¿éí äýìæëýã, çºâëºãºº ºãºõ, ýð¿¿ë ìýíäèéí áîëîâñðîëûã äýýøë¿¿ëýõýä ìýðãýæëèéí ýì÷, ýìíýëãèéí àæèëòíóóä, íèéãìèéí àæèëòàí ãîë ¿¿ðýã ã¿éöýòãýõ áºãººä ýïèëåïñèòýé õ¿ì¿¿ñèéã íèéãìèéí õàðèëöààíä èäýâõòýé îðóóëæ íèéãýì õàìò îëîíä òóëãóóðëàñàí ñýðãýýí çàñàë ýì÷èëãýýã òîäîðõîé õºòºëáºðèéí äàãóó ÿâóóëàõ íü ¿ð ä¿íòýé þì. Òèéìýýñ õ¿í àìûí äóíä ýïèëåïñèéí òàëààðõ ýð¿¿ë ìýíäèéí áîëîâñðîëûã äýýøë¿¿ëýõ, ýì÷, ýìíýëãèéí àæèëòíóóäàä ìýðãýæëèéí ñóð-ãàë òûã òîãòìîë ÿâóóëàõ, ¿íäýñíèé õºòºëáºð áîëîâñðóóëàí áàòëóóëàõ, ñýòãýö, íèéãìèéí ýð¿¿ë ìýíäèéí òóñëàìæèéí àæëûã ñàéæðóóëàõ íü ç¿é ¸ñíû õýðýãöýý, øààðäëàãà òàâèãäàæ áàéãàà áèëýý.


Íîì ç¿é

1. Hanneke M. de Boer, Marco Mula, Josemir W Sander. “The global burden and stigma of epilepsy”. Epilepsy & Behavior. 2008; 12; 540–546

2. Helena Gauffn, Gullvi Flensner, Anne-Marie Landtblom. “Epilepsy in young adulthood: medical, psychosocial and functional aspects” Linköping University Medical Dissertations No.1309, Epilepsy & Behavior 2011;22(4)293-7

3. Ã.Öàãààíõ¿¿, Ö.Äýëãýðìàà “Ìýäðýë ñóäëàë” 2014; 297-300

4. Caroline K. Mbuba, Charles R. Newton “Packages of Care for Epilepsy in Low- and Middle-Income Countries” PLoS Medicine. 2009;6(10)

5. Gretchen L. Birbeck “EPILEPSY CARE IN DEVELOPINGCOUNTRIES” Epilepsy Currents, 2010. Vol. 10, No. 4 75–79

6. Seo-Young Lee, Ki-Young Jung,Keun Lee, Sang Do Yi,Yong Won Cho “Prevalence of Treated Epilepsy in Korea Based on NationalHealth Insurance Data” Neuroscience2012; 27: 285-290

7. Robert T. Fraser, Erica K. Johnsonet al “Managing epilepsy well: Self-management needs assessment” Epilepsy & Behavior, WA, USA, 2011, Volume 20. Pages 291–298

8. Helena Gauffin “Epilepsy in young adulthood:medical, psychosocial andfunctional aspects” 2012 Pages 1–66

9. Anthony K. Ngugi, Christian Bottomley, Immo Kleinschmidt “Estimation of the burden of active and life-time epilepsy” Epilepsia, 2010, 51(5):883–890,

10. Intisar A. G. Khudhur, Fakhria J. Mehabes “Impact of epilepsy on patient’s physical and psychosocial functioning” HEALTH SCIENCE JOURNAL 2012. Volume 6, Issue 3

11. Michael D HILLS. “The psychological and social impact of epilepsy” Neurology Asia 2007; 12 (Supplement 1) : 10-12

12. Tai Sharon. “Social and Psychological Issues in Patients with Epilepsy” Novel Aspects on Epilepsy. 2011; 16: 295-304

13. Marco Mula,Bettina Schmitz. “Depression in Epilepsy-Mechanisms and Therapeutic Approaches” Therapeutic Advances in Neurological Disorders, Novara, Italy. Germany. 2009; 2(5): 337–344

14. PauCelada, M.Victoria Puig, Francesc Artigas “Serotonin modulation of cortical neurons and

networks”, Frontiers in Integrative Neuroscience, Barcelona, Spain. 2013;Volume7, Article 25, 1-20.

15. Eduardo Pineda, Don Shin, Raman Sankar, Andrey M. Mazarati “Comorbidity between epilepsy and depression: Experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms” Epilepsia, California, U.S.A. 2010; 51(Suppl. 3): 110–114,

16. Gyorgy Bagdy, Valeria Kecskemeti, Pal Riba, Rita Jakus “Serotonin and epilepsy” Journal of Neurochemistry, Budapest, Hungary, 2007, 100, 857–873

17. Marco Mula,Bettina Schmitz. “Depression in Epilepsy-Mechanisms and Therapeutic Approaches” Therapeutic Advances in Neurological Disorders, Novara, Italy. Germany. 2009; 2(5): 337–344 1

18. Hills MD. Reducing discrimination against people with epilepsy in New Zealand. Neurol Asia 2004; 9 (Suppl 1): 50-3.

19. Mendez M. “Disorders of mood and affect in epilepsy. In: Sackellares JC, Berent S, eds. Psychological disturbances in epilepsy. Boston: Butterworth-Heinemann, 1996: 125-41.

20. Bruce Hermann, Ann Jacoby, “The psychosocial impact of epilepsy in adults”. Epilepsy Behav. 2009.15(0 1): S11–S16.

21. Jones JE, Bell B, Fine J, Rutecki P, Seidenberg M, Hermann B. A “Controlled Prospective Investigation of Psychiatric Comorbidity in Temporal Lobe Epilepsy”. Epilepsia. 2007; 48:2357–2360

22. A Akinsulore, A Adewuya “Psychosocial aspects of epilepsyin Nigeria: a review ” Afr J Psychiatry 2010;13:351-356

23. Najam-us Sahar “Assessment of Psychological Distress in Epilepsy ” Epilepsy Research and TreatmentVolume 2012, Article ID 171725, 7 pages

24. Hamdy Fouad Moselhy, “Psychosocial and Cultural Aspects of Epilepsy” Novel Aspects on Epilepsy. 2011; 16: 295-304 2-10.

25. O’Donoghue, G Gooddridge, K Redhead, J S Duncan“ Assessing the psychosocial consequences ofepilepsy” British Journal of General Practice, 1999, 49, 211-214.

26. Juri Katchanov, Gretchen L Birbeck “Epilepsy care guidelines for low- and middleincomecountries ” BMC Medicine 2012, 10:107

27. Pamela J. Thompson “ Psychosocial outcome in epilepsy” chapter 39


28. Elise Robinson, Colleen DiIorio, Lara DePadilla “Psychosocial Predictors of Lifestyle Management In Adults withEpilepsy ” Epilepsy Behav. 2008 October ; 13(3): 523–528

29. Sherifa Ahmad Hamed, Nabil Abdel-Hakim Metwaly, “Depression in adults with epilepsy: Relationship to psychobiological variables” World Journal of Neurology. 2012; 28; 2(1): 1-10

30. Jakson, M.J.and D.Turkington “Depression and anxiety in epilepsy” J.Neurol.Neurosurg Psychiatry, 2005.76: 145-146.

31. Bernard S. Chang, M.D., and Daniel H. Lowenstein “Epilepsy ” Thenew england journalofmedicine2003;349:1257-66.

32. Hung A, Hu V, Kwong KL, Kwong NS, Lee W, Wong C, Yip E, Liu Y, Cheung SK, Loong E, Leung KT, Ho J. ”Collaboration of Epilepsy Education Programme on a hospital and community basis”.Poster Presentation. Hong Kong Hospital Authority Convention 2008

33. Soraya Otero “Psychopathology and psychological adjustment inchildren and adolescents with epilepsy” World Journal of Pediatrics2009;5(1):12-17

34. Pushparaja H Shetty, Ravishankar K Naik,AO Saroja, K Punith “Quality of life in patients with epilepsy in India” J Neurosci Rural Pract. 2011.2(1): 33–38.

35. Deirdre P. McLaughlin • Ken McFarland “A randomized trial of a group based cognitive behavior therapyprogram for older adults with epilepsy ” J Behav Med (2011) 34:201–207

36. Parfene, C.,T.L. Stewart and T.Z. King “Epilepsy stigma and stigma by association in the workplace”. Epilepsy Behav, 2009.15: 461-466.

37. Smeets, V.M.,B.A.van Lierop, J.P. Vanhoutvin, A.P. Aldenkamp and F.J.Nijhuis, “Epilepsy and employment: Literature review”. Epilepsy Behav., 2007.10: 354-362.

38. Christine Charyton,John O. Elliott “The impact of social support on health related quality of life in persons with epilepsy”Epilepsy Behav. 2009 Dec;16(4):640-5.

39. Gigi Smith, Pamela L. Ferguson, Lee L. Saunders “Psychosocial factors associated with stigma in adults with epilepsy” Epilepsy Behav. 2009 Nov;16(3):484-90.

40. Lu B, Elliott, Jo. Beyond seizures and medications: Normal activity limitations, social support and mental health in epilepsy” Epilepsia 2012; 53, e25-e28.

41. Michael Pramuka,Rick Hendrickson, Anne Zinski, “A psychosocial self-management program for epilepsy: A randomized pilot study in adults” Epilepsy Behav. 2007 Dec;11(4):533-45

42. Roos Rodenburg, Janelle L. Wagner, Joan K. Austin, “Psychosocial issues for children with epilepsy” Epilepsy & Behavior 2011; Volume 22, , Pages 47–54

43. Baskind, R. and G.L. Birbeck. “Epilepsy associated stigma in sub-Saharan Africa: The social landscape of a disease”. Epilepsy Behav., 2005. 7: 68-73.

44. Wess, M, J.Ramakrishna “Stigma interventions and research for international health” Lancet. 2006;367, 536-538

45. Whatley, A.D., C.K. Diiorio and K. Yeager, 2010. Examinning the relationships of defressive symptoms, stigma, social support and regimen-specific support on quality of life in adult patients with epilepsy.Health Educ.Res., 25: 575-584.

46. Bagley,C. “Social prejudice and the adjustment of people with epilepsy”. Epilepsia, 1972.13: 33-45.

47. Kate Collins, T.B., P.R. Gamfield, C.S and K. Lee, 2007. People with epilepsy are often perceived as violent. Epilepsy Behav.,10: 69-76.

48. Rafael, F., D. Houinato, P. Nubukpo, O.M.Dubrenol and D.S.Tran et al., 2010. Sociocultural and psychological features of perceitved stigma reported by people with epilepsy in Benin. Epilepsia,6: 1061-1068.

49. Jacoby,A.,D.Snape and G.A. Baker. “Epilepsy and Social Identity: The stigma of a chronic neurological disorder.Lancet Neurol”, 2005. 4: 171-174.

50. Morrell, M.J, “Stigma and epilepsy”. Epilepsy Behav., 2002. 3:21-25.

51. Ä.Õàíäìàà, À.Òîâóóäîðæ “Ýïèëåïñèòýé õ¿-ì¿¿ñèéí ñàäàí òºðëèéíõíèé óíàëò òàòàëòûí òàëààðõ ìýäëýã, õàíäëàãà” Ìîíãîëûí àíàãààõ óõààí, 2013, 3(165)


Õ¿¿õýä, ºñâºð íàñíûõíû àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãîõèéõ ¿çýãäëèéí òóõàéä

(Õýâëýëèéí òîéì)

Ç.Õèøèãñ¿ðýí, Ä.Îþóíñ¿ðýí ÀØÓ¯ÈÑ, ÀÓÑ, Ñýòãýöèéí ýð¿¿ë ìýíäèéí òýíõèì

[email protected]

Abstract

About fenomen of Suiside of children and youth and of suiside attempts

Z.Khishigsuren, D.Oyunsuren MNUMS, School of Medicine, Department of Mental Health

[email protected]

Each suicide is a personal tragedy that prematurely takes the life of an individual and has a continuing ripple effect, dramatically affecting the lives of families, friends and communities.Suicidal behavior may be seen in all agegroups, but its incidence among young peopleand adolescentshas increased in recent years. Suicide was the second leading cause of death among 15-29 year olds, globally. WHO Adolescent Health Report disclose that major depression leads teenage boys and girls aged 10-19 to disability, and total 1.2 million teenagers were died due to the three leading causes of adolescent’s death such as road traffic accidents, HIV, and suicidal behavior. In Mongolia, up to now, a comprehensive study for defining prevalence, incidence, causes and influencing factors of fatal and non-fatal suicide cases among teenagers has not yet been conducted. Media broadcast shows increase in fatal and non-fatal suicidal behavior lately in Mongolia’s society which worries the public. According to study results Global School based Student Health Survey 2013, 23 % of total 5393 students aged 12-17 were seriously considered attempt suicidal behavior; 9.6% were did attempt suicidal behavior in the past one year, girls attempts were more than boys as reported. Thus social mental health disturbance require comprehensive study to identifyfatal and non-fatal suicidal behavior causes and pathways among adolescents. There’s necessity to plan care service in the near future.


Àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäîë íü óõàìñàðëàãäñàí ¿éë àæèëëàãàà áºãººä àëü ÷ íàñíû õ¿ì¿¿ñò òîõèîëääîã. Ãýâ÷ ñ¿¿ëèéí ¿åä äýëõèé äàõèíàà àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî èõñýæ áàéãàà áà ìàíàé óëñûí õýìæýýíä ÷ ºñºí íýìýãäýõ õàíäëàãàòàé áàéíà. Ìàíàé óëñàä õ¿¿õýä, ºñâºð íàñíûõíû àìèà åã¿¿òãýë, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäëûã íàðèéâ÷ëàí ñóäëààã¿é áîëîâ÷ õ¿¿õ-äèéí ýð¿¿ë ìýíäèéí áàéäëûã òîãòîîõ, ñóðãóóëüä ñóóðèëñàí ñóäàëãààíààñ ¿çâýë îõèä, õºâã¿¿äèéí äóíä àìèà åã¿¿òãýõ áîäîë òºðºõ, àìèà åã¿¿òãýõ òºëºâëºãººòýé ãýæ õàðèóëñàí òîî áàðèìò õàðü-öàíãóé ºíäºð ãàð÷ áàéãàà íü àíõààðàë òàòàæ áàéíà.

Ò¿¿í÷ëýí ºíãºðñºí æèëä ìàíàé óëñàä õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýñýí òîõèîëäëóóä õýâëýë ìýäýýëëèéí õýðýãñëýýð öàöàãäàõ áîëñîí íü ýíý àñóóäëûã íàðèéâ÷ëàí ñóäëàõ øààðäëàãà áàéíà ãýäãèéã èëýðõèéëæ áàéíà.

Õ¿¿õýä ºñ âºð íàñíûõíû àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ øàëòãààí, íºëººëºõ õ¿÷èí ç¿éëñ, óðüä÷èëàí ñýðãèéëýõ àðãûã íàðèéâ÷ëàí ñóäëàõ íü ìàíàé óëñûí õýìæýýíä íîòîëãîîíä ñóóðèëñàí áàðèìòòàé áîëîõûí çýðýãöýý óðüä÷èëàí ñýðãèé ëýõ, òîõèîëäëûí òîîã áóóðóóëàõ, õ¿¿õäýä ñýòãýë ç¿éí òóñëàìæ ¿éë÷èëãýý ¿ç¿¿ëýõýä ÷óõàë à÷ õîë áîãäîëòîé õýìýýí ¿çýæ áàéíà.

ÄÝÌÁ-ûí ñóäàëãààíààñ ¿çâýë 2012 îíä äýëõèé äàõèíàà íèéò 804 000 õ¿í àìèà åã¿¿òãýæ íàñ áàðñàí áîë çàì òýýâðèéí îñîë, ÄÎÕ, àìèà åã¿¿òãýñíèé óëìààñ 10-19 íàñíû 1.2 ñàÿ îõèä, õºâã¿¿ä íàñ áàðñàí õàðàìñàëòàé òîî áàðèìò áàéíà.

Ãýâ÷ ÄÝÌÁ àìèà åã¿¿òãýëýýñ óðüä÷èëàí ñýðãèéëýõ áîëîìæòîé õýìýýí ¿çýæ áàéãàà áºãººä 2010 îíä äýëõèé äàõèíàà íèéò õ¿í àìûí àìèà åã¿¿òãýëèéí òîîã 10%-èàð áóóðóóëàõ çîðèëò äýâø¿¿ëñýí áàéíà.

Èéìä ìàíàé óëñ ãýñýí ýíýõ¿¿ çîðèëòûã õýðýãæ¿¿ëýõýä ººðñäèéí õóâü íýìðýý îðóóëàõ ¿¿ðýãòýé õýìýýí ¿çýæ áàéíà.


Àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäëûí òóõàé åðºíõèé îéëãîëò, òàðõàëò

Øèíæëýõ óõààíû îéëãîëòîîð çîðèóäààð ººðèéíõºº àìèà òàñëàõ ¿çýãäëèéã àìèà åã¿¿òãýë (ñóèöèä), çîðèóäààð ººðèéí ýð¿¿ë ìýíäýý õîõèðîîõ, ãýìòýýõèéã àìèà åã¿¿òãýõ îðîëäëîãî (ïàðàñóèöèä) õýìýýí ¿çäýã [1]. Õ¿íèé àìüäðàëûí ìº÷ëºã á¿ðò íèéãýì, ñýòãýëç¿é, áèîëîãèéí òóëãàìäñàí àñóóäëóóä áàéäàã áºãººä ¿¿íèéã õýðõýí äàâàí òóóëàõ íü íýã òàëààñ õóâü õ¿íèé ñýòãýëç¿éí îíöëîã, áóõèìäëàà òàéëàõ áîëîí òóõàéí íºõöºëä äàñàí çîõèöîõ ÷àäâàð íºãºº òàëààñ õ¿íä òîõèîëäîæ áóé òóëãàìäñàí àñóóäëûí õ¿÷, ¿ðãýëæëýõ õóãàöààíààñ õàìààðäàã. Èéìä õ¿¿õýä, ºñâºð íàñíûõàíä ÷ ãýñýí òóëãàìäñàí àñóóäëóóä áàéäàã.

Àìèà åã¿¿òãýë íü óõàìñàðëàãäñàí ¿éëäýë áàéäàã áºãººä õ¿¿õýä 2-3 íàñàíä ¿õëèéí òóõàé åðºíõèé îéëãîëòòîé,àéäàñ òºðäºã õýäèé ÷ ºñâºð íàñàíä àìüäðàëûí ¿íý öýíèéã á¿ðýí óõààð÷ ÷àäààã¿é, õèéñâýð îéëãîëò òºäèé áàéäàã áàéíà2.

Àìèà åã¿¿òãýõ òºðõ ¿éë õýìýýõ îéëãîëòîíä àìèà åã¿¿òãýõ òóõàé áîäîë òºðºõ, àìèà åã¿¿òãýõ òóõàéãàà òºñººëºí áîäîõ, àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ àðãàà òºëºâëºõ, ¿éëäëèéã òºãñ, ýñâýë òºãñ áóñ ¿éëäýõ ãýñýí îéëãîëòóóä á¿ãä õàìààðíà.

Äýëõèé äàõèíàà ñ¿¿ëèéí æèë¿¿äýä àìèà åã¿¿òãýõ òºðõ ¿éë íü õ¿í àìûí íàñ áàðàëòûí òýðã¿¿ëýõ øàëòãààíû òîîíä îðîõ áîëëîî. Àìèà åã¿¿òãýõ îðîëäëîãî õèéõ øàëòãààíûã çîðèëãîîð íü àâ÷ ¿çâýë:

• Àìèà åã¿¿òãýõ æèíõýíý òºðõ ¿éë-ãîë çîðèëãî íü àìèà òºãñ åã¿¿òãýõ àñóóäàë ó÷èð àìü íàñàíä àþóëòàé àðãûã ñîíãîäîã

• ¯ç¿¿ëýõ õýëáýðèéí àìèà åã¿¿òãýõ îðîëäëîãî õèéõ- áóñäûí àíõààðëûã ººðèéí òóëãàìäñàí àñóóäàëä ÷èãë¿¿ëýõèéí òóëä àìü íàñàíä àþóëòàé áóñ, õºíãºí àðãóóäûã ñîíãîäîã.

• ªºðèéãºº ãýìòýýõ òºðõ ¿éë- ýìãýã òºðõòýé, ìàí ñóóðñàí õ¿ì¿¿ñ ñýòãýë öî÷èðäëîî èëýð-õèéëýõäýý ººðòºº áèåìàõáîäûí ºâäºëò ¿¿ñãýõ çàìààð ¿éëäýë õèéäýã.

• Çîëã¿é òîõèîëäîë- ñýòãýöèéí ýìãýãèéí óëìààñ àìèà åã¿¿òãýõ ¿éëäýë õèéõèéã õýëæ áîëíî ãýæ àíãèëæýý [3].

Ñóäëàà÷èä àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäëûã îëîí òàëààñ íü àâ÷ ¿çäýã áºãººä íýã õýñýã íü õ¿í àéäàñ, ò¿ãø¿¿ð, ñýòãýëç¿éí òààëàìæã¿é áàéäëààñ ººðèéãºº õàìãààëæ ººðòºº ò¿ðýìãèéëýë ¿éëäýæ áóé ¿çýãäýë

(àóòîàãðåññèÿ), ýñâýë ººðòºº ºâäºëò çîâèóð ¿¿ñãýæ áóé ìàçîõèçìûí õýëáýð ãýæ ¿çäýã áîë íºãºº õýñýã íü àìèà åã¿¿òãýë íü àìüäðàëààñ õàãàöàõ õàìãèéí ýìãýíýëòýé àðãûã àøèãëàí ñýòãýëç¿éí ãýìòëýý áèåìàõáîäûí ò¿âøèíä äóóñãàæ áóé ¿çýãäýë ãýæ ¿çäýã áàéíà [3, 27].

ÄÝÌÁ-ûí ìýäýýãýýð ñ¿¿ëèéí 45 æèëä àìèà åã¿¿òãýë 60-èàð íýìýãäñýí áà ÿëàíãóÿà õ¿¿õýä çàëóóñûí äóíä àìèà åã¿¿òãýë íü òóëãàìäñàí àñóóäàë áîëæ 15-19 íàñíû õºâã¿¿äèéí íàñ áàðàëòûí øàëòãààíû 3-ð áàéðàíä îðæ áàéãàà àæýý [4].

2009 îíû áàéäëààð ÎÕÓ-ä íèéò íàñ áàðàëòûí 3-ð øàëòãààíä àìèà åã¿¿òãýë îðæ áàéñàí áîë ºñâºð íàñíûõíû àìèà åã¿¿òãýõ òîõèîëäëûí òîîãîîð äýëõèéä 1-ðò îðæýý [4].

ÄÝÌÁ-ûí “ªñâºð íàñíûõíû ýð¿¿ë ìýíä” òàéëàíãààñ ¿çâýë 2012 îíä äýëõèé äàõèíàà 1.2 ñàÿ õ¿¿õýä íàñ áàðñàí áà 10-19 íàñíû îõèä õºâã¿¿äèéí íàñ áàðàëòûí øàëòãààíû ýõíèé 3 áàéðàíä çàì òýýâðèéí îñîë, ÄÎÕ, àìèà åã¿¿òãýõ òîõèîëäîë îðæýý [5].

Ò¿¿í÷èëýí ÄÝÌÁ-ûí “Àìèà åã¿¿òãýëýýñ óðüä÷èëàí ñýðãèéëüå” òàéëàíä (2014) äóðüäñàíààð 2012 îíä äýëõèé äàõèíàà 804 000 õ¿í àìèà åã¿¿òãýæ íàñ áàðñàí èéíõ¿¿ àìèà åã¿¿òãýë ýðñ èõñýæ áàéãàà íü ñýòãýë ò¿ãøýýñýí àñóóäàë áîëæ áóéã öîõîí òýìäýãëýñýí áàéíà [6].

Õýäèéãýýð äýëõèéí óëñ îðíóóäàä àìèà åã¿¿òãýë, àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí òîõèîëäëûí òîîí ¿ç¿¿ëýëò áàéäàã õýäèé ÷ äýýðõ òîõèîëäëûã á¿ðòãýõ íýãäñýí òîãòîëöîî áàéäàãã¿é ó÷èð áîäèòîé, õàíãàëòòàé òîî õýìýýí ¿çýõýä ó÷èð äóòàãäàëòàé þì [2, 7-8].

Õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ øàëòãààí, íºëººëºõ õ¿÷èí ç¿éëñ

Õýâëýëèéí ìýäýýëëýýñ ¿çâýë àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãûã èõýíõèäýý ñýòãýöèéí õóâüä õàðüöàíãóé ýð¿¿ë õ¿ì¿¿ñ õèéäýã áºãººä õàðèí íèëýýä íü ñýòãýëç¿éí òóëãàìäñàí àñóóäàëòàé, õàðüöàíãóé öººíõ íü îíîøëîãäñîí ñýòãýöèéí ýìãýãòýé õ¿ì¿¿ñ áàéäàã. Èéìä õ¿¿õýä àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ øàëòãààíûã åðºíõèéä íü ñýòãýöèéí ýìãýãòýé õîëáîîòîé, ñýòãýöèéí ýìãýãýýñ áóñàä øàëòãààíòàé ãýæ 2 àíãèëæ áîëíî. Õàðèí àìèà åã¿¿òãýõ, àìèà åã¿¿òãàõ îðîëäëîãî õèéõýä áèîëîãè, íèéãýì, ñýòãýëç¿éí õ¿÷èí ç¿éëñ íºëººëäºã ãýæ ¿çäýã [1].

Õ¿¿õýä ñýòãýë ò¿âøèí, ýð¿¿ë ºñºõºä ãýð á¿ëèéí ¿¿ðýã ÷óõàë áºãººä ýöýã ýõèéí õàéð õàëàìæ, ýýíýãøèë, àìüäðàëûí õýâ ìàÿã, õ¿¿õäèéí


õ¿ì¿¿æëèéí îð÷èí, õ¿ì¿¿æëèéí õýëáýð, àõìàäûí ¿ëãýð äóóðàéëàë, ãýð á¿ëèéí ãèø¿¿äèéí õàðèëöàà íü õ¿¿õäèéí èðýýä¿éä èõýýõýí íºëººëäºã [2, 9].

Õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ øàëòãààíûã á¿ëýãëýí ¿çâýë:

• Ãýð á¿ëèéí á¿òýö àëäàãäñàí áóþó õîéä ýöýã, ýõòýé

• Ãýð á¿ëèéí äîòîîäîä õàðèëöààíû çºð÷èëòýé

• Ãýð á¿ëèéí áóðóó õ¿ì¿¿æèë- õýò áóðõàí÷ëàí òàõèõ, õàðàà õÿíàëòã¿é õ¿ì¿¿æèë, õàòóó ãàðûí õ¿ì¿¿æèë, õàðøèëäñàí õ¿ì¿¿æèë ãýõ ìýò [10].

• Áýëãèéí, ¿ë õàéõðàõ áîëîí áèåìàõáîäûí õ¿÷èðõèéëýëä ºðòºæ áàéñàí, ñýòãýëèéí ãýìòëèéí äàðààõ õàðèó óðâàë èëýð÷ áóé ¿åä [11-14].

• Îéð äîòíû õ¿ì¿¿ñ íü õ¿íäýýð ºâ÷èëñºí áóþó íàñ áàðñàí

• Àõóé àìüäðàëûí ìàòåðèàëëàã õ¿÷èí ç¿éëñèéí õîìñäîë, ãýð á¿ëèéí ñàíõ¿¿ãèéí õ¿íä íºõöºë

• Ñóðãóóëü, áàãø, ¿å òýíãèéíõýíòýé õîëáîîòîé àñóóäëóóä, äàðàìò, øàõàëò [15]

• ¯åðõýë íºõºðëºë á¿òýëã¿éòýõ

• Óäàìä íü ñýòãýöèéí ýìãýãòýé, àìèà åã¿¿òãýñýí, àìèà åã¿¿òãýõ îðîëäëîãî õèéæ áàéñàí õ¿í áàéäàã

• Ãýìò õýðýãò õîëáîãäîõ

• ªñâºð íàñíû îõèäûí õ¿ñýýã¿é æèðýìñëýëò

• Àðõè, ìàíñóóðóóëàõ áîäèñ õýðýãëýõ, òîãëîî-ìîíä äîíòîõ çýðýã äîíòîëòûí óëìààñ [16-18]

• Õ¿¿õýä, ºñâºð íàñíûõàí áèåèéí õ¿íä ºâ÷íººð ºâ÷ëºõ [19]

• Ñýòãýöèéí ýìãýãýýð ÿëàíãóÿà ñýòãýë ãóòðàõ ýìãýãýýð ºâ÷ëºõ [20-22]

• Äàãàí äóóðàéõ ñýäýë (Âåðòåðèéí õàìøèíæ) [23-24]

• Áýëãèéí ÷èã áàðèìæààòàé õîëáîîòîé àñóóä-ëóóä, áýëãèéí öººíõ áàéõ [25]

• Õ¿¿õäèéí òºðõ ¿éëòýé õîëáîîòîéãîîð àìèà åã¿¿òãýõ çîðèëãîòîé áèø áîëîâ÷ òóõàéí ¿éëäëèéã õèéõýä àìü íàñ, ýð¿¿ë ìýíä õîõèð÷ áîëçîøã¿é ýðñäýëòýé àëõàìûã õèéäýã áàéíà. Òóõàéëáàë: ãàðûí ñóäñàíä ç¿ñëýã õèéõ, àìüñãàëàà áîîãäóóëæ óíàõ, áàéøèíãèéí äýýâýð, àâòîìàøèíû ãðàæ çýðýã ºíäºð ç¿éë äýýã¿¿ð ã¿éæ õàðàéõ, áèåäýý ãýìòýë ó÷ðóóëæ

öóñ ãàðãàõ ãýõ ìýò [22, 26].

• Áóñäûí àíõààðëûã òàòàõ, áóñäààð ººðèéãºº õàéðëóóëàõ çîðèëãîîð ãýõ çýðýã îëîí øàëò-ãààíòàé áàéäàã áàéíà [27].

Ãýðýýñëýë íü àìèà åã¿¿òãýñýí øàëòãààí, ñýäëèéã òîãòîîæ áîëîõ áàðèìò áè÷èã áîëîâ÷ ãýðýýñëýë áè÷èõ íü õàðüöàíãóé õîâîð áàéäàã. Jackobs (1976) õ¿ì¿¿ñ ãýðýýñëýëäýý ºâ÷èëñºí õ¿íä ºâ÷íèéõºº òóõàé, áóñàä õ¿ì¿¿ñ àìèà åã¿¿òãýõýä õ¿ðãýñýí áîë øàëòãààíûã íü, õýí íýãýíä çàõèñà ¿ëäýýõ çîðèëãîîð, óã ¿éëäëèéã õèéõ áîëñîí øàëòãààíàà òàéëáàðëàí áè÷èõ íü îëîíòàà áàéäàã õýìýýí àíãèëæ ¿çñýí áàéäàã áàéíà [28].

Àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéæ áîëçîøã¿é ¿åä èëðýõ åðºíõèé øèíæ¿¿ä

Õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõèéí ºìíº èëýðäýã øèíæ¿¿äèéã äàðààõ áàéäëààð àíãèëäàã áàéíà. ¯¿íä:

1. ¯ãýýð èëýðõèéëýõ-Øèéäâýðëýæ ÷àäàõã¿é áàéãàà àñóóäëûíõàà òóõàé îéð äîòíû õ¿ì¿¿ñòýý ÿðèõ, ÿðüæ áóé ç¿éë íü çàõèàñ çàõèæ áóé àãóóëãàòàé áàéõ, ¿õëèéí òóõàé ÿðèõ áóþó áóñäààñ àñóóõ, öààøèä àìüäðàõ õ¿ñýëã¿é áàéãàà òóõàé, ººðèéíõºº àìèéã åã¿¿òãýõ áîäîëòîé áàéãàà çýðýã àñóóäëûã ¿ãýýð èëýðõèéëíý

2. Òºðõ ¿éëýýð èëýðõèéëýõ- õóâèéíõàà õàäãàëäàã ýä ç¿éëñèéã áóñäàä áýëýãëýõ, õèéæ áàéñàí äóòóó àæëàà ã¿éöýýõ, õîîë èõ èäýõ ýñâýë õîîëíîîñ òàòãàëçàõ, õýò èõ óíòàõ, íîéð ìóóäàõ, õè÷ýýëýýñýý õºíäèéðºõ, ñóðëàãà ìóóäàõ, íàéç íºõäººñºº õºíäèéðºõ, çîæèã ãàíöààðäìàë áîëîõ, öî÷ðîìòãîé, áîäëîãîøðîíãóé áîëîõ

3. Òóõàéí íºõöºë áàéäàëòàé õîëáîîòîé ¿¿ñýõ øèíæ¿¿ä-àìèà åã¿¿òãýõýýð øèéäñýí áîë áóñäààñ çîæèãðîõ, ººðèéãºº áóñäûí ºìíº õ¿÷ ÷àäàëã¿é áîëñîí ìýò ìýäðýõ, ãýð á¿ë ñàëàõ, ýñâýë õýð¿¿ë ìàðãààí áîëñîí ¿åä òºðõ ¿éëýýð õàðèó óðâàë ¿ç¿¿ëýõ çýðýã øèíæ¿¿äýýð èëýðíý. Àìèà åã¿¿òããýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ áîëçîøã¿é õ¿¿õýä ºñâºð íàñíûõíû 75% íü ãàäàãø ¿ã ÿðèà, òºðõ ¿éëýýð õàðèó óðâàë èëýðõèéëäýã ó÷èð àæèãëàëò ñàéí õèéâýë ýðò èëð¿¿ëýõ áîëîìæòîé ãýæ ¿çäýã áàéíà [29].

Õ¿¿õýä ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõäýý àøèãëàäàã àðãóóä

Äýëõèé äàõèíàà àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõäýý àøèãëàäàã àðãóóä íü õàðüöàíãóé îéðîëöîî áàéäàã ÷ òóõàéí á¿ñ


íóòãèéí õºãæèë, áàéãàëü öàã óóðûí îíöëîã çýðãýýñ õàìààðàí õàðèëöàí àäèëã¿é àðãóóäûã õýðýãëýäýã òàë áàéíà.

Àëü ÷ óëñ îðîíä àìèà åã¿¿òãýã÷äèéí îëîíõè íü ººðèéãºº áîîìèëîõ, ºíäðººñ ¿ñðýõ, ãàëò çýâñýã õýðýãëýäýã áîë àìèà åã¿¿òãýõ îðîëäëîãî õèéõäýý ýì áîëîí õèìèéí áîäèñûã õýðýãëýí ººðèéãºº õîðäóóëàõ, õóðö, èðòýé ¿ç¿¿ðòýé ç¿éëýýð ñóäñàà õàíàõ, ººðèéãºº ç¿ñýõ çýðýã àðãóóäûã èë¿¿òýé àøèãëàäàã àæýý. Õ¿éñèéí õóâüä àâ÷ ¿çâýë õ¿¿õýä, íàñàíä õ¿ðýã÷èä àäèëõàí ýðýãòýé÷¿¿ä íü àìèà åã¿¿òãýõ òîõèîëäîë èë¿¿, îõèä ýìýãòýé÷¿¿ä àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäîë íü èë¿¿ ¿ç¿¿ëýëòòýé áàéäàã [30-32].

ÀÍÓ-ä õóóëü áóñààð áóó ýçýìøèõ ¿çýãäýë ãàçàð àâñàíòàé õîáîîòîéãîîð àìèà åã¿¿òãýñýí òîõèîëäëûí ãóðàâíû íýã íü ãàëò çýâñãýýð ¿éëäýãääýã áîë Õÿòàä, Øðè-Ëàíê, Ýíýòõýã, Âüåòíàì çýðýã õºäºº àæ àõóé ýðõýëäýã óëñ îðíóóäàä ãàçàð òàðèàëàíä, õîðòîí øàâüæ óñòãàõàä ºðãºí õýðýãëýäýã ïåñòèöèäýýð õîðäîõ áóþó àìèà åã¿¿òãýõ ¿çýãäýë èõ áàéäàã áºãººä íèéò á¿ðòãýãäñýí òîõèîëäëûí 60 ãàðóé õóâèéã ýçýëäýã áàéíà [5, 33-36].

Ìàíàé îðîíä õèéñýí ñ¿¿ëèéí ¿åèéí ñóäàëãààíààñ ¿çâýë 2013 îíä Õîðäëîãûí ÿàðàëòàé òóñëàìæèéí òºâººð ¿éë÷ë¿¿ëýãñäèéí èõýíõè íü (31.5%) ìàíñóóðóóëàõ áîëîí ñýòãýöýä íºëººò ýì ÿëàíãóÿà àìèòðèïòèëèí, êàðáàìàçåïèí õýðýãëýæ àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí áàéíà [37].

Õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäîë Ìîíãîë óëñàä ñóäëàãäñàí áàéäàë

Ìàíàé óëñàä õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà å¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäëûí òàðõàëò, øàëòãààí, íºëººëºõ õ¿÷èí ç¿éëñ, ¿ç¿¿ëæ áóé òóñëàìæ ¿éë÷èëãýýíèé òàëààð õèéñýí áèå äààñàí, öîãö ñóäàëãàà îäîîãîîð áàéõã¿é áàéíà.

2003 îíä 1992-2002 îíû òîî áàðèìòàíä òóëãóóðëàí Óëààíáààòàð õîòûí õýìæýýíä õèéñýí ñóäàëãààãààð 10-17 íàñàíä àìèà åã¿¿òãýñýí òîõèîëäîë 146, àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí 376 òîõèîëäîë á¿ðòãýãäñýí áîë 2003-2008 îíóóäàä 10-17 íàñàíä àìèà åã¿¿òãýñýí 240 òîõèîëäîë á¿ðòãýãäæýý [38-39].

Ìàíàé óëñàä õèéãäñýí çàðèì íýã ñóäàëãààíû ¿ç¿¿ëýëòýýñ ¿çâýë: 2010 îíû Ìîíãîëûí ºñâºð ¿åèéíõíèé ýð¿¿ë ìýíäèéí ñóäàëãààãààð 13-15 íàñíûõíû 19.2% íü àìèà åã¿¿òãýõ òàëààð áîäñîí, 8.4% íü àìèà åã¿¿òãýõ òºëºâëºãººòýé ãýæ õàðèóëæ áàéñàí àæýý [40]. Õàðèí ÄÝÌÁ, ÝÌß, Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñíèé òºâ õàìòðàí ÿâóóëäàã

“Äýëõèé äàõèíû ñóðãóóëüä ñóóðèëñàí ñóäàëãàà-2013”-ààñ ¿çâýë ñóäàëãààíä õàìðàãäñàí 5393 õ¿¿õäèéí äºðâºí õ¿¿õýä òóòìûí íýã íü ñ¿¿ëèéí íýã æèëèéí äîòîð àìèà åã¿¿òãýõ òóõàé áîäîæ, äîëîîí õ¿¿õýä òóòìûí íýã íü àìèà åã¿¿òãýõýýð òºëºâëºæ, àðâàí ñóðàã÷ òóòìûí íýã íü àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí ãýñýí òîî áàðèìò ãàð÷ýý [41]. 13-15 íàñíû îõèäûí 26.1% íü àìèà åã¿¿òãýõ áîäîëòîé, 10.4% íü àìèà åã¿¿òãýõ òºëºâëºãººòýé ãýñýí íü ¿å òýíãèéí õºâã¿¿äýýñ èë¿¿ ¿ç¿¿ëýëò áîëæ áàéíà [41].

Ýð¿¿ë ìýíäèéí õºãæëèéí òºâººñ ãàðãàñàí ýð¿¿ë ìýíäèéí ¿ç¿¿ëýëòýýð 2013 îíä Ìîíãîë óëñ 2 ñàÿ 390.3 õ¿í àìòàé, ¿¿íýýñ 0-15 íàñíû õ¿¿õýä 27.4%, 15-64 íàñíûõàí 68.8%-èéã ýçýëæ áàéñàí áîë 2009 îíû áàéäëààð 0-18 íàñíûõàí 987.7000 áàéâ. Ìîíãîë óëñûí õýìæýýíä 2013 îíä àìèà åã¿¿òãýñýí òîõèîëäîë 465 á¿ðòãýãäñýíýýñ 397 íü ýðýãòýé, 68 ýìýãòýé, 10000 õ¿í àìä 15.7 áàéãàà áà óðüä îíûõîîñ 6.1 äàõèí èõýññýí àæýý [42].

2014 îíä õèéãäñýí õ¿¿õýä õàìãààëëûí áàãö ñóäàëãààíû ä¿íãýýð 2013 îíä 59 õ¿¿õýä àìèà åã¿¿òãýñýí ãýæ ìýäýýëæýý [43]. Ñ¿¿ëèéí ¿åä ºñâºð íàñíûõàí àìèà åã¿¿òãýæ áóé òàëààð îëîí íèéòèéí õýâëýë ìýäýýëëèéí õýðýãñëýýð ÿðüæ, íèéòýëæ áàéãàà áîëîâ÷ íîòîëãîîíä ñóóðèëñàí ñóäàëãàà, øàëòãààí ñýäëèéã òîãòîîñîí òîî áàðèìò, àìèà åã¿¿òãýñýí õ¿¿õä¿¿äèéí àð ãýðèéíõýíä ¿ç¿¿ëñýí ñýòãýëç¿éí òóñëàìæ, àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí ºñâºð íàñíûõàíä ñýòãýëç¿éí çºâëºãºº ºãäºã áàéãóóëëàãóóäûí òàëààðõ ìýäýýëýë òîäîð-õîé áóñ áàéíà. Èéìä ýíýõ¿¿ ñýäâèéã ìàíàé óë-ñàä öààøèä ã¿íçãèéð¿¿ëýí ñóäëàõ, óðüä÷èëàí ñýðãèéëýõ àðãà õýìæýýã òºëºâëºõ, õýðýãæ¿¿ëýõ àñóóäàë òóëãàìäñàí àñóóäëûí íýã áîëæýý.

Õ¿¿õýä, ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõýýñ óðüä÷èëàí ñýðãèéëýõ àðãóóä

ÄÝÌÁ àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäëûã áóóðóóëàõ áîëîìæòîé õýìýýí ¿çýæ “Àìèà åã¿¿òãýõýýñ ñýðãèéëüå” (2014) òàéëàíä äóðüäñàíààð 2013 îíû 5 äóãààð ñàðä õóðàëäñàí äýëõèéí ýð¿¿ë ìýíäèéí 66 äóãààð ÷óóëãàíààð 2020 îíä äýëõèé äàõèíàà àìèà åã¿¿òãýõ òîõèîëäëûã 10%-èàð áóóðóóëíà õýìýýõ çîðèëòûã äýâø¿¿ëýí òàâüñàí áàéíà [6].

Àìèà åã¿¿òãýë, àìèà åã¿¿òãýõ îðîëäëîãî õèéõ òîõèîëäëûã ñóäëàõ ÿâöàä “äàëä àìèà åã¿¿òãýë” ãýñýí îéëãîëò áàéäàã áºãººä ¿¿íä: àìüñãàë áîîãäñîí, øàëòãààíã¿éãýýð ºíäðººñ óíàñàí, ãàëò çýâñãèéí óëìààñ àìèà àëäñàí, õºëäñºí, óñàíä óíàñàí çýðýã çîëã¿é òîõèîëäëûí äîòîð àìèà åã¿¿òãýñýí òîõèîëäîë áàéõ ìàãàäëàëòàé ãýæ ¿çäýã [33].


Àìèà åã¿¿òãýñýí, àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí õ¿ì¿¿ñèéí äîòîð áóñäûí îéëãîëòîîð ýð¿¿ë õ¿í áàéâ÷ ñýòãýöèéí ýð¿¿ë ìýíäèéí õóâüä àâ÷ ¿çâýë òóëãàìäñàí àñóóäàëòàé, ñòðåññ áóõèìäàëòàé, àñóóäëàà çºâ øèéäýæ ÷àäàõã¿é ÿâæ áàéñàí õ¿ì¿¿ñ ýíýõ¿¿ ¿éëäëèéã õèéõ íü îëîíòàà. Èéìä àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõýýñ ñýðãèéëýõèéí òóëä ãýð á¿ëèéí ãèø¿¿ä, íàéç íºõºä áèå áèåíýý îéëãîëöîõ, ãýð á¿ë, àõóé àìüäðàëûíõàà òóõàé ÿðèëöàõ, àñóóäëàà øèéäâýðëýõýä íü òóñëàõ, äýìæèõ, çºâ øèéäâýð ãàðãàõàä íü òóñëàõ áóþó ººðñäºº òóñëàõ áîëîìæã¿é áîë ìýðãýæëèéí õ¿ì¿¿ñýýñ äýìæëýã àâàõàä íü òóñëàõ õýðýãòýé.

Õ¿¿õýä ºñâºð íàñíûõàí àìèà åã¿¿òãýõ, àìèà åã¿¿òãýõ îðîëäëîãî õèéõýýñ óðüä÷èëàí ñýðãèéëýõ àíõíû àëõàì íü ãýð á¿ëèéí, ýöýã ýõèéí õàéð õàëàìæàà ¿ð õ¿¿õýääýý øèíãýýõ, õàëóóí äóëààí õàíäàõ, õ¿¿õäýý çºâ õ¿ì¿¿æ¿¿ëýõýä àíõààðàõ, ãýð á¿ëèéí äîòîîä õàðèëöààãàà ýåðýã áàéëãàõ, àëü ÷ õýëáýðèéí õ¿÷èðõèéëëýýñ ¿ð õ¿¿õäýý õàìãààëàõ, õ¿¿õäèéí ñóðëàãà, õ¿ì¿¿æèë, õàìò îëíû õàðèëöààíä àíõààðëàà õàíäóóëàõ, õ¿¿õýäòýéãýý õàëóóí äîòíî õàðèëöàí ÿðèëöäàã áàéõ íü ÷óõàë ãýæ ¿çýæ áàéíà [44]. Äàíè óëñàä õ¿¿õýä, ºñâºð íàñíûõíû äóíäàõ àìèà åã¿¿òãýëèéí òîîã áóóðóóëàõûí òóëä ýöýã, ýõ, òºðºë òºðºãñºä íü õ¿¿õýäòýé õýðõýí äîòíî õàðèëöàõ, ÿìàð òóñëàìæ äýìæëýã ¿ç¿¿ëýõ òàëààð ìýäýýëýë, çºâëºãºº àãóóëñàí ñóðãàëòûí õºòºëáºðèéã òóñãàéëàí áîëîâñðóóëæ áîëîâñðîëûí á¿õ øàòíû áàéãóóëëàãóóäàä àøèãëàäàã áàéíà [45].

Àëü ÷ íàñíû õ¿ì¿¿ñèéí àìèà åã¿¿òãýõ, àìèà åã¿¿ò ãýõ îðîëäëîãî õèéõýä íºëººëºõ øàëòãààí íü ñýòãýöèéí ýìãýã òýð òóñìàà ñýòãýë ãóòðàë, ñîëèîðîë, àðõè ìàíñóóðóóëàõ áîäèñ õýðýãëýõ ýìãýã áàéäàã òóë àëü áîëîõ ýðò îíîøëîõ, öàã òóõàéä íü øààðäëàãàòàé òóñëàìæèéã ¿ç¿¿ëýõ, ýì÷ëýõ àñóóäàëä àíõààðëàà õàíäóóëàõ øààðäëàãàòàé [46-47].

Àìèà ýã¿¿òãýõ ýðñäýëòýé ¿éë÷ë¿¿ëýã÷òýé ýìíýëç¿éí ÿðèëöëàãà õèéæ ýðñäýëèéí çýðãýýð íü: ýðñäýëã¿é, áàãà çýðýã ýðñäýëòýé, äóíä çýðãèéí ýðñäýëòýé, ºíäºð ýðñäýëòýé, ìàø ºíäºð ýðñäýëòýé ãýñýí 5 á¿ëýãò àíãèëàí ¿çäýã [48-50].

Àìèà åã¿¿òãýõ ýðñäýëèéí çýðãýýñ õàìààðàí ýìèéí áîëîí ýìèéí áóñ àðãóóäûã õýðýãëýí àìáóëàòîðèîð, óòñààð, èíòåðíåòýýð äàìæóóëàí çºâëºãºº ºãºõ áîëîí ýìíýëýãò õýâò¿¿ëýí ýì÷ëýõ òóñëàìæ ¿ç¿¿ëäýã [10]. Ýìèéí áóñ àðãóóäààñ òóõàéí íºõöºë áàéäàë, òóëãàìäñàí àñóóäëààñ õàìààðàí ñýòãýë çàñëûí àðãà, ÿëàíãóÿà ñýòãýö òºðõ ¿éëèéí ñýòãýë çàñàë èë¿¿ ¿ð ä¿íòýé ãýæ ¿çäýã [19, 51].

Àìèà åã¿¿òãýõýýñ óðüä÷èëàí ñýðãèéëýõ áîëîìæòîé

ãýæ ¿çäýã ó÷èð ÄÝÌÁ 2003 îíîîñ ýõëýí æèë á¿ðèéí 9-ð ñàðûí 10-íû ºäðèéã àìèà åã¿¿òãýõýýñ óðüä÷èëàí ñýðãèéëýõ îëîí óëñûí ºäºð õýìýýí çàðëàæ òýìäýãëýí ºíãºð¿¿ëäýã áèëýý [52].

Íîì ç¿é

1. Ñ.Áÿìáàñ¿ðýí. Ñýòãýöèéí ýìãýã ñóäëàë. ÓÁ. 2007, õ-271-273

2. www.suicide.com. Ñóèöèä-ïðîáëåìà ñîâðåìåííîãî îáùåñâòà.

3. Â.Â. Ôàðèíîâè÷. Ïñèõîëîãè÷åñêèå àñïåêòû ñóèöèäà è âîçìîæíîñòü èõ èíòåðïðåòàöèè. Ñîâðåìåííàÿ çàðóáåæíàÿ ïñèõîëîãèÿ. №3/2013. ñòð 122-127

4. Ò.Ñ.Ïàâëîâà. Äèàãíîñòèêà ðèñêà ñóèöèäàëü-íîãî ïîâåäåíèÿ äåòåé è ïîäðîñòêîâ â îáðàçî-âàòåëüíûõ ó÷ðåæäåíèÿõ. Ñîâðåìåííàÿ çàðó-áåæ íàÿ ïñèõîëîãèÿ. №4 / 2013. ñòð 79-89

5. WHO. News release. 14 May 2014

6. WHO. Preventing suicide. A global imperative. 2014.

7. WHO. Media centre suicide. September 2014.

8. Hepp U, Stulz N et all. Methods of suicide used by children and adolescents. Eur. Child Adolescent Psychiatry.2012; 21(2), 67-73

9. Â.À.Ðîçàíîâ, À.Ñ.Ðàõèìêóëîâà, À.È.Óõàíîâà. Îùóùåíèå áåññìûñëåííîñòè ñóùåñòâîâàíèå ó ïîäðîñòêîâ ñâÿçü ñ ñóèöèäàëüíûìè ïðîÿâ ëå íèÿìè è ïñèõè÷åñêèì çäîðîâüåì. Ñóèöèäîëîãèÿ № 3 (16) 2014, p 34-41

10. Á.Ñ. Ïîëîæèé, Å.À. Ïàí÷åíêî. Äèôôåðåíöèðî-âàí íàÿ ïðîôèëàêòèêà ñóèöèäàëüíîãî ïîâå-äåíèÿ. Ñóèöèäîëîãèÿ №1, 2012, ñòð 8-12

11. Jorge Lopez- Castroman, Nadine Melhem et all. Ñåêñóàëüíîå íàñèëèå â ðàííåì äåòñ êîì âîçðàñòå óñèëèâàåò ñóèöèäàëüíûå íàìå-ðåíèÿ. World psychiatry 12: 2, June 2013. p 142-147

12. Mehmet Eskin. The role of childhood sexual abuse, childhood gender nonconformity, self- esteem and parental attachment in predicting suicide ideation and attempts in Turkish young adults. Suicidology online 2012; 3:114-123

13. David Lester. Female suicide Bombers. Clues from journalists. Suicidology Online 2011; 2:62-66

14. Rick Nauert. Suicide Risk Among Abused Children. www. Psychocentral. com. 2008

15. B.C.Ben Park, Jung Jin Kim, David Lester. Reason for committing suicide in South Korean university students. Suicidology Online 2011; 2: 11-16


16. Í.Ä.Óçëîâ, Å.Ñ.Ñòðÿïóíèíà. Ñàìîîòíîøåíèå ïîäðîñòêîâ ñ ïîòåíöèàëüíûìè ðèñêàìè ñóèöè äàëüíîãî è àääèêòèâíîãî ïîâåäåíèÿ. Ñóèöèäîëîãèÿ. № 4 (13), 2013, ñòð 41-47

17. Â.À. Ñîëäàòêèí, Ä.×.Ìàâàíè, À.Â. Äúÿ÷åíêî. Èãðîâàÿ çàâèñèìîñòü: Êðèìèíîãåííîñòü è ñóèöèäîãåííîñòü. Ñóèöèäîëîãèÿ №1, 2012, ñòð 13- 17

18. Þ.Â.Ðàçâîäîâñêèé. Àëêîãîëü è ñóèöèä â ñòðà-íàõ âîñòî÷íîé Åâðîïû. Ñóèöèäîëîãèÿ №3 (16) 2014, p 18-26

19. D.Wasserman, Z.Richmer, D. Rujescu et all. The European psychiatric Association guidance on suicide treatment and prevention. Europian psychiatry 27(2012) 129

20. Ñ.Â. Áîéêîâ, Ì.Ë. Þëäàøåâ. Àóòîàãðåññèÿ ó áîëüíûõ ñ àôôåêòèâíûìè íàðóøåíèÿìè. Ñóèöèäîëîãèÿ №1, 2012, ñòð 53-55

21. Þ.Êîðêåéëà. Ïðåäóïðåæäåíèå ñàìîóáèéñòâ â Ôèíëÿíäèè: Î÷åâèäíûé óñïåõ. Ñîöèàëüíàÿ è êëèíè÷åñêàÿ ïñèõèàòðèÿ. 2013. ò 23, № 1, ñòð 46- 48

22. À.Ñ. Ðàõèìêóëîâà, Â.À. Ðîçàíîâ. Ñóèöèäàëü-íîñòü è ñêëîííîñòü ê ðèñêó ó ïîäðîñòêîâ: Áèîïñèõîñîöèàëüíûé ñèíòåç. Ñóèöèäîëîãèÿ №2 (11), 2013, ñòð 8

23. Î.Â. Âèõðèñòþê. Âëèÿíèå ñðåäñòâ ìàññîâîé èíôîðìàöèè íà ñóèöèäàëüíîå ïîâåäåíèå ïîäðîñòêîâ è ìîëîäåæè. Îáçîð çàðóáåæíûõ èñòî÷íèêîâ. Ñîâðåìåííàÿ çàðóáåæíàÿ ïñèõî-ëîãèÿ. № 1 / 2013. ñòð 100-108

24. www. Psychiatry. Ru. The Sorrows of Young Werther (Ñòðàäàíèÿ ìîëîäîãî Âåðòåðà.)

25. Ñ.È. Âîðîøèëèí. Ðàññòðîéñòâà ïîëîâîé îðèåí òàöèè è ñóèöèäàëüíîå ïîâåäåíèå: ïðà-âîâûå è ñîöèàëüíûå àñïåêòû. Ñóèöèäîëîãèÿ №1, 2012, ñòð 39

26. Rebecca C. Groschwitz, Paul L. Plener. The neurobiology of non-suicidal self-injury; Reviw. Suicidology Online 2012;3:24-32.

27. Â.À.Æìóðîâ. Ïñèõîïàòîëîãèÿ. Èðêóòñê. 1994. ×àñòü I.

28. Bijou Yang , David Lester. The presentation of the Self: An Hypothesis about Suicide notes. Suicidology Online 2011; 2:75-79

29. Richard Blonna. Coping with stress in a changing world. New York. 2005. p 145

30. D.De Leo, A.Milner et all. The WHO START study. Suicidal behaviors across different areas

of the world. Hogrefe publishing. Crisis 2013.

31. A.Varnik, K.Kolves, C M van der Feltz-Cornelis et all. Suicide methods in Europe; Gender specific analysis of countries participating in the “European Alliance Against Depression”. J Epidemiol Community Health 2008; 62;545-551, 2007

32. Kemuel L. Philbrick, James R.Rundell, Pamela J.Netzel, Lames L.Levenson. England. 2012. p 67-69

33. Ì.Â.Ìîðåâ, Þ.Å. Øìàòîâà, Å.Á. Ëþáîâ. Äèíà-ìèêà ñóèöèäàëüíîé ñìåðòíîñòè íàñåëåíèÿ Ðîññèè: Ðåãèîíàëüíûé àñïåêò. Ñóèöèäîëîãèÿ. №1 (14), 2014, ñòð 3

34. National Association of School Psychologists. Youth gun violence fact sheet. 2012

35. WHO. Violence prevention the evidence. Guns, knives and pesticides: reducing access to lethal means. 2009. p 1-18

36. WHO. Pesticides and health. 2004.

37. Í.Öýíãýëìàà. Õîðäëîãûí ÿàðàëòàé òóñëàì-æèéí ¿íäýñíèé òºâ. ÓÁ. 2014. ¯íäýñíèé ñåìè-íàðûí ìàòåðèàëààñ.

38. ÄÝÌÁ, ÝÌß, ÑÝÍÒ. “Àìèà åã¿¿òãýõèéã çàâä-ñàí, àìèà åã¿¿òãýñýí òîõèîëäëûí òàðõâàð ç¿éã ñóäàëñàí” ñóäàëãààíû àæëûí òàéëàí. ÓÁ. 2003.

39. Ç.Õèøèãñ¿ðýí, Ä.Îþóíñ¿ðýí. “2003-2008 îíóó äàä Ìîíãîë óëñàä àìèà åã¿¿òãýñýí, àìèà åã¿¿òãýõ îðîëäëîãî õèéñýí òîõèîëäëûí òàðõàëò” ñóäàëãààíû òàéëàí. ÓÁ.2014.

40. WHO. Health of adolescent in Mongolia. 2010.

41. ÝÌß, ÄÝÌÁ, Íèéãìèéí ýð¿¿ë ìýíäèéí ¿íäýñ-íèé òºâ. “Äýëõèé äàõèíû ñóðãóóëüä ñóóðèëñàí ýð¿¿ë ìýíäèéí ñóäàëãàà- Ìîíãîë 2013 ¿ð ä¿í” ñóäàëãààíû òàéëàí. ÓÁ. 2014

42. Ýð¿¿ë ìýíäèéí õºãæëèéí òºâ. Ýð¿¿ë ìýíäèéí ¿ç¿¿ëýëò-2013.

43. Õ¿¿õýä õàìãààëëûã áýõæ¿¿ëýõ ñòðàòåãè 2010-2015. Õ¿¿õýä õàìãààëëûí áàãö ñóäàëãàà-2014.

44. Ë.Ë.Êóçüìèøèíà, Å.Ñ. Àìåëèíà, À.À. Ïåðìÿ-êîâà, Å.À.Õîõëîâà. Ñòèëè ñåìåéíîãî âîñ-ïè òàíèÿ, îòå÷åñòâåííàÿ è çàðóáåæíàÿ êëàñ ñè ôèêàöèÿ. Ñîâðåìåííàÿ çàðóáåæíàÿ ïñèõîëîãèÿ.№1 / 2013. ñòð 16-23

45. Õ¿íèé àþóëã¿é áàéäëûí ñóäàëãààíû òºâ. Ìîíãîëûí àìèà õîðëîãñäûí òàëààðõ ñóäàëãàà. ÓÁ. 2006.


46. Berman A.L. Estimating the population of survivors of suicide. Suicide and Life Threatening Behavior, 41(1), 110-116

47. Benjamin N. Shain. Suicide attempts in adolescents. Pediatrics 2007; 120; 669.

48. Cynthia A, Beevers M.A. Mental health assess-ment, management of suicidal clients. PPT

49. À.À.Ìèäüêî, Á.Â. Áèðîí, Â.À. Ðîçàíîâ. Ñóèöè-äàëü íîå ïîâåäåíèå ìóæ÷èí. Ñóèöèäîëîãèÿ №4 (13), 2013, ñòð 17- 22

50. ÂÎÇ. Ïðåäîòâðàùåíèÿ ñàìîóáèéñòâ ñïðà-âî÷ íîå ïîñîáèå äëÿ êîíñóëüòàíòîâ. Æåíåâà 2006.

51. Pelkonen M, Marttunen M. Child and adolescent suicide: Epidemiology, risk factors, and approaches to prevention. Pediatric drugs.2003;5 (4): 243-65

52. Alexandra Fleishmann, Diego De Leo. The World Health Organizations Report on suicide. Crisis 2014; Vol. 35: 289- 291


Ø¯¯ÌÆ, ÁÎÄÎË, ÝÐÃÝÖ¯¯ËÝË

Õèïïîêðàò áóñ õàðèí Èìõîòåï-Àíàãààõ

Óõààíû æèíõýíý ýöýã

Í.Ìºíõò¿âøèíÀíàãààõ óõààíû õ¿ðýýëýí

Abstract

Not Hippocrates but Imhotep is the True Father of Medicine

N.MunkhtuvshinMedical Research Institute

Anybody who has dedicated himself for the medicine knows the Hippocratic Oath. It is an ethical framework of the physicians. It was written by Hippocrates (460-370 BCE), as we respect him “father of medicine” since two thousand years. However, the scientists of medical history suggest that Imhotep (2650–2600 BCE) is the author of Edwin Smith Papyrus, the oldest ancient Egyptian medical text. Imhotepwas treating ill patients with modern techniques. Imhotep was a Chancellor of the King Djoser, High Priest of Heliopolis, Scribe, Architect, Astronomer and Magician. As Hippocrates accomplishments was prominent in the history of medicine, since 400 years BCE, but Imhotep was the first physician from the mists of antiquity. The papyrus looks like the textbook for military surgeon. It presents the examination, the diagnosis and prognosis of 48 typical cases. Imhotep diagnosed and treated over 200 diseases. He treated tuberculosis, gallstones, appendicitis, gout and arthritis. He also performed surgery and practiced some dentistry. He extracted medicine from plants. It is accurate to call Imhotep as “the father of medicine”, as he lived approximately 2600 years before Hippocrates and practiced a type of science and medicine.

Pp.74-77, Pictures 6, References 15

ªðíèéí Àíàãààõûí ýðäýìä øàìäñàí õýí á¿õýí Õèïïîêðàòûí òàíãàðàãèéã ìýääýã áèëýý. Õèïïîêðàòûí òàíãàðàã àíàãààõ óõààíä áèå ñýòãýëýýý çîðèóëñàí õýí áîëîâ÷ äàãàæ ìºðäºõ ¸ñ ç¿éí ¿íäýñ þì. Ýíýõ¿¿ òàíãàðàãèéí áè÷ãèéã “Àíàãààõ Óõààíû ýöýã” õýìýýí íýðëýæ áèä á¿õýí ø¿òýí áèøèð÷èðñýí ýðòíèé Ãðåêèéí íýðò ýì÷ Õèïïîêðàò (ÌÝª 460-370 îí) áè÷ñýí ýñâýë ò¿¿íèé àéëäâàðûã íýãýí ãàðûí øàâü íü ñèéð¿¿ëýí áè÷èæ ¿ëäýýñýí íü áèäýíä ºâëºí èðæýý ãýæ ¿çäýã. Ãýâ÷ ºíºº ¿åä õî¸ð ìÿíãàãàðóéæèëèéí òóðø ò¿¿íä õ¿ëýýëãýæ àñàí àíàãààõ óõààíû àíõäàã÷èéí èõ õ¿íäëýëèéã ººð÷ëºõ ò¿¿õèéí øèíý íºõöºë áàéäàë ¿¿ñýâ. Ó÷èð íü,õ¿ì¿¿í òºðºëõòºíèé ò¿¿õýíä îëäîîä áàéãàà Àíàãààõ Óõààíû õàìãèéí ýðòíèé ñóðâàëæ áè÷èã áîëîõ Ýäâèí Ñìèòèéí ¿éñíèé áè÷ãýýñ õººæ ¿çýõ¿é äîð Õèïïîêðàòààñ á¿¿ð ºìíº 27 äóãààð çóóíä (ÌÝª 2700-2600 îí)àìüäàð÷ àñàí ýðòíèé Ìèñèðèéí (Åãèïåò) ñóóòõ¿ì¿¿í Èìõîòåï (àíãë. Imhotep, ãðåê.Imuthes) îð÷èí ¿åèéí àðãààð ºâ÷òýé õ¿íèéã ýì÷èëæ áàéæýý[1]. Èìõîòåï áîë ýðòíèé Ìèñèð îðíîî àíõ òºð óëñ áàéãóóëæ àñàí ôàðàîíû ò¿ð¿¿ õààäûí ¿åèéí (ÌÝª 2686-2250) ãóðàâäóãààð óãñàà çàëãàìæëàëûí Æîçåð (Djoser) õààíû øàäàð

ñàéä, òºðèéí ò¿øýý,ýðòíèé Åãèïåòèéí íèéñëýë Õåëèîïîëèñ äàõü íàðíû Ðà áóðõíû èõ òàõèë÷ áàéæýý (Çóð.1).

Òýðáýýð îëîí òàëò ãîö àâüÿàñòàí, ÿðóó íàéðàã÷, çîõèîë÷, óðàí áàðèìàë÷, ã¿í óõààíòàí,çîõèîí á¿òýýã÷, óðàí èëòãýã÷, îäîí îðîí÷, óðàí áàðèëãà÷, èíæåíåð, óâüäàñòàí (çóðõàé÷, ýì÷, çºí÷, íàðûã õàìòàòãàñàí íýð) áàéñàí áàéíà [2, 3, 4, 5]. Ò¿¿íèé Æîçåð õààíä çîðèóëæ Ñàêêàðàõûí õºíäèéä áàðèóëñàí, åðòºíöèéí äîëîîí ãàéõàìøãèéí íýã, 61 ìåòð ºíäºð,àíõíû øîâõ îðîéòøàòàëñàí áóíõàí ïèðàìèäûí (Çóð.2) íóóö ºíºº õèð òàéëàãäààã¿é ë áàéíà [4,6].

Figure 1. Imhotep


Ýðòíèé Ãðåê, Ðîìä Èìõîòåïèéã 3000 ãàðóé æèë áóðõàí÷ëàí ø¿òýæ àñàí áàéäàã. Ãðåê÷¿¿ä Åãèïòèéã ýðõøýýëäýý îðóóëæ àâààä Èìõîòåïèéí àëäàð öóóã áèøðýí ø¿òýæ ò¿¿íèé àíàãààõûí ñóðãààëü, ýì÷èëãýýíèé àðãûã ºâëºí àâ÷, ò¿¿íä çîðèóëàí òóñãàé ñ¿ì áàðèóëæ ¿éëñ á¿òýýëèéã íü ¿ðãýëæë¿¿ëæ áàéæýý. Ãðåê÷¿¿äèéí ¿åä áàðèóëñàí Èìõîòåïèéí ñ¿ì îëîí ¿åèéí òóðø àíàãààõ óõààíû ñóðãàëòûí òºâ áàéñàí áàéíà. Èìõîòåïèéí ìàòåìàòèêèéí ñèñòåì, óðàí áàðèëãà, äóóí ø¿ëýã ëýë [3], àíàãààõ óõààíû áè÷âýðèéí ºâ ñî¸ë èõýä àëäàðøæýý. Ò¿¿íèéã Ýäâèí Ñìèòèéí ¿éñíèé áè÷ãèéã çîõèîã÷ õýìýýí ¿çýõ áîëîâ [8].

Ýäâèí Ñìèò áîë Àìåðèêèéí ìèñèð÷ (Egyptologist), 1862 îíä Ëóêñîðò áàéõäàà Ìóñòàôà Àãõà ãýäýã íàéìàà÷ààñ íýãýí ¿éñýí áè÷èã õóäàëäàæ àâñàí íü õîæèì “Ýäâèí Ñìèòèéí ¿éñíèé áè÷èã” (Çóð. 4) íýðýýð ò¿¿õýíä àëäàðøæýý. Ò¿¿íèé ºì÷ëºëä áàéñàí ýíýõ¿¿ áè÷ãèéã îõèí íü Íüþ-Èîðêèéí ò¿¿õèéí íèéãýìëýãò áýëýãëýæ õ¿í òºðºëõòíèé õ¿ðòýýë áîëãîñîí áàéíà. Óã ¿éñíèé áè÷ãèéã àíõ íýðò ìèñèð÷ Æåéìñ Õåíðè Áðèñòåä 1930 îíä îð÷óóëæ ýðòíèé Åãèïòèéí àíàãààõ óõààíû òàëààðõ òºñººëëèéã ¿íäñýýð íü ººð÷èëñºí þì.

Figure 2.View of Saqqara necropolis, including Djoser’sstep pyramid (centre), the Pyramid of Unas (left) and the Pyramid of Userkaf (right).

Figure 3.Limestone statue of Djoser

Figure 4.Plates VI&VII of the Edwin Smith Papyrus at the Rare Book Room, New York Academy of Medicine

Ò¿¿íèé øîõîéí ÷óëóóãààð Æîçåð õààíû áèåèéí õýìæýýòýé óðëàí á¿òýýñýí äýëõèéí õàìãèéí ýðòíèéä òîîöîãäîõ äóðñãàëûí ÷óëóóí õºøºº (Çóð.3) Êàéð õîòûí ìèñèð¿¿äèéí ìóçåéä áàéäàã àæýý [7].

Figure 5.Hippocratic oath

Åãèïåòèéí àíàãààõ óõààíû òàëààðõ õ¿ì¿¿ñèéí òºñººëëèéã ¿íäñýýð íü ººð÷èëñºí þì [8]. Ìàíàé ¿åèéí ñî¸ëò åðòºíö ýíýõ¿¿ îð÷óóëãûã õ¿ðòýë ýðòíèé Åãèïòèéí àíàãààõ óõààíûã íàìèí÷ëàë, òàõèëãà, ñ¿ñýãëýë, äîìûí ¸ñ, òàéëãûí ò¿âøèíä áàéñàí õýìýýí óõààð÷ àñàí áèëýý.

Õèïïîêðàò áîë àíàãààõ óõààíû ò¿¿õýíä ìºíõºðñºí ýðòíèé Ãðåêèéí Ïåðèêëèéí ¿åèéí àëäàðò ýì÷ (Çóð.5). Ò¿¿íèé ¿çýë îíîë äýýð òóëãóóðëàñàí Õèïïîêðàòûí ñóðãóóëèéã ¿íäýñëýí áàéãóóëæ îëîí çóóíû ¿å ¿åèéí ýì÷ íàð ñóð÷ õ¿ì¿¿æèæ èðñíèé ó÷èð ò¿¿íèéã “Àíàãààõ Óõààíû Ýöýã” õýìýýí íýðëýæ õ¿íäýëñýýð èðñýí áèëýý [9]. Ò¿¿íèé ýíý ñóðãóóëü ñ¿ñýã áèøðýë, ìºðãºëèéí


çàí ¿éë, çàëáèðàë äýýð óëàìæèëæ èðñýí ýðòíèé Ãðåêèéí àíàãààõ óõààíä ýðãýëò õèéæ àíàãààõ óõààíûã òàíèí ìýäýõ¿é äýýð ñóóðèëñàí áèå äààñàí ìýðãýæèë áîëãîí õºãæ¿¿ëñýí þì. Ìóõàð ñ¿ñýã íî¸ðõîæ áàéñàí òýð öàã ¿åä Õèïïîêðàò ºâ÷èí ýìãýã íü áàéãàëèéí øàëòãààíààð ¿¿ñäýã. ãýæ ¿çýæ áàéâ [10].

Õèïïîêðàò ìàø îëîí ºâ÷òºí äýýð àæèãëàëò õèéæ ºâ÷íèé øèíæ òýìäýã, ºâ÷èí ¿¿ñ÷ õºãæñºí ò¿¿õ ÿâöûã íýã á¿ð÷ëýí áè÷èæ òýìäýãëýäýã áàéæýý.Òýðáýýð äàë ãàðóé á¿òýýë òóóðâèñàíû äîòîð õàëóóðàëò ºâ÷í¿¿ä, õàòãàà, òàòðàí, ñ¿ðüåý, ¿åíèé ºâ÷èí, ãàõàéí õàâäàð, õóìõàà ºâ÷íèé òóõàé íàðèéí òîäîðõîé áè÷èæ ¿ëäýýæýý. Õèïïîêðàòûí ¿éëñ á¿òýýë àâüÿàñ áèëýã äýëõèéí àíàãààõ óõààíû ò¿¿õýíä òóéëûí õ¿íäòýé áàéð ýçýëäýã õýäèé ÷ ìàíàé äýëõèé äýýð çóó ãàðóé ìÿíãàí æèëèéí ºìíº õ¿í ä¿ðñò ñàðìàã÷íû ìèòîõîíäðèéí ÄÍÕ-ä ÿâàãäñàí õóâüñëûí à÷ààð îþóí óõààíò õ¿í õîìî ñàïèåíñ ¿¿ñ÷,àí÷ ò¿¿âýðëýã÷ îìãóóäíü àðâàí ìÿíãàí æèëèéí ºìíº àìüòàí ãýðø¿¿ëæ, çóðãààí ìÿíãàí æèëèéí ºìíº áóóäàé òàðüæ ñóðààä,àíõíû á¿òöýò íèéãýì, õîò óëñ, òºð óëñ áàéãóóëæ ýõýëñýíýðòíèé Åãèïòèéí ñî¸ëûí ¿ëãýð ìýò îëîí äîìîãò ãàéõàìøèã äîòðîîñ Èìõîòåïèéí ñóó áèëýã îíöãîé òîäîð÷ ãýðýëòýõ áîëîâ. Èìõîòåï 200 ãàðóé ºâ÷èí îíîøëîæ ýì÷èëäýã áàéñíààñ ãýäýñ õýâëèéí 15 ºâ÷èí, äàâñàãíû 11 ºâ÷èí, øóëóóí ãýäýñíèé 10 ºâ÷èí, í¿äíèé 29 ºâ÷èí, àðüñ õóìñ, õýëíèé 18 ºâ÷íèéã ÿëãàí îíîøëîæ ýì÷èëäýã áàéæýý. Èìõîòåï ñ¿ðüåý, öºñíèé ÷óëóó, ìóõàð îëãîé, òóëóé, ¿åíèé ºâ÷íèéã ýì÷ëýõ àðãûã íàðèéâ÷ëàí áè÷èæ ¿ëäýýæýý. Èìõîòåï ìýñ çàñàë õèéäýã, ø¿ä, í¿¿ð àìíû çàðèì íàðèéí ìýñ àæèëáàðûã õèéæ áàéñàí áàéíà. Èìõîòåï óðãàìàëûí õàíäíààñ ýì ãàðãàæ àâäàã áàéæýý. Òýðáýýð àìèí ÷óõàë ýðõòýí¿¿äèéí áàéðëàë, ¿¿ðýã àæëûã ìýäýæ áàéñàí áà öóñíû ýðãýëòèéã ìýääýã áàéæýý. Ò¿¿íèéã ýðòíèé Åãèïåò, Ãðåêò àíàãààõûí áóðõàí õýìýýí ø¿òýæ èðñýí áà ýðòíèé Ãðåêèéí àíàãààõ óõààíû Àñêëåïèóñ áóðõíû ä¿ðä òîäðóóëæ áàéæýý. Ôàðàîíû ò¿ð¿¿ õààäûí ¿åèéí ñóðâàëæ áè÷èãò õààíû îðäíû òýðã¿¿í øàäàð ñàéä, èõ òàõèë÷, óâèäàñòàí íàð óëñ ¿íäýñòíèé åðºíõèé ýì÷èéí ¿¿ðãèéã äàâõàð ã¿éöýòãýäýã áàéñàí òóõàé òýìäýãëýí ¿ëäýýæýý. ÌÝª 525 äóãààð îíä Ïåðñèéí ýçýíò ã¿ðíèé ýðõøýýëä îðîõ õ¿ðòýë ýðòíèé Åãèïòèéí øàøíû äîìãèéí ¿çëýýð áîë åðòºíöèéã á¿òýýã÷ Ïòàõ áóðõàí, äàéí, òàõàë ñ¿éðëèéí îõèí òýíãýð Ñåõìåòáóðõàí, Èìõîòåï ãýãýýíòýí ãóðàâûã Ìåìôèñûí ãóðâàí ãàéõàìøèã õýìýýäýã áàéæýý.

Õýâ ãàëèãààñ ¿íäýñëýí Ýäâèí Ñìèòèéí ¿éñíèé áè÷ãèéã ýðòíèé Åãèïåòèéí õî¸ðäàõü çàâñðûí ¿å áóþó ÌÝª 1500 îíû ¿åä áè÷ñýí [11] ãýæ ¿çäýã

áîëîâ÷ ºã¿¿ëýìæèéí õýëáýð, áè÷ãèéí ä¿ðýì, íýð òîìü¸î, õóó÷èí õýëëýãèéí òàéëáàðààñ íü ¿çýõýä ò¿ð¿¿ õààäûí ¿åä õîëáîãäîõ ñóðâàëæ çîõèîëîîñ õýñýã÷ëýí ñèéð¿¿ëñýí íü õàðàãääàã.Ò¿ð¿¿ õààäûí ¿åèéí îäîí îðîí, òîîíû óõààí, çóðõàéí áè÷èã, ÿðóó íàéðàã, óðàí áàðèëãà, àíàãààõ óõààíû îëîí ñóðâàëæ áè÷ãèéí ýõ á¿òýýã÷èéã ìºøãºõ á¿ðèéä ýðëèéí çàì ÿâæ ÿâæ Èìõîòåïò õ¿ð÷ î÷äîã. Èìõîòåïèéí òîì æèæèã õýä õýäýí áàðèìàë ºíºº ¿åèéã õ¿ð÷ èðñíýýñ ò¿¿íèéã ñàíâààðòàí ìýò ä¿ðñýëñýí áàðèìàë åð íü áàéäàãã¿é, õàðèí Ïàðèñûí Ëóâðûí ìóçåéä áàéäàã ñàíäàë äýýð ñóóæ áóé ºâäºã äýýðýý ¿éñíèé áè÷ãýý äýëãýñýí ñàõàë ¿ñýý àâñàí ìýðãýí òàõèë÷èéí áàðèìàë íü (Çóð.6) èõ àëäàðòàé.

Ìÿíãàí æèëäýý öººí çàÿàæ àñàí èõ ñýòãýã÷, ãýãýýíòýí íàðûí íýã Èìõîòåïûã îäîîãîîñ 4600 æèëèéí ºìíº äýýä òýíãýðýýñ õ¿í òºðºëõòºíä èëãýýñýí íü ýðòíèé Åãèïåòýä òîõèîæ îð÷èí öàãèéí àíàãààõ óõààíûã ¿¿ñãýí õºãæ¿¿ëæ áèäíýý ºâë¿¿ëñýí íü þóòàé èõ õóâü. Ýäâèí Ñìèòèéí ¿éñíèé áè÷ýýñ íü 4.68 ìåòð óðò, õóéëààñòàé, áàðóóíààñ ç¿¿í òèéø ä¿ðñýí ¿ñýã, àâèàí ¿ñýã, öàãààí òîëãîéí ýëåìåíò õàâñàðñàí ýðòíèé Åãèïåò ¿ñãýýð òàòàëãàí áè÷ñýí, í¿¿ðýí òàëäàà 17 áàãàíà 377 ìºð, àð òàëäàà 5 áàãàíà 92 ìºð áè÷ýýñòýé, ýõ çîõèîëûã õàð áýõýýð, òàéëáàð ¿ãèéã óëààí áýõýýð áè÷ñýí àíàãààõ óõààíû ò¿¿õèéí ¿íýò ºâ ñî¸ë þì. Óã ¿éñíèé áè÷ãèéí àãóóëãà íü öýðãèéí ìýñ çàñàë÷ íàðò çîðèóëñàí ñóðàõ áè÷èã õýëáýðòýé, àíàòîìûí 90 ãàðóé íýð òîìü¸î àãóóëñàí, áèåèéí äýýä òîëãîéí õýñãýýñ ýõëýýä äîîøîî í¿¿ð àì, õ¿ç¿¿, àð íóðóó, äýýä äîîä ìº÷íèé ýðõòýí òóñ á¿ðèéí ãýìòýë, øàðõ, õóãàðàë, õàâäàð, ìóëòðàëûí 48 òîõèîëäëûã áè÷ñýí áàéäàã [12]. ×èíãýõäýý òîõèîëäîë á¿ðèéã îíîøëîõ çîðèëãîîð àøèãëàäàã áàéñàí õàðàõ, ¿íýðëýõ, òýìòðýõ, èëýõ, ñóäàñ áàðèõàðãóóäûã òóñ á¿ðò íü áè÷ýýä îíîø òàâèõ, òàâèëàí òîãòîîõ òóõàé ºã¿¿ëýí áè÷æýý. Îíîøèéã “Áè ýì÷èëæ ÷àäàõ ºâ÷èí”, “Áè ýì÷ëýõèéí òºëºº ç¿òãýõ ºâ÷èí”, “Áè ýì÷ëýõ áîëîìæã¿é ºâ÷èí” õýìýýí ãóðâàí á¿ëýãò õóâààäàã áàéæýý [13]. Ýöýñò íü ýì÷èëãýýíèé àðãóóäûí òóõàé áè÷ñýí áàéíà. ¯¿íä øàðõàíä î¸äîë òàâèõ [14], äàðæ áîîõ, æèí òàâèõ, èäýýëñýí øàðõûã çºãèéí áàëààð ýì÷ëýõ, ñýðãèéëýõ, èë öóñ àëäàëòûã ò¿¿õèé ìàõààð äàðæ áîîõ [11], òàðõè, íóðóó íóãàñ, ìº÷íèé õóãàðàëûí ¿åä õºäºëãººíã¿é áîëãîæ ÷èã òàâèõ áîëîí áóñàä îëîí àðãûã áè÷ñýí áàéäàã. Òàðõèíû ãàäàðãóó, òàðõèíû õàëüñ, íóãàñíû óñíû òóõàé àíàãààõ óõààíû ò¿¿õýíä àíõ ò¿ð¿¿ ýíýõ¿¿ ¿éñíèé áè÷èãò òýìäýãëýñýí áàéäàã [15] áà òàðõèíû ãýìòëýýñ áîëæ ñààæèëò, õºäºëãººíèé ýìãýã, ìýäýýã¿é áîëîõ óðõàã ¿ëääýã òóõàé áè÷ñýí áàéäàã áàéíà.


Àíàãààõ óõààíû ò¿¿õ÷ íàð Ýäâèí Ñìèòèéí ¿éñíèé áè÷ýýñáîë ýðòíèé Åãèïåòèéí ìýðãýä Õèïïîêðàòààñ 2600 îð÷èì æèëèéí ºìíºàíàãààõ óõààíûã øèíæëýõ óõààíû õýëáýðòýé ¿¿ñãýí õºãæ¿¿ëæ èðñíèéõºäëºøã¿é áàòàëãàà ìºíèé ó÷èð Èìõîòåïûã “Àíàãààõ Óõààíû æèíõýíý ýöýã” õýìýýí ¿çýõ áîëîâ [1].

Íîì ç¿é

1. William Osler, The Evolution of Modern Medicine, Kessinger Publishing 2004, p.12

2. The Egyptian Building Mania, ActaDivrna, Vol. III, Issue IV, January, 2004

3. Barry J. Kemp, Ancient Egypt Routledge 2005, p.159

4. Imhotep (Egyptian architect, physician, and statesman) - Encyclopedia Britannica

5. http://whatiscivilengineering.csce.ca/history_engineering.htm

6. Jaromir Malek ‘The Old Kingdom” in The Oxford History of Ancient Egypt by Ian Shaw (ed.) Oxford University Press paperback 2002. p.92

7. J. Kahl “Old Kingdom: Third Dynasty” in The Oxford Encyclopedia of Ancient Egypt by Donald Redford (ed.) Vol.2, p. 592

8. James Henry Breasted, “The Edwin Smith Surgical Papyrus: published in facsimile and hieroglyphic transliteration with translation and commentary in two volumes”. (University of Chicago Oriental Institute publications, v. 3–4. Chicago: University of Chicago Press, 1991),9.

9. Boylan, Michael (2006), Hippocrates, Internet Encyclopedia of Philosophy, retrieved September 28, 2006.

10. Garrison, Fielding H. (1966), History of Medicine, Philadelphia: W.B. Saunders Company.

11. James P. Allen, “The Art of Medicine in Ancient Egypt”. (New York: The MetropolitanMuseum ofArt, 2005), 70.

12. John F. Nunn, “Ancient Egyptian Medicine”. (Normal, OK: University of Oklahoma Press, 1996), 26–28.

13. Ritner, Robert K. “Medicine” The Oxford Encyclopedia of Ancient Egypt (2001). Oxford Reference Online.Web. Oct. 2011.

14. R. Sullivan “The Identity and Work of the Ancient Egyptian Surgeon”. Journal of the Royal Society of Medicine. 89, no 8 (1996): 469.

15. Wilkins, Robert H. Neurosurgical Classics. USA: American Association of Neurological Surgeons, Thieme, 1992. Print.


ÌÝÄÝÝËÝË, ÑÓÐÒÀË×ÈËÃÀÀ

Áÿìáàà îâîãòîé Öýðýíöîî

(Äîêòîðàíò, Àíàãààõûí Øèíæëýõ Óõààíû

¯íäýñíèé Èõ Ñóðãóóëü)

“Ýëýãíèé õàâäðûí ýñýä Áàéãàë Ã¿¿íõºõ (Scutellaria Baicalensis Georgi) óðãàìëûí ¿ç¿¿ëýõ íºëººã in vitro îð÷èíä ñóäàëñàí ä¿í” ñýäâýýð 2014 îíû 5 äóãààð ñàðûí 22-íû ºäºð Óëààíáààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí áàéíà.

Ìîíãîë óëñàä ýëýãíèé õàâäðûí ºâ÷ëºë èõñýõ õàíäëàãàòàé áàéãàà áºãººä ýìèéí ýì÷èëãýýíä ãàæ íºëºº áàãàòàé óðãàìëûí ãàðàëòàé ýì õýðýãëýõ õàíäëàãà íýìýãäýæ ýíý ÷èãëýëèéí ñóäàëãàà ýð÷èìòýé ºðíºæ áàéíà. Áèäíèé ñóäàëãààíû àæëûí çîðèëãî áîë Áàéãàë Ã¿¿íõºõ (Scutellaria baicalensis Georgi) óðãàìëûí õàíäíû ýëýãíèé õàâäðûí ýñýä ¿ç¿¿ëýõ íºëººã in vitro îð÷èíä ñóäëàí òîãòîîõ ÿâäàë þì. Áàéãàë Ã¿¿íõºõ óðãàìëûí ãàçðûí äýýä õýñãèéí õàíä íü ýëýãíèé õàâäðûí àíõäàã÷ ýñèéí ºñãºâºð-PCC, íîõîéí áººðíèé MDCK øóãàìàí ýñ øóãàìàí ýñ¿¿äèéí õóâààãäàë, ºñºëò, øèëæèí õºäëºõ ÷àäâàð, õîîðîíäîî íààëäàõ ÷àäâàðûã äàðàíãóéëæ áàéâ. Áàéãàë Ã¿¿íõºõ óðãàìëûí ãàçðûí äýýä õýñãèéí õàíäààð ¿éë÷ëýõýä ýëýãíèé àíõäàã÷ ºìºíãèéí ýñèéí ºñãºâºðèéí àïîï òîçûí ôðàãìåíòûí àãóóëàìæ õÿíàëòûí ºñãº-âºðèéíõººñ ÿëãààã¿é áàéëàà. Áàéãàë Ã¿¿íõºõ óðãàì-ëûí ãàçðûí äýýä õýñãèéí õàíä íü ýëýãíèé àíõäàã÷ ºìºíãèéí ýñèéí àïîïòîçèéí ïðîöåññèéã ºäººëã¿é õàðèí òðàíñìåìáðàíû óóðãóóä òýäãýýðèéã êîäëîõ ãåíèéí ýêñïðåññèéã äàðàíãóéëñíààð õàâäðûí ýñèéí ºñºëò õóâààãäëûã ñààòóóëæ áàéíà. Áàéãàë Ã¿¿íõºõ óðãàìëûí õàíä íü àíòèîêñèäàíò èäýâõòýé áàéíà.

Øîíõóóçûí Ýíõòºð

(Äîêòîðàíò, ÝÕÝÌ¯Ò)

“Õ¿¿õäèéí óóøãèíû öî÷ìîã äóò-ìàãøëûí îíî øèëãîîíû àñóóäàëä” ñýäâýýð 2014 îíû 05 äó ãààð ñàðûí

22-íû ºäºð Óëààíáààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëëàà.

Ìàíàé îðîíä áàãà íàñíû õ¿¿õäýä òîõèîëäîõ óóøãèíû öî÷ìîã ¿ðýâñëèéã ñ¿¿ëèéí 40 ãàðóé æèëä òàë á¿ðýýñ íü ñóäàëæ, õ¿¿õäèéí óóøãè ñóäëàëä òóëãàìäàæ áóé îëîí ÷óõàë àñóóäëûã øèéäâýðëýñýí õýäèé ÷ ýíäýãäýëä õ¿ðãýõ ãîë øàëòãààíû íýã áîëîõ àìüñãàëûí öî÷ìîã äóòìàãøèë, ò¿¿íèé îíöãîé õýëáýðèéí àñóóäàë òºäèé ë á¿ðýí ñóäëàãäààã¿é áàéíà. ßëàíãóÿà, õ¿¿õäýä òîõèîëäîõ “ç¿ðõíèé áóñ øàëòãààíò óóøãèíû õàâàí”, “àìüñãàëûí öî÷ìîã äèñòðåññ õàìøèíæ”, “óóøãèíû çàâñðûí ýäèéí

¿ðýâñýë” çýðýã èæèë òºñòýé, àìü íàñàíä îíö àþóëòàé áàéäàë íºõöºëä¿¿ëäýã ýìãýã¿¿ä, àìüñãàëûí äóòìàãøèë áà óóøãèíû äóòìàãøëûí òàëààð íýãäñýí öîãö îéëãîëòã¿é, òîõèîëäëûí äàâòàìæ òîäîðõîéã¿é, îíîøèëãîî, ýì÷èëãýýíèé îëîí àñóóäàë á¿ðýí øèéäâýðëýãäýýã¿é áàéãàà íü ýíýõ¿¿ ñóäàëãààã õèéæ ã¿éöýòãýõ ¿íäýñëýë áîëæýý.

Ñóäëàà÷ õ¿¿õäèéí àìü òýíññýí òºëºâèéí ¿åèéí óóøãèíû öî÷ìîã äóòìàãøëûí îíöëîãèéã ñóäàëæ, îíîøèëãîîíû àñóóäëûã øèéäâýðëýõ çîðèëãî òàâèí àæèëëàñàí áàéíà. Ñóäàëãààíû àæëûí õ¿ðýýíä 2007-2012 îíä ÝÕÝÌ¯Ò-èéí Õ¿¿õäèéí ýð÷èìò ýì÷èëãýýíèé òàñàãò õýâòýí ýì÷ë¿¿ëñýí íèéò 5322 õ¿¿õäýýñ ÓÖÄ îíîøëîãäñîí òîõèîëäîë á¿ðèéã ñóäàëãààíä õàìðóóëñàí áàéíà. ÓÖÄ áà ò¿¿íèé ýìíýëç¿éí ¿íäñýí 2 õýëáýðèéí òîõèîëäëûí äàâòàìæ, òàâèëàí, ýìíýëç¿éí áà ýìãýã á¿òöèéí îíöëîãèéã ñóäëàõàä ýìíýëç¿éí ïðîñïåêòèâ; ýíäýãäýëä íºëººëºõ çàðèì ýðñäýëò õ¿÷èí ç¿éëñèéã òîäðóóëàõàä òîõèîëäîë-õÿíàëòûí; SpÎ2/FiÎ2 õàðüöààíû ìýäðýã áà ºâºðìºö ÷àíàðûã òîäîðõîéëîõîä àæèãëàëòûí ïðîñïåêòèâ ñóäàëãààíû àðãûã òóñ òóñ àøèãëàæýý. Ìýäýýëëèéã Stata ïðîãðàìì àøèãëàí ä¿ðñëýõ, íýã áà îëîí õ¿÷èí ç¿éëèéí àðãààð áîëîâñðóóëæ, ÓÖÄ-ûí SpO2/FiO2 áà PaO2/FiO2 õàðüöààíû ÿëãààã òîãòîîõîä ROC ìóðóéã àøèãëàñàí áàéíà. Ñóäàëãààíû ¿ð ä¿íä òóëãóóðëàí äàðààõ ä¿ãíýëòýíä õ¿ðñýí áàéíà.

¯¿íä:1. Ìàíàé îðîíä õ¿¿õäèéí àìü òýíññýí òºëºâèéí

¿åä ýð÷èìò ýì÷èëãýýíèé 1000 õýâòýëò òóòàìä ÓÖÄ-ûí 11.5 òîõèîëäîë îíîøëîãäîæ, ò¿¿íèé õ¿íä õýëáýð (ÀÖÄÕØ) äàâàìãàé (55.7%) òîõèîëäîæ áàéíà. Óóøãèéã àíõäàã÷ààð ãýìòýýæ áàéãàà çîíõèëîõ øàëòãààí íü óóøãèíû ¿ðýâñýë (59.0%), õî¸ðäîã÷îîð ãýìòýýæ áàéãàà ãîëëîõ øàëòãààí íü Ò¯ÕØ (13.1%), ¿æèë (9.9%), ýì, õèìèéí (6.7%) áà õèéí (3.3%) áîäèñîîð õîðäîëò áàéíà.

2. ÓÖÄ-ûí íàñ áàðàëò 60%, ¿¿íýýñ ÓÖÃ-òýé õàðüöóóëàõàä ÀÖÄÕØ-èéí ýíäýãäýë èë¿¿ (67.7%) íü óã ýìãýã íàñ áàðàëò ºíäºðòýé áóéã õàðóóëæ áàéíà. ÓÖÄ-ûí ýíäýãäýëä ¿æèë (OR 2.7), Ò¯ÕØ (OR 2.8), óãàðòñàí áà õîðäñîí (OR 1.30), 3 áà ò¿¿íýýñ îëîí ýðõòýí òîãòîëöîîíû ãýìòýö (OR 3.1), àíõíààñàà õ¿÷èëòºðºã÷èéí õàíãàìæèéí àëäàãäàë èõòýé áàéõ (OR 1.14) çýðýã íü à÷ õîëáîãäîë á¿õèé ýðñäýëò õ¿÷èí ç¿éëñ áîëæ áàéíà.

3. Ýìíýëç¿éä íü õ¿íä õýëáýðèéí àìüñãàëûí äóòìàãøèë, óóøãèíû õàâàí, õºõðºëò, àìüñãàë

Ìîíãîëûí àíàãààõ óõààíû ñàëáàðò 2014 îíä ýðäìèéí çýðýã õàìãààëñàí ñóäëàà÷èä

ÌÝÄÝÝËÝË, ÑÓÐÒÀË×ÈËÃÀÀ 79

äýìæèõ îðëóóëàõ øààðäëàãà, Î2 ýì÷èëãýýíä

òýñâýðëýã õºõðºëò, óóøãèíû íýâ÷äýñò ººð÷-ëºëò òîäîðõîéëîãäîæ áàéíà. ÓÖÄ öî÷ìîã, ò¿ðãýí ÿâöòàé, òóõàéëáàë, ºäººã÷ õ¿÷èí ç¿éëñ íºëººëñíèé äàðààõ 6-48 öàãèéí äîòîð ¿¿ñ÷, õóðäàöòàé ¿ãäðýí õ¿íäýð÷, öóëöàí, öóëöàí-õÿëãàñàí ñóäàñíû ñàðüñ, óóøãèíû çàâñðûí ýä èë¿¿òýé ºðòºæ, óóøãè õàâàãíàõ, óóøãèíû óÿí ÷àíàð àëäàãäàõ, ôèáðîçæèõ çýðýã ýìãýã ïðîöåññ ÿâàãäàæ áàéíà.

4. ÓÖÄ-ûí SpO2/FiO2 õàðüöààíû îíîøèëãîîíû ìýäðýã áà ºâºðìºö ÷àíàð, ROC ìóðóéí çýðãýýñ ä¿ãíýõýä öóñíû õèéí øèíæèëãýý õèéõ áîëîìæã¿é íºõöºëä ïóëüñîêñèìåòðèéí øèíæèëãýýã îíîøèëãîîíä îðëóóëàí àøèãëàõ áîëîìæòîéã õàðóóëæ áàéíà.

Ñóäëàà÷ ñóäàëãààíûõàà ¿ð ä¿íã ýìíýëç¿éí ïðàêòèê ¿éë àæèëëàãààíä íýâòð¿¿ëæ, îëîí á¿òýýë òóóðâèí ýì÷ ñóäëàà÷äûí õ¿ðòýýë áîëãîñîí òºäèéã¿é òóñëàìæ ¿éë÷èëãýýíèé øàòëàë á¿ðä çîðèóëñàí îíîøèëãîî ýì÷èëãýýíèé çºâëºìæ, ãàðûí àâëàãà áè÷ñýí áàéíà.

Äàãäàíáàçàðûí Íÿìäîðæ

(Äîêòîðàíò, ÀØÓ¯ÈÑ)

“Òàðâàãàíû áîð ººõíèé á¿òýö, ò¿¿íèé íºëººã íîéð áóë÷èðõàéí ¿ðýâñëèéí ýìãýã

çàãâàðò ñóäàëñàí ä¿í” ñýäâýýð 2014 îíû 5 äóãààð ñàðûí 29-íä Ìîíãîë óëñ, Óëààíáààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí áàéíà

Ýíýõ¿¿ ñóäàëãààãààð áîð ººõíèé ýäýä ëèìôîèä ýäèéí áººãíºðºë áàéãààã òîäîðõîéëñîíîîñ ãàäíà òóðøèëò ñóäàëãààãààð íîéð áóë÷èðõàéí öî÷ìîã ¿ðýâñëèéí ¿åä òàðâàãàíû “Õ¿í ìàõ” áóþó áîð ººõèéã õýðýãëýõ íü íîéð áóë÷èðõàéí ãàäààä ø¿¿ðëèéã ýð÷èìæ¿¿ëæ, äàðõëàà äàðàíãóéëæ äýë¿¿, óóøãèíä öî÷ìîã ¿ðýâñýë ¿¿ñãýæ áàéãàà õýäèé ÷ íîéð áóë÷èðõàéí ¿ðýâñýë àðõàãøèí ãàäààä ø¿¿ðëèéí èäýâõ ýñðýãýýð ñóëàð÷ áàéãàà ¿åä áîð ººõíèé ýäèéí áýëäìýëèéí òîõèðñîí òóíã ýì÷èëãýýíèé çîðèëãîîð õýðýãëýñýí òîõèîëäîëä ÍÁ-í ãàäààä ø¿¿ðëèéí õýñãèéí ø¿¿ðýë íèéëýãæ¿¿ëýõ ¿éë àæèëëàãààã èäýâõæ¿¿ëæ, õàðèí äàðõëààã äàðàíãóéëàõ ¿éë÷ëýëòýé áàéæ áîëîõ þì ãýñýí òààìàãëàëûã äýâø¿¿ëëýý.

Çºâëºìæ

• ÍÁÖ¯-èéí ¿åä òàðâàãàíû “Õ¿í ìàõ”-íû öèéä-ìýãèéí ýì÷èëãýý ¿ð ä¿í ìóóòàéãààð áàðàõã¿é ºâ÷èíã õ¿íäð¿¿ëæ áîëîõ òàëòàé. Èéìýýñ Åâðîïûí àíàãààõ óõààíû ýìèéí ýì÷èëãýýíèé

äàðàà òóí õýìæýýã òààðóóëæ õýðýãëýõ íü õ¿ëýýñýí ¿ð ä¿íã àâàõ á¿ðýí áîëîìæòîé þì.

• ÍÁ¯-èéí ýðò ¿åä äàðõëààíû óðâàëûã ñýðãýýõýä ÷èãëýñýí, õàðèí õîæóó ¿åä àóòîèììóí ìåõà-íèçìààð óóë áóë÷èðõàé ¿ðýâñýõ ºðíºëèéã äàðàíãóéëàõ äàðõëàà ç¿ãøð¿¿ëãèéí ýì÷èëãýý õèéõ íü íýí çîõèìæòîé.

• Òàðâàãàíû “Õ¿í ìàõ” õýìýýõ áîð ººõíèé ýäèéã íîéð áóë÷èðõàéí ¿ðýâñýëä ñàéí ãýñýí àì äàìæñàí ÿðèàãààð àãíàñàí õóãàöàà, õàäãàëñàí ãîðèì òîäîðõîéã¿é ç¿éëèéã àâ÷ õýðýãëýõ íü óã ºâ÷íèéã óëàì ñýäðýýõýýð áàðàõ-ã¿é äààìæðóóëàõ òàëòàéã àíõààðàõ.

Ëõàìñ¿ðýí Æàâçìàà

(Äîêòîðàíò, ÀØÓ¯ÈÑ-èéí ÃÀÀ ñàëáàð ñóðãóóëü)

“Àðõàã ãëîìåðóëîíåôðèòèéí íàìæìàë ¿åä Áèãýðèéí ýëñýí ñóâèëëûí ¿ð ä¿í” ñýäâýýð 2014

îíû 6 äóãààð ñàðûí 03-íû ºäºð Óëààíáààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí.

Áººðíèé öî÷ìîã áîëîí àðõàã ºâ÷íèé òîî ñ¿¿ëèéí ¿åä äýëõèé äàÿàð õóðäàöòàé ºñ÷ õ¿í àìûí õºäºëìºðèéí ÷àäâàð àëäàëò, íàñ áàðàëòûí ¿íäñýí ãîë øàëòãààí áîëæ áàéãààã ýðäýìòýä “ïàíäåìèÿ” ãýæ ä¿ãíýæ áàéíà.

Äýëõèéä: Íàñàíä õ¿ðýã÷äèéí äóíä áººðíèé ýìãýã 16.8%

Ìîíãîëä: Øýýñ áýëãýñèéí òîãòîëöîîíû ºâ÷èí (ØÁÇª 10000 õ¿í àìä 766,4) ºâ÷ëºëèéí òýðã¿¿ëýõ øàëòãààíû 3-ðò îðæ áàéíà.

Ìàíàé îðíû õóâüä 2012 îíû áàéäëààð ÓÊÒÝ-ò ýðõòýí øèëæ¿¿ëýí ñóóëãàõ õàãàëãàà õèéãäñýí íèéò 109 ºâ÷òºíèé 94 áóþó 86,2% íü áººð øèëæ¿¿ëýí ñóóëãàõ õàãàëãàà áàéñíû 84 òîõèîëäîë áóþó 90%-ã àðõàã ãëîìåðóëîíåôðèò ýçýëæ áàéíà.

Èéìýýñ áèä ÓÀÓ-íû çººëºí çàñëûí íýã áîëîõ ýëñýí õó÷ëàãà, ñóâèëãààã õîîë ýì÷èëãýý, íàðàí øàðëàãà, èíãýíèé õîîðìîã óóëãàõ çýðýã ýì÷èëãýýí¿¿äòýé õîñëóóëàí õýðýãëýæ àðõàã ãëîìåðóëîíåôðèòèéí äàõèëò õîîðîíäûí çàéã óðòàñãàõ, ñýäðýëèéã íàìäààõ, ãàðàõ õ¿íäðýëýýñ ñýðãèéëýõýä ÷óõàë à÷ õîëáîãäîëòîé ãýæ ¿çñýí.

Àðõàã ãëîìåðóëîíåôðèòòýé ñóâèëóóëàã÷äàä èëðýõ ýìíýëç¿éí øèíæ òýìäã¿¿äèéí (îð÷èí ¿åèéí áîëîí ÓÀÓ-íû) ººð÷ëºëòèéã ýëñýí õó÷ëàãà, ñóâèëãààíû ¿ð ä¿íãýýð òîîöñîí.

Àðõàã ãëîìåðóëîíåôðèòòýé ñóâèëóóëàã÷äûí øýý -


ñýíä ãàðàõ ººð÷ëºëòèéã Óëàìæëàëò àíà ãààõ óõààíû øýýñ øèíæëýõ àðãààð øèíæèëæ, ìèêðîñêîïè, òóóçàí îíîøëóóð áîëîí øýýñíèé á¿ðýí àâòîìàò àíàëèçàòîðûí àðãààð áàòàëãààæóóëæ ýëñýí õó÷ëàãà, ñóâèëãààíû ¿ð ä¿íã òîîöîæ ãàðãàâ.

Àðõàã ãëîìåðóëîíåôðèòèéí íàìæìàë ¿åä Áèãý-ðèéí ýëñýí ñóâèëëûí ¿ð ä¿íã ñóäëàí òîãòîîñîí.

Àðõàã ãëîìåðóëîíåôðèòòýé ñóâèëóóëàã÷äàä ýëñýí õó÷ëàãà, ñóâèëãààíû ºìíº áà äàðààõ ¿åèéí øýýñ, õºëñ, áèåä ãàð÷ áóé áèî ýíåðãèéí ººð÷ëºëòèéã ÕÖÇ-ûí øèíæèëãýýíèé àðãààð òîäîðõîéëæ ¿ð ä¿íã òîîöñîí.

Ñóäëàà÷ ñóäàëãààíûõàà ¿ð ä¿íã ýìíýëç¿éí ïðàêòèê ¿éë àæèëëàãààíä íýâòð¿¿ëæ, îëîí á¿òýýë òóóðâèí ýì÷ ñóäëàà÷äûí õ¿ðòýýë áîëãîñîí òºäèéã¿é òóñëàìæ ¿éë÷èëãýýíèé øàòëàë á¿ðä çîðèóëñàí îíîøèëãîî ýì÷èëãýýíèé çºâëºìæ, ãàðûí àâëàãà áè÷ñýí áàéíà.

Ñýðýýíýíãèéí Ýíõáîëä

(Äîêòîðàíò, ÕªÑ¯Ò)

“Ìîíãîë óëñûí Ýð¿¿ë ìýíäèéí ìýäýýëëèéí òîãòîëöîîã áî ëîâñ ðîíãóé áîëãîõ àñóó-äàëä” ñýäâýýð 2014 îíû 6 äóãààð ñàðûí 5-íû ºäºð,

Óëààíáààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí áàéíà

Ìîíãîë óëñàä 1930 îíä ýð¿¿ë ìýíäèéí òîî á¿ðòãýë õàðèóöñàí íýã ìýðãýæèëòýí àæèëëàæ ýõýëñíýýñ õîéø ýð¿¿ë ìýíäèéí ìýäýý, ìýäýýëëèéã á¿ðòãýæ öóãëóóëàõ àæèë ýõýëñýí áà ºíººã õ¿ðòýë ìýäýý ìýäýýëëèéã öóãëóóëàõ, íýãòãýõ, äàìæóóëàõ, áîëîâñðóóëàõ, ä¿í øèíæèëãýý õèéõ, ýðãýí ìýäýýëýõ ¿éë àæèëëàãàà á¿õèé ýð¿¿ë ìýíäèéí ìýäýýëëèéí íýãäñýí òîãòîëöîî áîëîí õºãæººä áàéíà. Ñ¿¿ëèéí æèë¿¿äýä ìýäýýëýë, õàðèëöàà õîëáîîíû îð÷èí ¿åèéí òåõíîëîãè ýð¿¿ë ìýíäèéí ñàëáàðò àñàð õóðäàöòàé íýâòðýí îðæ èðæ áàéíà. Èéìýýñ ÝÌÌÒ-íû ºíººãèéí áàéäëûã áîäèòîéãîîð ¿íýëæ òîäîðõîéëñíîîð ìýäýýëëèéí òåõíîëîãèéã ýð¿¿ë ìýíäèéí ñàëáàðò áîäëîãî, òºëºâëºãººòýéãýýð íýâòð¿¿ëýõ áîëîìæèéã á¿ðä¿¿ëýõ íü ýíýõ¿¿ ñóäàëãààã ÿâóóëàõ ¿íäýñëýë áîëñîí áàéíà.

Ñóäëàà÷ Ìîíãîë óëñûí ÝÌÌÒ-íû õóóëü, ýðõ ç¿éí îð÷èí, íººöèéí ºíººãèéí áàéäëûã ñóäëàí, öààøèä áîëîâñðîíãóé áîëãîõ àðãà çàìûã òîäîðõîéëîõ çîðèëãèéã òàâüæ àæèëëàñàí áàéíà. Ñóäàëãààíä íèéò 53 ýð¿¿ë ìýíäèéí áàéãóóëëàãûí 1147 õ¿íèéã õàìðóóëñàí áà àñóóìæ ñóäàëãàà, SWOT øèíæèëãýý, òîîí áà ÷àíàðûí àðãóóäûã àøèãëàñàí áà òîî, ìýäýýëýëä ñòàòèñòèêèéí “SAS” ïðîãðàìì àøèãëàí ä¿í ¿ð ä¿íä äåñêðèïòèâ áîëîí ðåãðåññ ñòàòèñòèê øèíæèëãýý õèéæýý.

Ñóäàëãààíû ¿ð ä¿íä òóëãóóðëàí äàðààõ ä¿ãíýëòýíä õ¿ðñýí áàéíà. ¯¿íä:

• Ýð¿¿ë ìýíäèéí ìýäýýëëèéí ¿éë àæèëëàãààã çîõèöóóëæ áóé õóóëü, ýðõ ç¿éí îð÷èí øààðäëàãà õàíãàõã¿é áàéíà. ÝÌÌÒ-ã õºãæ¿¿ëýõ ñòðàòåãè áàòëàãäñàí áîëîâ÷ õýðýãæ¿¿ëýõ ÷àäàâõè á¿ðäýýã¿é (63.2 õóâü), ìýäýýëëèéí ¿éë àæèëëàãààã çîõèöóóëñàí õóóëü, ñòàíäàðò, æóðìóóä áîëîâñðîãäîí ãàðààã¿é áàéíà.

• Ýð¿¿ë ìýíäèéí ìýäýýëëèéí ÷èãëýëýýð àæèëëàæ áóé ñòàòèñòèê÷ ýì÷, ìýäýýëëèéí òåõíîëîãèéí ìýðãýæèëòí¿¿ä òîîíû õóâüä õàíãàãäñàí áîëîâ÷, õ¿íèé íººöèéã õºãæ¿¿ëýõ ÷èãëýëýýð õèéãäýæ áóé ñóðãàëò, àæèë÷äûí òîãòâîð ñóóðüøèë, ìýðãýøñýí áàéäàë õàíãàëòã¿é áàéíà. ÝÌÌÒ-íû õºãæèëä õ¿íèé íººö 19 õóâü, ñàíõ¿¿ãèéí íººö 37 õóâèàð áóþó èõ íºëºº ¿ç¿¿ëäýã áàéõàä ýð¿¿ë ìýíäèéí áàéãóóëëàãóóäûí ìýäýýëëèéí ¿éë àæèëëàãààíä çàðöóóëæ áóé ñàíõ¿¿, õºðºíãº îðóóëàëò äóòìàã, óëñûí òºñºâò á¿ðýí òóñãàãääàãã¿é áàéíà.

• Ìýäýýëëèéí òåõíîëîãèéí êîìïüþòåð, äîòîîä ñ¿ëæýý çýðýã õàòóó äýä á¿òýö ýìíýëã¿¿äýä áàéãàà áîëîâ÷ ÝÌÌÒ-ã íýãäñýí áàéäëààð õºãæ¿¿ëýõýä øààðäëàãàòàé òîíîã, òºõººðºìæèéí õàíãàìæ, ò¿¿íèé øèíý÷ëýë, àøèãëàëòûí òàëààðõ ñàëáàðûí íýãäñýí áîäëîãîã¿é ÿâæ èðñýí áàéíà. Ýìíýëýãò õýðýãëýæ áóé ïðîãðàì õàíãàìæ (19.5 õóâü -25.3õóâü) ýõëýë òºäèé íýâòýðñýí áàéäàëòàé áàéíà. ÝÌÌÒ-íû õºãæèëä òîíîã òºõººðºìæ, òåõíîëîãèéí íººö 16 õóâèàð íºëººëæ áàéíà.

Áàäàð÷ Æàðãàëñàéõàí

(Äîêòîðàíò, ÀØÓ¯ÈÑ)

“Óìàéí ëåéîìèîìèéí çàðèì ýðñäýëò õ¿÷èí ç¿éëñ, áè÷èë á¿òöèéí îíöëîí áîëîí Ð53, Ki67 óóðãèéí îíîøèëãîîíû à÷ õîëáîãäîë” ñýäâýýð 2014 îíû 11 ä¿ãýýð ñàðûí 27-íû

ºäºð Óëààíáààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí áàéíà.

Óìàéí ëåéîìèîìä õàâäàð äàðàíãóéëàã÷ Ð53, ¿ðæëèéí Ki67 óóðãèéí èëðýë, ýñèéí ìèòîçèéí èäýâõæèëèéã òîäîðõîéëñíîîð ëåéîìèîìèéí ýíãèéí áîëîí ¿ðæèëòýé õýëáýð¿¿äèéí ýìãýã æàì, á¿òöèéí ÿëãàà, ò¿ðãýí óðãàëòûí îíöëîã, ëåéîìèîì ¿¿ñýõýä íºëººëºõ çàðèì ýðñäýëò õ¿÷èí ç¿éëñèéã ýðò èëð¿¿ëæ, óðüä÷èëàí ñýðãèéëýõ àðãà õýìæýý àâñíààð ºâ÷ëºëèéã áóóðóóëàõ, á¿òöèéã íàðèéâ÷ëàí òîäîðõîéëæ, ò¿¿íä òîõèðñîí ýì÷èëãýýíèé îíîâ÷òîé çàãâàðûã ñîíãîõ áîëîìæòîé áîëëîî.

ÌÝÄÝÝËÝË, ÑÓÐÒÀË×ÈËÃÀÀ 81

Óìàéí ¿ðæèëòýé ëåéîìèîì èëýðñýí, íºõºí ¿ðæèõ¿éí íàñíû, õ¿¿õýä òºð¿¿ëýõ õ¿ñýëòýé ýìýãòýé÷¿¿äýä ýðõòíèé ¿éë àæèëëàãààã õàäãàëàõ ìýñ çàñàë ýì÷èëãýýã ñîíãîõ íü ëåéîìèîöèò ýñèéí ýìãýã ººð÷ëºëò (õýò òîìðîõ æèæèãðýõ ã.ì), øèíýýð ñóäàñæèëò ¿¿ñýõ, ýñèéí ¿ðæëèéí èäýâõæèëèéã ñààòóóëñíààð ýñèéí õºòºëáºð÷èëñºí ¿õýë ÿâàã-äàõ ôèçèîëîãèéí ¿éë ÿâö ñýðãýõ (àïîïòîç) áîëîìæòîéã èëð¿¿ëñýíä ñóäàëãààíû àæëûí ïðàêòèê à÷ õîëáîãäîë îðøèíî.

Çºâëºìæ: 1. Óìàéí ëåéîìèîì íü ñàëñòûí äîîð áàéðëàñàí,

óìàéãààñ ìº÷ëºãã¿é öóñ àëäàæ áàéãàà, õàâäðûí õýìæýý òîì (12 äîëîî õîíîãòîé æèðýìñíèé õýìæýýíýýñ òîìîðñîí), îëîí òîîíû çàíãèëààòàé (4-ººñ îëîí) öýâýðøñýíèé äàðàà ëåéîìèîì õýìæýýãýýð áàãàñàõã¿é áàéõ, õàâäðûí çàíãèëààã øóëæ àâñíû äàðàà äàõèõ, óìàéí ñàëñòûí õýò ¿ðæèë õàâñàðñàí òîõèîëäîëä õàâäðûí óðãàëò èäýâõæèæ, ãºëãºð áóë÷èíãèéí ýñ ¿ðæèõ ýðñäýëòýé ó÷èð ìýñ çàñëààð àâñàí ëåéîìèîìèéí çàíãèëààíä Ð53, Ki67 óóðãóóäèéí ÿëãàðàë, ìèòîçèéí èäýâõæëèéã òîäîðõîéëîõ íü ëåéîìèîìèéí õýëáýðèéã (ýíãèéí áîëîí ¿ðæèëò) òîãòîîí, ëåéîìèîñàðêîìîîñ òºãñ ÿëãàí îíîøëîõîä ÷óõàë à÷ õîëáîãäîëòîé.

1.1. Óìàéí ëåéîìèîìòîé, íºõºí ¿ðæèõ¿éí íàñíû, õ¿¿õýä òºð¿¿ëýõ õ¿ñýëòýé ýìýãòýéä ýðõòíèé ¿éë àæèëëàãàà õàäãàëàõ ìýñ çàñëûã õèéõ íü ãºëãºð áóë÷èíãèéí ýñèéí õýò òîìðîë, øèíýýð ñóäàñæèëò ¿¿ñýõ, ýñèéí ¿ðæèë çýðãèéã ñààòóóëæ, õàâäðûí ýñèéí õºòºëáºð÷èëñºí ¿õëèéã (àïîïòîç) èäýâõæ¿¿ëýõýä ÷èãëýíý.

1.2. Óìàéí ãºëãºð áóë÷èíãèéí ýñèéí ¿ðæèë, óìàéí ñàëñòûí á¿òöèéí ººð÷ëºëòèéã (óìàéí càëñòûí õýò çóçààðàë) òîäîðõîéëîõ íü ýðõòíèé ¿éë àæèëëàãààã õàäãàëàõ ìýñ çàñàë ýì÷èëãýýíèé äàðàà çàíãèëààíû äàõèí óðãàëòààñ ñýðãèéëýõ çîðèëãîîð äààâàð ýì÷èëãýý õèéõ ¿íäýñëýë áîëíî.

2. Ëåéîìèîìèéí ¿åä óìàéí ñàëñòàíä ãàæèãøèëò õýò ¿ðæèë, áàéðàí áîëîí ò¿ãìýë õàòèíãàðøèë, óéëàíõàéíöàðò áóë÷èðõàéëàã õýò ¿ðæèë çýðýã ýìãýã ººð÷ëºëò¿¿ä ¿¿ñäýã ó÷ðààñ ýðõòíèé ¿éë àæèëëàãàà õàäãàëàõ ìýñ çàñàë ýì÷èëãýýíèé ºìíº óìàéí õºíäèéãººñ õóñàì àâ÷, ñàëñòûí áàéäëûã ¿íýëýí, õàâäðûí òàëààñ íü àíõààðàõ õýðýãòýé. Ëåéîìèîìèéí ¿åä óìàéí ñàëñòàíä ãàæèãøèëò õýò ¿ðæèë èëýðñýí áîë óìàéã àâàõ ýì÷èëãýýíèé òºãñ àðãûã ñîíãîíî.

Áààòàðûí Îòãîí

(Äîêòîðàíò, ÓÍÒÝ)

“Ýð÷èìò ýì÷èëãýýíèé ïðàê-òèêò òîõèîëäîæ áóé àíòè-áèîòèêò òýñâýðòýé íÿíãààð

¿¿ñãýãäñýí ¿æëèéí çàðèì îíöëîã” ñýäâýýð 2014 îíû 11 ä¿ãýýð ñàðûí 27-íû ºäºð Óëààí-áààòàð õîòíîî àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí áàéíà.

Íÿíãèéí àíòèáèîòèêò òýñâýðæèëò íü áàéãàëèéí øàëãàðëûí íýã õýëáýð áºãººä àíòèáèîòèêèéí õýðýãëýý (çîõèñòîé áà çîõèñã¿é) íü òýñâýðæèëòèéí ãîëëîõ øàëòãààí áîëäîã. Íÿí àíòèáèîòèêò òýñâýðæèõ íü òààìàã áîëîí íîòîëãîîò àíòèáèîòèê ýì÷èëãýýíèé ¿ð ä¿íã áóóðóóëæ ¿æèëòýé ºâ÷òºíèé òàâèëàíä ñºðãººð íºëººëíº. Òóõàéí ýð¿¿ë ìýíäèéí áàéãóóëëàãà, ýìíýëýã, îðîí íóòãèéí õ¿ðýýí äýõ íÿíãèéí àíòèáèîòèêò òýñâýðæèëòèéí îíöëîã, àíòèáèîòèêò òýñâýðòýé íÿíãèéí äàâàìãàéëàë çýðãèéã ñóäëàí òîãòîîæ ñóäàëãààíä ñóóðèëñàí àíòèáèîòèê ýì÷èëãýýíèé áîäëîãî, óäèðäàìæòàé áàéõ íü íÿíãèéí àíòèáèîòèêò òýñâýðæèëòèéã õÿçãààðëàõ, ºðòºã çàðäëûã áóóðóóëàõ, ¿æëèéí ýì÷èëãýýíèé ¿ð ä¿íã äýýøë¿¿ëýõýä ÷óõàë íºëººòýé áàéäàã.

Ýìíýëãèéí äîòîîä õàëäâàð (ÝÄÕ)-ûí óëìààñ ºâ÷òºíèé ýìíýëãèéí îð õîíîã óðòàñ÷, îëîí òîîíû íýìýëò øèíæèëãýý, îíîøëîãîî, ýì÷èëãýý õèéõ øààðäëàãà ¿¿ñ÷ ºðòºã çàðäàë íýìýãäýí, ºâ÷òºíèé ýìíýëç¿éí ÿâö õ¿íäýð÷, ýì÷èëãýýíèé ¿ð ä¿í áóóðàõ øàëòãààí áîëäîã.

ÝÄÕ-ûã òàíäàí ìýäýýëæ íîòîëãîîíä ñóóðèëñàí õÿíàëòûí àðãà õýìæýýã õýðýãæ¿¿ëýõ íü òîõèîëäëûã áóóðóóëàõ ãîë àðãà çàì þì. Ýíýõ¿¿ ñóäàëãàà íü àíòèáèîòèêò òýñâýðòýé íÿí áîëîí Ýìíýëãèéí äîòîîä õàëäâàðûí óëìààñ ¿¿ññýí ¿æëèéí ýìíýëç¿éí îíöëîãèéã ñóäàëæ òîõèîëäëûã áóóðóóëàõ àðãà çàìûã òîäîðõîéëîõîä ÷èãëýñýí áîëíî.

Óã ñóäàëãààã Óëñûí Íýãä¿ãýýð Òºâ ýìíýëãèéí ýð÷èìò ýì÷èëãýýíèé òàñàãò óãòóóëñàí êîãîðò çàãâàðààð õèéñýí áà 2011 îíû 1-ð ñàðààñ 2012 îíû 8-ð ñàðä ýì÷ëýãäñýí, íÿí ñóäëàëûí ýåðýã ñîðüöîîð ¿æëèéí îíîø íü áàòëàãäàæ ñóäàëãààíä õàìðóóëàõ øàëãóóð ¿ç¿¿ëýëò õàíãàñàí 215 ºâ÷òºíä àíòèáèîòèêò òýñâýðòýé íÿíãààð õàëäâàðëàãäñàí áàéäàë, ýíý õàëäâàðûí øàëòãààíò ¿æëèéí ýìíýëç¿éí îíöëîãèéã ñóäàëñàí áîëíî.

Çºâëºìæ:1. Óëààíáààòàð õîòûí êëèíèêèéí áîëîí îðîí

íóòãèéí íýãäñýí ýìíýëã¿¿ä Îëîí óëñûí ýìíýëãèéí äîòîîä õàëäâàðûí õÿíàëòûí õîðîîíû òàíäàëò ñóäàëãààíû öàõèì ñ¿ëæýýíä ãèø¿¿íýýð ýëñýí îðæ ººðèéí ýìíýëãèéí õàëäâàðûí áàéäëûã õÿíàæ, áóñàä óëñ îðíû ¿ç¿¿ëýëòòýé õàðüöóóëàí, ýìíýëãèéí äîòîîä õàëäâàðààñ óðüä÷èëàí ñýðãèéëýõ, áóóðóóëàõ àðãà õýìæýýã íîòîëãîîíä ñóóðèëñàí àðãààð çîõèîí áàéãóóëàõ íü ç¿éòýé.


2. Ýð÷èìò ýì÷èëãýýíèé òàñàãò íýâòðýëòýò àæèëáàð õèéõ, íýâòðýëòýò òºõººðºìæòýé ºâ÷òºíèé àñàðãàà ñóâèëãààã ã¿éöýòãýõ ¿åä õàëäâàðààñ ñýðãèéëýõ õÿíàëòûí õºòº÷èéã áàðèìòëàí, óã õºòº÷èéí áèåëýëòèéí õÿíàëòûí õóóäñóóäûã õºòëºí àæèëëàæ õýâøèõ, õýðýã-æèëòýíä íü õÿíàëò õèéäýã òîãòîëöîîã áèé áîëãîõ íü ýìíýëãèéí äîòîîä õàëäâàðûã áóóðóóëàõ ÷óõàë à÷ õîëáîãäîëòîé.

3. Óëààíáààòàð õîò áîëîí îðîí íóòàãò àíòè-áèîòèê òýñâýðæèëòèéã òîãòìîë ñóäëàí õÿíàñ-íû ä¿íä àíòèáèîòèêèéí òààìàã ýì÷èëãýýã èë¿¿ îíîâ÷òîé áîëãîõ, õàëäâàðûí õ¿íäðýë, ¿æëèéí íàñ áàðàëòûã áóóðóóëàõ, îð õîíî ãèéã áîãèíîñãîõ, ºðòºã çàðäëûã õýìíýõ áîëîë-öîîòîé.

4. Ýìíýëãèéí äîòîîä õàëäâàðûí äýãäýëò ãàðñàí òîõèîëäîëä àâàõ àðãà õýìæýýíèé óäèðäàìæ áîëîâñðóóëàõ, ìîëåêóë-ýïèäåìèîëîãèéí øèí-æèë ãýýíä ñóóðèëñàí õàëäâàðûí ãîëîìòûí ñóäàëãààã öîãö áàéäëààð õýðýãæ¿¿ëñíýýð òóõàéí õàëäâàð íü áóñàä ºâ÷òºíä äàìæèí òàðõàõààñ ñýðãèéëýõ, öàã àëäàëã¿é îíîøëîõ, õàðèó àðãà õýìæýý àâàõ íºõöëèéã á¿ðä¿¿ëíý.

5. Àíòèáîòèêò òýñâýðòýé íÿíãèéí õàëäâàð èëýðñýí òîõèîëîëä õàëäâàð öààøèä òàðõàõààñ ñýðãèéëæ õàëäâàðòàé ºâ÷òºíèéã òóñãààðëàõ áîëîëöîîãîîð õàíãàõ, òóñãààðëàõ ºðººíä îðîõ ýðõ á¿õèé ýì÷, ñóâèëàã÷äûí òîîã àëü áîëîõ õÿçãààðëàõ, ýýëæ á¿ðýýñ çºâõºí íýã ñóâèëàã÷èéã òîìèëîí àæèëëóóëàõ çààëòòàé. Òóñãààðëàõ ºðººíä îðîõäîî õàëäâàðààñ õàìãààëàõ íýã óäààãèéí ºìñãºë õýðýãëýõ, ýì÷èëãýý ¿éë÷èëãýýã ã¿éöýòãýýä ºðººíººñ

ãàðàõäàà ¿¿äýíä òàéëæ áèò¿¿ìæëýëòýé õîãèéí ñàâàíä õèéãýýä ãàðàà õàëäâàðã¿éòãýäýã íºõöºëèéã á¿ðä¿¿ëæ õýâø¿¿ëýõ, ºâ÷òºíèé áè÷èã áàðèìò, êàðò çýðãèéã ºðººíèé ãàäíà áàéðëóóëäàã áàéõ çýðýã íü ÷óõàë à÷ õîëáîã-äîëòîé. Òóñãààðëàõ ºðººíèé áîëîìæã¿é òà ñàã, íýãæ¿¿äýä àíòèáèîòèêò òñýâýðòýé íÿíãèéí õàëäâàðòàé ºâ÷òºíèéã îðîí äýýð íü òóñãààðëàõ áîëîìæòîé.

6. ÝÄÕ òàðõàëòûã õÿçãààðëàõ àðãà õýìæýýíèé õàìãèéí ÷óõàë õýñýã íü ãàðûí õàëäâàðã¿éòãýë þì. Ýì÷, ñóâèëàã÷, àìüñãàëûí ýì÷èëãýýíèé ìýðãýæèëòýí, ðåíòãåí òåõíèê÷, ôèçèê ýì-÷èëãýý, õºäºëãººí çàñëûí ìýðãýæèëòýí ãýõ ìýò ºâ÷òºíèé ýì÷èëãýý ¿éë÷èëãýýíä îðîëöäîã á¿õ àæèëòíóóäûí ãàð õàëäâàðã¿éòãýëèéí áàéäëûã òàíäàõ áà òàíäàëòûã òîãòìîë õóãà-öààíû äàâòàìæòàéãààð (òóõàéëáàë óëè ðàëä íýãýýñ äîîøã¿é óäàà) õèéæ, ñóðãàëò çîõèîí áàéãóóëäàã òîãòîëöîîã á¿ðä¿¿ëýí àæèëëàõ çààëòòàé. ªâ÷òºíèé õýâòýæ áàéñàí îð, òàâèëãà õýðýãñýë, òîíîã òºõººðºìæèéã çîõèõ æóðìûí äàãóó õàëäâàðã¿éòãýæ, ÷àíàðûí õÿíàëòûã îð÷íû íÿí ñóäëàëûí øèíæèëãýýãýýð õÿíàäàã áàéõ øààðäëàãàòàé.

7. Ýì÷, ýìíýëãèéí àæèëëàãñàä áîëîí àðä èðãýäýä àíòèáèîòèêèéí çîõèñòîé õýðýãëýýíèé òàëààð òàñðàëòã¿é ñóðãàëò, ñóðòàë÷èëãààã çîõèîí áàéãóóëàõ, àíòèáèîòèê ýìèéí òýñâýðæèëòèéã íýìýãä¿¿ëæ áàéãàà áóðóó äàäàë çóðøëûã àðèëãàõ, óðüä÷èëàí ñýðãèéëýõ àðãà àðãà÷ëàëä ñóðãàõ õºòºëáºðèéã õýðýãæ¿¿ëýõ íü ýíý òºðëèéí ºâ÷èí ýìãýã¿¿äèéã áóóðóóëàõ ¿íäñýí àðãà ìºí.

ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍÛ ÀÊÀÄÅÌÈÉÍ ÃÈØ¯¯ÄÈÉÍ ¯ÉË ÀÆÈËËÃÀÀÍÛ ÒÀÉËÀÍ, 2014 ÎÍ 83

2015-01-14

1. Áè÷èæ íèéòë¿¿ëñýí á¿òýýë: íèéò 30, ¿¿íä – íîì 2 [àíãëè õýë äýýð], ýðäýì øèíæèëãýýíèé ºã¿¿ëýë 24 [¿¿íýýñ 5 íü àíãëè õýë äýýð], ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë 4 [àíãëè õýë äýýð] (Õàâñðàëò 1). ¯¿ãýýð ìèíèé íèéòë¿¿ëñýí íèéò á¿òýýë 945 áîëñíîîñ, 56 á¿òýýë íü GoogleScholar õàéëòûí òîãòîëöîîíä á¿ðòãýãäýæ, íèéò 1318 óäàà èø òàòàãäñàíààð, h-index=14, i10-index=16 áîëñîí áîë, Researchgate õàéëòûí òîãòîëöîîíä 66 á¿òýýë ìààíü á¿ðòãýãäñýíèéã áóñàä ñóäëàà÷èä 5000 ãàðóé óäàà ¿çýæ, 2108 óäàà õóóëàí àâ÷, 770 óäàà èø òàòàæ, ÷àíñàà 112.32, RGScore=29.29 ãýñýí ¿ç¿¿ëýëò ãàðñàí áàéíà (Õàâñðàëò 2);

2. Îðîëöñîí ýðäýì øèíæèëãýýíèé õóðëóóä, òàâüñàí èëòãýë áà óíøñàí ëåêö¿¿ä: 14 (Õàâñðàëò 3);

3. Óäèðäàæ õàìãààëóóëñàí ñóäëàà÷: 1– ÕªÑ¯Ò-èéí Âèð¿ñ ñóäëàëûí ëàáîðàòîðèéí ýì÷ Ã¿íðýãæàâûí Íÿìàà ìèíèé óäèðäëàãààð 2011-2014 îíä RSV-èéí ñóäàëãààã õèéæ, “Ìîíãîë óëñàä 2010-2013 îíä ÿëãàñàí àìüñãàëûí çàìûí ñèíöèòèàëü âèð¿ñèéí ãåíåòèê òºðõ” ñýäâýýð 2014.06.18-íä ÀØÓ¯ÈÑ äýýð Àíàãààõ óõààíû ìàãèñòðèéí çýðýã õàìãààëñàí;

4. Óäèðäàí ã¿éöýòãýæ áóé ñóäàëãààíû àæëóóä:

1) ßïîí óëñûí Òîõîêóãèéí Èõ ñóðãóóëèéí Àíàãààõ óõààíû ñóðãóóëüòàé õàìòðàí àæèëëàõ ãýðýý-íèé õ¿ðýýíä 2011 îíîîñ óã ñóðãóóëèéí Âèð¿ñ ñóäëàëûí òýíõèìòýé õàìòðàí “Òîìóóãèéí äàìæèí òàðõàëòûí ñóäàëãàà”-ã Óëààíáààòàð õîòûí Áàãàíóóð, Äîðíîãîâü àéìãèéí Ñàéíøàíä, Ç¿¿íáàÿí ñóìäàä õèéæ áàéíà.

2) Ôðàíö óëñûí Ìåðü¸ãèéí Ñàíòàé õàìòðàí àæèëëàõ ãýðýýíèé äàãóó 2011-2013 îíä Óëààíáààòàð õîòûí Áàÿíç¿ðõ ä¿¿ðãèéí íýãäñýí ýìíýëãèéã ò¿øèãëýí ïíåâìîíèéí ¿¿ñãýã÷èéí á¿òöèéí ñóäàëãààã õºãæèæ áóé áóñàä 8 îðîíòîé (ÁÍÕÀÓ, Áðàçèë, Êàìïó÷è, Ìàäàãàñêàð, Ìàëè, Ïàðàãâàé, Õàéòè, Ýíýòõýã)

õàìòðàí íýãäñýí àðãà÷ëàëààð õèéæ, ýõíèé ºã¿¿ëëèéã íèéòë¿¿ëýâ.

3) Ìîíãîë óëñûí Øèíæëýõ óõààí, òåõíîëîãèéí ñàíãààñ 2012-2014 îíä ñàíõ¿¿æ¿¿ëæ áàéãàà “Õ¿íèé òîìóóãèéí âèð¿ñèéí íóòãèéí îìãóóäûí ýìèéí áîäèñò òýñâýðæèëòèéí ìîëåêóë ãåíåòèêèéí ñóäàëãàà” ñýäýâò ñóóðü ñóäàëãààíû äàãóó ÕªÑ¯Ò-èéí Âèð¿ñ ñóäëàëûí ëàáîðàòîðèä 100 ãàðóé îìîã ñîíãîí àâ÷ ñóäàëãàà õèéæ äóóñààä îäîî áîëîâñðóóëàëò õèéæ áàéíà.

4) ÀÍÓ-ûí Òàéëàíä äàõü Çýâñýãò õ¿÷íèé àíàãààõûí ñóäàëãààíû õ¿ðýýëýíòýé õàìòðàí Ìîíãîëûí Çýâñýãò õ¿÷íèé àíãèóä, ÕªÑ¯Ò-èéí Âèð¿ñ ñóäëàëûí ëàáîðàòîðèä 2013-2016 îíä õýðýãæ¿¿ëýõ “Ìîíãîëûí çýâñýãò õ¿÷íèé àëáàí õààã÷äûí ÒÒª-íèé à÷ààëàë” ñýäýâò àæëûí õ¿ðýýíä àòëàãäñàí àðãà÷ëàëûí äàãóó ñóäàëãàà õèéæ áàéíà.

5) Ìîíãîë óëñûí Øèíæëýõ óõààí, òåõíîëîãèéí ñàíãààñ 2013-2015 îíä ñàíõ¿¿æ¿¿ëæ áàéãàà “Áýëãèéí çàìààð äàìæèí õàëäâàðëàõ âèð¿ñò õàëäâàðûí òàðõàëò, ñýðãèéëýõ àðãà” ñýäýâò ñóóðü ñóäàëãààíû õ¿ðýýíä áàòëàãäñàí àðãà÷ëàëûí äàãóó ÕªÑ¯Ò, ÕÑ¯Ò-ä 1000 ãàðóé ñîðüö öóãëóóëæ, “Ãÿëñ” Àíàãààõ óõààíû òºâä í¿êëåéí õ¿÷èëä ñóóðèëàñàí 2 òºðëèéí àðãààð 12 òºðëèéí ¿¿ñãýã÷ íýã çýðýã èëð¿¿ëýõ ñóäàëãààã õèéæ äóóñãààä áîëîâñðóóëõàëò õèéæ áàéíà.

Àêàäåìè÷ Ï.Íÿìäàâàà

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Ï.Íÿìäàâààãèéí 2014 îíû òàéëàí

Õàâñðàëò 1

2014 îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàãñààëò

1. Íîì

1.1.Àíãëè õýëýýð

1.2.1. P.Nymadawa [Editor-in-Chief] (2014): Annual Report 2013/2014, US-Mongolia Cooperative Agreement “Developing Sustainable Influenza Surveillance Network” IU51IP000331, Ulaan-

Íýã. Íèéãìèéí ýð¿¿ë ìýíäèéí ñàëáàð

1.1 Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í Ï.Íÿìäàâààãèéí 2014 îíû òàéëàí (Íèéãìèéí ýð¿¿ë ìýíäèéí áîëîí áèî-àíàãààõûí ñàëáàð çºâëºë)

ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍÛ ÀÊÀÄÅÌÈÉÍ ÃÈØ¯¯ÄÈÉÍ

¯ÉË ÀÆÈËËÃÀÀÍÛ ÒÀÉËÀÍ, 2014 ÎÍ


baatar, Admon, Co., Ltd., 256 pp., DDC 616.203 H-987 ISBM 978-99973-0-382-0 http://www.flu.mn/mgl/ index.php?option=com_content&task=view&id=1235&Itemid=51;

1.2.2. P.Nymadawa [Editor-in-Chief] (2014): Final Progress Performance Report 2009/2014, US-Mongolia Cooperative Agreement “Developing Sustainable Influenza Surveillance Network” IU51IP000331, Ulaanbaatar, Admon, Co., Ltd., 20 pp., DDC 614.518 Ny-97 ISBM 978-99973-0-396-7 http://www.flu.mn/mgl/index.php?option=com_content&task=view&id=1236&Itemid=51;

2. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë2.1. Ìîíãîë õýëýýð2.1.1. Ï.Íÿìäàâàà (2014): Åðºíõèé ýðõëýã÷èéí

ìýíä÷èëãýý, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №1(12): 3-4;

2.1.2. Ï.Íÿìäàâàà (2014): Ýïîíèì íýðòîìú¸îíû ó÷èð, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №1(12): 72-73;

2.1.3. Ï.Íÿìäàâàà (2014): Áðóöåëë¸ç áà áðóöåëë, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №1(12): 74-76;

2.1.4. Ï.Íÿìäàâàà (2014): 2013 îíû àíàãààõ óõààí, ôèçèîëîãèéí ñàëáàðûí Íîáåëèéí øàãíàëûã ýñèéí áèîëîãè÷èä àâëàà, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №1(12): 77-78;

2.1.5. Ï.Íÿìäàâàà (2014): Åðºíõèé ýðõëýã÷èéí ìýíä÷èëãýý, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №2(13): 3-4;

2.1.6. Ï.Íÿìäàâàà (2014): ÄÝÌÁ òîìóóãèéí èðýõ óëèðëûí âàêöèíû íàéðëàãûã çàðëàëàà, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №2(13): 38-39;


2.1.8. Ï.Íÿìäàâàà (2014): Óëààíáóðõàí – Äýë-õèéí õºðñíººñ àðèëàõ ýýëæýý õ¿ëýýñýí ºâ÷èí, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №4(57): 47-50;


2.1.10. Ï.Íÿìäàâàà (2014): Òîìóóãèéí òàíäàëòûí òîãòîëöîîíû ÷àäàâõèéã áýõæ¿¿ëýõýýð ÀÍÓ-ûí ªÕÑÒ-òýé õàìòðàí 2005-2014 îíä õýðýã-æ¿¿ëñýí òºñëèéí ¿ð ä¿í, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №5(58): 20-24;

2.1.11. Ï.Íÿìäàâàà (2014): ¯ë ¿çýãäýã÷èéã ìºø-ãºñºí äº÷èí æèë (Àíàãààõûí âèð¿ñ ñóäëàë÷èéí äóðñàìæ), Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîí-ãîëûí ñýòã¿¿ë, №5(57): 100-101;

2.1.12. Ï.Íÿìäàâàà (2014): Åðºíõèé ýðõëýã÷èéí ìýíä÷èëãýý, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîí-ãîëûí ñýòã¿¿ë, №6(59): 4;

2.1.13. Ï.Íÿìäàâàà (2014): Òàðõèíû “ëóóæèí” ñóä-ëàà ÷èä ýíý îíû àíàãààõ óõààí, öèçèîëîãèéí ñàëáàðûí Íîáåëèéí øàãíàë àâëàà, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №6(59): 4;

2.1.14. Ï.Íÿìäàâàà (2014): “Ìîíãîëûí ¿íäýñíèé íýâòýðõèé òîëü” ãýý÷èéí òóõàé, Ìîíãîëûí àíàãààõ óõààí, №2(168): 112-114;

2.1.15. Í.Áàÿñãàëàí, Á.Äàðìàà, Ñ.Öîãòñàéõàí, Ï.Íÿìäàâàà (2014): Õ¿íèé àäåíîâè¿ñò õàëä-âàð (Õýâëýëèéí òîéì), Õàëäâàðò ºâ÷èí ñóä-ëàëûí Ìîíãîëûí ñýòã¿¿ë, №5(58): 31-41;

2.1.16. À.Áóðìàà, Ã.Íÿìàà, Ï.Íÿìäàâàà (2014): “Òîìóóãèéí õÿíàëòûí àñóóäàë-VIII” – Îëîí óëñûí òîìóó ñóäëàà÷äûí ÷óóëãà, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №1(12): 79-80;

2.1.17. Á.Äàðìàà, À.Áóðìàà, Í.Áàÿñãàëàí, Ã.Íÿìàà, Ö.Íàðàíçóë, Á.Ãàíöîîæ, Ï.Íÿìäàâàà (2014): Ìîíãîë óëñàä 2013-2014 îíû òîìóóãèéí óëèðàë äàõü òîìóó, òîìóó-òºñò ºâ÷íèé òàíäàëòûí ä¿í, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №5(58): 5-11;

2.1.18. Ö.Íàðàíçóë, Æ.Ñàðàíòóÿà, Á.Äàðìàà, Ã.Íÿìàà, Í.Áàÿñãàëàí, Ñ.Öàöðàë, Ï.Íÿìäàâàà (2014): 2013-2014 îíä Ìîíãîë óëñàä ÿëãàñàí òîìóóãèéí âèð¿ñèéí ýìýíä òýñâýðæèëòèéã ñóäëàñàí ä¿í, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №5(58): 12-16;

2.1.19. Ã.Íÿìàà, Í.Ôóæè, Õ.Îòîìàðó, ×.Ìàéöýöýã, Á.Äàðìàà, À.Ñóçóêè, Õ.Îøèòàíè, Ï.Íÿìäàâàà (2014): Ìîíãîë óëñàä 2011-2013 îíä ÿëãàñàí àìüñãàëûí çàìûí ñèíöèòèàëü âèð¿ñèéí ãåíåòèê òºðõ, Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë, №3(56): 20-27;

2.2. Àíãëè õýëýýð

2.2.1. A.Burmaa, T.Kamigaki, B.Darmaa, P.Nymadawa, H.Oshitani (2014): Epidemiology and impact of influenza in Mongolia, 2007–2012, Influenza and other respiratory viruses, 8(5): 530-37;

2.2.2. S.G.Muthuri, S.Venkatesan, P.R.Myles, J.Leonardi-Bee, T.S.A.Al Khuwaitir, A.Al Mamun,


A.P.Anovadiya, E.Azziz-Baumgartner, C.Báez, M.Bassetti, B.Beovic, B.Bertisch, I.Bonmarin, R.Booy, V.H.Borja-Aburto, H.Burgmann, B.Cao, J.Carratala, J.T.Denholm, S.R.Dominguez, P.A.D.Duarte, G.Dubnov-Raz, M.Echavarria, S.Fanella, Z.Gao, P.Gérardin, M.Giannella, S.Gubbels, J.Herberg, A.L.Higuera Iglesias, P.H.Hoger, X.Hu, Q.T.Islam, M.F.Jiménez, A.Kandeel, G.Keijzers, H.Khalili, M.Knight, K.Kudo, G.Kusznierz, I.Kuzman, A.Kwan, I.Lahlou Amine, E.Langenegger, K.B.Lankarani, Y-S.Leo, R.Linko, P.Liu, F.Madanat, E.Mayo-Montero, A.McGeer, Z.Memish, G.Metan, A.Mickiene, D.MikiC, K.G.I.Mohn, A.Moradi, P.Nymadawa, M.E.Oliva, M.Ozkan, D.Parekh, M.Paul, F.P.Polack, B.A.Rath, A.H.Rodríguez, E.B.Sarrouf, A.C.Seale, B.Sertogullarindan, M.M.Siqueira, J.Skr�t-Magier�o, F.Stephan, E.Talarek, J.W.Tang, K.K.W.To, A.Torres, S.H.Törün, D.Tran, T.M.Uyeki, A.van Zwol, W.Vaudry, T.Vidmar, R.T.C.Yokota, P.Zarogoulidis, J.S.Nguyen-Van-Tam (2014): Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant dataThe Lancet Respiratory Medicine, 2(5): 395-404;

2.2.3. V.S.Picot, T.Bénet, M.Messaoudi, J-N.Telles, M.Chou, T.Eap, J.Wang, K.Shen, J-W.Pape, V.Rouzier, S.Awasthi, N.Pandey, A.Bavdekar, S.Sanghvi, A.Robinson, B.Contamin, J.Hoffmann, M.Sylla, S.Diallo, P.Nymadawa, B.Dash-Yandag, G.Russomando, W.Basualdo, M.M.Siqueira, P.Barreto, F.Komurian-Pradel, G.Vernet, H.Endtz, P.Vanhems, G.Paranhos-Baccalà (2014): Multicenter case–control study protocol of pneumonia etiology in children: Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL network), BMC Infectious Diseases, 14(1): 635-44;

2.2.4. Z.Xiang, S.Tsatsral,C.Liu, L.Li, L.Ren, Y.Xiao, Z.Xie, H.Zhou, G.Vernet, P.Nymadawa, K.Shen, J.Wang (2014): Respiratory Infection with Enterovirus Genotype C117, China and Mongolia, Emerg. Infect. Dis. 20(6): 1075–77;

2.2.5. B.Yunusbayev, M.Metspalu, E.Metspalu, A.Valeev, S.Litvinov, R.Valiev, V.Akhmetova, E.Balanovska, O.Balanovsky, S.Turdikulova, D.Dalimova, P.Nymadawa, A.Bahmanimehr,

H.Sahakyan, K.Tambets, S.Fedorova, N.Barashkov, I.Khidiatova, E.Mihailov, R.Khusainova, L.Damba, M.Derenko, B.Malyarchuk, L.Osipova, M.Voevoda, L.Yepiskoposyan, T.Kivisild, E.Khusnutdinova, R.Villems (2014): The Genetic Legacy of the Expansion of Turkic-Speaking Nomads Across Eurasia bioRxiv, pp.005850-87;

3. Ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë

3.1. Ìîíãîë õýëýýð

3.1.1. Í.Áàÿñãàëàí, Ö.Íàðàíçóë, ×.Ìàéöýöýã, Ã.Íÿìàà, Á.Äàðìàà, Ñ.Öîãòñàéõàí, Ï.Íÿìäàâàà (2014): Ìîíãîë óëñàä èäýâõèòýé ýðãýëòýíä áàéãàà àäåíîâèð¿ñèéí ãåíåòèê õýâøèíæèéã ñóäëàñàí ä¿í, “Õàëäâàðò ºâ÷íèé òóëãàìäñàí àñóóäàë” Ýðäýì øèíæèëãýý, îíîë ïðàêòèêèéí äîëäóãààð áàãà õóðàë, 2014 îíû 11 ä¿ãýýð ñàðûí 28, Èëòãýëèéí òîâ÷ëîë, “Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë”, №6(59): 25;

3.1.2. Ö.Íàðàíçóë, Æ.Ñàðàíòóÿà, Á.Äàðìàà, Ã.Íÿìàà, Í.Áàÿñãàëàí, Ñ.Öàöðàë, Ï.Íÿìäàâàà (2014): 2013-2014 îíä Ìîíãîë óëñàä ÿëãàñàí òîìóóãèéí âèð¿ñèéí ýìýíä òýñþýðæèëòèéã ñóäëàñàí ä¿í, “Õàëäâàðò ºâ÷íèé òóëãàìäñàí àñóóäàë” Ýðäýì øèíæèëãýý, îíîë ïðàêòèêèéí äîëäóãààð áàãà õóðàë, 2014 îíû 11 ä¿ãýýð ñàðûí 28, Èëòãýëèéí òîâ÷ëîë, “Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë”, №6(59): 25-26;

3.1.3. Â.Íàðàíöýöýã, Ï.¯íýí÷èìýã, Á.Îþóíáèëýã, Ï.Íÿìäàâàà, À.Ñàðàíöýöýã, Ê.À.Àèòîâ (2014): ÄÎÕ-òîé ºâ÷òºíèé íàñ áàðàëòûí çîíõèëîõ øàëòãààí, “Õàëäâàðò ºâ÷íèé òóëãàìäñàí àñóóäàë” Ýðäýì øèíæèëãýý, îíîë ïðàêòèêèéí äîëäóãààð áàãà õóðàë, 2014 îíû 11 ä¿ãýýð ñàðûí 28, Èëòãýëèéí òîâ÷ëîë, “Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë”, №6(59): 23;

3.1.4. Á.Îþóíáèëýã, Ï.¯íýí÷èìýã, Â.Íàðàíöýöýã, Ï.Íÿìäàâàà, À.Ñàðàíöýöýã, Ê.À.Àèòîâ (2014): ÕÄÕÂ/ÄÎÕ áà ñ¿ðüåýãèéí õàâñàðñàí õàëäâàðûí òàðõâàðç¿é, ýìíýëç¿éí îíöëîã, “Õàëäâàðò ºâ÷íèé òóëãàìäñàí àñóóäàë” Ýðäýì øèíæèëãýý, îíîë ïðàêòèêèéí äîëäóãààð áàãà õóðàë, 2014 îíû 11 ä¿ãýýð ñàðûí 28, Èëòãýëèéí òîâ÷ëîë, “Õàëäâàðò ºâ÷èí ñóäëàëûí Ìîíãîëûí ñýòã¿¿ë”, №6(59): 21-22;


2. https://www.researchgate.net/profi le/Pagbajab_Nymadawa accessed on Dec.31, 2014

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Ï.Íÿìäàâààãèéí

2014 îíû òàéëàí

Õàâñðàëò 2

Ýðäýì øèíæèëãýýíèé á¿òýýëèéí ÷àíñàà

1. http://scholar.google.com/citations?hl=en&user accessed on Dec.31, 2014

1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

160

120

80

40

0

Citations per year


Îðîëöñîí ýðäýì øèíæèëãýýíèé õóðëóóä, òàâüñàí èëòãýë áà óíøñàí ëåêö¿¿ä

№ Ëåêö, èëòãýëèéí íýð Îãíîî õààíà óíøñàí

1 Íîòîëãîîíä òóëãóóðëàñàí àíàãààõ óõààí áà ëàáîðàòîðèéí øèíæèëãýý (ëåêö)

2014.01.22 “×èíãèñ” Çî÷èä áóóäëûí òîì òàíõèì, ÝÌØÓÈÑ çîõèîí áàéãóóëñàí “Íîòîëãîîíä òóëãóóðëàñàí àíàãààõ óõààí” ýðäýì øèíæèëãýýíèé áàãà õóðàë

2 Review of China Country Report -2014 (èëòãýë)

2014.03.18-21 WHO WPRO Regional Verification Committee for Measles Elimination Review Meeting , Seoul, Korea

2 Õ¿íèé àìüñãàëûí çàìûí öî÷ìîã õàëäâàð ñýäýýã÷ âèð¿ñ¿¿ä: Äýëõèé äàõèíä áà Ìîíãîëä (ëåêö)

2014.04.11 ÝÌØÓÈÑ-èéí Ñî¸ëûí òºâ,ÝÌØÓÈÑ: Ýðäìèéí ÷óóëãàí

3 Ðîòàâèð¿ñò õàëäâàð (ëåêö) 2014.06.17 ÝÌØÓÈÑ-èéí Ñî¸ëûí òºâ, Ìîíãîëûí Ãàñòðî-ýíòåðîëîãèéí Õîëáîîíû “Õîîë áîëîâñðóóëàõ ýðõòýí ñóäëàëûí äîëîî õîíîã” ÷óóëãàí

4 Óëààíáóðõàí ºâ÷íèé òàõàëò òàðõàëòûã òàñ ëàí çîãñîîñíûã áàòàëãààæóóëàõ ÄÝÌÁ-ûí õýìæ¿¿ð¿¿ä (ëåêö)

2014.06.26-27 “Êîðïîðåéò” çî÷èä áóóäàë, “Óëààí áóðõàíã¿é Ìîíãîë” Äàðõëààæóóëàëòûí ¯íäýñíèé Çºâëºëãººí

5 Ýìíýëç¿éí øààðäëàãûã õàíãàõ ëàáîðà-òîðèéí øèíæèëãýýíèé õºãæëèéí õàíäëàãà (ëåêö)

2014.07.08 “Õàíãàðüä” Îðäîí, ÕªÑ¯Ò, Íèéñëýëèéí Ýð¿¿ë ìýíäèéí ãàçðààñ õàìòðàí çî-õèîí áàéãóóëñàí “Õàëäâàðò ºâ÷íèé îíîø ëîãîîíû ëàáîðàòîðèéí á¿òýö, ¿éë àæèëëàãààã îíîâ÷òîé çîõèîí áàéãóóëàõ” ñýäýâò ÿðèëöëàãà

6 MAMJE and MongolMed (èëòãýë) 2014.08.15-17 Palace of Independence, Ulaanbaatar, Mongolia, APAME Convention-2014

7 Ìèêðîáèîëîãèéí îíîøç¿éí ëàáîðàòîðèéí øèíæèëãýýíèé îð÷èí ¿åèéí õºãæèë, õàíäëàãà (ëåêö)

2014.08.20-21 “Ãÿëñ” Àíàãààõ óõààíû òºâ, “Ëàáîðàòîðèéí îíîøëîãîîíû äýâøèë-6” Ñóðãàëò-ñåìè-íàð

8 Äàðõëààæóóëàëòûí õóóëèéã õýðõýí áî-ëîâñ ðóóëæ, ÓÈÕ-ààð áàòëóóëæ áàéñàí òóõàé (ëåêö)

2014.10.06 “Òóóøèí” çî÷èä áóóäàë, ÓÈÕ, “Ñýáèí Èíñòèòóò õàìòðàí çîõèîí áàéãóóëñàí “Äàðõ ëààæóóëàëòûí õóóëü, ýðõç¿éí îð ÷èí, ñàíõ¿¿æ¿¿ëýëèéí òîãòâîðòîé áàéäàë” ÿðèëöëàãà

9 “Àíàãààõ óõààíû ìîíãîë íýðòîìú¸îã òºëºâø¿¿ëýõ àñóóäàëä (èëòãýë)

2014.10.13-14 ØÓÀ-èéí Õ¿ðýýëýíã¿¿äèéí áàéð, ØÓÀ-èéí Õýë, çîõèîëûí õ¿ðýýëýí çîõèîí áàéãóóëñàí “Ìîíãîë íýðòîìú¸î ñóäëàë – 90” ýðäýì øèíæèëãýýíèé áàãà õóðàë

10 Ìîíãîë óëñ äàõü âèð¿ñò õåïàòèòèéí òàíäàëò, õÿíàëò: ºíãºðñºí, îäîî áà èðýýä¿é (ëåêö)

2014.10.30 ÝÕÝÌÕ¯Ò

11 Òîìóóãèéí òàíäàëòûí òîãòîëöîîíû ÷à äàâ õèéã áýõæ¿¿ëýõýýð ÀÍÓ-ûí ªâ÷íèé õÿíàëò, ñýðãèéëýëòèéí òºâòýé 2004-2014 îíä õàìòðàí õýðýãæ¿¿ëñýí òºñëèéí ¿ð ä¿í (èëòãýë)

2014.11.20-21 “Êîðïîðåéò” Çî÷èä áóóäàë, Òîìóóãèéí ¯íäýñíèé çºâëºëãººí - 7

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Ï.Íÿìäàâààãèéí 2014 îíû òàéëàí

Õàâñðàëò 3


12 Õàëäâàðò ºâ÷íèé ëàáîðàòîðèéí îíîø-ëîãîîíû ºíººãèéí õàíäëàãà, òóëãàìäñàí àñóóäàë, îð÷èí ¿åèéí äýâøèë (ëåêö)

2014.11.27-28 ÝÌß-íû Ñóðãàëò, ìýäýýëëèéí òºâ,ÝÌß çîõèîí áàéãóóëñàí “Ëàáîðàòîðèéí òóñëàìæ, ¿éë÷èëãýýíèé ÷àíàðûã ñàéæ ðóó-ëàõ íü” çºâëºëäºõ óóëçàëò

13 Àêàäåìè÷ Áàçàðûí Äýìáýðýë – Ìîíãîëûí òºð, íèéãìèéí ãàðàìãàé ç¿òãýëòýí (èëòãýë)

2014.12.09 Ñýëýíãý àéìãèéí íýãäñýí ýìíýëãèéí õóðëûí òàíõèì, Ñýëýíãý àéìãèéí Çàñàã äàðãûí òàìãûí ãàçàð çîõèîí áàéãóóëñàí Àêàäåìè÷ Á.Äýìáýðýëèéí 80 íàñíû îéä çîðèóëñàí ýðäýì øèíæèëãýýíèé áàãà õóðàë

14 Molecular Epidemiology of Human Rhinovirus Infection in Mongolia (èëòãýë)

2014.12.14-17 Les Pencieres, Annecy, France,GABRIEL Annual Meeting 7


2014 îíû 12 äóãààð ñàðûí 23

1. Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä îðîëöñîí òóõàé

2013 îíû òàéëàíã áè÷èæ ÷óóëãàíààð õýëýëö¿¿ëýâ.

2014 îíû ¿éë àæèëëàãààíû òºëºâëºãºº áîëîâñðóóëàí áàòëóóëæ, õýðýãæ¿¿ëýõ àæëûã çîõèîí áàéãóóëàâ.

2014 îíä ÌÀÓÀ-èéí èõ ÷óóëãàíû 5, Èõ ÷óóëãàíààð õýëýëöñýí 6 àñóóäëààð èëòãýë, òàíèëöóóëãà áîëîâñðóóëàí õýëýëö¿¿ëëýý. Èõ ÷óóëãàí, òýðã¿¿ëýã÷äèéí õóðëûí òýìäýãëýë õºòºëæ àðõèâò øèëæ¿¿ëëýý.

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí á¿ðýí æàãñààëò: Íèéò 12, ¿¿íä: íîì 2, ýðäýì øèíæèëãýýíèé ºã¿¿ëýë 6, ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë 3, õàíûí èëòãýë 1 (Õàâñðàëò 1);

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýëèéí íýð, òîâ÷ëîë, õýâëýãäñýí áîë ò¿¿íèé èøëýë: ãàäààäûí õóðàëä îðîëöñîí 1, äîòîîäûí õóðàë, çºâëºëãººíä îðîëöñîí 16, çîõèîí áàéãóóëñàí 3 (Õàâñðàëò 2);

4. Óäèðäàæ, çºâëºæ õàìãààëóóëñàí ñóäëàà÷èä: Óäèðäàæ õàìãààëóóëñàí àíàãààõ óõààíû äîêòîð 1 (Á.È÷èíõîðëîî. Õ¿í áà îð÷èíä ìºíãºí óñíû áîõèðäëûí ¿ç¿¿ëýõ íºëºº, ÀÓÄ çýðýã ãîðèëñîí á¿òýýë, 2014), óäèðäàæ áóé 3

5. Àëáàí ¸ñíû ø¿¿ìæ õèéñýí 1: Ã.Îòãîí, “Ýêîëîãèéí ÿíç á¿ðèéí á¿ñèéí õ¿¿õäèéí áèå áÿëäðûí ºñºëò, ôèçèîëîãèéí çàðèì ¿ç¿¿ëýëò” ñýäýâò àíàãààõûí øèíæëýõ óõààíû äîêòîðûí çýðýã ãîðèëñîí á¿òýýëèéí ø¿¿ìæ, 2014

6. Óäèðäñàí ñóäàëãàà:

• Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ñóäàëãààíû ºíººãèéí ò¿âøèí, òºñëèéí óäèðäàã÷, ÄÝÌÁ, 2014, 52õ

• Ïåðèíàòàë ýíäýãäëèéí òàðõàëò, øàëòãààí, íºëººëºõ õ¿÷èí ç¿éëèéí ñóäàëãàà, 2014-2016

7. Çºâëºõººð àæèëëàñàí ñóäàëãàà:

• Óñ õàíãàìæèéí àþóëã¿é áàéäàë, ãàäàðãûí óñíû õèìè áèîëîãèéí áîõèðäîëòûí ò¿âøèí, õ¿í

àìûí ýð¿¿ë ìýíäýä ¿ç¿¿ëýõ íºëºº 2012-2014

• Ìîíãîë óëñûí 1-10 íàñíû õ¿¿õäèéí õàð òóãàëãà, çýñ, öàéðûí õîðäëîãûí ñóäàëãàà èííîâàöèéí òºñºë 2013-2016

8. Áîëîâñðóóëñàí óäèðäàìæ, æóðàì: 3• ¯ð õºâðºëèéí ñóäàëãààíû ¸ñç¿éí óäèðäàìæ,

Ýð¿¿ë ìýíäèéí ñàéäûí òóøààë, 2014 îí, Äóãààð 29

• ¯¿äýë ýñèéí ñóäàëãààíû ¸ñç¿éí óäèðäàìæ, Ýð¿¿ë ìýíäèéí ñàéäûí òóøààë, 2014 îí, Äóãààð 29

• “Ýì÷èëãýýíèé çîðèóëàëòààð øèíýýð ãàð÷ áàéãàà áîëîí íàíîòåõíîëîãèéí á¿òýýãäýõ¿¿íèé ñóäàëãàà ÿâóóëàõ, ïðàêòèêò íýâòð¿¿ëýõ ¿éë àæèëëàãààã çîõèöóóëàõ æóðàì”, Ýð¿¿ë ìýíäèéí ñàéäûí òóøààë, 2014, Äóãààð 165

9. APAME 2014 âåá õóóäàñ íýýæ àæèëëóóëàâ.

10. Áóñàä: Ìîíãîëûí àíàãààõ óõààíû ñýòã¿¿ë¿¿-äèéí ìýäýýíèé ñàí “Ìîíãîëìåä”-èéã áàÿ-æóóëæ 4000 ãàðóé ìýäýýëëèéã îðóóëàâ.

11. Õàâäàð ñóäëàëûí ñóäàëãààíû õºòºëáºðèéí òºñëèéã áîëîâñðóóëàõ àæëûã çîõèîí áàéãóóëæ, ØÓÒÑ-ä òàíèëöóóëàõààð õ¿ðã¿¿ëýâ (2014-10 ñàð).

12. Îþóíëàã ýìýãòýé÷¿¿äèéí 2 äóãààð ÷óóëãàíä àíàãààõûí ñàëáàðààñ òºëººëºë îðîëöóóëàõ àæëûã çîõèîí áàéãóóëëàà.

13. Õîâä àéìàãò “Áàðóóí á¿ñèéí ïåðèíàòàëü òóñëàìæèéí òóëãàìäñàí àñóóäàë” ñýäâýýð ñóðãàëò, ñåìèíàð çîõèîí áàéãóóëæ, ýíý ÷èã-ëýëýýð õèéñýí àæëûí òóõàé ìýäýýëëèéã ÝÌß-íû âåá õóóäñààð ñóðòàë÷ëàâ. Ïåðèíàòàë ýíäýãïëèéí òàðõàëò, íºëººëºõ õ¿÷èí ç¿éëèéí ñóäàëãààíû ñàíàë áîëîâñðóóëæ, ÄÝÌÁ-ä òàíèäöóóëæ, äýìæ¿¿ëæ, ñóäàëãààíû àðãàç¿éã áîëîâñðóóëæ, ýðäìèéí çºâëºë, àíàãààõ óõààíû ¸ñç¿éí õîðîîãîîð õýëýëö¿¿ëæ, ñóäàë-ãààã ýõë¿¿ëëýý.

Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð Á.Áóðìààæàâ

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í,

Åðºíõèé ýðäýìòýí íàðèéí áè÷ãèéí äàðãà, Àíàãààõûí Øèíæëýõ Óõààíû äîêòîð,

ïðîôåññîð Á.Áóðìààæàâûí 2014 îíû àæëûí òàéëàí


Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Á.Áóðìààæàâûí

2012 îíû àæëûí òàéëàí

Õàâñðàëò 1

2011 ÎÍÄ ÁÈ×ÈÆ ÍÈÉÒË¯¯ËÑÝÍ Á¯ÒÝÝËÈÉÍ ÆÀÃÑÀÀËÒ

1. ÍÎÌ

1.1. Ìîíãîë õýëýýð:

ää Á¿òýýëèéí çîõèîã÷, íýð

1. Ìîíãîëûí àíàãààõûí îþóòíû ýðäìèéí ÷óóëãàíû èëòãýëèéí õóðààíãóé, 978-99973-63-28-2, 2014, 127õ, 7,9õõ

2. Àíàãààõ óõààíû ¸ñç¿éí óäèðäàìæ, 2014, 98õ, 8,2õõ

2. Ýðäýí øèíæèëãýýíèé ºã¿¿ëýë

ää Á¿òýýëèéí çîõèîã÷, íýð

Ãàäààäàä

1. A.Enkhjargal, B.Burmaajav, B.SuvdHealth Impact assessment of ambient air pm10 and 2.5 on acute and chronic RCD and CVD in UlaanbaatarMongolian Journal of Health Sciencec, 2014, Vol. 11, Issue 1, p.49-52

2. B.Suvd, B.Burmaajav, Sh.Myagmarjav, U.Oyunchimeg, S.Lkhamsuren.Prevalence of skin lesions of newborns: a cross-sectional observational study in Mongolia. Mongolian Journal of Health Sciencec, 2014, Vol. 11, Issue 1, p.80-83

3. Amarzaya Jadambaa, Jeffery Spickett, Burmaajav Badrakh, Rosana E. NormanThe Impact of the Environment on Health in Mongolia A Systematic ReviewAsia and Pacific Journal of Public Health, 2014, August 10

Äîòîîäîä

4. Á.Ñóâä, Á.Áóðìààæàâ10 õ¿ðòýëõ íàñíû õ¿¿õäèéí äóíäàõ ìîíãîë õºõ òîëáîíû òàðõàëò, Ìîíãîë óëñ, 2014 îíÌîíãîëûí àíàãààõ óõààí ñýòã¿¿ë, 2014, 2, õ.25-28

5. Ö.Ñîëîíãî, Ç.Ãýðýëìàà, Á.ÁóðìààæàâÌîíãîë óëñûí áàðóóí á¿ñèéí ïåðèíàòàëü ýíäýãäëèéí ºíººãèéí ò¿âøèíÌîíãîëûí àíàãààõ óõààí ñýòã¿¿ë, 2014, 2, õ.49-42

6. Ì.Ï¿ðýâæàâ, Ç.Àðèóíàà, Î.×èìýäñ¿ðýí, Ä.Öýíä-Àþóø, Á.ÁóðìààæàâÌîíãîëûí óëàìæëàëò àíàãààõ óõààíû ñóäàëãààíû çàðèì àñóóäàëÌîíãîëûí àíàãààõ óõààí ñýòã¿¿ë, 2014, 2, õ.61-66



Ää Çîõèîã÷, á¿òýýëèéí íýð1. È÷èíõîðëîî Á, Çîëæàðãàë Í, Ò¿ìýíæàðãàë Ä, Áóðìààæàâ Á, Ñàðàíòóÿà Æ. Õ¿ðýýëýí áóé îð÷íû

õºðñíèé áàêòåðò ìºíãºí óñíû áîõèðäëûí íºëººëëèéã ñóäàëñàí ä¿í. Áèî-àíàãààõûí ñàëáàðûí ýðäìèéí ÷óóëãàí-56 èëòãýëèéí õóðààíãóé, 2014, õ,64-65

2. Ö.Ñîëîíãî, Ç.Ãýðýëìàà, Á.Áóðìààæàâ Íÿðàéí íýí øààðäëàãàòàé òóñëàìæèéí ÷àíàðûã ñóäàëñàí çàðèì ¿ð ä¿íÌîíãîëûí àíàãààõûí îþóòíû ýðäìèéí ÷óóëãàíû èëòãýëèéí õóðààíãóé, 978-99973-63-28-2, 2014, õ.11-12


6.2. Ãàäààä õýëýýð

3. Öýãìýä Ñ., Áóðìààæàâ Á., Áîëîðìàà, È., Îþóí-Ýðäýíý Î, Íÿìñ¿ðýí Ë., Õîíãîðçóë Á., Õèøèãò Æ., Áàòäýëãýð Ø.Êèøå÷íàÿ èíôåêöèÿ è îáåñïå÷åííîñòü ïèòüåâîé âîäû â íàñåëåíèÿÂñåðîññèéñêîé êîíôåðåíöèè «Îáùèå çàêîíîìåðíîñòè ôîðìèðîâàíèÿ ïðîôåññèîíàëüíûõ è ýêîëîãè÷åñêè îáóñëîâëåííûõ çàáîëåâàíèé: ïàòîãåíåç, äèàãíîñòèêà, ïðîôèëàêòèêà», Ã.Èðêóòñê, Ðîññèéñêàÿ Ôåäåðàöèÿ, Îêòÿáðü, Ìàòåðèàëû âñåðîññèéêîé êîíôåðåíöèè, 2014, Ñ.134-136

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Á.Áóðìààæàâûí


Õàâñðàëò 2

Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë

ää Õóðëûí íýð, îãíîî Îðîëöîî

1. Ìîíãîëûí àíàãààõûí ñýòã¿¿ë ç¿éí àíõíû ñèìïîçèóì Àíàãààõ óõààíû ñýòã¿¿ëç¿éí õºãæèë ñýäâýýð èëòãýë õýëýëö¿¿ëýâ

2. ØÓÀ, ¯íäýñíèé àðä÷èëñàí íàìààñ çîõèîí áàéãóóëñàí ¿íäýñíèé ¿çëèéí òàëààðõ õýëýëö¿¿ëýã

îðîëöîæ “Ìîíãîë õºõ òîëáûí òàðõàëòûí ñóäàëãààíû” ä¿íãýýñ òîâ÷ ìýäýýëýë õèéâ

3. “Õ¿ðýýëýí áóé îð÷èí-ýð¿¿ë ìýíä” ñåìèíàð, 2014-6 “Óóð àìüñãàëûí ººð÷ëºëò-ýð¿¿ë ìýíä” ñýäâýýð èëòãýë õýëýëö¿¿ëýâ

4. Íîòîëãîîíä òóëãóóðëàñàí àíàãààõ óõààí ÓÍÒÝ-èéí ýðäýì øèíæèëãýýíèé õóðàë

Ñàíàë, çºâëºãºº ºãºâ

5. ÓÕÒÝ-èéí 2014 îíû ýðäýì øèíæèëãýýíèé õóðàë Ñàíàë, çºâëºãºº ºãºâ

6. Àíàãààõ óõààíû á¿òýýë áè÷èõ àðãàç¿éí îëîí óëñûí ñóðãàëò, 2014-8-13-14

Çîõèîí áàéãóóëëàà

7. Àçè, íîìõîí äàëàéí áàðóóí á¿ñèéí ñýòã¿¿ë¿¿äèéí õîëáîîíû ÷óóëãàí, 2014, 8-ñàðûí 15-17

Çîõèîí áàéãóóëñàí“MAMJE and MonmgolMed” ñýäâýýð èëòãýë õàìòðàí õýëýëö¿¿ëñýí.

8. ÕÑ¯Ò-èéí Ýðäýì øèíæèëãýýíèé áàãà õóðàë Îðîëöîâ

9. Õ¿íèéã îðîëöóóëñàí ñóäàëãààíä õ¿íèéã õàìãààëàõ ¸ñç¿é, Óëààíáààòàð õîò, ÝÌß, ÕªÑ¯Ò, Òàéëàíä äàõü ÀÍÓ-ûí Öýðãèéí àíàãààõ óõààíû õ¿ðýýëýí, FERCAP õàìòðàí çîõèîí áàéãóóëñàí, 2014, 9 ñàðûí 22-24

Õàìòðàí çîõèîí áàéãóóëñàí“Ìîíîë äàõü àíàãààõ óõààíû ¸ñç¿éí òîãòîëöîî” ñýäâýýð èëòãýë õýëýëö¿¿ëëýý

10. Ñóäàëãàà, áîëîâñðóóëàëò, èííîâàöèéí ¿éë àæèëëàãààíû ñòàòèñòèêèéí ìýäýýëýë áîëîâñðóóëàõ, òàéëàãíàõ ÷èãëýëýýð ÁØÓß-ààñ çîõèîí áàéãóóëñàí ñóðãàëò /2014-10-16/.

îðîëöîâ

11. Óóð àìüñãàëûí ººð÷ëºëò, ýð¿¿ë ìýíäýä ¿ç¿¿ëýõ íºëººëºë, äàñàí çîõèöîõ áîëîìæóóä 5 äóãààð õóðàë

Óóð àìüñãàëûí ººð÷ëºëò, óíäíû óñíû ÷àíàð, àþóëã¿é áàéäàëä ¿ç¿¿ëýë íºëºº, äàñàí çîõèöîõ ÷àäàâõèéí ¿íýëãýý ñýäâýýð èëòãýë áýëòãýæ õýëýëö¿¿ëëýý.

12. ÁØÓß-íû çàõèàëãààð õýðýãæ¿¿ëæ áóé Øèíæëýõ óõààíû 108 áîòü áè÷èõ ¿éë àæèëëàãààíû õ¿ðýýíä áè÷èæ äóóññàí 18 áîòèéí çîõèîã÷äîä òàëàðõàë èëýðõèéëýõ ¸ñëîë

Îðîëöîâ.

13. Ýõ õ¿¿õäèéí ýð¿¿ë ìýíäèéí òóëãàìäñàí àñóóäëóóä ñýäâýýð çîõèîí áàéãóóëñàí ýðäýì øèíæèëãýýíèé õóðàë, ÝÕÝÌ¯Ò- 2014-11-21

Íîòîëãîîíä òóëãóóðëàñàí àíàãààõ óõààí ñýäâýýð ëåêö óíøèâ


14. Íýðò ñî¸í ãýãýýð¿¿ëýã÷ Îíõîäûí Æàìúÿí ã¿íèé ìýíäýëñíèé 150 æèëèéí îéä çîðèóëñàí ýðäýì øèíæèëãýýíèé õóðàë2014-11 ñàðûí 24

Aíàãààõûí ñàëáàðûí õ¿ðýýëýí, òºâ¿¿äèéí òºëººëëèéã îðîëöóóëæ, ººðºº îðîëöîâ

15. Íèéñëýëèéí àãààðûí áîõèðäëûã áóóðóóëàõ àðãà çàì, áîëîìæóóä ýðäýì øèíæèëãýýíèé õóðàëä îðîëöîæ, 11 ñàðûí 27

“Àãààðûí áîõèðäîë, íèéãìèéí ýð¿¿ë ìýíäèéí òóëãàìäñàí àñóóäëóóä” ñýäâýýð èëòãýë õýëýëö¿¿ëëýý.

16. Øèíæëýõ óõààí, òåõíîëîãè, èííîâàöèéí ¿éë àæèëëàãààíû îëîí òàëò îðîëöîî ñýäýâò ÷óóëãà óóëçàëòàä ñàëáàðûí õàìò îëíûã çîõèîí áàéãóóëæ îðîëöîâ 11 ñàðûí 26-27

Ñàëáàðûí áàéãóóëëàãóóäûã çîõèîí áàéãóóëæ îðîëöóóëàâ

17. Øèíæëýõ óõààíû àæèëòíû áàÿðûí ¿éë àæèëëàãààíû õ¿ðýýíä Ìîíãîëûí øèíæëýõ óõààíû 2014 îíä ñýäýâò ¿çýñãýëýíä ñàëáàðûí õàìò îëíûã õàðèóöàæ îðîëöóóëëàà. 11 ñàðûí 28-29

Ñàëáàðûí áàéãóóëëàãóóäûã çîõèîí áàéãóóëæ îðîëöóóëàâ

18. Ìîíãîëûí Àíàãààõûí îþóòíû ýðäìèéí 3 äóãààð ÷óóëãàí, 2014-12-04

Çîõèîí áàéãóóëñàí

2. Áóñàä îðîíä

ää Õóðëûí íýð, îãíîî Îðîëöîî

1. Âñåðîññèéñêîé êîíôåðåíöèè «Îáùèå çàêîíîìåðíîñòè ôîðìèðîâàíèÿ ïðîôåññèîíàëüíûõ è ýêîëîãè÷åñêè îáóñëîâëåííûõ çàáîëåâàíèé: ïàòîãåíåç, äèàãíîñòèêà, ïðîôèëàêòèêà», Ã.Èðêóòñê, Ðîññèéñêàÿ Ôåäåðàöèÿ, Îêòÿáðü

Ä.Îòãîíáàÿð, Á.Áóðìààæàâ, Æ.Êóïóë. “Ãèãèåíè÷åñêàÿ îöåíêà äåòñêèõ èãðóøåê” è Öýãìýä Ñ., Áóðìààæàâ Á., Áîëîðìàà, È., Îþóí-Ýðäýíý Î, Íÿìñ¿ðýí Ë., Õîíãîðçóë Á., Õèøèãò Æ., Áàòäýëãýð Ø. “Êèøå÷íàÿ èíôåêöèÿ è îáåñïå÷åííîñòü ïèòüåâîé âîäû â íàñåëåíèÿ


Íýã.

- ÀÓÕ-èéí ýðäìèéí çºâëºëèéí äýä äàðãààð àæèëëàæ, òàâàí õóðëûã óäèðäàí 8 àñóóäàë øèéäâýðëýñýí.

- ÌÀÓÀ-ûí õóðàëä 60%-èéí èðöòýé îðîëöîæ 3 óäàà ¿ã õýëæ, ñàíàë ãàðãàñàí.

Õî¸ð. Á¿òýýë

1. Ìîíãîëûí ýð¿¿ëèéã õàìãààëàõ (ñóðàõ áè÷èã íîìîî áàÿæóóëàí òàâàí á¿ëýã íýìæ, õýâë¿¿ëñýí 2013-2014 îí)

2. ØÓÀ-èéí õýë çîõèîëûí õ¿ðýýëýíãèéí XXXV áîòü, äýâòýð 1-12 Àìàí çîõèîë ñóäëàë, ÓÁ 2014

“Øèíæààí Óéãàðûí òîðãóóä àðäûí äóóíû ºâ” Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë õýâë¿¿ëñýí (õóóäàñ 152-159)

3. ÁÍÕÀÓ-ûí ØÓªÇÎ-íû Õîâîã ñàéð àéìàãò õóðàëäñàí Æàíãàð ñóäëàëûí îëîí óëñûí

õóðàëä “Òîðãóóäûí èõ, áàãà í¿¿äýë, òîðãóóä ñóäëàë” èëòãýë õýëýëö¿¿ëñýí, 2014 îí VII ñàð

4. Äîðíî, ºðíº ýòãýýäýä çîð÷ñîí òýìäýãëýë (íîì, 2013-2014)

Ãóðàâ. Ñóðãàëò, ñóäàëãàà

- Ìîíãîëûí õ¿í àìûí äóíäàõ “Õàëäâàðò áóñ àðõàã ºâ÷íèé òàðõàëò”-ààð ñóäàëãàà õèéæ ä¿ãíýëò ãàðãàñàí

- Àñïèðàíò ×óëóóíààãèéí äîêòîðûí àæèëä ä¿ãíýëò õèéæ ø¿¿ìæ áè÷ñýí

- “À÷” ÀÓÄýÑóðãóóëüä “Îð÷èí ¿å áà ýì÷èéí ¸ñ ç¿é” õè÷ýýë çààæ áàéíà

- ªäðèéí ñîíèí, “Open door” ñîíèíä “Êàïèòàëèñò ìîíãîëûí ñîöèàëèñò ýð¿¿ë ìýíä”, “Ýð¿¿ë ìýíä ýð¿¿ë áàéíà óó” øèíæëýõ óõààíû íèéòëýëèéí ºã¿¿ëýë áè÷èæ õýâë¿¿ëñýí.

Ïðîôåññîð Ö.Ìóõàð

2015.01.22

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í

Ö.Ìóõàðûí 2014 îíû àæëûí òàéëàí


1. Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèë-ëàãààíä îðîëöñîí òóõàé

ÌÀÓÀ-èéí 2013 îíû ÷óóëãàíóóäàä òîãòìîë îðîëöîæ èðñýí áà çàðèì ÷óóëãàí äýýð àñóóëò òàâüæ, ñàíàëàà õýëæ áàéñàí. Òóñ àêàäåìèéí Íèéãìèéí ýð¿¿ë ìýíäèéí ñàëáàðààñ çîõèîí áàéãóóëñàí òºëºâëºãººò àæèë, àðãà õýìæýýíä îðîëöîæ èðñýí.

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàã ñààëò

2014 îíä äàðààõü á¿òýýë òóóðâèæ, õýâëýí íèéòë¿¿ëñýí. ¯¿íä:

1. Îðãèë Á. Ýìíýëç¿éí ýì ñóäëàë áà ýìýí ýì÷èë-ãýý. Ðåäàêòîð Á.Öýðýíäàø. ÓÁ., 2014, 594 õ.

2. Áàëãàíæàâ Á., Îðãèë Á. Íàðò õîðâîîãèéí äºð-âºí ç¿ã, íàéìàí çîâõèñò. ÓÁ., 2014, 236 õ.

Áè÷èæ, íèéòë¿¿ëñýí ºã¿¿ëëýã¿¿ä

1. Ãýðýýð ¿ç¿¿ëýõ ñóâèëàõóéí òóñëàìæèéí õºãæ-ëèéí ò¿¿õ (Ä.Ñîëîíãî, Ñ.Íàðàí÷èìýã íàðûí õàìò). ªðõèéí àíàãààõ óõààí, 2014, № 1(31), 56-61 äýõ òàë

2. ªðõèéí ýð¿¿ë ìýíäèéí òºâ¿¿äèéí ¿éë àæèëëàãààã øèíý øàòàíä ãàðãàöãààÿ. ªðõèéí àíàãààõ óõààí, 2014, № 2(32), 4-8 äàõü òàë

3. Àíàãààõûí òºãñºëòèéí ºìíºõ ñóðãàëòûí ÷àíàð, ¿ð íºëººã äýýøë¿¿ëýõ àñóóäàëä

(“À×” ÀÓÄÑóðãóóëèéí ñóðãàìæ, æèøýýí äýýð). Àíàãààõ óõààíû áîëîâñðîë ñýòã¿¿ëä íèéòë¿¿ëýõýýð ºãñºí

3. Áóñäûí ýðäýì øèíæèëãýýíèé á¿òýýëä ø¿¿ìæ õèéñýí áàéäàë

2014 îíä äàðààõü á¿òýýë¿¿äýä ø¿¿ìæ õèéñýí áîëíî:

1. Àíàãààõ óõààíû äîêòîðûí (Ph.D) çýðýã ãîðèëæ, Ñàíäàãæàâ îâîãòîé Áîëîðìààãèéí òóóðèâñàí “Óëààíáààòàð õîòûí íàñàíä õ¿ðñýí õ¿í àìä

¿ç¿¿ëýõ ç¿ðõ ñóäàñíû ºâ÷íèé òóñëàìæèéã áîëîâñðîíãóé áîëãîõ íü” ñýäýâò á¿òýýëèéí ýöñèéí õàìãààëàëò äýýð õèéñýí ø¿¿ìæ. 2014 îíû 6-ð ñàð.

2. Àíàãààõ óõààíû áîëîâñðîëûí äîêòîð Ã.Îòãîíîîñ àíàãààõûí øèíæëýõ óõààíû äîêòîðûí çýðýã ãîðèëîõîîð òóóðèâñàí “Ìîíãîëûí ýêîëîãèéí ÿíç á¿ðèéí á¿ñèéí õ¿¿õäèéí áèå áÿëäðûí õºãæèë áà ôèçèîëîãèéí çàðèì ¿ç¿¿ëýëò¿¿ä” á¿òýýëèéí ýöñèéí õàìãààëàëò äýýð õèéñýí ø¿¿ìæ. 2014 îíû 7-ð ñàð.

4. Ñàíàà÷èëãààðàà õèéæ ã¿éöýòãýñýí àæèë:

ÝÌÑàéäûí øèéäâýðýýð ßàìíû äýðãýäýõ ìýðãýæëèéí 2 ñàëáàð çºâëºë (Íèéãìèéí ýð¿¿ë ìýíäèéí áà ÝÌÀØÒ-èéí)-èéí á¿ðýëäýõ¿¿íä îðæ àæèëëàí, òóõàéí ¿åä òàâèãäñàí àñóóäëóóäûí õ¿ðýýíä òºñºë áîëîâñðóóëàõ, õýëýëöýõ, ñàíàë ºãºõ çýðýãò îðîëöîæ èðëýý. Ìºí ñóì, ºðõèéí èõ, áàãà ýì÷ íàðûí çýðãèéí øàëãàëò àâàõ ¿éë àæèëëàãààíä áèå÷ëýí îðîëöñîí áîëíî.

Ìºí äàðààõü íîìûí ðåäàêòîðîîð àæèëëàñàí:

1) Àíõàí øàòíû òóñëàìæèéí ìýðãýæèëòýíä ìýðãýæëèéí çýðýã îëãîõ øàëãàëòûí ãàðûí àâëàãà. Øèíý÷ëýí ýìõýòãýñýí 3 äàõü õýâëýë. ÝÌß, Àíõàí øàòíû òóñëàìæèéí ìýðãýæëèéí ñàëáàð çºâëºë, Ìîíãîëûí ºðõèéí àíàãààõ óõààíû ìýðãýæèëòí¿¿äèéí õîëáîî. ÓÁ., 2014, 536 õ.

2) Ã¿íäýãìàà Ö, Áàÿðöýöýã Ö. Ýìèéí æîðûí ëàâëàõ. 2 äàõü õýâëýë. ÓÁ., 2014, 179 õ.

3) Õîîë áîëîâñðóóëàõ ýðõòýíèé ýìãýã ñóäëàë. Îðîñ õýëíýýñ îð÷óóëñàí Ò.Ñîëîíãî. ÓÁ., 2014, 272 õ

Òîâ÷ òàéëàí áýëòãýñýí Á.Îðãèë

2015-01-16


Á.Îðãèëûí 2014 îíû àæëûí òàéëàí


2015 îíû 1-ð ñàðûí 22

1. ÌÀÓÀ-èéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä îðîëöñîí òóõàé

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàãñààëò

Íîì, ñóðàõ áè÷èã

Çîõèîã÷îîð:

- “Õ¿¿õäèéí ºâ÷èí” ñóðàõ áè÷èã 3 äàõü õýâëýë

Õÿíàí òîõèîëäóóëñàí

- ªðõèéí àíàãààõ óõààíû ñóðàõ áè÷èã. õõ 23. Îð÷óóëãûã õÿíàí òîõèîëäóóëàâ

- Øèíæëýõ óõààíû á¿òýýë áè÷èõ îëîí óëñûí ÷èã õàíäëàãà. õõ 15

- Îðøèõóéí çàÿàã äýýäëýõ¿é. õõ 12.75

ªã¿¿ëýë:

- Äàÿàð ýð¿¿ë ìýíä. ªðõèéí àíàãààõ óõààí 2014 № 1(31)4-6

- Some issues of professional cares on the cardiovascular diseases among the urban adults. Mongolian Journal of Health Sciences. Vol 11., Issue 1. April 2014 p 115-116

- ªðñºëäººíººñ õàìòûí àæèëëàãààíä. Innovation, Vol 8, No 3, 07 ñàð, 68-70

- Assessment of changes in health care needs. World Hospitals and Health Services. Vol 50, No 1, 27-31

Èëòãýë- Àíàãààõ óõààíû àÿëàë æóóë÷ëàëûí ºíººãèéí

áàéäàë. “Ìîíãîë óëñ äàõü ýð¿¿ë ìýíäèéí àÿ-ëàë æóóë÷ëàë” çºâëºëäºõ óóëçàëò. ÀØÓ¯ÈÑ. 2014 îíû 3-ð ñàðûí 21

- Higher and Medical Education System in Mongolia. Mongolia-Japan medical forum. Ulaanbaatar. September 2014.

3. Óäèðäàæ õàìãààëóóëñàí ñóäëàà÷èä

- Ñ.Áîëîðìàà. Óëààíáààòàð õîòûí íàñàíä õ¿ðñýí õ¿í àìä ¿ç¿¿ëýõ ç¿ðõ ñóäàñíû ºâ÷íèé òóñëàìæèéã áîëîâñðîíãóé áîëãîõ íü. ÀÓ-û äîêòîðûí çýðãèéã 2014 îíû 6-ð ñàðûí 5-íä õàìãààëñàí

4. Àëáàí ¸ñíû ø¿¿ìæ

- Ë.Æàâçìàà. Àðõàã ãëîìåðóëîíåôðèòèéí íàìæ-ìàë ¿åä Áèãýðèéí ýëñýí ñóâèëëûí ¿ð ä¿í. ÀÓ-íû áîëîâñðîëûí äîêòîðûí (Ph.D) çýðýã ãîðèëñîí íýã ñýäýâò á¿òýýëèéí àëáàí ¸ñíû ø¿¿ìæèéã 2014 îíû 6-ð ñàðûí 3-íä õèéâ.

5. Çºâëºõººð àæèëëàñàí áàéäàë

- Ýð¿¿ë ìýíäèéí àæèëòíû öàëèí õºëñíèé òîã-òîëöîî, àæëûí à÷ààëàë, õºäºëìºðèéí íîðì òîãòîîõ ñóäàëãàà

Àíàãààõ óõààíû äîêòîð, ïðîôåññîð Í.Ñ¿ìáýðçóë


Í.Ñ¿ìáýðçóëûí 2014 îíû àæëûí òàéëàí


Íýã. Ñóðãàëò

Øèíýýð áîëîâñðóóëñàí ñòàíäàðò õºòºëáºð¿¿ä:

- Áàêàëàðâûí ñóðãàëòàíä “Õ¿¿õýä ºñâºð ¿åèéí ýð¿¿ë ìýíä, ýð¿¿ë àõóé” ÍÝÌ IV, V êóðñ

- Ìàãèñòðûí ñîíãîíû õè÷ýýë “Ýõ õ¿¿õäèéí ýð¿¿ë ìýíä”

1. Øèíýýð òºãñºëòèéí ãàðäàí øàëãàëòûí 10 ñîðèë

2. Íîì ñóðàõ áè÷èã ãàðûí àâëàãà:

- “Óðüä÷èëàí ñýðãèéëýõ àíàãààõ óõààí” õè÷ýý-ëèéí õàìòàðñàí ãàðûí àâëàãà

- “Õ¿¿õýä, ºñâºð ¿åèéí ýð¿¿ë ìýíä, ýð¿¿ë àõóé” õè÷ýýëèéí ãàðûí àâëàãà

Õî¸ð. Ýðäýì øèíæèëãýý

Ñýòã¿¿ëä: 1 ä¿ãýýð çîõèîã÷

- ÝÌØÓÈÑ- ñýòã¿¿ä 1

- Ýðèí- ñýòã¿¿ëä 1

Äîòîîäîä: èëòãýë – 1 çîõèîã÷ “Õàâäðûí ýì÷ íàðûí àæëûí à÷ààëàëûí ¿íýëãýý” ÍÝÌÑ, Ýðäìèéí ÷óóëãàí-57.

Ñóäàëãààíû òàéëàí:

- Ýì÷, ýìíýëãèéí àæèëòíû öàëèí õºëñ àæëûí íîðì íîðìàòèâûí ñóäàëãàà

Ñóäàëãààíû áàãò:

- Ýì÷, ýìíýëãèéí àæèëòíû öàëèí õºëñ àæëûí íîðì íîðìàòèâûí ñóäàëãàà

- Áè÷èë óóðõàéä àæèëëàãñàäûí ýð¿¿ë ìýíäèéí ýðñäýëèéí ¿íýëãýý

Ìàãèñòð óäèðäñàí: 1

Ä.Õèøèãòîãòîõ – Õ¿¿õäèéí õîîë òýæýýë, ºñºë-òºíä íºëººëºõ íü

Äîêòîðûí àæèëä ýêñïåðòèéí àõëàã÷:

Ä.Îþóíöýöýã – Àíàãààõûí áîëîâñðîë îëãîõ ñóðãàë-òàíä ìàãàäëàí èòãýìæëýëèéí ¿ç¿¿ëýõ íºëººëºë

Çîõèîñîí õóðàë:

Àíàãààõûí áàãø ×.×¿ëòýìäîðæ àãñíû íýðýìæèò ÝØÁ õóðàë çîõèîí áàéãóóëëàõàä (2,5 ñàÿ) ñàíõ¿¿æèëòàä îðîëöñîí.

Ñýòã¿¿ëèéí ðåäàêöèä:

“Ýð¿¿ë ìýíäèéí øèíæëýõ óõààí”

- “ÍÝÌ-Ýðèí”

Ìýðãýæëèéí “ÍÝÌ”-èéí çºâëºëä ãèø¿¿í

ÝÌß-ààñ áàòàëñàí 2 àæëûí õýñýãò àæèë ëàñàí.

“Í¿õýí æîðëîí” ñòàíäàðò áîëîâñðóóëàõ

- “Óñíû àþóëã¿é áàéäëûí òºëºâëºãºº” áîëîâñ-ðóóëàõ

Àíàãààõ óõààíû äîêòîð, ïðîôåññîð ×.Öîëìîí

Íèéãìèéí Ýð¿¿ë Ìýíäèéí Ñóðãóóëèéí

Îð÷íû ýð¿¿ë ìýíäèéí òýíõèìèéí áàãø ×.Öîëìîíãèéí



2015-îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàãñààëò

1. Íîì, Ãàðûí àâëàãà: 2

- Î. ×èìýäñ¿ðýí áóñàä

- Óðüä÷èëàí ñýðãèéëýõ àíàãààõ óõààíû ¿íäýñ

- Õàìòàðñàí

- Ýïèäåìèîëîãèéí ãàðûí àâëàãà

2. Ðåäàêòîðëàñàí íîì: 2

a. Ýìíýëýãèéí ìåíåæåð - ãàðûí àâëàãà

b. Ýð¿¿ë ìýíäèéí íèéãìèéí àæèë – íîì

3. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë: 13

- Ìîíãîë õýë äýýð: 7

1. Ãàíòóÿà Ä, Àíãàðìºðºí Ä, Ìºíõ-Ýðäýíý Ë, Áàòáàÿð À, Óíäðàì Ë, ×èìýäñ¿ðýí Î. Àãààðûí áîõèðäîë íÿðàéí òºðºõ ¿åèéí æèíä íºëººëñºí ¿ð ä¿íãýýñ Innovation. 2014;(3):61-63.

2. Ãàíòóÿà Ä, Õ¿äýð÷óëóóí Í, Àíãàðìºðºí Ä, Ìºíõ-Ýðäýíý Ë, Óíäðàì Ë, ×èìýäñ¿ðýí Î. Àãààðûí áîõèðäîë áà äóòóó òºðºëòèéí õàìààðëûã ñóäàëñàí çàðèì ¿ð ä¿íãýýñ. Innovation. 2014;(4):25-28

3. Ä.Àíãàðìºðºí, Ä.Ãàíòóÿà, Á.Áàòçîðèã, Ä.Àâèðìýä, Î.×èìýäñ¿ðýí Ìîíãîë óëñûí õºõíèé ºìºíãººð ºâ÷èëñºí ýìýãòýé÷¿¿äèéí àìüäðàõ ÷àäâàðûí ñóäàëãàà. Îíîø ñýòã¿¿ë. 2014;99-120

4. Á.Æàðãàë, Ã.Ýíõæàðãàë, Î.×èìýäñ¿ðýí, Ë.Ìºíõ-Ýðäýíý, ×àíã-×óàí ×àí, Óëààíáààòàð õîòûí àãààðûí áîõèðäîë, ýð¿¿ë ìýíäýä íºëººëºõ ýðñäýëò õ¿÷èí ç¿éë, Ýêîëîãè ñýòã¿¿ë, õýâëýëòýíä

5. Ä.Ãàíòóÿà, Ä.Àíãàðìºðºí, Î.×èìýäñ¿ðýí, Ë.Óíäðàì, Ë.Ìºíõ-Ýðäýíý, À.Áàòáàÿð, Àãààðûí áîõèðäîë íÿðàéí òºðºõ ¿åèéí æèíä íºëººëñºí ¿ð ä¿íãýýñ, Innovation ñýòã¿¿ë, Vol.8, No.3, July 2014: 60-63

6. Ä.Ãàíòóÿà, Í.Õ¿äýð÷óëóóí, Ë.Óíäðàì, Ä.Àíãàð-ìºðºí, Ë.Ìºíõ-Ýðäýíý, Î.×èìýäñ¿ðýí, Àãààðûí áîõèðäîë áà äóòóó òºðºëòèéí õàìààðëûã ñóäàëñàí çàðèì ¿ð ä¿íãýýñ, Vol.8, No.4, Oct 2014: 24-28

7. Á.Æàðãàë, Ã.Ýíõæàðãàë, Ë.Ìºíõ-Ýðäýíý, Î.×èìýäñ¿ðýí, ××.×àí, Õ¿¿õäèéí øýýñýíä îëîí öàãèðàãò ¿íýðò í¿¿ðñóñòºðºã÷ (1-OHP)-

èéí àãóóëàìæ òîäîðõîéëñîí ä¿í, Íèéãìèéí Ýð¿¿ë Ìýíäèéí Ýðèí ñýòã¿¿ë, Vol.3: 99-100

Îëîí óëñûí ñýòã¿¿ëä: - 61. Gantuya D, Undram L, Chimedsuren O. Survey

results on birthrates registered in Ulaanbaatar. Mongolian journal of health sciences. 2014;11 (1)90-93

2. Gantuya D, Undram L, Chimedsuren O. Is air pollution lowers baby birth weight in Ulaanbaatar, Mongolia. Online Journal, Open Access Library Journal /http://www.oalib.com/

3. N.Khuderchuluun, M.Purevjav, N.Sumberzul, O.Chimedsuren“Assessment of changes in health care needs The official journal of the international hospital federation World Hospital and Health Services. 2014;(50):27-30

4. Myagmarchuluun Sainnyambuu, Chimedsuren Ochir, Tolmon Chultemdorj, Oyuntogos Lkhasuren, Survey findings on evaluation of general medical practitioners workload of Mongolia, Mongolian Journal of Health Sciences, volume … 2014.

5. Ñ.Ìÿãìàð÷óëóóí, Î.×èìýäñóðýí, ×.Öîëìîí, Í.Õ¿äýð÷óëóóí, Ë.Îþóíòîãîñ, Ðåçóëòàòû èññëåäîâàíèÿ îáîñíîâàíèå óñòàíîâëåíèÿ íîðìàòèâîâ íàãðóçêè è íîðì òðóäà ìåäèöèíñêèõ ñïåöèàëèñòîâ, Ìåæäóíàðîäíûé íàó÷íî-èññëåäîâàòåëüñêèé æóðíàë, №6 (25) 2014, ×àñòü 2, 57-60

6. Global surveillance of cancer survival 1995–2009:analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) Claudia Allemani, Hannah K Weir, Helena Carreira, Rhea Harewood, Devon Spika, Xiao-Si Wang, Finian Bannon, Jane V Ahn, Christopher J Johnson,Audrey Bonaventure, Rafael Marcos-Gragera, Charles Stiller, Gulnar Azevedo e Silva, Wan-Qing Chen, Olufemi J Ogunbiyi, Bernard Rachet,Matthew J Soeberg, Hui You, Tomohiro Matsuda, Magdalena Bielska-Lasota, Hans Storm, Thomas C Tucker, Michel P Coleman,and the CONCORD Working Group*, Ochir C, - Lancet, Published Online November 26, 2014http://dx.doi.org/10.1016/,S0140-6736 (14) 62038-9

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Î.×èìýäñ¿ðýíãèéí


Õàâñðàëò 1


Èëòãýë¿¿ä: 151. Î.Chimedsuren, “Environmental health and

challenges of Mongolia”, Michigan University, 2014. April

2. O.Chimedsuren, Kirk Smith, B Purevdorj, - Air pollution health effect of Ulaanbaatar, Clean air fund. 2014, April

3. O.Chimedsuren, E Erdenechimeg, Health assessment of miners and their families, Switzerland, WHO, 2014. October

4. Á.Æàðãàë, ¯è-Êàé Õóàíã, Ë.Ìºíõ-Ýðäýíý, Î.×èìýä ñ¿ðýí, ×.×.×àí, Ã.Ýíõæàðãàë, Àãààðûí ¿íäñýí áîõèðäóóëàã÷ àçîòûí äàâõàð èñýë, õ¿õðèéí äàâõàð èñëèéí òàðõàëòûã ñóäàëñàí ä¿íãýýñ, “Îð÷èí áà õ¿¿õäèéí ýð¿¿ë àõóé” ýðäýì øèíæèëãýýíèé õóðëûí õóðààíãóé, 2014: 9-10

5. Á.Æàðãàë, ¯é-Êàé Õóàíã, Ë.Ìºíõ-Ýðäýíý, Î.×èìýäñ¿ðýí, ××.×àí, Ã.Ýíõæàðãàë, Àãààðûí ¿íäñýí áîõèðäóóëàã÷ àçîòûí äàâõàð èñýë, õ¿õðèéí äàâõàð èñëèéí òàðõàëòûã ñóäàëñàí ä¿í, Íèéãìèéí Ýð¿¿ë Ìýíäèéí Ýðèí ñýòã¿¿ë, Vol.3: 9

6. Ãàíòóÿà Ä, ×èìýäñ¿ðýí O. Íÿðàéí òºðºëòèéí æèíä áîëîí óðàãò àãààðûí áîõèðäëûí ¿ç¿¿ëýõ íºëººëëèéã Óëààíáààòàð õîòûí òîõèîëäîëä ñóäàëñàí íü. Íèéãìèéí Ýð¿¿ë Ìýíä -56. Ýðäìèéí ÷óóëãàí. 2014;57

7. Ãàíòóÿà Ä, ×èìýäñ¿ðýí O. Íÿðàéí òºðºëòèéí æèíä àãààðûí áîõèðäëûí ¿ç¿¿ëýõ íºëººëëèéã 2009-2011 îíû õîîðîíä ñóäàëñàí íü. Îð÷èí áà õ¿¿õäèéí ýð¿¿ë àõóé. Ýðäýì øèíæèëãýýíèé áàãà õóðàë-2014 àìàí èëòãýë

8. Ä.Àíãàðìºðºí, Ä.Ãàíòóÿà, Á.Áàòçîðèã, Ä.Àâèð-ìýä, Î.×èìýäñ¿ðýí. Íºõºí ¿ðæèõ¿éí íàñíû õºõíèé ºìºíãººð ºâ÷èëñºí ýìýãòýé÷¿¿äèéí àìüäðàõ ÷àäâàðûí ñóäàëãàà. Íèéãìèéí Ýð¿¿ë Ìýíä -56. Ýðäìèéí ÷óóëãàí. 2014;76

9. Ä.Àíãàðìºðºí, Ä.Ãàíòóÿà, Á.Áàòçîðèã, Ä.Àâèðìýä, Î.×èìýäñ¿ðýí. Ìîíãîë óëñûí õºõíèé ºìºíãººð ºâ÷èëñºí ýìýãòýé÷¿¿äèéí àìüäðàõ ÷àäâàðûí ñóäàëãàà. Õ¿ðýë òîãîîò- 2014 àìàí èëòãýë

10. Â.Áàÿðìàà, Ë.Íàñàíöýíãýë, Ò.Ìàíäõàé, Å.Ãóëæàíàò, Á.Áàòçîðèã, Í.Òóÿà, Ä.Äàâààëõàì, Î.×èìýäñ¿ðýí. Õ¿í àìûí äóíäàõ ñýòãýë ò¿ãøèëòèéí áàéäëûã èëð¿¿ëñýí ä¿íãýýñ. Ýðäìèéí ÷óóëãàí-56, Ýìíýëç¿éí ñàëáàð.2014;30

11. Â.Áàÿðìàà, Ë.Íàñàíöýíãýë, Ò.Ìàíäõàé, Å.Ãóëæàíàò, Á.Áàòçîðèã, Í.Òóÿà, Ä.Äàâààëõàì, Î.×èìýäñ¿ðýí, Õ¿í àìûí äóíäàõ ñýòãýë ãóòðàõ áàéäëûã èëð¿¿ëñýí ä¿íãýýñ, Ýðäìèéí ÷óóëãàí-56, Ýìíýëç¿éí ñàëáàð.2014;31

12. Ñ.Ìÿãìàð÷óëóóí, Î.×èìýäñ¿ðýí, ×.Öîëìîí, Í.Õ¿äýð÷óëóóí, Ä.Íàðàíñ¿õ áóñàä. Ýì÷ íàðûí àæëûí à÷ààëëûã ìýðãýæëýýð õàðüöóóëàí ñóäëàñàí ¿ð ä¿í. Õºäºëìºðèéí ýð¿¿ë ìýíä Ýðäýì øèíæèëãýýíèé õóðàë. 2014 îí. Èëò-ãýëèéí õóðààíãóé, 19-20

13. S.Myagmarchuluun, O.Chimedsuren, L.Oyun-togos, “The workload evaluation of healthcare workers in selected two hospitals in Ulaanbaatar, Mongolia”, The 7th Conference of the Asian medical education association-AMEA-2013, PP51, pages 189.

14. S.Myagmarchuluun, Ch.Tolmon, O.Chimed-suren, Khuderchuluun N, L.Oyuntogos, “Survey findings on evaluation of traumatologist’s workload in Mongolia” in Bejing, sep 14-16, 2014, PHP41

15. Myagmarchuluun S., Chimedsuren O., Tsolmon Ch., Khuderchuluun N., Naransukh D, Oyuntogos L. Survey finding on evaluation of medical doctors work load by professions. Current Issues in Mongolia and Korea, Ulaanbaatar, Mongolia, 2014. Abstract book. 127-128


Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í Ë.Ýðäýíýáàÿðûí

2014 îíû òàéëàí

1. Ìîíãîëûí Àíàãààõ óõààíû Àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä îðîëöñîí òóõàé

- ÀØÓ-íû Àêàäåìèéí õóðàëä 4 óäàà, ñàëáàð çºâëºëèéí õóðàëä 3 óäàà îðæ, 5 óäàà àæèë õýðãèéí ñàíàë òàâüñàí.

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàãñààëò:

- Íîì 4, ýðäýì øèíæèëãýýíèé ºã¿¿ëýë 15, àøèãòàé çàãâàðûí ãýð÷èëãýý 2 (Õàâñðàëò)

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýëèéí íýð, òîâ÷ëîë, õýâëýãäñýí áîë ò¿¿íèé èøëýë:

- 5 óäàà îðîëöîæ 14 èëòãýë òàâüñàí. (Õàâñðàëò)

4. Óäèðäàæ, çºâëºæ õàìãààëóóëñàí ñóäëàà÷èä:

- Äýä äîêòîðûí ø¿¿ìæ 1

- Ìàãèñòðûí ø¿¿ìæ 2 (Õàâñðàëò 3)

Ä/ä Õèéæ áîëîâñðóóëñàí àæèëßìàð ÿàìíû

äààëãàâàðààðÃ¿éöýòãýñýí

õóãàöàà

1 Õàð òàìõè ìàíñóóðàëòòàé òýìöýõ òºâ òàíèëöóóëãà ÝÌß, ÕÇß 2014.01-03 ñàð

2 Àääèêòîëîãèéí ¿íäýñíèé òºâ áàéãóóëàõ òàíèëöóóëãà ÝÌß, ÕÇß 2014.01-03 ñàð

3 Àðõèíû õîðäëîãî òàéëàõ ýì÷èëãýý ¿ç¿¿ëýõ æóðàì ÝÌß, ÕÇß 2014.01-04 ñàð

4 Öàãäààãèéí àëáàíû õóóëèíä ñàíàë ºãºõ ÝÌß, ÕÇß 2014.05 ñàð

5 Ñîãòóóðóóëàõ óíäààíû õÿíàëòûí òóõàé õóóëèéí òºñëèéí ¿çýë áàðèìòëàë

ÝÌß, ÕÇß 2014.05-07 ñàð õ¿ðòýë

6 Õºòºëáºð áàòëàõ òóõàé ìàíñóóðóóëàõ áîëîí ñýòãýöýä íºëººò áîäèñûí õóóëü áóñ ýðãýëòòýé òýìöýõ òóõàé õºòºëáºð áîëîâñðóóëàõ

ÝÌß, ÕÇß 2014.04-08 ñàð õ¿ðòýë

7 Ìîíãîë õ¿íèé àðõèíä äîíòîõ çóðøëûã àðèëãàõ çàãâàð÷ëàë ÝÌß, ÕÇß 2014. 09 ñàð

8 Íèéãýì õàìò îëîíä òóëãóóðëàñàí (ÑÂÒ) ýì÷èëãýý ¿éë÷èëãýýíèé òóñëàìæ

ÝÌß, ÕÇß 2014.10 ñàð

9 Äîíòîõ ýìãýãèéí õàìààðëûã ñóäëàõ àíàãààõ óõààíû íîì 25 õõ ÝÌß, ÕÇß 2014.01-2014.12 ñàð9.1 Õ¿í àìä ¿ç¿¿ëýõ íàðêîëîãèéí òóñëàìæ 44 õõ íîì (Öóâðàë 3

íîì)

Ë.Ýðäýíýáàÿðûí 2014 îíû Ñàëáàðûí òºëºâëºãººíèé áèåëýëò

2014.01.20

1. ÌÀÓÀêàäåìèéí ¿éë àæèëëàãààíä èäýâõèòýé ¿ð á¿òýýëòýé îðîëöîíî.

2. Ìîíãîë óëñûí àðõèäàëò, õàð òàìõè, ñàíñóóðàëòàé òýìöýõ ñòðàòåãè, êîíöåïöè áîëîâñðóóëæ äýýä ãàçàðò íü ºðãºí áàðèíà.

3. Ìîíãîë óëñûí õ¿í àìä ¿ç¿¿ëýõ ñýòãýö - íàðêîëîãèéí äóíä óðò õóãàöààíû ñòðàòåãè áîëîâñðóóëíà.

4. Ñýòãýö, íàðêîëîãèéí íýð òîìú¸îíû òàéëáàð òîëü ãàðãàíà.

5. Äîíòîõ ýìãýãèéí ýì÷èëãýý 50 õõ íîì áè÷íý.

6. Àðõèäàëò, äîíòîëòûã ýì÷ëýõ ýì÷èëãýý öóâðàë 6 àðãûã áîëîâñðóóëæ ïðàêòèêò íýâòð¿¿ëíý.

Ïðîô. Ë.Ýðäýíýáàÿð

5 Áóñàä ýð¿¿ë ìýíä, Øèíæëýõ óõààíû òàëààð òºâèéí õýâëýëä àñóóäàë äýâø¿¿ëñýí ºã¿¿ëýë 3, 2 óäàà ÿðèëöëàãà ãàðãàñàí.


Õî¸ð. Ýìíýëç¿é

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í Ä.Áààñàíæàâûí


2014 îíû 12 äóãààð ñàðûí 25

1. Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä îðîëöñîí òóõàé:

1) ÌÀÓÀ-èéí 2014 îíû ÷óóëãàíóóäàä îðîëöîæ õýëýëöñýí àñóóäëóóäûã øèéäâýðëýõýä îðîë-öîâ.

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí á¿ðýí æàã-ñààëò:

Íèéò 9, ¿¿íä:

Íîì – 1

Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë –1

Ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë – 4,

Áóñàä – 4 (Õàâñðàëò 1)

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýëèéí íýð, òîâ÷ëîë, õýâëýãäñýí áîë ò¿¿íèé èøëýë: 4 (Õàâñðàëò 2) ;

4. Áóñàä:

1. Áààç òàñãèéí õ¿ðýýíä ÄÝÌÁ, ÌÌÑÑàíãèéí õ¿ðýýíä õýðýãæ¿¿ëýõ òàðõèíû õàðâàëòûí õóðö ¿åèéí òºðºëæñºí òàñàã áàéãóóëæ, ¿éë àæèëëàãààíä îðóóëàõ çýõýö àæèëä îðîëöîæ òóñàëæ èðñíèé çýðýãöýýãýýð ìýäðýëèéí çºâëºõ ýì÷èéí ¿éë àæèëëàãààã ºäºð á¿ð ã¿éöýòãýæ, îëîí çóóí õ¿íèéã ¿çýæ çºâëºí, ïðàêòèêò áàéíãà òóñàëæ èðëýý.

2. Õîëáîîíû Ãåðìàí Óëñûí Óëüì õîòûí Èõ ñóðãóóëèéí Ìýäðýëèéí ýìíýëãèéí äîêòîð,

ïðîôåññîðóóäòàé õàìòðàí “Õàæóóãèéí õàòèíãàðàëò õàòóóðàë” ºâ÷íèéã Ìîíãîë õ¿í àìûí äóíä èëð¿¿ëýõ êëèíèê-ýïèäåìèîëîãè, ìîëåêóë-ãåíåòèêèéí ñóäàëãààã õàìòðàí õèéõ òàëààð ñàíàë ñîëèëöîæ óóëçàëò-ñåìèíàð çîõèîí áàéãóóëàâ.

3. Äîðíîä àéìãèéí Çàñàã äàðãà, ÝÌÃ-ûí çàõèàëãààð òóñ àéìãèéí õ¿í àìûí äóíäàõ ºâ÷ëºë, íàñ áàðàëòàíä íºëººëæ áàéãàà ýðñäýëò õ¿÷èí ç¿éëñèéã èëð¿¿ëýõ ñóäàëãààíû àæèëä îðîëöîæ àéìãèéí òºâèéí 3 áàã, 3 ñóìûí 600 õ¿í àìûã õàìðóóëàí àñóóìæ, ¿çëýã, øèíæèëãýý õèéëýý.

4. Àâñòðàëè óëñûí Ñèäíåé õîòûí Äæîðæè èíñ òèòóòûí ìýäðýëèéí ñàëáàðòàé õàìò -ðàí Õ¿í àìä ñóóðèëñàí òàðõèíû õàð-âàëòûí á¿ðòãýë ñóäàëãàà õèéõ òà ëààð òóñ õ¿ðýýëýíãèéí çàõèðàë Ãðåéã Àíäåðñîíòîé òîõèðîëöîæ, áýëòãýë àæëûã ýõýëæ ñóäàë-ãààíû àñóóìæ, êàðòûã áîëîâñðóóëààä áàé-íà (ñýäýâ, àðãà÷ëàëûí òàëààð).

5. Õîâä àéìãèéí Çýðýã ñóìûí õ¿í àìä ¿ç¿¿ ëýõ ýìíýëãèéí òóñëàìæ, ýð¿¿ë ìýí-äèéí ñóðãàëò, ñóäàëãàà õèéõ ÀÓÕ-èéí ìýðãýæëèéí áàãò ìýäðýëèéí ñåêòîðîîñ 1 ÝØÀ îðîëöîæ òóñ ñóìûí õ¿í àìûã á¿ðýí õàìðóóëëàà.

Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð Ä.Áààñàíæàâ

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Ä.Áààñàíæàâûí 2014 îíû àæëûí òàéëàí

Õàâñðàëò 1

2014 îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàã-ñààëò

1. Íîì – 11.1. Ìîíãîë õýëýýð – 1

“Ìýäðýëèéí óäàìøëûí ºâ÷íèé ìîëåêóë-ãåíå òèêèéí ìîíãîë äàõü çàðèì øèíæ áàéäàë” (ÀÍÓ-ûí ìýäðýë, ãåíåòèêèéí ìýðãýæèëòí¿¿äòýé õàìòðàí õèéñýí ñóäàëãààíû òàéëàíãèéí ìàòåðèàë, ¿ð ä¿í)

Óëààíáààòàð õîò, 2014 îí. 64 õóóäàñòàé

1.2. Áóñàä õýëýýð - áàéõã¿é

2. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë

2.1. Ìîíãîë õýëýýð - 1

Ä.Áààñàíæàâ, ß.Ýðäýíý÷èìýã, Á.×èìýãëõàì, Ò.Ñàðàíöýöýã, Á.Îþóíãýðýë, Ä.Áîëîðìàà

“Ìîíãîë îðíû ç¿¿í áà òºâèéí á¿ñèéí çàðèì àéì ãèéí õ¿í àìûí äóíä ìýäðýëèéí óäàìøëûí ºâ÷íèé (ÌÓª) á¿òýö, òàðõàëòûí òºâøèí” //Ìîíãîëûí Àíàãààõ óõààí ñýòã¿¿ë. 2014, №2. õ 12-17.

2.2. Áóñàä õýëýýð-áàéõã¿é



1. Íîì – 11.1. Ìîíãîë õýëýýð – 1

“Ìýäðýëèéí óäàìøëûí ºâ÷íèé ìîëåêóë-ãåíå òèêèéí ìîíãîë äàõü çàðèì øèíæ áàéäàë” (ÀÍÓ-ûí ìýäðýë, ãåíåòèêèéí ìýðãýæèëòí¿¿äòýé õàìòðàí õèéñýí ñóäàëãààíû òàéëàíãèéí ìàòåðèàë, ¿ð ä¿í)

Óëààíáààòàð õîò, 2014 îí. 64 õóóäàñòàé

1.2. Áóñàä õýëýýð - áàéõã¿é



Ä.Áààñàíæàâ, ß.Ýðäýíý÷èìýã, Á.×èìýãëõàì, Ò.Ñàðàíöýöýã, Á.Îþóíãýðýë, Ä.Áîëîðìàà

“Ìîíãîë îðíû ç¿¿í áà òºâèéí á¿ñèéí çàðèì àéì ãèéí õ¿í àìûí äóíä ìýäðýëèéí óäàìøëûí ºâ÷íèé (ÌÓª) á¿òýö, òàðõàëòûí òºâøèí” //Ìîíãîëûí Àíàãààõ óõààí ñýòã¿¿ë. 2014, №2. õ 12-17.




1. Ä.Áààñàíæàâ, Ï.Àëòàíöýöýã “Ýãýìíèé äîîðõ àðòåðèéí áºãëºðºëòèéã äîïïëåðîãðàôààð èëð¿¿ ëýõ àðãà, ò¿¿íèé ýìíýë ç¿éí àñóóäàëä” “Ýðäìèéí ÷óóëãàí 2014-Õàìòäàà á¿òýýñýí 60 æèë” // (Ï.Í Øàñòèíû íýðýìæèò ÓÃÒÝ-èéí 60 æèëèéí îéä çîðèóëñàí ýðäýì øèíæèëãýý îíîë ïðàêòèêèéí áàãà õóðëûí ýìõýòãýëä. õ 64-65.

2. Ä.Áààñàíæàâ, Ò.Ìàíäàõ, Ñ.Äàðèéìàà “Íàñàíä õ¿ ðýãñäýä òîõèîëääîã óäàìøëûí íóãàñíû àìèîò ðîôè ºâ÷íèé áóëüáî-ñïèíàëüíûé õýë áýð Êåííåäèãèéí ºâ÷èí ýìíýëç¿éãýýð îíîøëîãäñîí òîõèîäîë” Ýðäìèéí ÷óóëãàí 2014-Õàìòäàà á¿òýý-ñýí 60 æèë” //Ï.Í Øàñòèíû íýðýìæèò ÓÃÒÝ-èéí 60 æèëèéí îéä çîðèóëñàí ýðäýì øèíæèëãýý îíîë ïðàêòèêèéí áàãà õóðëûí ýìõýòãýëä

3. Ä.Áààñàíæàâ, Ñ.Ñýëýíãý, ß.Ýðäýíý÷èìýã, Á.Îþóí ãýðýë, Ò.Ñàðàíöýöýã, Ä.Áîëîðìàà, Á.×èìýãë õàì, Ë.Ã.Ãîëüäôàðá, Ñ.Íÿìõèøèã, Ê.Ñèâàêóìàð “Ìýäðýëèéí óäàìøëûí ºâ÷íèé ìîëåêóë-ãåíåòèêèéí ìîíãîë äàõü çàðèì øèíæ áàéäàë” //Ìýäðýëèéí òºâèéí ýðäìèéí ÷óóëãàí-2014. õ 24-30

4. Ä.Áààñàíæàâ, Ñ.Ñýëýíãý, ß.Ýðäýíý÷èìýã, Á.Îþóí ãýðýë, Ò.Ñàðàíöýöýã, Ä.Áîëîðìàà, Á.×è-ìýãëõàì, Ë.Ã.Ãîëüäôàðá, Ñ.Íÿìõèøèã, Ê.Ñèâà-êó ìàð “Òàðõèíû áàãà õàðâàëòûí õýâ øèí æ¿¿ä

ýìíýëç¿éí îíöëîã, íºëººëºõ õ¿÷èí ç¿éëñ” //Ìýä-ðýëèéí òºâèéí ýðäìèéí ÷óóëãàí-2014. õ 18-24


4. Áóñàä


4.1.1. Ýðäýì øèíæèëãýýíèé äóóññàí àæëûí òàéëàí – 1

“Ìýäðýëèéí çîíõèëîí òîõèîëäîõ ýìãýãèéí ìîëåêóë–ãåíåòèêèéí ñóäàëãàà” øèíæëýõ óõààíû ñóóðü ñóäàëãàà. 2011-2013 îíä ã¿éöýòãýæ, äóóññàí àæëûí òàéëàíã 2014 îíä ÝÌß, ÁÑØÓß, ØÓÒÑàíä õ¿ëýýëãýí ºãñºí.

Óäèðäàã÷: ÀØÓ-íû äîêòîð Ä.Áààñàíæàâ.

2. Çîõèîã÷èéí ýðõèéí ãýð÷èëãýý – 4

• “Ìîíãîë îðíû ç¿¿í áà òºâèéí á¿ñèéí 6 àéìãèéí õ¿í àìûí äóíä ìýäðýëèéí óäàìøëûí çîí-õèëîõ ºâ÷í¿¿äèéí òàðõàëòûí ò¿âøèí” №5932. 2014.03.03

• “Áóë÷èíãèéí íóãàñíû ãàðàëòàé äèñòàë àò-ðîôè-V(ÁÍãÄÀ V) áà Øàðêî-Ìàðè-Òóò ºâ÷èí 2D(ØÌÒ2Ä) õýâøèíæ¿¿äèéí ýìíýëç¿éí ÿëãàí îíîøëîãîî” №5935. 2014.03.03

• Ïðîòåîëèïèä óóðãèéí ãåíèéí øèíý ýêçîí 3Â ìóòàöè íü õîæóó ýõëýëòýé ñïàñòèê ïàðàïëåãè 2-ð õýâøèíæèéí øàëòãààí áîëîõ íü. Ýíý äýä õýâøèíæ íü ýìýãòýé ãýð á¿ëèéí ãèø¿¿äýä ÿíç á¿ðèéí ïåíåñòðàíñòàé áàéäàã íü” №5933. 2014.03.03

• Ìîíãîëûí õ¿í àìûí äóíä óäàìøëûí ìèî òîíèéí äèñòðîôè ºâ÷íèé 2 äýä (ÌÄ1,ÌÄ2) õýâ øèíæ ìîëåêóë-ãåíåòèêèéí øèíæèëãýýãýýð èëýðñýí íü” №5934. 2014.03.03

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Ä.Áààñàíæàâûí 2014 îíû àæëûí òàéëàí

Õàâñðàëò 2

Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëö-ñîí áàéäàë, òàâüñàí èëòãýëèéí íýð

Ìîíãîëä

1. “Ýãýìíèé äîîðõ àðòåðèéí áºãëºðºëòèéã äîïï ëå-ðîãðàôààð èëð¿¿ëýõ àðãà, ò¿¿íèé ýìíýë ç¿éí àñóóäàëä” “Ýðäìèéí ÷óóëãàí 2014-Õàìòäàà á¿òýýñýí 60 æèë” Ä.Áààñàíæàâ, Ï.Àëòàíöýöýã// (Ï.Í Øàñòèíû íýðýìæèò ÓÃÒÝ-èéí 60 æèëèéí îéä

Õàâñðàëò 1

2014 îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàã ñààëò


çîðèóëñàí ýðäýì øèíæèëãýý îíîë ïðàêòèêèéí áàãà õóðëûí ýìõýòãýëä. õ 64-65.

2. “Íàñàíä õ¿ðýãñäýä òîõèîëääîã óäàìøëûí íó-ãàñ íû àìèîòðîôè ºâ÷íèé áóëüáî-ñïèíàëüíûé õýëáýð Êåííåäèãèéí ºâ÷èí ýìíýëç¿éãýýð îíîø-ëîãäñîí òîõèîäîë” Ò.Ìàíäàõ, Ñ.Äàðèé ìàà, Ä.Áààñàíæàâ “Ýðäìèéí ÷óóëãàí 2014- Õàìòäàà á¿òýýñýí 60 æèë” //Ï.Í Øàñòèíû íýðýìæèò ÓÃÒÝ-èéí 60 æèëèéí îéä çîðèóëñàí ýðäýì øèíæèëãýý îíîë ïðàêòèêèéí áàãà õóð ëûí ýìõýòãýëä

3. “Ìýäðýëèéí óäàìøëûí ºâ÷íèé ìîëåêóë-ãåíåòèêèéí ìîíãîë äàõü çàðèì øèíæ áàéäàë”

Ä.Áààñàíæàâ, Ñ.Ñýëýíãý, ß.Ýðäýíý÷èìýã, Á.Îþóí ãýðýë, Ò.Ñàðàíöýöýã, Ä.Áîëîðìàà, Á.×èìýãëõàì, Ë.Ã.Ãîëüäôàðá, Ñ.Íÿìõèøèã, Ê.Ñèâàêóìàð //Ìýäðýëèéí òºâèéí ýðäìèéí ÷óóëãàí-2014.õ 24-30

4. “Òàðõèíû áàãà õàðâàëòûí õýâ øèíæ¿¿ä ýìíýëç¿éí îíöëîã, íºëººëºõ õ¿÷èí ç¿éëñ” Ä.Áààñàíæàâ, Ñ.Ñýëýíãý, ß.Ýðäýíý÷èìýã, Á.Îþóíãýðýë, Ò.Ñàðàíöýöýã, Ä.Áîëîðìàà, Á.×èìýãëõàì, Ë.Ã.Ãîëüäôàðá, Ñ.Íÿìõèøèã, Ê.Ñèâàêóìàð //Ìýäðýëèéí òºâèéí ýðäìèéí ÷óóëãàí-2014.õ18-24


1. Àçè, Íîìõîí äàëàéí îðíóóäûí àíàãààõ óõààíû ñýòã¿¿ëèéí õîëáîîíû õóðëûã ÝÌß-òàé õàìòðàí 2014 îíû 8-ð ñàðä çîõèîí áàéãóóëñàí.

2. Ìîíãîëûí ìýñ çàñëûí íèéãýìëýãòýé õàìòðàí Ìîíãîëûí ìýñ çàñàë÷äûí ÷óóëãà óóëçàëòûã 2014.11.28-íä çîõèîí áàéãóóëñàí.

3. Õºâñãºë àéìàãò 2 êðåäèòèéí ñóðãàëò çîõèîí áàéãóóëñàí.

4. Äîðíîä àéìãèéí Çàñàã äàðãûí òàìãûí ãàçðûí çàõèàëãààð “Äîðíîä àéìãèéí íàñàíä õ¿ðñýí õ¿í àìûí ºâ÷ëºëèéí áàéäàë, ýðñäýëò õ¿÷èí ç¿éëèéí òàðõàëòûí ñóäàëãàà” òºñºë õýðýãæ¿¿ëñýí.

Á¿òýýë:

1. Íîì-1 “Ìîíãîëûí ìýñ çàñëûí íýãýí çóóí” ÓÁ, 2014 -500õ

2. ÝØª

1. Consideration of Laparoscopic Cholecystectomy in Mongolia (I)-Laparoscopic Cholecystectomy:Complication and Conversion Rate

Journal of International wkonkwang culture /Whonkwang HealthScience University/

vol 4, № 1 /serial number 8/Oct. 10. 2014

B.Batbold

2. Consideration of Laparoscopic Cholecystectomy in Mongolia (II)-Laparoscopic Cholecystectomy in Acute Calculus Cholecystitis- Mongolian Experience

Journal of International wkonkwang culture /Wonkwang HealthScience University/

vol 4, № 1 /serial number 8/Oct. 10. 2014

B.Batbold

3. “Ç¿ðõíèé ýëáýã òîõèîëääîã ãàæãóóäûã õàðèóöäàã ãåí¿¿äèéí ÄÍÊ íóêëåîòèäèéí äàðààëëûã ìîëåêóë ãåíåòèêèéí íàðèéí àðãûã àøèãëàí òàéëæ óíøèí, ãåíåòèêèéí øàëòãààíòàé ç¿ðõíèé ãàæèã ¿¿ñýõ, ìàãàäëàëûã ñóäàëñàí íü” ÌÀÓ ñýòã¿¿ë, ÓÁ, №2, õ.18-24

Èëòãýë:

“Ìýñ àæèëáàðûí äàðààõ ãåïàòèòèéí Â, Ñ âèð¿ñèéí òàðõàëòûã òîãòîîõ íü” 2014, ÓÊÒÝ-èéí Ýðäìèéí áè÷èã

Àêàäåìè÷ Í.Áààñàíæàâûí 2014 îíä õèéñýí àæèë


2015 îíû 1 ä¿ãýýð ñàðûí 12

1. Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàíä 5 óäàà, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä 2 óäàà îðîëöëîî. Ñàíõ¿¿ãèéí õÿíàëòûí õîðîîíû ãèø¿¿íèé ¿¿ðýãò àæëûã ã¿éöýòãýæ èðëýý;

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí á¿ðýí æàãñààëò: íèéò 1, ¿¿íä - íîì 1/ õÿíàí òîõèîëäóóëñàí/;

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýë, õýâëýãäñýí áîë ò¿¿íèé èøëýë:

4. Óäèðäàæ, çºâëºæ õàìãààëóóëñàí ñóäëàà÷èä: 1 Àíàãààõ óõààíû äîêòîð;

5. Áóñàä: äîðîîñ ¿çíý ¿¿

2014 îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàã ñààëò

1. Íîì


¹ Íîìûí íýð Çîõèîã÷ Åðºíõèéðåäàê òîð

1. Ãåìîäèàëèç /20 õ/õ/ Ä.Õóðöáàÿð Õ.Ãýëýã-æàìö

2. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë

1. Ìîíãîëä

1. Ñîëîíãîñûí Ñåóëûí èõ ñóðãóóëèéí ýì÷ íàðòàé õàìòðàí “Áººðíèé àðõàã äóòàãäëûí îíîøëîãîî, ýì÷èëãýý ñýðãèéëýëò ” ñýäýâò ñåìèíàð 2014 îíû 4-ð ñàðä çîõèîí áàéãóóëñàí.

Õàâñðàëò 3

3. 2014 îíä óäèðäàæ, çºâëºæ çýðýã õàìãààëóóëñàí ñóäëàà÷èä

Àðõàã ãëîìåðóëîíåôðèòèéí íàìæìàë ¿åä Áèãýðèéí ýëñýí ñóâèëàëûí ¿ð ä¿í, Ë. Æàâçìàà, /Ãîâü Àëòàé àéìãèéí Àíàãààõûí Êîëëåæèéí áàãø/ 2014 îíû 6 ñàðä

4 . Áóñàä:

1. ÀØÓ¯ÈÑ-èéí ÀÓÑ-èéí Ýðäýìòäèéí çºâëºëèéí ãèø¿¿íèé ¿¿ðýã õ¿ëýýæ, íèéò 19 óäààãèéí õóðàëä îðîëöñîí.

2. Äîðíîä àéìàãò Áººðíèé ºâ÷íèé òóëãàìäñàí àñóóäëààð 2 ºäðèéí ñåìèíàð 2014 îíû 3 ñàðä õèéæ, 50 ãàðóé ýì÷ íàð îðîëöñîí.

3. Ýð¿¿ë ìýíä ÒÂ-ýýð Àêàäåìè÷òýé ÿðèëöàõ öàã íýâòð¿¿ëýãò îðîëöîæ, 2014 îíû 12 ñàðûí 27 ºäºð ýôèðò ãàðñàí.

4. Ýð¿¿ë ìýíä ÒÂ-ýýð Öèñòèò ºâ÷íèé òàëààð íýã öàãèéí íýâòð¿¿ëýã õèéñýí.

Àêàäåìè÷ Õ. Ãýëýãæàìö

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í Õ.Ãýëýãæàìöûí





- ×óóëãàíû õóðàëä 3 óäàà ñóóñàí , 2 ñàíàë òàâüñàí.

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí á¿ðýí æàãñààëò: íèéò 2 , ¿¿íä

- Ýðäýì øèíæèëãýýíèé èëòãýë 2 (Õàâñðàëò 1);

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýëèéí íýð,

òîâ÷ëîë, õýâëýãäñýí áîë ò¿¿íèé èøëýë: - (Õàâñðàëò 2) ;

- 3 óäàà îðîëöîæ, 2 óäàà èëòãýë òàâüñàí

4. Óäèðäàæ, çºâëºæ õàìãààëóóëñàí ñóäëàà÷èä: - (Õàâñðàëò 3) ;

- 2014 îíä ¿ã¿é áîëíî.

5. Áóñàä: Ýð¿¿ë ìýíä, øèíæëýõ óõààíû òàëààð Ìîíãîëä àíõ óäàà õéèæ íýâòð¿¿ëñýí ÌÌÇ-ûí äýâøèëòýä øèíý òåõíîëîãè, ìýñ çàñëûí àðãà : 2 (õàâñðàëò 4)

Àêàäåìè÷ À. Íîòà

Õàâñðàëò 1

1. Ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë:

1.1 Ìîíãîë õýëýýð - 2

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í À. Íîòàãèéí 2014 îíû àæëûí òàéëàí

Õàâñðàëò 2

1. Ýðäýì øèíæèëãýýíèé õóðàë çºâºëãººíä îðîëöñîí áàéäàë

1.1 Ìîíãîëä 3 óäàà

- Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í

- À. Íàòîãèéí 2014 îíû àæëûí òàéëàí

- Õàâñðàëò 3

Áóñàä: Ýð¿¿ë ìýíä øèíæëýõ óõààíû òàëààð:

1. Ìîíãîëûí ÌÌÇ-ûí ïðàêòèêò àíõ óäàà õèéæ íýâòð¿¿ëñýí ÌÌÇ-ûí øèíý äýâøèëòýä òåõíîëîãè ìýñ çàñëûí àðãà- 2

2. Áàÿí-ªëãèé àéìàãûí ÝÌ-ûí ñàëáàðûí 2014-2024 îíóóäàä õºãæ¿¿ëýõ ñòðàòåãè òºëºâëºëòèéí àñóóäàëóóä

2.1 ÓÈÕ-ûí ãèø¿¿ä, Àéìãèéí çàñàã äàðãà, Ýð¿¿ë ìýíäèéí ãàçðûí äàðãà, ñàëáàðûí ýðõëýã÷ íàðòàé õàìòàðñàí çºâºëãººí

2.2 Õºäººãèéí õ¿í àìä ÌÌÇ-ûí ÿàðàëòàé òóñëàìæ ¿ç¿¿ëýõ àñóóäàëä (èëòãýë)

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í À. Íîòàãèéí 2014 îíû àæëûí òàéëàí

ÌÀÓÀ-èéí ãèø¿¿í, ÀØÓ-íû äîêòîð,

ïðîôåññîð À.Íîòàãèéí 2014 îíû àæëûí òàéëàí


2015 îíû 1 ä¿ãýýð ñàð 23


- ×óóëãàíä-3, ñàëáàð çºâëºëèéí õóðàëä 3 óäàà îðæ 3 óäàà ñàíàë òàâüñàí.

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí á¿ðýí æàãñààëò:

- Íîì-2 (Õàâñðàëò № 1)

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýëèéí íýð, òîâ÷ëîë, õýâëýãäñýí áîë ò¿¿íèé èøëýë:

- ÎÓ- ûí õóðàë çîõèîí áàéãóóëæ 2 óäàà îðîëöîæ 2 óäàà èëòãýë òàâüñàí.

(Õàâñðàëò № 2)4. Óäèðäàæ, çºâëºæ õàìãààëóóëñàí ñóäëàà÷èä:- Ìàãèñòðèéí ø¿¿ìæ-2 (Õàâñðàëò № 3)

Áóñàä: - Ýð¿¿ë ìýíä, øèíæëýõ óõààíû òàëààð òºâèéí

õýâëýë ñýòã¿¿ëä 2 ºã¿¿ëýë, 1 ÿðèëöëàãà ãàðãàñàí.

Àêàäåìè÷ Ä. Ñýðæýý

Ìîíãîëûí Àíàãààõ Óõààíû àêàäåìèéí ãèø¿¿í Ä. Ñýðæýýãèéí 2014 îíû àæëûí òàéëàí

Õàâñðàëò № 1


1. Íîì

1.1 Ìîíãîë õýëýýð: “Ýìíýë ç¿éí ç¿ðõíèé öàõèëãààí áè÷ëýã” 2 äàõü õýâëýë

(Îð÷èí ¿åèéí öîãö ìýäëýãèéã íýã äîðîîñ)1.2. “Ç¿ðõíèé ¿ç¿¿ëáýðò õýò àâèàí îíîøëîãîî” 2

äàõü õýâëýë


Ä.Ñýðæýýãèéí 2014 îíû àæëûí òàéëàí



1. Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä îðîëöñîí òóõàé:

ÌÀÓÀ-èéí 2014 îíû óëèðàë òóòìûí ÷óóëãàí áîëîí ýìíýëç¿éí ñàëáàðûí ¿éë àæèëëàãààíä òîãòìîë îðîëöîæ, õýëýëöñýí àñóóäëààð ñàíàë áîäëîî èëýðõèéëæ èðñýí;

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàãñààëò

1. Òóóðâèñàí íîì:

1.1. Öàãààíõ¿¿ Ã., Äýëãýðìàà Ö. Ìýäðýë ñóäëàë (ìýðãýæëèéí ñóðàõ áè÷èã), ÓÁ., Àäìîí, 2014, 756 õ., 75.6 õýâë, õóóäàñ

1.2. Öàãààíõ¿¿ Ã. (ðåä) “Ìýäðýë ñóäëàë” ñýòã¿¿ë, 2014, 1: 98 õ., 2: 71 õ.

1.3. Öàãààíõ¿¿ Ã. (ðåä) “Ìýäðýë ñóäëàëûí îíîë-ýìíýëç¿éí çàðèì àñóóäàë” (“Theoretical and Clinical Aspects of Neurology”) Îëîí óëñûí ÝØ-íèé õóðëûí ýìõýòãýë (International Forum-2014), ìîíãîë, àíãëè õýëýýð, ÓÁ., 2014, 86 õ.

2. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë:

2.1. Àìàðæàðãàë Ì., Òîâóóäîðæ À., Öàãààíõ¿¿ Ã. Ãýìò ëèéí äàðààõ ýïèëåïñèéí àñóóäàëä. “Ýð¿¿ë ìýíäèéí øèíæëýõ óõààí” ñýòã¿¿ë, ÓÁ., 2014, 4, õ. 52-55

2.2. Õàíäìàà Ä., Òîâóóäîðæ À., Öàãààíõ¿¿ Ã. Óëààíáààòàð õîòûí õ¿í àìûí äóíäàõ óíàëò òàòàëòûí òàëààðõ îéëãîëò, ìýäëýã, õàíäëàãà, ò¿¿íä íºëººëºõ çàðèì õ¿÷èí ç¿éëñ “Ìîíãîëûí àíàãààõ óõààí” ñýòã¿¿ë, ÓÁ., 2014, 3, õ. 30-36

2.3. Ýíõáîëä Ä., Äýëãýðìàà Ö., Öàãààíõ¿¿ Ã. Òàðõèíû àðòåðèéí ö¿ëõýíò õàðâàëòûí ìýñ çàñëûí ¿ð ä¿íã ñóäàëñàí íü. “Ìýäðýë ñóäëàë” ñýòã¿¿ë, ÓÁ., 2014, 1, õ. 7-11

2.4. Öàãààíõ¿¿ Ã. “ßñíû áîðîîëîëòîä Æîíø-5

íàéðëàãûí ¿ç¿¿ëýõ ¿éëäëèéã ñóäàëñàí ä¿í” Í.Àðèóíæàðãàëûí ÀÓ-íû äîêòîðûí çýðýã ãîðèëæ òóóðâèñàí á¿òýýëä áè÷ñýí ø¿¿ìæ, ÓÁ., 2014, 108õ.

3. Ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë:

3.1. Àìàðæàðãàë Ì., Òîâóóäîðæ À., Öàãààíõ¿¿ Ã. Ãýìòëèéí äàðààõ ýïèëåïñèéí ýìíýëç¿é, ÿâöûí îíöëîã. ÀØÓ¯ÈÑ, ÀÓÑ, Ýðäìèéí ÷óóëãàí-56, ÓÁ., 2014, õ. 121-122

3.2. Õàíäìàà Ä., Äàâàà Ã., Òîâóóäîðæ À., Öàãààíõ¿¿ Ã. Óíàëò òàòàëòûí òàëààðõ ìýäëýã, õàíäëàãàä íºëººëºõ çàðèì õ¿÷èí ç¿éëñ. ÀØÓ¯ÈÑ, ÀÓÑ, Ýðäìèéí ÷óóëãàí-56, ÓÁ., 2014, õ. 125-126

3.3. Ýíõáîëä Ä., Äýëãýðìàà Ö., Öàãààíõ¿¿ Ã. Òàðõèíû àðòåðèéí ö¿ëõýíò õàðâàëòûí ìýñ çàñëûí ¿ð ä¿íã ñóäàëñàí íü. “Ìýäðýë ñóäëàë” ñýòã¿¿ë, ÓÁ., 2014, 2, õ. 7-11

4. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýë, õýâëýãäñýí áîë ò¿¿íèé èøëýë:

4.1. Öàãààíõ¿¿ Ã. Òàðõèíû ñóäàñíû âàñêóëèò. “Ìîíãîëûí ìýäðýëèéí ýì÷ íàðûí ÷óóëãàí”, 2014 îíû 6-ð ñàðûí 21-23

4.2. “Ìýäðýë ñóäëàëûí îíîë-ýìíýëç¿éí çàðèì àñóóäàë” (“Theoretical and Clinical Aspects of Neurology”) Îëîí óëñûí ÝØ-íèé õóðàë (International Forum-2014), ÓÁ., 2014, 8-ð ñàðûí 23-25.

4.3. “Òîëãîé ýðãýõ õàìøèíæ” ñýäâýýð çîõèîãäñîí ìýäðýë, ÷èõ, õàìàð õîîëîéí ýì÷ íàðûí õàìòàðñàí ñóðãàëò-ñåìèíàð. 2014 îíû 11-ð ñàðûí 15-16

ÌÀÓÀ-èéí ãèø¿¿í Ïðîôåññîð Ã.Öàãààíõ¿¿

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í, ïðîôåññîð

Ã.Öàãààíõ¿¿ãèéí 2014 îíû àæëûí òàéëàí


Ãóðàâ. Áèîàíàãààõ

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í Ã.Áàòáààòàðûí




- ×óóëãàíä 4, ñàëáàð çºâëºëèéí õóðàëä 1 óäàà îðñîí,

2. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí á¿ðýí æàãñààëò: íèéò 14, ¿¿íä íîì 1, ýðäýì øèíæèëãýýíèé ºã¿¿ëýë 6, ýðäýì øèíæèëãýýíèé èëòãýëèéí òîâ÷ëîë 5 (Õàâñðàëò 1);

3. Ýðäýì øèíæèëãýýíèé õóðàë, çºâëºëãººíä îðîëöñîí áàéäàë, òàâüñàí èëòãýëèéí íýð, òîâ÷ëîë, õýâëýãäñýí;

- 6 óäàà îðîëöîæ, 6 èëòãýë òàâüñàí

4. Áóñàä: Àøèãòàé çàãâàðûí ãýð÷èëãýý 1, òåëåâèç ðàäèîä 5 ÿðèëöëàãà ãàðãàñàí.

Àíàãààõ óõààíû äîêòîð, ïðîôåññîð Ã.Áàòáààòàð

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Ã.Áàòáààòàðûí 2014 îíû àæëûí òàéëàí

Õàâñðàëò 1


1. Íîì

1.1. Ìîíãîë õýëýýð: Äàðõëàà ñóäëàëûí ¿íäýñ

1.2. Áóñàä õýëýýð


2.1. Ìîíãîë õýëýýð-5

2.2. Áóñàä õýëýýð-1



3.2. Áóñàä õýëýýð-1

4. Áóñàä



Íîì, ñóðàõ áè÷èã

• Ã.Áàòáààòàð, Ñ.Öîãòñàéõàí, Ñ.×èìèäöýðýí, ×.Áàòòîãòîõ. Äàðõëàà ñóäëàë. Ìºíõèéí ¿ñýã. Óëààíáààòàð. 2014 îí. 65,4 õ.õ

ªã¿¿ëýë ãàäààä

• Zolmunkh N, Khandsuren B, Chimedtseren S, Tsogtsaikhan S, Batbaatar G. Determination of serum IgE titer in patients with atopic dermatitis. Current advances in microbiology and immunology. 19-21 June, 2014. Ulaanbaatar. Abstract book 27

ªã¿¿ëýë äîòîîä

• Á.Áîëîð÷èìýã, Á.Æàâ, Ã.Áàòáààòàð. ªíä-ãºâ÷èéí îëîí óéëàíõàéðàõ õàì øèíæèéí ¿åèéí ñòåðîéä äààâðûí ººð÷ëºëò, Ýõ áàðèõ ýìýãòýé÷¿¿ä ñóäëàëûí òóëãàìäñàí àñóóäàë-2014 îí, õóðëûí ýìõýòãýë, 2014.02.07

• Ñ.Àðèóíòóÿà, À. Ñàðóóëò¿âøèí, Ä. Ýíõòóÿà, Ä.Çóëãýðýë, Ñ.Öîãòñàéõàí, Ã. Áàòáààòàð, Ñ. ×èìèäöýðýí. Ëþïóñíåôðèòèéí ¿åä èéëäñèéí àóòîýñðýã áèå îíîøëîãîîíû öýãí¿¿ð ¿ç¿¿ëýëò áîëîõ íü. Ýð¿¿ë Ìýíäèéí Øèíæëýõ Óõààí.

• Ó.Óäâàë, Ç.Óðàíãîî, Cheng-Yen Kao, Ý.Áîëîðìàà, Ý.Ìºíõòóÿà, Ã.Áàòáààòàð, Æ.Ñàðàíòóÿà, Ò.Õîñáàÿð “Óëñûí êëèíèêèéí íýãäñýí ýìíýëýãò ºñãºâºðëºñºí ª¯ÂË ÿëãàðóóëàã÷ ãðàì ñºðºã ñàâõàíöàðûí àíòè-áèîòèê òýñâýðæèëòèéí õýëáýð ç¿éí ñóäàëãàà” “Ýìç¿é” ñýòã¿¿ë. 2014 îí 014;(29)10:50-52

• Àðèóíòóÿà Ñ, Ñàðóóëò¿âøèí À, Ýíõòóÿà Ä, Çóëãýðýë Ä, Öîãòñàéõàí Ñ, Áàòáààòàð.Ã, ×èìèäöýðýí Ñ “Ýðõòýí ºâºðìºö áóñ àóòîèììóí ºâ÷íèé ¿åä èéëäñèéí àóòî-ýñðýãáèå èëð¿¿ëñýí ä¿í” Ìîíãîëûí Àíàãààõ Óõààí ñýòã¿¿ë. 2014;1(167):3-6

• Ñ.Öýíäñ¿ðýí, Í.Íàðàíáààòàð, Ñ.Öîãòñàéõàí, Ã.Áàòáààòàð. Á ç à á õ ý õ ò ä. Ýð¿¿ë Ìýíäèéí Øèíæëýõ Óõààí, 2014, 10(1)(29), MMID : 4242

Îëîí óëñûí õóðàëä èëòãýñýí èëòãýë

• E.Enkhtamir,S.Chimedtseren, A.Saruultuvshin, S.Tsogtsaikhan, G.Batbaatar, M. Munkhzol. ”Importance of serum autoantibodies in the diagnostics of secondary glomerulonephritis” abstracts for the 4th International forum of “Current advances in Microbiology and Immunology”. 19-21June, 2014. UB Mongolia. p24


Èëòãýë äîòîîä

• 1.Ö.Ýðäýìáèëýã, Ã.Íàðõàæèä, Ã.Áàòáààòàð, Ã.Ýíõ-Óíäðàì, Ý.Ñîëîíãî, ß.Æàäðà, Ä.Ýíõ-Àìãàëàí. Æèðýìñíèé ¿åèéí ïðåíàòàëü õýò àâèéí îíîøèëãîîíû ÷àíàðûã ¿íýëýõ íü. MCR 2014, Õóðëûí ýìõýòãýë, 2014 îí, 30-32,

• Ã.Áàòáààòàð, Ã.Íàðõàæèä, ª.Îþóíø¿ð, Á.Á¿æèíëõàì, Ë.Áàòò¿âøèí, Á.Îþóíòºãñ, Ò.Ãàíöýöýã. Áàìáàéí ¿éë àæèëëàãààíû èõñýõ ýìãýãòýé ºâ÷òí¿¿äèéí äóíä ñýòãýöèéí òàëààñ èëðýõ ººð÷ëºëò¿¿äèéã õîðäëîãûí çýðýã, äààâðûí ººð÷ëºëòòýé õîëáîí ñóäëàõ íü. Îþóòíû Ýðäìèéí ÷óóëãàí-2014. Ýðäýì øèíæèëãýýíèé õóðëûí èòãýëèéí ýìõýòãýë, 115-116

• Ó.Óäâàë, Ç.Óðàíãîî, Cheng-Yen Kao, Ý.Áîëîð ìàà, Juinn-Jong Wu, Ð.×óëààíõ¿¿,

Á.Áàòíàñàí, Ð.Îþóí÷èìýã, Ý.Ìºíõòóÿà, Ã.Áàòáààòàð, Æ.Ñàðàíòóÿà, Ò.Õîñáàÿð “ª¯ÂË ÿëãàðóóëäàã Ãðàì ñºðºã áàêòåðèéí àíòèáèîòèê òýñâýðæèëòèéí õýâøèíæèéã ñóäàëñàí ä¿í” Õ¿ðýëòîãîîò- 2014 Ýðäýì øèíæèëãýýíèé õóðàë, èëòãýëèéí õóðààíãóé, õóóäàñ 147-150

• Àðèóíòóÿà Ñ, Ñàðóóëò¿âøèí À, Öîãòñàéõàí Ñ, Áàòáààòàð Ã, ×èìèäöýðýí Ñ “Áººðíèé ò¿¿äãýíöðèéí ¿ðýâñëèéí ¿åä èéëäñèéí àóòî-ýñðýãáèå îíîøëîãîîíû øàëãóóð ¿ç¿¿ëýëò áîëîõ íü” ÀØÓ¯ÈÑ, Áèî-Àíàãààõûí ñàëáàðûí “Ýðäìèéí ÷óóëãàí-56”. ÓÁ õîò. 2014;12

Àøèãòàé çàãâàð

• Íºõºí ¿ðæèõ¿éí íàñíû ìîíãîë ýìýãòýéí ãîíàäîòðîïèí áîëîí ñòåðîéä äààâðûã òî äîð -õîéëîõ çàãâàð÷ëàë Ã.Áàòáààòàð, Á.Áîëîð-÷èìýã


Íýã. ÌÀÓÀ-í òýðã¿¿ëýã÷èäèéí õóðàë, àæëûí õýñãèéí õóðàë, àêàäåìèéí ÷óóëãàíä òóõàé á¿ð îðîëöîæ, ñàíàë, áîäëîî èëýðõèéëæ èðëýý.

Õî¸ð. 2014 îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýë

2.1. Íîì (Îðîñ õýëýýð)

2.1.1. Ñóäëààä áàðøã¿é ýðäìèéí äàëàé (ñîíãîìîë á¿òýýë¿¿ä), 2014 îí, I áîòü 15,2 õõ.

2.2. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë (Ìîíãîë õý-ëýýð)

2.2. 1. Ýëýãíèé õàâäðûí ýñýä ýëëèïèí áýëäìýë íº-ëººëºõ òóõàé ìîëåêóë ìåõàíèçìûí òààìàãëàë (Çîõèîã÷äûí õàìò), Ìîíãîëûí Àíàãààõ Óõààí, 2014 îí, №3, õ.8-13.

2.2. 2. ×àöàðãàíà (Hippophae Rhamnoides L.) æèìñ-íèé òîñíû õ¿÷ëèéí ñóäàëãàà (çîõèîã÷äûí õàìò), ìºí òýíä, õ.47-50

2.2. 3. Áººð ýì÷ëýõ ¿éëäýëòýé áýëäìýë¿¿äèéí ôàð-ìà êîëîãèéí ñóäàëãààíû ä¿íãýýñ (çîõèîã÷äûí õàìò), ìºí òýíä, õ.55-58.

2.2. 4. Äåíòîñ 1% ãåëü ýìèéí òåõíîëîãè, ñòàíäàðò-÷èëàëûí ñóäàëãàà, (çîõèîã÷äûí õàìò) ìºí òýíä, õ.59-66.

2.2. 5. Íèéëìýë íàéðëàãà á¿õèé óðãàìëûí ãàðàë-òàé áýëäìýëèéí ýëýãíèé ºâ÷ëºëä íºëººëºõ ¿éëäëèéí ñóäàëãàà (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.20-26.

2.2. 6. Õàíèàëãà íàìäààõ ¿éëäýëòýé óðãàìëûí ãàðàëòàé ñèðîï áýëäìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ä¿íãýýñ (çîõèîã÷äûí õàìò) ìºí òýíä, õ.47-49

2.2. 7. ×àöàðãàíà æèìñíèé çàðèì áèîëîãèéí èäýâõò íýãäëèéí äèíàìèê ñóäàëãàà (çîõèîã÷äûí õàìò), Õºäºº àæ àõóéí øèíæëýõ óõààí, 2014 îí, Òóñãàé äóãààð, õ.19-24.

2.3. Ýðäýì øèíæèëãýýíèé èëòãýë (ìîíãîë õý-ëýýð)

2.3. 1. Ìîíãîë õóí÷èð (Astragalus mongolicus Bunge)–ûã õýýðèéí á¿ñýä ¿ðýýð íóòàãøóóëàí òàðèìàëæóóëñàí ñóäàëãààíû ä¿í (çîõèîã÷äûí õàìò) Ýðäìèéí ÷óóëãàí-56 (Ýì ç¿éí ñàëáàð õóðàëäààí) ÓÁ, 2014 îí, õ.97-100.

2.3. 2. Óðãàìëûí ãàðàëòàé áýëäìýëèéí ºò ãºí õàòàëòûí ýñðýã ¿éëäëèéã òîãòîîõ ôàð-ìàêîëîãèéí ñóäàëãààíû ä¿íãýýñ (çîõèîã÷äûí õàìò) “Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý, ¿éëäâýðëýë, çàõ çýýë-2014”, Îëîí óëñûí ýðäýì øèíæèëãýýíèé õóðàë, Óëààíáààòàð, 2014 îí, õ.116-118.

2.3. 3. Áººðíèé ¿ðýâñýë ýì÷ëýõ ¿éëäýëòýé áýëä-ìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ¿ð ä¿íãýýñ (çîõèîã÷äûí õàìò) ìºí òýíä.õ.119-122.

Ãóðàâ. Ðåäàêòîðëàñàí íîì,

3.1. Ë.Õ¿ðýëáààòàð. Ýêåïåðèìåíòàëüíûå äîê ëè-íè ÷åñ êèå èññëåäîâàíèÿ áåçîïàñíîñòè ôàð-ìàêîëîãè÷åñêîé àêòèâíîñòè ëåêàðñòâåííîãî ïðåïàðàòà “ÈÌÌÓÍÎÑ”. Óëààíáààòàð, 2014. 10õõ

3.2. Äîìîãò íóòãèéíõíû äàëàé èõ ¿éëñ, Óëààíáààòàð, 2014 îí, 34,16õõ.

Äºðºâ. Çºâëºæ õàìãààëóóëñàí ýðäýìòýí,

Ã.Îòãîí. Ôèçè÷åñêîå ðàçâèòèå è íåêîòîðûå ôèçèî ëîãè÷åñêèå ïîêàçàòåëè äåòåé ðàçëè÷íûõ ýêîëîãè÷åñêèõ ðåãèîíîâ Ìîíãîëèè.

Àíàãààõûí øèíæëýõ óõààíû äîêòîð, 2014.07.07-íä õàìãààëñàí.

Òàâ. ßðèëöëàãà,

5.1. ßðèëöëàãà (øèíý ýìèéí òóõàé), 2014.01.11. Ì¯ÎÍÒÂ.

5.2. ßðèëöëàãà (Õîðò õàâäðûí ýñðýã ýìèéí òóõàé), ¯íäýñíèé øóóäàí ñîíèí, 2014.09.25. №133 (2119)

Òàéëàí áè÷ñýí, Àêàäåìè÷ Ë.Ëõàãâà

2015.01.13

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í, àêàäåìè÷ Ë.Ëõàãâûí



1. Àíàãààõûí øèíæëýõ óõààíû äîêòîðûí çýðýã õàìãààëñàí á¿òýýëèéí çºâëºõººð àæèëëàñàí2. Àíàãààõ óõààíû äîêòîðûí çýðýã ãîðèëñîí á¿òýýëèéí çºâëºõººð àæèëëàñàí3. Áè÷ñýí íîì 24. Õàìòûí á¿òýýë-15. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë-26. Èëòãýë-37. ØÓÒ-èéí òºñºë õ¿ëýýëãýí ºãñºí-18. ØÓÒ-èéí òºñëèéí çºâëºõººð àæèëëàæ áóé-1

Àêàäåìè÷ Ö.Ëõàãâàñ¿ðýí

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí Åðºíõèéëºã÷,

Àêàäåìè÷ Ö.Ëõàãâàñ¿ðýíãèéí 2014 îíû àæëûí òàéëàí


1. Òºñºëò àæèë

1.1 „Òºðºëõèéí õºãæëèéí ãàæãààñ ñýðãèéëýõ æèðýìñíèé õÿíàëòûí öîãö àðãûã íýâòð¿¿ëýõ íü “ØÓÒÑ-èéí òºñºëò àæëûí çºâëºõººð àæèëëàæ 2014 îíä äóóñãàæ òàéëàí õ¿ëýýëãýí ºãºâ. Óã òºñºë ÝÕÝÌ¯Ò-ä õýðýãæèæ ïðåíàòàëü îíîøëîãîîíû ëàáðàòîðè àøèãëàëòàíä îðîâ.

1.2 „Ýïèëåïñèéí óäàìøèë, ìîëåêóë ãåíåòèêèéí ñóäàëãàà” ñýäýâò èíîâàöèéí òºñëèéí óäèðäàã÷ààð àæèëëàæ áàéíà. Óã òºñºë 2014-2016 îíä õýðýãæèõ áºãººä 2014 îíû ñàíõ¿¿æèëò íü 9-ð ñàðä îðæ èðñýí òóë àæèë äºíãºæ ýõëýýä áàéíà.

2. Õýâë¿¿ëñýí ºã¿¿ëýë

2.1 Æèðýìñýí ¿åä ÒÕÃ èëð¿¿ëýõ áèîõèìèéí ñêðèíèíã øèíæèëãýý (Æ.ãàíç¿ã, ª.Îþóí÷èìýã, Ï.Ýðõýìáóëãàí íàðûí õàìò) ÌÀÓ.2014 №2(168)92-97

2.2 Äàóíû õàì øèíæèéã æèðýìñíèé ýðò ¿åä èëð¿¿ëýõ îíîøëîãîîíû àëîãðèòì (çºâëºìæ) õàìòûí á¿òýýë 1-ð çîõèîã÷îîð) ÌÀÓ 2014 №2 (168) õ98-100

2.3 Äàóíû õàìøèíæ áîëîí ÒÕÃ-èéã æèðýìñýí ¿åä èëð¿¿ëýõ øèíæèëãýýíèé ä¿íãýýñ (õàìòûí á¿òýýë) ÝÌØÓ ñýòã¿¿ë 2014 òóñãàé äóãààð õóóäàñ 29

2.4 Õàâäðûí ãåíåòèê (òîéì ºã¿¿ëýë) Innovation ñýòã¿¿ë (õýâëýëä)

3. Èëòãýë

3.1 Çàðèì õðîìîñîìûí áîëîí ÒÕÃ-èéã èëð¿¿ëýõ

õî¸ðîë, ãóðâàë ñîðèëûí ä¿í. 2014 ÁÀÑ, Ýðäìèéí ÷óóëãàí 56

3.2 Äàóíû õàìøèíæèéí ýìíýë ç¿éí îíîøèéã öèòîãåíåòèêèéí øèíæèëãýýãýýð áàòàëñàí ä¿í (ª.Îþóí÷èìýã, Æ.Ãàíç¿ã, Ï.Ýðõýìáóëãàí., È.Ï¿ðýâäîðæ) ÁÀÑ. Ýðäìèéí ÷óóëãàí-56. 2014 îí

4. Øèíý á¿òýýëèéí ïàòåíò

4.1 21-ð õðîìîñîìûí ýìãýãèéã æèðýìñíèé ýðò ¿åä èëð¿¿ëýõ àðãûí çàãâàð÷ëàë øèíý á¿òýýëèéí №3972 (È.Ï¿ðýâäîðæ, ª.Îþóí÷èìýã, Æ.Ãàíç¿ã, Ã.Ìýíäñàéõàí) ÌÓ-ûí îþóíû ºì÷èéí ãàçðûí äàðãûí 2014 îíû 58-ð òóøààë

5. Æ.Ãàíç¿ã, Ì.Ï¿ðýâäîðæ, Ä.Ñàí÷èðìàà íàðûí äîêòîðûí àæëûí óäèðäàã÷ààð àæèëëàæ áàéíà.

6. Øèíæëýõ óõààíû ñóðòàë÷èëãàà

6.1 „Áàãø äîð ìºðãºì¿¿” ñýäâýýð 3 óäàà

6.2 „ ªºðòºº èòãýæ ºðººëèéã äàãóóëàõ ÷àäâàð” ñýäâýýð 4 óäàà òóñ òóñ ëåêö óíøèæ

6.3 „Êëîíû àðãà àíàãààõ óõààíä”, „Ýðèí öàãèéí ãåíåòèêèéí øèíæëýõ óõààíû õºãæèë” ñýäâýýð òåëåâèçèéí ÿðèëöëàãà 3 óäàà õèéâ.

7. Óäàìç¿éí çºâëºãºº

Õîò õºäººãèéí 37 õ¿íä óäàìç¿éí ¿çëýã, øèíæèëãýý õèéñýí çºâëºãºº ºãñºí.

Ïðîôåññîð È.Ï¿ðýâäîðæ2014.01.24

Ìîíãîëûí Àíàãààõ Óõààíû Àêàäåìèéí ãèø¿¿í,

ïðîôåññîð È.Ï¿ðýâäîðæèéí 2014 îíû àæëûí òàéëàí


Äºðºâ. Ýìç¿é, Óëàìæëàëò àíàãààõ

Àêàäåìè÷ Øàðàâûí Áîëäûí 2014 îíä õèéñýí àæëûí òàéëàí

Øèíæëýõ óõààíû àêàäåìèéí áîëîí Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä çîõèõ ̧ ñîîð îðîëöîæ èðëýý.

Íýã. 2013-2014 îíä “Óëàìæëàëò àíàãààõ óõààíû òóëãóóð á¿òýýë¿¿ä” èííîâàöèéí òºñëèéí ¿ð ä¿íã õ¿ëýýëãýí ºãºâ. ¯¿íä:

- Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû òàéë-áàðò äýýæ áè÷èã íîì;

- History and Development of Traditional Mon-golian Medicine íîìûã àíãëè õýëýýð;

- Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì íàéðëàãûí ñóäëàë íîì;

- Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì ñóäëàë íîìûã òóñ òóñ õýâë¿¿ëýâ.

Ýíý òºñëèéí à÷ õîëáîãäëûã äàðààõ áàéäëààð òîäîðõîéëæ áàéíà.

1/ “Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì íàéðëàãûí ñóäëàë” íîì íü Ýíýòõýã, Òºâºä, Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû òóëãóóð á¿òýýë, ãîë ãàðûí àâëàãà “Àëòàíãýðýë” ñóäàð”-ûí 24 ä¿ãýýð á¿ëýã, “ßçãóóðûí ¿íäýñ” áîëîí Ëàìûí ãýãýýí, Èøäàíçàíâàíæèë, Ðîëáèéäîðæ íàðûí òºâºä õýëýýð áóé àíàãààõ óõààíû õîâîð ñóäðûã ìîíãîë, çàðèì á¿òýýëèéã àíãëè õýëýýð îð÷óóëæ, ìîíãîë áè÷ãýýð áè÷èæ õàâñàðãàñíû çýðýãöýý, 293 ¸ãò, èëò ºã¿¿ëýõ íýðýíä òàéëáàð õèéæ, Ìîíãîëûí àíàãààõ óõààíû òîâ÷ ò¿¿õ, ñóðâàëæ áè÷ãèéí ñóäàëãààíû òîéìûã íýãòãýí ãàðãàâ. ¯¿ãýýð ýíý á¿òýýëèéí øèíýëýã òàë òîäîðõîéëîãäîíî.

2/ Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ò¿¿õòýé õîëáîîòîé ýõ ñóðâàëæ, àðõåîëîãèéí îëäâîðóóäûã ìîíãîë, òºâºä, õÿòàä õýëýýð áè÷èãäñýí àíàãààõ óõààíû ýðòíèé á¿òýýë¿¿äýä áóé áàðèìò, íîòîëãîîòîé óÿëäóóëàí òóñãàéëàí ñóäàëæ, óëàìæëàëò àíàãààõ óõààíû õºãæëèéã òîäîðõîé ¿å¿äýä õóâààí, àíàãààõ óðëàã, çàñëûí ¿¿ñýë, õºãæëèéí 5000 æèëèéí õºãæëèéã òîäðóóëàí óëìààð ìîíãîë ýì÷, ìààðàìáà íàðûí á¿òýýë äýõ îíîë àðãà ç¿éí øèíýëýã îéëãîëò, øèíæëýõ óõààíû îëîëòóóä áîëîí ýð¿¿ë àìüäðàõ óëàìæëàëò ìýäëýãèéã íýãòãýí áè÷ñýíä History and Fundamentals of Traditional Mongolian Medicine á¿òýýëèéí øèíýëýã òàë îðøèíî.

3/ Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì íàéðëàãûí ñóäëàë á¿òýýë íü íýã òàëààñ Ìîíãîë Óëñ áîëîí îëîí óëñûí ò¿âøèíä óëàìæëàëò

àíàãààõ óõààíû óðãàìàë, àìüòàí, ýðäýñ îðñîí ñîíãîäîã, õîâîð (íóóö) ýì íàéðëàãûí òàëààð õèéãäñýí ýðäýì ñóäëàëûí àæëûí ¿ð ä¿íã íýãòãýí óëìààð òºâºä õýëýýð óëàìæëàãäàæ èðñýí ýìèéí íîì ñóäðûí àãóóëãàòàé õîñëóóëàí òóóðâèãäàæ, íºãºº òàëààñ ïðàêòèêààð øàëãàãäñàí ìýäëýãèéã íîòîëãîîíä ñóóðèëàí áàòàëãààæóóëàõ áîëîìæèéã íýýæ ¿¿ãýýðýý ñóðàõ áè÷èã, ñóäàëãààíû ñóóðü ìàòåðèàë áîëîõ òºäèéã¿é ñóäëàà÷äàä ýðäìèéí àæëûí çàãâàð áîëíî õýìýýí ¿çýæ áàéíà.

4/ Óëàìæëàëò àíàãààõ óõààíä ºðãºí õýðýãëýãääýã íýí õîâîðäñîí ýìèéí óðãàìàë, ýðäýñ, ìººã, àìüòíû ýìèéã îëæ òîãòîîí, íýðøèë, òàíèõ àðãà, á¿òýö, àíãèëàë, íîìõîòãîõ àðãà, õýðýãëýõ çààëòûã òîäðóóëàí óëàìæëàëò àíàãààõ óõààíä ñóðàëöàã÷ íàðò çîðèóëæ ýìò áîäèñûã çºâ òàíèõ ãàðûí àâëàãà Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì ñóäëàëûí ñóðàõ áè÷ãèéã õýâë¿¿ëýâ. ¯¿íä:

- ÌÓÀÓ-íû ýì ñóäëàëûí ò¿¿õ, îíîëûí îéëãîëòûã îí äàðààëëûí äàãóó øèíý÷ëýí áè÷ñýí.

- Ýìèéí ò¿¿õèé ýäèéã 17 õýñýãò õóâààæ, íèéò ºðãºí õýðýãëýãääýã 270 øàõàì ç¿éëèéí ýìèéí ò¿¿õèé ýäèéí æàãñààëò õèéæ, àâ÷ ñóäàëãàà ÿâóóëæ, ýìèéí ò¿¿õèé ýäèéí òîäîðõîéëîëòûã õèéâ.

- Óðãàìàë ñóäëàëûí óõààíû ñóóðü ìýäëýã, àíãèëàë, àìüòàí, ýðäýñ, ìººãíèé ãàðàëòàé ýìèéí ò¿¿õèéí ýäèéí òóõàé åðºíõèé îéëãîëò íýãòãýí áè÷ñýí.

- Ýìèéí ò¿¿õèé ýäýä àãóóëàãäàõ çàðèì áèîëîãèéí èäýâõèò áîäèñûí òîäîðõîéëòûã îðóóëñàí.

- Ýìèéí ò¿¿õèé ýäèéí íýð òîìü¸îã ÿíç á¿ðýýð áè÷äýã áàéñíûã íýã ìºð áîëãîõ îðîëäëîãî õèéñýí.

- Ýì ñóäëàëûí ñóðàõ áè÷èãò õóó÷íû ìîíãîë ìààðàìáà, ýì÷ íàðûí àìàí ÿðèà, õóó÷, õîâîð ÷óõàã ìýäýý, áàðèìòûã ºíººãèéí ìýäëýãèéí õýðýýð îëæ òîãòîîí îðóóëàâ.

Õî¸ð. “Óëàìæëàëò àíàãààõ óõààíûã äýëãýð¿¿ëýõ” òºñëèéí (2004-2013) òàéëàíã àíãëè, ìîíãîë õýëýýð áè÷èæ õýâë¿¿ëýâ. Õýðýãæ¿¿ëýã÷: “Âàíñýìáýð¿¿-Ìîíãîë” ÒÁÁ, Ñàíõ¿¿æ¿¿ëýã÷: Íèïïîí ñàí, Õàìòðàí àæèëëàñàí: Ìîíãîë Óëñûí Ýð¿¿ë ìýíäèéí ÿàì.

Òºñëèéí ¿íäñýí çîðèëãî íü áóääûí øàøèíòàé õàìò õîðèãëîãäîîä áàéñàí 5000 æèëèéí ò¿¿õòýé Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíûã ñýðãýýí


õºãæ¿¿ëýõýä õóâü íýìðýý îðóóëæ, ýð¿¿ë ìýíäèéí àíõàí øàòíû òóñëàìæ, ¿éë÷èëãýýã óëàìæëàëò àíàãààõ óõààíû àðãûã àøèãëàõ çàìààð àðä èðãýäýä õ¿ðãýõ, íèéãìèéí ýð¿¿ë ìýíäèéí õºãæèëä õóâü íýìðýý îðóóëàõàä îðøèæ áàéâ. Ýäãýýð ¿éë àæèëëàãààíû õ¿ðýýíä:

- Óëàìæëàëò àíàãààõ óõààíû ýì á¿õèé “ªðõèéí ýìèéí ñàí”-ã ìàë÷èí ºðõ á¿ðò òàðààõ;

- Óëàìæëàëò àíàãààõ óõààíû ìýðãýæëèéí ýì÷ íàð õºäºº îðîí íóòàãò î÷èæ ÿâóóëûí îíîøèëãîî, ýì÷èëãýýã ¿íý òºëáºðã¿é õèéõ;

- Ìîíãîë Óëñûí Ýð¿¿ë ìýíäèéí ÿàì, àéìãèéí ýð¿¿ë ìýíäèéí ãàçàð, ñóìûí ýìíýëýãòýé õàìòðàí îðîí íóòãèéí ýìíýëýãò àæèëëàæ áàéãàà ýì÷, ýìíýëãèéí àæèë÷èä áîëîí íóòãèéí èðãýäýä óëàìæëàëò àíàãààõ óõààíû ñóðãàëò ÿâóóëàõ ãýõ ìýò àæëóóäûã õèéæ ã¿éöýòãýâ.

“ªðõèéí ýìèéí ñàí”-ã 3 àéìãèéí 4 ñóìûí 2000 ºðõèéí 10000 õ¿íä àøèãëóóëàõààð òºëºâëºñºí õýäèé ÷ öàð õ¿ðýýãýý òýëñýýð ºíãºðñºí 10 æèëèéí äîòîð 8 àéìãèéí 35 ñóìûí 20000 ºðõèéí 100000 îð÷èì õýðýãëýã÷èäòýé áîëæýý.

Ýíýõ¿¿ òºñëèéã õýðýãæ¿¿ëñýíýýð ñóìûí ýìíýëãèéí ýì÷ íàðûí ãýðýýð ÿâàõ äóóäëàãûí òîî ýðñ öººð÷, èðãýäèéí ýìíýëýãò î÷èæ ¿ç¿¿ëýõ íü áàãàññàí ãýõ ìýò òîäîðõîé ¿ð ä¿í ãàðñàíû çýðýãöýý óëàìæëàëò àíàãààõ óõààíû ýì÷èëãýýíèé àðãûã ýð¿¿ë ìýíäèéí àíõàí øàòíû òóñëàìæèíä àøèãëàæ àìæèëòàíä õ¿ðñýí õîâîðõîí æèøýý õýìýýí ÄÝÌÁ-ûí Åðºíõèé íàðèéí áè÷ãèéí äàðãà ºíäºðººð ¿íýëñýí áºãººä Ìîíãîë Óëñàä àìæèëòòàé õýðýãæñýí óã òºñëèéí ¿ð ä¿íã Ç¿¿í ºìíºä Àçèéí óëñ îðíóóäûí çàñãèéí ãàçàðò òàíèëöóóëñàí þì. ¯¿íèé ¿ð ä¿íä ºíººãèéí áàéäëààð Ìüÿíìàðûí õîëáîîíû óëñ, Òàéëàíäûí âàíò óëñ, ÁÍÑÂÓ-ûí Çàñãèéí ãàçàð Ìîíãîëä õýðýãæñýí òºñëèéã çàãâàð áîëãîí õýðýãæ¿¿ëæ ýõëýýä áàéíà.

2014 îíä áè÷èæ íèéòë¿¿ëñýí áîëîí áóñàä á¿òýýëèéí òîâ÷îî

ä/ä Á¿òýýëèéí àíãèëàëÁ¿òýýëèéí

òîî1 Íîì 2

2 Òºñëèéí òàéëàí 4

3 Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë 6

4 Ñîíèíä áè÷ñýí ºã¿¿ëýë 1

5 Óäèðäñàí àæèë (ìàãèñòð) 4

6 Òåëåâèçä ºãñºí ÿðèëöëàãà 5

7 Íèéò 22

Õàâñðàëò

ä/ä Á¿òýýëèéí íýð Òºðºë

Õýâëýãäñýí ñýòã¿¿ë áîëîí ýìõòãýëèéí íýð

Îí ÕóóäàñÕàìòàðñàí

çîõèîã÷

Íýã. Íîì

1Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì íàéðëàãûí ñóäëàë

Íîì “Ìºíõèéí ¿ñýã” õýâëýëèéí ¿éëäâýð, ÓÁ

2014 317 õ

Ö.Ìºíõòóÿà, Ç.ÀðèóíààÁ.ÁîëîðÁ.ÖýðýíöîîÑ.Îòãîíá¿ðýí

2Ìîíãîëûí óëàìæëàëò àíàãààõ óõààíû ýì ñóäëàë

Íîì “Ìºíõèéí ¿ñýã” õýâëýëèéí ¿éëäâýð, ÓÁ

2014 301 õÁ.Õ¿ðýë÷óëóóí, Á.Áîëîð íàðûí õàìò

Õî¸ð. Òàéëàí

3

Óëàìæëàëò àíàãààõ óõààíûã äýëãýð¿¿ëýõ”òºñëèéí òàéëàí, 2004-2013

Òàéëàí ÂÑÃ õýâëýëèéí êîìïàíè, ÓÁ

2014 157 õ Æ.Òîãòîõáàÿð


4 “Dissemination of Traditional Medicine” (2004-2013)

Òàéëàí ÂÑÃ õýâëýëèéí êîìïàíè, ÓÁ

2014 151 õ

5 “Óëàìæëàëò ýìèéí ò¿¿õèé ýä áîëîí æîðûí ìýäýýëëèéí ñàí á¿ðä¿¿ëýõ ñóäàëãàà äýä òºñëèéí òºãñãºëèéí òàéëàí (2012-2014 îí)

Òàéëàí ÓÁ 2014 25 õ

6 “Óëàìæëàëò àíàãààõ óõààíû òóëãóóð á¿òýýë¿¿ä”

Òàéëàí ÓÁ 2014 19 õ

Ãóðàâ. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë

7 Ø¿íãèéí íîìîíä áóé õàëóóí, õ¿éòýí îíîëûí çàðèì àñóóäëóóä.

Ìîíãîëûí ýì ç¿é, ýì ñóäëàë ñýòã¿¿ë, ÓÁ

2014 №2 (5), õ.48-52

Á.Ãàí-ªðíºõ, áóñàä

8 Íèéòëýã õýðýãëýäýã ñóäàëãààíû àðãóóä


2014 №2 (5), õ.53-56

9 Ýðäñèéí ãàðàëòàé çàðèì ò¿¿õèé ýäèéí èëò ºã¿¿ëýõ íýðèéí òóõàé


2014 №2 (5), õ.48-52

Ë.Àíõöàöàðàë, áóñàä

10 Óëàìæëàëò àíàãààõ óõààíû òóëãóóð á¿òýýë¿¿ä


2014 №2 (5), õ.57-59

Á.Ìºíãºíòóÿà

11 “Ñ¿ìáý õàìáà Èøáàëæèðûí á¿òýýëèéí ñóäàëãàà, ñýòãýëãýýíèé ãàéõàìøèã”

Ìîíãîëûí àíàãààõ óõààí ñýòã¿¿ë.

2014 №4 (170)õ.11-28

Á.Îþóí-Ýðäýíý

12 “¯çýñãýëýíò í¿äýí ÷èìýã çîõèîëä áóé èëò ºã¿¿ëýõ íýðèéí ñóäàëãàà”

Îíîø ñýòã¿¿ë 2014 Ë.Àíõöàöðàë

Äºðºâ. Áîäëîãûí áàðèìò áè÷èã

13 0-3 íàñòàé õ¿¿õäèéí õºãæëèéí õºòºëáºð áîëîâñðóóëàõàä áàðèìòëàõ ¿çýë áàðèìòëàë

2014 ÑÇÕ¯Ò

14 Õºãæëèéí áýðõøýýë ñóäëàëûã 2014-2017 îí õ¿ðòýë õºãæ¿¿ëýõ ¿íäñýí ÷èãëýë

2014 ÑÇÕ¯Ò

15 Ýð¿¿ë ìýíäèéí àíõàí øàòíû òóñëàìæ ¿ç¿¿ëäýã ýì÷, ýìíýëãèéí àæèëòàíä çîðèóëñàí õºãæëèéí áýðõøýýëèéã ýðò ¿åä èëð¿¿ëýõ ãàðûí àâëàãà

2014 ÑÇÕ¯Ò

Òàâ. Ñîíèíä áè÷ñýí ºã¿¿ëýë

16 Õ¿¿õäèéí õºãæëèéí õîöðîãäëûã ýðò èëð¿¿ëñíýýð áýðõøýýëèéã 30 õóâèàð áóóðóóëàõ áîëîìæòîé

ªã¿¿ëýë ªäðèéí ñîíèí 2014 № 184


I. Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí ÷óóëãàí, ñàëáàð çºâëºëèéí ¿éë àæèëëàãààíä îðîëöñîí òóõàé:

Òàéëàíãèéí õóãàöààíä ÌÀÓÀ-èéí ÷óóëãàí ñàëáàð Çºâëºëèéí ¿éë àæèëëàãààíä òîãòìîë îðîëöîæ èðñýí.

II. Áè÷èæ íèéòë¿¿ëñýí á¿òýýëèéí æàãñààëò:

Ýíý õóãàöààíä ýðäýì øèíæèëãýýíèé äîîðõ á¿òýýë¿¿äèéã áóñàä ñóäëàà÷èäòàé õàìòðàí áè÷èæ õýâë¿¿ëñýí.

A. Íîì ýìõýòãýë

1. Òºãñ çîõèðîëò òîãòîëöîîò íýãòãýìýë àíàãààõ óõààí íýðòýé íîì áè÷èæ õýâëýëä øèëæ¿¿ëýõýä áýëòãýæ áàéíà.

2. Ìîíãîëûí Óëàìæëàëò àíàãààõ óõààí òîãòìîë ñýòã¿¿ëèéí № 3, 4-èéã áýëòãýõýä îðîëöîí õýâ-ë¿¿ëýýä áàéíà.

B. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë

1. Àìüòíû õ¿÷èëòºðºã÷èéí äóòàãäëûã òýñâýðëýõ ÷àäâàðò “Àäàïòîí-6” áýëäìýëèéí íºëºº. Áàëüõàåâ È.Ì, Äàãâàöýðýí Á, Íèêîëàåâ Ñ.Ì. Ìîíãîëûí óëàìæëàëò àíàãààõ óõààí öóâðàë-3, Äóãààð 1, õ. 37-40

2. Áàéãàëèéí ãàðàëòàé àäàïòîãåíèé ýëýã õàì-ãààëàõ èäýâõè. Áàëüõàåâ È.Ì, Äàãâàöýðýí Á, Íèêîëàåâ Ñ.Ì. Ìîíãîëûí óëàìæëàëò àíàãààõ óõààí öóâðàë-3, Äóãààð 1, õ. 40-45

3. “Àïèëàê”, “Ïîëèôèòîòîí”, “Àäàïòîí-6”, àäàïî-ãåí áýëäìýë¿¿äèéí àêòîïðîòåêòîð èäýâõè. Áàëüõàåâ È.Ì, Äàãâàöýðýí Á, Íèêîëàåâ Ñ.Ì. Ìîíãîëûí óëàìæëàëò àíàãààõ óõààí öóâðàë-3, Äóãààð 1, õ. 45-49

4. Óëàìæëàëò Íàðó-3 æîðûí áèîëîãèéí èäýâõèéí ñóäàëãàà. À.Òºãºëäºð, Ö.Õîíãîðçóë, Ç.Îþóí, Â.Ñàðàí÷èìýã, Á.Äàãâàöýðýí. Ìîíãîëûí àíà-ãààõ óõààí 2014. 167(1) 51-54

5. Antimicrobial activity of drug Naru-3 on gram Positive and gram negative microorganism. International journal of Pharm Tech Research. Coden (USA): LJRIF. Vol. 6, No 3, pp. 894-898. Tuguldur. A, Khongorzul Ts, Narangerel B, Dagvatseren B.

6. Antimicrobial effect of Annona squamosa ethyl acetate extract. International journal of Pharma and Bio Sciences 2014, vol.5, issue 4, pp-236.

7. Ö.Íÿìäýìáýðýë, Á.Äýæèäìàà, Ã.Á¿ðýíáààòàð, Á.Äàãâàöýðýí. Òýíãýðèéí ä¿ëèé ìººã (Calvatia

gigantea Batstc. Ex Pers)-íèé ñïîð ýìèéí ò¿¿õèé ýäèéí ¿éëäâýðëýã÷èéí ôàðìàêîïåéí ºã¿¿ëëèéí òºñëèéã áîëîâñðóóëñàí íü. Ìîí-ãîëûí Óëàìæëàëò Àíàãààõ Óõààí ñýòã¿¿ë, öóâðàë 2. Äóãààð 2, õ.128

8. Ö.Íÿìäýìáýðýë, Á.Äàãâàöýðýí “Çîìîøèí-6” òàíãèéí ôèòîõèìèéí ñóäàëãàà. ÌÓÀÓ ñýòã¿¿ë. ÓÁ, 2014 /õýâëýëòýíä/.

C. Ýðäýì øèíæèëãýýíèé õóðàë çºâëºëãººíä îðîëöñîí áàéäàë

1. S.M.Nikolaev, B.Dagvatsteren, A.G.Mondoloev, L.N.Shantanova, T.A.Asheeba, Y.B.Khobrakova, Ya.G.Rashuaeba, E.V.Petrov, S.A.Chukob. Prospects of the creation of multicomponent medicinal preparations with system effect on the base of Tibetan formula. The 1st International scientific conference on Mongolian Biodiressity Heritage. Folk remedy of Mongolia and developmental strategy of traditional knowledge. Ulaanbaatar. February II, Tue, 2014, p. 58-61

2. Òàðõè äîðãèëò ò¿¿íèéã çàñàõ ìîíãîëûí óëàìæëàëò áàðèà çàñëûí àðãûí òàëààðõè òîéì. Ìºí á¿òýýëä, õ. 167-177.

3. Ýðäýíý÷èìýã ×, Äàãâàöýðýí Á, Àðèóíàà Ç, Õèøãýý Ä, Ñóãàðæàâ Ý. Àëòàéí äàëàí õàëüñíû æèìñíýýñ øàõìàë ýìèéí õýëáýð ãàðãàí àâñàí ¿ð ä¿í. Ýðäìèéí ÷óóëãàí-56 Ýì ç¿éí ñàëáàð õóðàëäààí. Óëààíáààòàð. 2014.õ.43-47.

D. Ñàíàà÷ëàãààðàà õèéæ ã¿éöýòãýñýí àæëóóä1. Ìîíãîëûí Óëàìæëàëò àíàãààõ óõààí ñýò-

ã¿¿ ëèéã ÎÕÓ-ûí Áóðèàä, ªÌªÇÎ, ªìíºä Ñîëîíãîñûí õàìòûí àæèëëàãààòàé áàéãóóë-ëàãûí ýðäýìòýä ýì÷ ñóäëàà÷äûí äóíä ñóð-òàë÷ëàõ àæëûã çîõèîí ÿâóóëñàí.

E. Áóñàä àæëóóä

1. “Óëàìæëàëò ýì òàí íàéðóóëàõ çàð÷èì, òåõíîëîãèéí ñóäàëãàà” ñýäýâòýé ØÓÒ-èéí òºñëèéã 2012-2014 îíû õîîðîíä óäèðäàæ àæèëëàñàí.

2. Ýðäýì øèíæèëãýýíèé àæèëòàí Òºãºëäºðèéí “Óëàìæëàëò Íàðó-3 ýìèéí áèîëîãèéí èäýâõè” íýðòýé áèîëîãèéí óõààíû äîêòîðûí çýðýã õàìãààëñàí á¿òýýëèéí ýðäýì øèíæèëãýýíèé àæëûí çºâëºõººð àæèëëàñàí.

3. Á.Öýðýíöîî áàãøèéí “Ýëýãíèé õàâäðûí ýñýä Áàéãàëèéí ã¿¿í õºõ óðãàìëûí íºëºº” ñýäâýýð àíàãààõ óõààíû äîêòîðûí çýðýã õàìãààëñàí á¿òýýëèéí ýðäýì øèíæèëãýýíèé àæëûí çºâëºõ

Ìîíãîëûí Àíàãààõ óõààíû àêàäåìèéí ãèø¿¿í Á.Äàãâàöýðýíãèéí



4. Ä.Íÿìäîðæèéí “Òàðâàãàíû áîð ººõíèé á¿òýö, ò¿¿íèé íºëººã íîéð áóë÷èðõàéí ¿ðýâñëèéí ýìãýã çàãâàðò ñóäàëñàí íü” ñýäýâò àíàãààõ óõààíû äîêòîðûí çýðýã ãîðèëñîí á¿òýýëä àëáàí ¸ñíû ñàíàë ø¿¿ìæ áè÷ñýí.

5. Äîêòîðàíò È.Ì.Áàëüõàåâûí àíàãààõûí øèíæ-ëýõ óõààíû äîêòîðûí çýðýã ãîðèëñîí á¿òýýë, ýì÷ Ä.Àìàðçàÿàãèéí àíàãààõ óõààíû äîêòîðûí çýðýã ãîðèëñîí àæëûí çºâëºõ õèéæ áàéíà.

6. Óëàìæëàëò àíàãààõ óõààíû íýýëòòýé ºäºðëºã (10 ñàðä) çîõèîõ àæèëä õàìòðàí îðîëöîæ “Óëàìæëàëò àíàãààõ óõààíû ýð¿¿ë àæ òºðºõ ¸ñ”-íû òàëààð ëåêö óíøñàí.

7. Õ.×àãäàíõîðîëûí ìàãèñòðûí çýðýã õàìãààë-ñàí “Ýì òàíèõ óõààíä ìîíãîë÷óóäûí îðóóëñàí õóâü íýìýð” á¿òýýëä ýðäýì øèíæèëãýýíèé àæëûí çºâëºõººð àæèëñàí.

F. Áèåò á¿òýýë

1. Ýëýã õàìãààëàõ ¿éëäýëòýé “Ëîíàë” íýðòýé øèíý ýìèéí õèìè-ôàðìàêîëîãèéí ñóäàëãàà, ñòàíäàðò òåõíîëîãè, ýìíýëç¿éí ñóäàëãààã áóñàä ñóäëàà÷èäòàé õàìòðàí òºñºëò àæëûí õ¿ðýýíä õèéæ ã¿éöýòãýñýí.

ÌÀÓÀ-èéí ãèø¿¿í, Àíàãààõûí øèæëýõ óõààíû äîêòîð, ïðîôåññîð: Á.Äàãâàöýðýí


Íýã. Çîõèîñîí íîì, ñóðàõ áè÷èã (5 øèðõýã, íèéò 47,0 õõ):

1. Ìîíãîë õàíóóðûí óâäèñ ISBN 978-99973-45-31-8; 2014 îí,4,5 õõ

2. “Ìîíãîëûí àíàãààõûí ìýðãýä” ÕÕ áîòü, Â.È÷èíõîðëîî ISBN 978-99973-2-690-4; 2014 îí, 15,5 õõ

3. “Îðîéí äýýä î÷èðäàðà õóâèëãààí” ISBN 978-99973-2-585-3; 2014, 10,62 õõ

4. “Öýýëèéí öàãààí íºìðºãòí¿¿ä” 2014 îí, 10,0 õõ

5. Ýð¿¿ë áèåèéí áè÷èë á¿òöèéí àòëàñ” 2014 îí, 6,5 õõ

Õî¸ð. Ðåäàêòîðëàñàí íîì (1 øèðõýã, íèéò 31,5 õõ)

1. Õ¿íèé àíàòîìè (ñóðàõ áè÷èã) Çîõèîã÷ Ã.Äîðææàãäàã 2014 îí. 31,5 õ.õ.

Ãóðàâ. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë (ãàäààäàä 1, äîòîîäîä 5)

1. “Òóðøèëòûí àìüòàíä íîéð áóë÷èðõàéí öî÷ìîã ¿ðýâñýë ¿¿ñãýõ íü” (Ä.Íÿìäîðæ íàðûí õàìò) “ÝÐ¯¯Ë ÌÝÍÄÈÉÍ ØÈÍÆËÝÕ ÓÕÀÀÍ ” ñýòã¿¿ë 2014 Vol 10. №1 (29) Õ.87-90.

2. Áèãýðèéí “Òàâàí ýëñ” ñóâèëàëûí ýì÷èëãýýíèé îíîëûí ¿íäýñëýë (ã.Ï¿ðýâäîðæ, Ä.Íÿìäîðæ)

3. “Õ¿í, àìüòíû áîð ººõíèé á¿òöèéí îíöëîã ò¿¿íèé íºëººã íîéð áóë÷èðõàéí ¿ðýâñëèéí ýìãýã çàãâàðò ñóäàëñàí ä¿í” (Ä.Íÿìäîðæ íàðûí õàìò)

4. “Òóðøèëòûí àìüòàíä ¿¿ñãýñýí íîéð áóë÷èð-õàéí öî÷ìîã ¿ðýâñýëä òàðâàãàíû áîð ººõíèé íºëººã ñóäàëñàí ä¿í. ”(Ä.Íÿìäîðæ íàðûí õàìò) “ÝÐ¯¯Ë ÌÝÍÄÈÉÍ ØÈÍÆËÝÕ ÓÕÀÀÍ” ñýòã¿¿ë 2014 Vol 10. №2 (30)

5. “Îëîí þìíû àíõäàã÷ áîëîõîîð íü Îëîí õ¿íèé îãøîî òºðäºã áàéõ...” “ÎÍÎØ” ñýòã¿¿ë 2014 îí, № 2(62) õ.100-102.

6. Experimental study detection of CD4+ and CD8+T Cells in the -American Journal of Clinical and Experimental brown adipose tissue Medicine. 2014; 2(1). 4-8.

Äºðºâ. Ýðäýì øèíæèëãýýíèé èëòãýë (4)

1. “Íîéð áóë÷èðõàéí öî÷ìîã ¿ðýâñýëèéã òóðøèëòûí àìüòàíä ñåðóëåéíýýð ¿¿ñãýõ íü” /Ä.Íÿìäîðæ íàðûí õàìò/ Áèî-Àíàãààõûí ñàëáàðûí ýðäìèéí ÷óóëãàí -56 èëòãýëèéí õóðààíãóé

2. “Íîéð áóë÷èðõàéí öî÷ìîã ¿ðýâñýëòýé òóðøèëòûí àìüòàíä òàðâàãàíû áîð ººõíèé íºëººã ñóäàëñàí ä¿í” /Ä.Íÿìäîðæ íàðûí õàìò/ Áèî-Àíàãààõûí ñàëáàðûí ýðäìèéí ÷óóëãàí -56 èëòãýëèéí õóðààíãóé

3. “Õ¿í, àìüòíû áîð ººõíèé á¿òöèéí îíöëîã ò¿¿íèé íºëººã íîéð áóë÷èðõàéí ¿ðýâñëèéí ýìãýã çàãâàðò ñóäàëñàí ä¿í” (Ä.Íÿìäîðæ íàðûí õàìò)

4. “Ïðîôåññîð Áàçàðûí Äýìáýðýëèéí ñóðãàí õ¿ì¿¿æ¿¿ëýõ àðèóí ¿éëñ” (Ö.Ëõàãâàñ¿ðýí, ×.Öîëìîí)

Òàâ. Ø¿¿ìæ (2):

1. Áàÿðààãèéí Ìýíäõ¿¿ãèéí “Õ¿íèé áèåèéí á¿òýö ç¿éí õè÷ýýëèéí òåõíîëîãèä çàãâàð÷ëàõ àðãûã õýðýãëýõ áîëîìæ”–Áîëîâñðîëä ñóäëàëûí äîêòîð (Ph.D) çýðýã ãîðèëñîí á¿òýýëèéí æèíõýíý õàìãààëàëòûí ø¿¿ìæ. 2014 îí.

2. Ãàëñàíæàâûí Îòãîíû “Ôèçè÷åñêîå ðàçâèòèå è íåêîòîðûå ôèçèîëîãè÷åñêèå ïîêàçàòåëè äåòåé ðàçëè÷íûõ ýêîëîãè÷åñêèõ ðåãèîíîâ ìîíãîëèè”.–Äèññåðòàöèè íà ñîèñêàíèå ó÷åíîé ñòåïåíè (Sc.D) äîêòîðà ìåäèöèíñêèõ íàóê. 2014 ã.

Çóðãàà. Íèéòëýëèéí á¿òýýë (2):

1. Àêàäåìè÷, ïðîôåññîð Áîäèéí Äàãäàíáàçàðûí á¿òýýë, ãýðèéí íîìûí ñàíã–“Ñî¸í ãýãýýð¿¿-ëýã÷” òåëåâèç íîìûí õîéìîð, ãýðèéí íîìèûí ñàí áóëàíãààð 2014 îíû 2-ð ñàðä, ÑÃÇ. Ë.Îäîí÷èìýä õºòºëæ íýâòð¿ëñýí

2. “Ýð¿¿ë ìýíä” òåëåâèç, ÌÀÓÀêàäåìààñ õàìò-ðàí ÿâóóëäàã “Àêàäåìè÷òàé ÿðèëöàõ öàã” öóâðàë íýâòð¿¿ëãýýð Àêàäåìè÷ Ä.Áààñàíæàâ, Æ.Õàéðóëëà, Í.Áààñàíæàâ, Á.Öýðýíäàø, Õ.Ãýëýã æàìö íàðûí 5 öóâðàëûã Á.Äàãäàíáàçàð õºòëºí ÿâóóëñàí

ÌÀÓ-û àêàäåìèéí ãèø¿¿í, Àêàäåìè÷ Áîäèéí Äàãäàíáàçàðûí

2014 îíä õèéñýí àæëûí òàéëàí


Íýã. 2014 îíä áè÷èæ íèéòë¿¿ëñýí á¿òýýë

1.1. Íîì (Îðîñ õýëýýð)

1.1.1. Ë. Õ¿ðýëáààòàð. Ýêåïåðèìåíòàëüíûå äîê-ëè íè ÷åñêèå èññëåäîâàíèÿ áåçîïàñíîñòè ôàð ìàêîëîãè÷åñêîé àêòèâíîñòè ëåêàðñòâåí-íîãî ïðåïàðàòà “ÈÌÌÓÍÎÑ”. Óëààíáààòàð, 2014.10 õõ

1.1.2. Ë.Õ¿ðýëáààòàð. Äîêëèíè÷åñêèå èññëåäî-âàíèÿ ôàðìàêîëîãè÷åñêîé àêòèâíîñòè è áåçî-ïàñíî ñòè ïðåïàðàòà ñóòàëàê. Óëààíáààòàð, 2014.10 õõ

1.1.3. Øàðãàë íàâ÷èñ, Óëààíáààòàð, 2014 îí, 5,8 õõ.

1.2. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë (Ìîíãîë õýëýýð)

1.2.1. Ulambayar L., Khurelbaatar L., Munkhbat S. “Analysis of drug usage in treatment of H.pylori associated peptic ulcer disease” Mongolian journal of health sciences. April 2014.Issue 1.Volume 11. p. 5-8

1.2.2. “õàâäàðûí ýñðýã ¿éëäýë á¿õèé ýëëèïèí áýëäìýëèéí ¿éë÷ëýëèéí òàëààðõ ìîëåêóë áèîëîãèéí ìåõàíèçìûí øèíý òààìàãëàë” (Çîõèîã÷äûí õàìò), Ìîíãîëûí Àíàãààõ Óõààí, 2014 îí, №3, õ.8-13.

1.2.3. “×àöàðãàíà (hippophae rhàmnoides) æèìñíèé òîñíû õ¿÷ëèéí á¿ðäýëèéí ñóäàëãàà” (çîõèîã÷äûí õàìò), Ìîíãîëûí Àíàãààõ Óõààí, 2014 îí, №3, õ.47-50

1.2.4. “×àëõ, òàìèð òýíõýý ñàéæðóóëàõ áýëäìýëèéí ôàðìàêîëîãèéí ¿éëäëèéã òîãòîîõ ñóäàëãààíû ¿ð ä¿í” Ìîíãîëûí Àíàãààõ Óõààí, 2014 îí, №3, õ.51-54

1.2.5. “Áººð ýì÷ëýõ ¿éëäýëòýé áýëäìýë¿¿äèéí ôàðìàêîëîãèéí ñóäàëãààíû ¿ð ä¿í” (çîõèîã÷äûí õàìò), Ìîíãîëûí Àíàãààõ Óõààí, 2014 îí, №3, õ.55-58

1.2.6. “Äåíòîñ 1% ãåëü ýìèéí òåõíîëîãè, ñòàí-äàðò ÷èëëûí ñóäàëãàà” (çîõèîã÷äûí õàìò), Ìîíãîëûí Àíàãààõ Óõààí, 2014 îí, №3, õ.59-66

1.2.7. Áººðíèé ¿ðýâñýë ýì÷ëýõ ¿éëäýëòýé áýëä-ìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ¿ð ä¿í-ãýýñ. (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.4-7.

1.2.8. “Èáóìîí 100ìã/5ìã” 100 ìë õºâìºë ýìèéí ñòàíäàðò÷ëàëûí ñóäàëãààíû ä¿íãýýñ (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.8-10.

1.2.9. Íèéëìýë íàéðëàãà á¿õèé óðãàìëûí ãàðàë-òàé áýëäìýëèéí ýëýãíèé ºâ÷ëºëä íºëººëºõ ¿éëäëèéí ñóäàëãàà. (çîõèîã÷äûí õàìò) Ìîí-ãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.20-26.

1.2.10. Ýì÷èä õàíäñàí ìàðêåòèíãèéí èäýâõè æ¿¿-ëýëòèéã ñóäàëñàí çàðèì ä¿íãýýñ. (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.27-31.

1.2.11. ªíäºð çîîñîí öýöýã, øèíýñýðõ¿¿ áóäàðãàíà óðãàìëûí íèéëìýë õàíäíû ñåñêâèòåðïåíèé ëàêòîíûã HPLC àðãààð òîäîðõîéëñîí ä¿í. (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.32-36.

1.2.12. Àëëåðãîí 5ìã øàõìàë ýìèéí òåõíîëîãèéí ñóäàëãàà. (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.37-39.

1.2.13. Õàíèàëãà íàìäààõ ¿éëäýëòýé óðãàìëûí ãàðàëòàé ñèðîï áýëäìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ä¿íãýýñ. (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.47-49.

1.2.14. Óðãàìëûí ãàðàëòàé ºòãºí õàòàëòûí ýñðýã ¿éëäëèéã òîãòîîõ ôàðìàêîëîãèéí ñóäàëãààíû ¿ð ä¿íãýýñ. (çîõèîã÷äûí õàìò) Ìîíãîëûí ýì ç¿é, ýì ñóäëàë, 2014 îí, №1, õ.56-58.

1.2.15. ×àöàðãàíà æèìñíèé çàðèì áèîëîãèéí èäýâõò íýãäëèéí äèíàìèê ñóäàëãàà (çîõèîã÷äûí õàìò), Õºäºº àæ àõóéí øèíæëýõ óõààí, 2014 îí, Òóñãàé äóãààð, õ.19-24.

1.3. Ýðäýì øèíæèëãýýíèé èëòãýë (ìîíãîë õýëýýð)

1.3.1. Õîäîîäíû øàðõëàà ºâ÷íèé ýìèéí ýì÷èëãýýíä õèéñýí ABS/VEN ä¿í øèíæèëãýý. Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.10-13

1.3.2. Èáóìîí 100 ìã/5ìã 100 ìë õºâìºë ýìèéí ñòàíäàðò÷èëàëûí ñóäàëãààíû ä¿íãýýñ. Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.38-40.

1.3.3. “Êëîòðèìîí ëàà ýìèéí ÷àíàðûí ¿ç¿¿ ëýë-ò¿¿ äèéã òîäîðõîéëñîí ä¿í” Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.40-42.

1.3.4. ªíäºð çîîñîí öýöýã, øèíýñýðõ¿¿ áó-äàð ãàíà óðãàìëûí íèéëìýë õàíäíû ñåñêâè-òåðïåíèé ëàêòîíûã hplc àðãààð òîäîðõîéëñîí ä¿í. Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.42-46.

1.3.5. “Íàðèéí íàâ÷èò öàõèëäàã, õóóðìàã áóë ÷èð-õàéò îðòóóç, õîñ øèâ¿¿ðò óëààãàíàä àãóóëàãäàõ

Ìîíãîëûí àíàãààõ óõààíû àêàäåìèéí (ÌÀÓÀ) ãèø¿¿í Ë.Õ¿ðýëáààòàðûí

2014 îíä àæëûí òàéëàí


áèîëîãèéí èäýâõèò íýãäë¿¿ä” Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.55-60.

1.3.6. “Ýçàì 400 ìã/25ìã êàïñóëòàé ýìèéí òåõíîëîãè, ñòàíäàðò÷èëàëûí ñóäàëãàà” Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.79-82.

1.3.7. “Àëëåðãîí 5 ìã øàõìàë ýìèéí òåõíîëî ãèéí ñóäàëãàà” Ýì ç¿éí áîëîâñðîë, ýðäýì øèí-æèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.87-89.

1.3.8. Óðãàìëûí ãàðàëòàé íèéëìýë íàéðëàãàòàé áýëä ìýëèéí ýëýã õàìãààëàõ ¿éëäëèéí ñóäàë-ãàà. Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.98-101.

1.3.9. “Õàíèàëãà íàìäààõ ¿éëäýëòýé óðãàìëûí ãàðàëòàé ñèðîï áýëäìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ä¿íãýýñ”, Ýì ç¿éí áîëîñâðîë, ýðäýì øèíæèëãýý, ¿éëäâýðëýë, çàõ çýýë-2014/, õ 102-104

1.3.10. Óðãàìëûí ãàðàëòàé ºòãºí õàòàëòûí ýñðýã ¿éëäëèéã òîãòîîõ ôàðìàêîëîãèéí ñóäàëãààíû ¿ð ä¿íãýýñ. Ýì ç¿éí áîëîâñðîë, ýðäýì øèí-æèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ. 116-118

1.3.11. Áººðíèé ¿ðýâñýë ýì÷ëýõ ¿éëäýëòýé áýëä ìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ¿ð ä¿íãýýñ. Ýì ç¿éí áîëîâñðîë, ýðäýì øèíæèëãýý ¿éëäâýðëýë çàõ çýýë-2014 õ.119-122.

1.3.12. “Àëëåðãîí 5 ìã øàõìàë ýìèéí òåõíîëîãè áîëîí ñòàíäàðò÷ëàëûí çàðèì ñóäàëãàà” Ýðä-ìèéí ÷óóëãàí-56 ýì ç¿éí ñàëáàð õóðàë äààí. 2014 õ.86

1.3.13. “Èáóìîí 60 ìã ëàà ýìèéí ñòàíäàðò÷èëàëûí çàðèì ñóäàëãàà” Ýðäìèéí ÷óóëãàí -56 ýì ç¿éí ñàëáàð õóðàëäààí. 2014 õ.90

1.3.14. “Èáóìîí 100 ìë õºâìºë ýìèéí òåõíîëîãè, ñòàíäàðò÷èëàëûí ñóäàëãàà ” Ýðäìèéí ÷óóëãàí -56 ýì ç¿éí ñàëáàð õóðàëäààí. 2014 õ.93

1.3.15. “Ìîíãîë õóí÷èð (Astragalus mongolicus. Bunge)-èéã õýýðèéí á¿ñýä ¿ðýýð íóãàãøóóëàí òàðèìàëæóóëñàí ñóäàëãààíû ä¿í” Ýðäìèéí ÷óóëãàí -56 ýì ç¿éí ñàëáàð õóðàëäààí. 2014 õ.97

1.3.16. “Óðãàìëûí ãàðàëòàé õàíèàëãà íàìäààõ ¿éë äýëòýé ñèðîï áýëäìýëèéí ôàðìàêîëîãèéí ñóäàëãààíû ä¿íãýýñ”, “Ýðäìèéí ÷óóëãàí-56” ñýòã¿¿ë/Ýì ç¿éí ñàëáàð õóðàëäààí èëòãýë¿¿äèéí õóðààíãóé, ÓÁ, 2014, õ 101-103

1.3.17. Óðãàìëûí íèéëìýë íàéðëàãûí òóðøèë-òûí àìüòíû ýñèéí áîëîí øèíãýíèé äàðõ-ëààíä ¿ç¿¿ëýõ íºëºº. ÕÀÀÈÑ-èéí ýðäýì øèíæèëãýýíèé õóðëûí ýìõýòãýë

1.3.18. In vivo immunostimulatory effect of combined extracts from some medicinal plants. CAMI-2014. Abstract book. p.26-27

Õî¸ð. Ïàòåíò, Ñòàíäàðò, ¯éëäâýðëýã÷èéí ôàðìàêîïåèí ºã¿¿ëýë

2.1. Áàòëóóëñàí ïàòåíò

2.1.1. Âèòàãðèï ìºõëºã ýìèéí íàéðëàãà áà áýëòãýõ àðãà № 4047

2.1.2. Âèòàãðèï ñèðîï ýìèéí íàéðëàãà áà áýëòãýõ àðãà № 4048

2.2. Áàòëóóëñàí ñòàíäàðò

2.2.1. Ýëýãíèé çàäðàã MNS 6484; 2014

2.2.2. Áàðóãøèí Ñ áèîëîãèéí èäýâõèò á¿òýýãäýõ¿¿í MNS 6486; 2014

2.3. Áàòëóóëñàí ¿éëäâýðëýã÷èéí ôàðìàêîïåèí ºã¿¿ëýë -11

Ãóðàâ. Óäèðäàæ õàìãààëóóëñàí äîêòîð, ìàãèñòð

Ë. Óëàìáàÿð. Õåëèêà áàêòåðèéí øàëòãààíò õîäîîä äýýä ãýäýñíèé øàðõëàà ºâ÷íèé ¿åä õýðýãëýæ áóé ýìèéí õýðýãöýýíèé ñóäàëãàà.

Ýì ç¿éí óõààíû äîêòîð, 2014.11.-íä õàìãààëñàí.

Ã. Ãàí÷èìýã “Ýìèéí çàõ çýýë äýýðõ ìåð÷àí äàé-çèíãèéí çàðèì ñóäàëãàà” 2014. Ýì ç¿éí óõààíû ìàãèñòð

Äºðºâ. ßðèëöëàãà

4.1. Õýâëýë

4.1.1. Ë.Õ¿ðýëáààòàð: Ìîíãîë óëñ íýì¿¿ ¿éëäâýð-ëýëýý õºãæ¿¿ëæ áàéæ ë õºãæèíº. Khunnu.mn. 2014. 6 ñàðûí 23

4.1.1. Ë.Õ¿ðýëáààòàð: Ýì, õ¿íñíèé àãåíòëàãûã áàéãóóëàõ õýðýãòýé. Ìîíãîëûí ìýäýý ñîíèí /Ìºí vip76.mn ñàéòàä íèéòëýãäñýí/. 2014 îíû 02-ð ñàðûí 14

4.1.2. Ë.Õ¿ðýëáààòàð: “Íåôðîìîí” áýëäìýëèéã ÎÕÓ-ä õ¿ëýýí çºâøººð¿¿ëýõèéí òóëä òàâàí æèë çàðöóóëëàà. ªäðèéí ñîíèí. 2014 îíû 11 ñàðûí 26.

4.1.3. Ë.Õ¿ðýëáàòààð: Ìîíãîë áîòàíèê öýöýð-ëýãýýð… 2014 îíû 9 ñàðûí 13. Sonin.mn

4.1.4. Ë.Õ¿ðýëáààòàð: “Íåôðîìîí” ÷àíàðûí õóâüä Îðîñûí ýìèéí çàõ çýýëèéí òýðã¿¿ëýã÷ á¿òýýãäýõ¿¿íòýé ºðñºëäºõ ò¿âøèíä õ¿ðñýí. 2014 îíû 12 ñàðûí 23. Sonin.mn

4.1.5. Ìîíîñûí Õ¿ðýëáààòàð-Ìîíãîëûí Òîìàñ Ýäèñîí. 2014 îíû 11 ñàðûí 26. FORBES MONGOLIA ñýòã¿¿ë

4.2. Òåëåâèç:

4.2.1. Ýäèéí çàñàã÷ Ä.Æàðãàëñàéõàíû “De facto” íýâòð¿¿ëýã /NTV/ 2014 îíû 6-ð ñàð

4.2.2. “Àìæèëò” íýâòð¿¿ëýã (25-ð ñóâàã) 2014 îíû 12-ð ñàð

Òàéëàí áè÷ñýí, Àêàäåìè÷ Ë.Õ¿ðýëáààòàð

2015.01.13


ÌÀÓÀ-èéí ãèø¿¿í Ä.Öýðýíäàãâûí 2014 îíä õèéñýí àæëûí òàéëàí

Íýã. Óíøñàí ëåêö

Ä.ä Ëåêöèéí ñýäýâ Õýíä çîðèóëñàí Îðîëöîã÷òîî

Îãíîî

1 “Óëàìæëàëò àíàãààõ óõààíû äýëõèé íèéòèéí ÷èã õàíäëàãà, Ìîíãîë óëñàä õèéæ áàéãàà ñóäàëãààíû àæëûí òîéì”

Óëàìæëàëò àíàãààõûí ñóð-ãóóëèéí îþóòíóóä

120 2014 îíû 4 ä¿ãýýð ñàðûí

202 “Ýìíýëç¿éí ñóäàëãàà” Ýðäìèéí ÷óóëãàí- 35

Âàíñýìáýð¿¿ ýì÷ íàðûí ýð-äýì øèíæèëãýýíèé ÷óóëãàí, ýì÷ íàðò

200 5 ñàðûí 02

3 “Ýðäýì øèíæèëãýýíèé á¿òýýë áè÷èõ òóõàé”

Ýð¿¿ë ìýíäèéí õºãæëèéí òºâ òýé õàìòàðñàí êðåäèò ñóð-ãàëò

5637

4 ñàðä 2 óäàà

4 “Ñóäàëãààíû àðãà ç¿é” ÓÀÑ-èéí ñóäëàà÷, ìàãèñòð, äîêòîð îþóòíóóä

25 2014.06.09

5 Ìîíãîë÷óóäûí èäýý óíäààíû õýðýãëýý ýð¿¿ëæ¿¿ëýõ ¿íäýñ

Õîîë áîëîâñðóóëàõ ýðõòíèé ýìãýãèéí ñåìèíàð

250 2014. 06.20

6 Íîòîëãîîíä ñóóðèëñàí óëàìæëàëò àíàãààõ óõààí

Óëàìæëàëò àíàãààõ óõààíû ýì÷ íàðò

52 2014.10.15

8 Ñóäàëãààíû àðãà ç¿é ÓÀ îþóòàí 400 2014.9.259 Ýìíýëç¿éí òðèàë ñóäàëãàà Ìàãèñòð, äîêòîð 82 2014.12.20

Õî¸ð. Óäèðäñàí äîêòîð, ìàãèñòð

Ä.ä Íýð Õàìãààëñàí ñýäýâ Çýðýã Îãíîî

1 Áÿìáààãèéí Öýðýíöîî Áàéãàëèéí ã¿¿í õºõ óðãàìëûí õàâäðûí ýñýä ¿ç¿¿ëýõ íºëºº

Äîêòîð 2014.6.02

2 Ñàìïèëûí Áàãàí Þíà-4 øàõìàë ýìèéí ñóäàëãàà

Äîêòîð 2014.06.17

3 Ïàãâà Áóÿíæàðãàë “Íèéãìèéí ýð¿¿ë ìýíäèéí ñó âè ëàõóé” ñóðãàëòûí õº òºë-áºðèéí õýðýãöýýíèé ñóäàë-ãàà”

Ìàãèñòð 2014.6,15

4 Áàÿðñàéõàí Îäãýðýë “Ýâòàíàçèéí ýðõç¿éí çîõèöóóëàëò”

Ìàãèñòð 2014.2.19

5 Õàäáààòàð Àðèóíàà Ñïîðòûí óðò áóóãààð øàãàéí çîãñîõ ¿åèéí õºâ÷èí áèåèéí çàðèì áóë÷èíãèéí ¿íýëãýý”

Ìàãèñòð 2014,12,15

Ãóðàâ. Õýâë¿¿ëñýí ºã¿¿ëýë

1. D.Tserendagva, N.Bira, D.Tsendayush, D.Badamsuren. I.Buyan. Pharmacological study of Mongolian traditional medicinal plants in mammalian liver disease. The 2nd Taiwan-Mongolia joint forum on liver disease. Kaoshing, Taiwan, 2014.10.04 p103

2. D.Tserendagva. Introduction of Mongolian medicine. Korean international conference. Journal of KIOM, Korea, 2014.12.12

3. Ñ.Îþóíöýöýã, Á.Îþóíãîî, Ä.Öýðýíäàãâà. “Äýýä áîëîâñðîëûí áàéãóóëëàãàä ìàãàäëàí èòãýìæýëýëèéí ¿ç¿¿ëýõ íºëºº” Ýðäìèéí ÷óóëãàí-56, Ýð¿¿ë Ìýíäèéí Øèíæëýõ óõààí ñýòã¿¿ë. Òóñãàé äóãààð, 2014:5:1

4. Ì.Áàÿðìàà, Ä.Áàäàìñ¿ðýí, Ä.Öýðýíäàãâà. “Èçîíèàçèä ýìèéí ýëýãíèé ýñýä ¿ç¿¿ëýõ íºëºº” Îíîø ñýòã¿¿ë. Äóãààð 03:2014;(65)


5. Ä.Öýðýíäàãâà, Á.Öýðýíöîî. “Óëàìæëàëò àíà-ãààõ óõààíû èäýý óíäààíû ýðäýì ÷àäàë, ýð¿¿ëæ¿¿ëýõ ¿íäýñ” Îíîø ñýòã¿¿ë. Äóãààð 03:2014;(65) 153-155

6. Õ.Àðèóíàà, Ñ.Ìºíõáàÿðëàõ, Ä.Öýðýíäàãâà. “Ñïîðòûí óðò áóóãààð øàãàéí çîãñîõ ¿åèéí õºâ÷èí áèåèéí çàðèì áóë÷èíãèéí ¿íýëãýý”. Ìîíãîëûí áèå áÿëäàð ñýðãýýí çàñàõ àíàãààõ óõààíû ñýòã¿¿ë. Volume 4, 06 ñàð, 2014, õóóäàñ 33-36

7. À.Õàñáààòàð, Ñ.Òºìºðáàãàíà, Ä.Öýðýíäàãâà, Ï.Õýðëýí. Áàãà íàñíû õ¿¿õäýä ýëáýã òîõèîë-äîõ Ëýã Êàëâèè Ïýðòýñ ºâ÷èí. Ýð¿¿ë ìýíäèéí øèíæëýõ óõààí ñýòã¿¿ë, vol 12 №3 (31) õóóäàñ 143

Äºðºâ. Õýâë¿¿ëñýí íîì

“Øèíæëýõ óõààíû á¿òýýë áè÷èõ îëîí óëñûí ÷èã õàíäëàãà”. Ë.Áàòòºð, Ä.Öýðýíäàãâà. Óëààíáààòàð 2014, 15.3õõ “Ìºíõèéí ¿ñýã” ÕÕÊ

Ðåäàêòîð õèéñýí íîì

1. Í.Ìºíõæàðãàë,Ð.Ñàðàíòóÿà. Ëàáîðàòîðè ñóä ëàë, ñóðãàëòûí öºì õºòºëáºð, ýìíýëãèéí òóñãàé ìýðãýæèëòýíä çîðèóëàâ. Óëààíáààòàð 2014 îí.

2. Ö.Áàò÷èìýã, Á.Íýìýõáàÿð. Ëàáîðàòîðèéí õý-ðýã ëýýíèé ìàòåìàòèê. Óëààíáààòàð 2014 îí.

3. Ä.Öýíä-Àþóø, Ò.Àëèìàà, Á.Öýðýíöîî, ×.Áàòíàéðàìäàë, Á.Áàÿðìàà. Óëàìæëàëò àíàãààõ óõààíû îíîëûí ¿íäýñ. Óëààíáààòàð 2014 îí. 29.33 õõ “ Óäàì ñî¸ë” ÕÕÊ

4. Í.Îþóíöýöýã, Ä.Öýíä-Àþóø,Í.Òºìºðáààòàð, Ò.Àëèìàà. Ìîíãîë àíàãààõ óõààíû çàñàë. Óëààíáààòàð 2014 îí.

5. Ñ.Îëäîõ, Á.Öýðýíöîî, Ï.Áàòõóÿã. Ìîíãîë ýìèéí ñóäëàë. Óëààíáààòàð 2014 îí.

Òàâ. 2014 îíä îðîëöñîí îëîí óëñûí õóðàë:

1. Human participant protection course. Armed forces research institute medical sciences (AFRIMS), National Center for communicable disease, Forum for ethical review committees in the asian and western pacific region (FERCAP), Ministry of health Mongolia.

2. 3rd Asia Pacific Research Ethics conference (APREC 2014). Research ethics: Harmonising global principles with asia pacific practices. Singapore 27-28 March 2014.

3. Asia Pacific association of medical journal editors (APAME) convention 20148 Ulaanbaatar, Mongolia. 12-15 august 2014

4. Global, regional, national and community perspective on health professional education.Gunma University WHO Collaborating Centre Symposium.5 July 2014, in Maebashi Terrsa, Maebashi, gunma6

5. The 2nd Taiwan-Mongolia joint forum on liver disease. Kaoshing, Taiwan, 2014.10.04

6. D.Tserendagva. introduction of Mongolian medicine. Korean international conference. 2014.12.12

Òàéëàí áè÷ñýí: àíàãààõ óõààíû äîêòîð, ïðîôåññîð Ä.Öýðýíäàãâà



1. Íîì, òîâõèìîë:1. Tsetsegmaa S. et al. Medicinal Plants in

Mongolia. World Health Organization. ISBN 9879290616320. 235pages.

2. Ýðäýì øèíæèëãýýíèé ºã¿¿ëýë:2.1. Ìîíãîë õýëýýð

1. Á.Öýðýíäîëãîð, Ñ.Öýöýãìàà, Ã.×îéæàìö, Ë.Õ¿ðýëáààòàð, À.Áàÿíìºíõ.

“ªíäºð çîîñîí öýöýã, Øèíýñýðõ¿¿ áóäàðãàíà óðãàìëûí íèéëìýë õàíäíû òåõíîëîãèéí ñóäàëãàà”. Ýìç¿é ñýòã¿¿ë 2014 VIII áîòü №2(44) õ.162-168


1. Öýðýíäîëãîð Á, Öýöýãìàà Ñ, Õ¿ðýëáààòàð Ë, Íàðàíãýðýë Á, ×èìãýý Ö, Ëõàãâà Ë, ×îéæàìö Ã. ”Èììóíîñòèìóëèðóþùèé ýôôåêò ëå-êàðñò âåííûõ ïðåïàðàòîâ ðàñòèòåëüíîãî ïðîèñõîæäåíèÿ íà èììóííóþ ñèñòåìó ïîäî-ïûòíûõ æèâîòíûõ”. Ñèáèðñêèé ìåäèöèíñêèé æóðíàë. 2014. №2. ññ 85-88

2. Daariimaa Khurelbatü Gereltuya Dorj, Enkhtuul Bayarsaikhan, Munkhdelger Chimedsuren, Tsetsegmaa Sanjjav,Takeshi Morimoto, Michael Morley6 and Katharine Morley.

“Prevalence estimates of substandard drugs in Mongolia using a random sample survey” Springer Plus a Springer Open Journal 2014.3:709

3. Áóñàä àæèë1. Øèíý÷ëýí áîëîâñðóóëñàí “Ýì ¿éëäâýðëýëä

òàâèãäàõ åðºíõèé øààðäëàãà óëñûí ñòàíäàðò MNS 5524:2014” Ñòàíäàð÷èëàë Õýìæèëç¿éí ¯íäýñíèé Çºâëºëèéí 2014 îíû 4-ð ñàðûí 25-íû õóðëààð áàòëàãäàâ.

2. Ýìèéí õàäãàëàëò, ò¿ãýýëòýíä òàâèõ åðºíõèé øààðäëàãà MNS 5530:2014 óëñûí ñòàíäàðòûã øèíý÷ëýí áîëîâñðóóëæ” Ñòàíäàð÷èëàë Õýì-æèë ç¿éí ¯íäýñíèé Çºâëºëèéí 2014 îíû 10 äóãààð ñàðûí õóðëààð áàòëóóëñàí.

3. Òºðººñ ýìèéí òàëààð áàðèìòëàõ ýìèéí áîäëîãî 2014 îíû 10-ð ñàðûí 9-íä ÓÈÕ-ààð áàòëàãäñàí.

4. Óäèðäàæ õàìãààëóóëñàí ýðäýìòýä:1. Áî.Á¿ðýíáàò. “Öóñàí áîëîð êàïñóë ýìèéí

÷àíàðûí ñóäàëãààíû àñóóäàëä” ñýäâýýð ýìç¿éí óõààíû äîêòîðûí çýðýã ãîðèëñîí ýðäýì øèíæèëãýýíèé àæèë, 2014 îíû 1-ð ñàðä

2. Ñ.Áàãàíà. “Þíà-4 øàõìàë ýìèéí ñóäàëãàà” ñýäâýýð ýìç¿éí óõààíû äîêòîðûí çýðýã ãîðèëñîí ýðäýì øèíæèëãýýíèé àæèë (2014 îíû 6-ð ñàðä)-ã òóñ òóñ óäèðäàæ õàìãààëóóëàâ.

ÌÀÓÀ-èéí ãèø¿¿í Ñ.Öýöýãìààãèéí 2014 îíä õèéñýí àæëûí òàéëàí

Ñýòã¿¿ëèéí ðåäàêöèä ìàòåðèàë èð¿¿ëýõäýý ýíýõ¿¿ çààâðûã ìºðäºíº. ¯¿íä:

1. ªã¿¿ëëèéã ººðèéí õèéñýí ñóäàëãààíû àæëûí ¿ð ä¿íä ¿íäýñëýí áè÷ñýí áàéíà.

2. ªã¿¿ëëèéã À4 õóóäàñíû íýã òàëä 31 ìºðººð Arial øðèôòýýð, 12-ûí ¿ñãýýð áè÷íý.

3. Ñóäàëãààíû ºã¿¿ëýë íü “áèîàíàãààõ”, “ýìíýëç¿é”, “íèéãìèéí ýð¿¿ë ìýíä”, “ýìç¿é”, “óëàìæëàëò àíàãààõ óõààí” àíãèëëûí àëèíä îðîõûã ºã¿¿ëëèéí íýðèéí äîð áè÷èõ

4. Ñóäàëãàà øèíæèëãýýíèé ºã¿¿ëýë íü õ¿ñíýãò, çóðàã, íîì ç¿é, òîâ÷ëîëûã îðîëöóóëàí 10 õóóäàñíààñ õýòðýõã¿é õýìæýýòýé áàéíà.

5. ªã¿¿ëëèéí ýõýíä á¿òýýëèéí íýð, çîõèîã÷èéí íýð, çîõèîã÷èéí õàðúÿàëàãäàõ àëáàí áàéãóóëëàãûí íýð, ãîë ñóäëàà÷èéí å-ìàéë õàÿãèéã áè÷íý. Æ:

Ç¿ðõ ñóäàñíû çàðèì ýìãýãòýé õ¿ì¿¿ñèéí ñèéâýíãèéí ìàêðîìîëåêóëûã òîäîðõîéëñîí ä¿íãýýñ

Õýðýâ: Çîõèîã÷èä ººð ººð áàéãóóëëàãàä àæèëëàäàã áîë:

Ì.Ýðäýíýòóÿà1, Ë.Ëõàãâà2

1Àíàãààõûí øèíæëýõ óõààíû ¿íäýñíèé èõ ñóðãóóëü2Àíàãààõ óõààíû õ¿ðýýëýí e-mail: ãýæ áè÷íý.

“ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍ” ÑÝÒÃ¯¯ËÄ ªÃ¯¯ËÝË ÍÈÉÒË¯¯ËÝÕ ÇÀÀÂÀÐ

Ì.Ýðäýíýòóÿà, Ë.ËõàãâàÀíàãààõûí øèíæëýõ óõààíû ¿íäýñíèé èõ ñóðãóóëüe-mail:


6. Ñóäàëãààû ºã¿¿ëýë íü îðøèë, ìàòåðèàë, àðãà ç¿é, ¿ð ä¿í, õýëöýìæ, ä¿ãíýëò, íîì ç¿é ãýñýí õýñã¿¿äýýñ á¿ðäýíý. Ñóäàëãààíû àðãà òîâ÷, òîäîðõîé, îðøèë íü ò¿¿õ÷èëñýí óðò áóñ, óòãà ñàíààã äàõèí äàâòàëã¿é áè÷ñýí áàéíà.

7. ªã¿¿ëëèéã ñàéòàð íÿãòàëñàí, ìàòåìàòèê, õèìèéí òîìú¸îã øàëãàñàí, àëäàà ìàäàãã¿é áàéíà.

8. Çóðàãëàñàí ìàòåðèàëûí òîî öººí, çóðàãò áîñîî, õýâòýý òýíõëýãèéí óòãà, õýìæèõ íýãæèéã çºâ òîìú¸îëæ áè÷ñýí áàéõ, ôîòî çóðàã òîä áàéíà (Ôîòî çóðãèéã õàâñàðãàíà). Çóðãèéí íýðèéã çóðãèéí äîð áè÷íý.

9. Õ¿ñíýãò íü ñàéí øàõàæ õèéñýí, õ¿ñíýãòèéí á¿õ òîîí óòãà íü ºã¿¿ëëèéí àãóóëãàòàé á¿ðýí òîõèðñîí, õ¿ñíýãòèéí íýð òîâ÷, îíîâ÷òîé áàéíà.

10. Õ¿ñíýãò, çóðãèéí íýð, äóãààð, òàéëáàðûã àíãëè õýëýýð áè÷ñýí áàéíà.

11. Áèîàíàãààõ óõààíû ¸ñ ç¿éí àñóóäëûã ñóäàëãààíäàà õýðõýí çîõèöóóëñàí, ¸ñ ç¿éí õîðîîíû çºâøººðºë àâñàí òóõàé, ò¿¿íèéã õýðõýí ìºðäºæ àæèëëàñàí òóõàé òîâ÷ òóñãàñàí áàéíà.

12. Íîì ç¿éí æàãñààëòûã òóñãàé õóóäñàí äýýð, çîõèîã÷èéí íýðíèé ýõíèé ¿ñãèéí äàãóó öàãààí òîëãîéí äàðààëëààð (ýõëýýä ººðèéí îðíû, äàðàà íü ãàäààäûí çîõèîã÷òîé á¿òýýëèéã) ýñâýë, á¿òýýëä îðóóëñàí äàðààëëààð æàãñààæ áè÷íý. Íîì ç¿éí æàãñààëòàä çîõèîã÷èéí íýð, ºã¿¿ëëèéí íýð, õýâëýëèéí íýð, õýâëýñýí ãàçàð, îí, äóãààð, õóóäñûã çààâàë áè÷íý. Æ:

Áàäàìñýä Ö, Öýðýíäàø Á, Òóÿà Ñ. Ìîíãîë õ¿ì¿¿ñèéí öºñíèé õ¿¿äèéí õýò àâèàí øèíæèëãýýíèé ëàâëàìæ õýìæýý, “Ìîíãîëûí àíàãààõ óõààí”, 2015, No2, x.6-7

13.Ñóäàëãàà øèíæèëãýýíèé ºã¿¿ëýë, ëåêö, òîéì, çºâëºëãºº çýðýãò 300 ¿ãòýé àíãëè òîâ÷ëîë õèéõ áºãººä ò¿¿íä ºã¿¿ëëèéí ¿íäñýí àãóóëãûã òîâ÷ëîí áè÷ñýí áàéíà. Àíãëè òîâ÷ëîë íü introduction, Goal, Materials and Methods, Result (s) and Conclusion (s) ãýñýí á¿òýöòýé áàéíà. Òîâ÷ëîëûí ýõýíä ºã¿¿ëëèéí íýð, çîõèîã÷, áàéãóóëëàãûí íýðèéã á¿òíýýð íü àíãëèàð áè÷íý. ªã¿¿ëëèéí àíãëè òîâ÷ëîëä 5-8 õ¿ðòýë ¿ã, íýð òîìú¸î á¿õèé ò¿ëõ¿¿ð ¿ãèéã öàãààí òîëãîéí äàðààëëààð áè÷ñýí áàéíà.

14. Õýâëýëèéí òîéì, ëåêö íèéòë¿¿ëýõ áîë ò¿¿íèéã áýëòãýõýä 50-ñ äîîøã¿é ýõ ñóðâàëæ àøèãëàí áè÷ñýí áàéíà.

15. ªã¿¿ëëèéã íèéòë¿¿ëýõèéã çºâøººðñºí ýðäýì øèíæèëãýýíèé óäèðäàã÷èéí çºâøººðºë, áàéãóóëëàãûí çàõèðàë, ýðõëýã÷èéí àëáàí áè÷èãòýéãýýð èð¿¿ëíý.

16. Çîõèîã÷èä ãàðûí ¿ñýã çóðæ, ýðãýæ õîëáîî áàðèõ óòàñíû äóãààðûã áè÷ñýí áàéíà.

17. Ñýòã¿¿ëèéí ðåäàêöè íü ºã¿¿ëëèéã çàñàõ ýðõòýé áºãººä çîõèîã÷òîé òîõèðîëöñîíû ¿íäñýí äýýð òîâ÷èëñîí áàéäëààð íèéòë¿¿ëæ áîëíî.

18. Òóñ ñýòã¿¿ëä ºðãºí áàðüæ áóé ºã¿¿ëýë íü ºìíº íü ººð õýâëýëä íèéòëýãäýýã¿é áàéíà.

19. Äýýð äóðäñàí øààðäëàãûã õàíãààã¿é ºã¿¿ëëèéã ýçýíä íü áóöààíà.

20. Ñýòã¿¿ëä íèéòëýãäýæ áàéãàà ºã¿¿ëëèéí ýõèéã ýçýíä íü áóöààõã¿é.

21. Ñýòã¿¿ëä èð¿¿ëñýí õóãàöààã ºã¿¿ëëèéã ýöñèéí õóâèëáàðààð áýëýí áîëãîñîí ºäðººð òîîöíî.

22. ªã¿¿ëëèéã öààñàí äýýð õýâëýñýí 2 õóâü, âèð¿ñýýð õàëäâàðëàãäààã¿é flash äèñêýýð ýñâýë öàõèì øóóäàíãààð [email protected] õàÿãààð èð¿¿ëíý. Õîëáîî áàðèõ óòàñ: 9981-7218

23. Ñýòã¿¿ë íü ººðèéí îðëîãîîð õýâëýãääýã òóë ºã¿¿ëýë íèéòë¿¿ëýõ òºëáºðèéã õèéõäýý À4 õýìæýýíèé íýã í¿¿ð á¿ðèéã 10 àì.äîë-ààð òîîöîæ, òºãðºãò øèëæ¿¿ëýí ÕÕÁ äàõü “Ìîíãîëûí àíàãààõ óõààí” ñýòã¿¿ëèéí 499016080 òîîò äàíñàíä òóøààñàí áàðèìòûã àâ÷èðíà. Àëáàí áàéãóóëëàãóóä Ñýòã¿¿ëèéí äàíñàíä òºëáºð õèéõ áîë 1190822 ðåãèñòðèéí äóãààðûã àøèãëàíà.

24. Ñýòã¿¿ëä òàâèõ øààðäëàãûí òàëààðõ Òà á¿õíèé ñàíàëûã äóðòàéÿà õ¿ëýýí àâ÷, ¿éë àæèëëàãààíäàà òóñãàõûã õè÷ýýæ àæèëëàõ áîëíî.

Ðåäàêöèéí çºâëºë


“ÌÎÍÃÎËÛÍ ÀÍÀÃÀÀÕ ÓÕÀÀÍ” ÑÝÒÃ¯¯ËÈÉÍÐÅÄÀÊÖÈÉÍ ÇªÂËªË

Òýðã¿¿ëýã÷èä

1. Í.ÁààñàíæàâÅðºíõèé ýðõëýã÷, àêàäåìè÷, àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð,

Àðäûí ýì÷, Õºäºëìºðèéí áààòàð

2. Ä.Òóÿà Îðëîã÷ ýðõëýã÷, ýìç¿éí óõààíû äîêòîð

3. Á.ÁóðìààæàâÕàðèóöëàãàòàé íàðèéí áè÷ãèéí äàðãà, àíàãààõûí øèíæëýõ óõààíû äîêòîð,

ïðîôåññîð

4. Ø.Áîëä Àêàäåìè÷, Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð

5. Ä.Ä¿íãýðäîðæ Àêàäåìè÷, Ýìç¿éí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, ãàâúÿàò áàãø

6. Ý.Ëóâñàíäàãâà Àêàäåìè÷, àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, àðäûí ýì÷

7. Ë.ËõàãâàÀêàäåìè÷, àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷,

òºðèéí øàãíàëò

8. Ö.Ëõàãâàñ¿ðýíÀêàäåìè÷, àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, ýð¿¿ëèéí õàìãààëàõûí

ãàâúÿàò àæèëòàí

9. Ï.ÍÿìäàâààÀêàäåìè÷, àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, ýð¿¿ëèéã õàìãààëàõûí

ãàâúÿàò àæèëòàí

10 Á.Öýðýíäàø Àêàäåìè÷, àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð

Ãèø¿¿ä

11. Ä.Àìãàëàíáààòàð Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð

12. Ä.ÁààñàíæàâÀíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, øèíæëýõ óõààíû ãàâúÿàò

ç¿òãýëòýí

13 Æ.ÁàòñóóðüÁèîëîãèéí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, øèíæëýõ óõààíû ãàâúÿàò

ç¿òãýëòýí

14. Í.Äàâààöýðýí Àíàãààõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷, òºðèéí øàãíàëò

15. ß.Äàãâàäîðæ Àíàãààõ óõààíû äîêòîð, ïðîôåññîð

16. Ã.Æàìáà Àíàãààõ óõààíû äîêòîð, ïðîôåññîð, ýð¿¿ëèéã õàìãààëàõûí ãàâúÿàò àæèëòàí

17. Ö.ÌóõàðÀíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, ýð¿¿ëèéã õàìãààëàõûí ãàâúÿàò

àæèëòàí

18. Ä.Ìàë÷èíõ¿¿ Àíàãààõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷

19. Á.Ìºíõáàò Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð

20. Ï.Îíõóóäàé Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷, àðäûí ýì÷

21. Á.Îþóíáàò Àíàãààõ óõààíû äîêòîð, ïðîôåññîð

22. Æ.Îþóíáèëýã Áèîëîãèéí øèíæëýõ óõààíû äîêòîð, äýä ïðîôåññîð

23. À.ªëçèéõóòàã Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷

24. Æ.Ðàäíààáàçàð Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷

25. Ý.Ñàíæàà Àíàãààõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷, àðäûí ýì÷

26. Ö.Ñîäíîìïèë Àíàãààõ óõààíû äîêòîð, ýð¿¿ëèéã õàìãààëàõûí ãàâúÿàò àæèëòàí

27. Í.Öýíä Àíàãààõ óõààíû äîêòîð, ýð¿¿ëèéã õàìãààëàõûí ãàâúÿàò àæèëòàí

28. Ó.Öýðýíäîëãîð Àíàãààõûí øèíæëýõ óõààíû äîêòîð

29. Ã.×îéæàìö Àíàãààõ óõààíû äîêòîð, ïðîôåññîð

30. Á.Øèæèðáààòàð Àíàãààõ óõààíû äîêòîð, ïðîôåññîð, ãàâúÿàò áàãø

31. Ø.Ýíõöýöýã Àíàãààõ óõààíû äîêòîð, Ýìíýëãèéí óäèðäëàãûí øèíæëýõ óõààíû ìàãèñòð

32. Á.Ýðäýíý÷óëóóí Àíàãààõûí øèíæëýõ óõààíû äîêòîð, ïðîôåññîð, õ¿íèé ãàâúÿàò ýì÷

mongolmed.mnmongolmed.mn/uploads/editions/pdf/6c8c08972727529022d9d6...ÌÎÍÃÎËÛÍ...

Documents

Transcript of mongolmed.mnmongolmed.mn/uploads/editions/pdf/6c8c08972727529022d9d6...ÌÎÍÃÎËÛÍ...